<SEC-DOCUMENT>0001213900-21-017981.txt : 20210326
<SEC-HEADER>0001213900-21-017981.hdr.sgml : 20210326
<ACCEPTANCE-DATETIME>20210326160541
ACCESSION NUMBER:		0001213900-21-017981
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210326
DATE AS OF CHANGE:		20210326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		21777327

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_chinapharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>

<HEAD>

     <TITLE></TITLE>

</HEAD>

<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#9746; ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the fiscal year ended December 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>or</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#9744; TRANSITION REPORT UNDER SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the transition period from _________ to
_____________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission file number: 001-34471</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>China
Pharma Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>(Exact name of registrant as specified in
its charter)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>73-1564807</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction of</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>incorporation or organization)</I></P></TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(IRS Employer <BR>
Identification No.)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Second Floor, No. 17, Jinpan Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Haikou, Hainan Province, China 570216</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of Principal Executive Offices) (Zip
Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
the area code: <B>(011) 86 898-6681-1730</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities registered pursuant
to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CPHI</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities registered pursuant
to Section 12(g) of the Act: <B>None.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes &#9744; No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2) has been subject to
such filing requirements for the past 90 days. Yes &#9746; No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). Yes &#9746; No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9746;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company &#9744;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate market value
of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last
sold, or the average bid and ask price of such common equity, as of the last business day of the registrant&rsquo;s most recently completed
second fiscal quarter: $16,225,327 as of June 30, 2020, based on the closing price of $0.67 of the Company&rsquo;s common stock on such
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of outstanding
shares of the registrant&rsquo;s common stock on March 22, 2021, was 45,579,557.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Documents Incorporated by
Reference: None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K ANNUAL REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FISCAL YEAR ENDED DECEMBER 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 80%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_001">Business.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_002">Risk Factors.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">14</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_003">Unresolved Staff Comments.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">34</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_004">Properties.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">34</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_005">Legal Proceedings.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">34</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_006">Mine Safety Disclosures.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">34</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_007">PART II</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_008">Market for the Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">35</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_009">Selected Financial Data.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">35</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_010">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">36</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_011">Quantitative and Qualitative Disclosures about Market Risk.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">42</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_012">Financial Statements and Supplementary Data.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">42</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_013">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">42</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_014">Controls and Procedures.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">42</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_015">Other Information.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">43</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_016">PART III</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_017">Directors, Executive Officers and Corporate Governance.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">44</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_018">Executive Compensation.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">46</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_020">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">48</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_021">Certain Relationships and Related Transactions, and Director Independence.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">49</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_022">Principal Accountant Fees and Services.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">49</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_023">PART IV</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_024">Exhibits, Financial Statement Schedules.</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">50</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_025">SIGNATURES</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">51</TD></TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_026">EXHIBIT INDEX</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">52</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aa_027">FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The statements contained in
this report with respect to our financial condition, results of operations and business that are not historical facts are &ldquo;forward-looking
statements&rdquo;. Forward-looking statements can be identified by the use of forward-looking terminology, such as &ldquo;anticipate&rdquo;,
&ldquo;believe&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;intend&rdquo;, &ldquo;seek&rdquo;, &ldquo;estimate&rdquo;, &ldquo;project&rdquo;,
&ldquo;could&rdquo;, &ldquo;may&rdquo; or the negative thereof or other variations thereon, or by discussions of strategy that involve
risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained
in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other
factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors
affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report
including in &ldquo;Risk Factors&rdquo; in Item 1A and some of which are discussed in our other filings with the SEC. These forward-looking
statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results
may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements
that have been made regarding anticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These risk factors should
be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may
issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons
acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors
not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&rsquo; expectations
or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date
of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;) expressly state that the safe harbor for forward-looking statements does not apply
to companies that issue penny stock. If we are ever considered to be an issuer of penny stock, the safe harbor for forward-looking statements
may not apply to us at certain times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="aa_001"></A><B>ITEM 1.</B>&nbsp;<B>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are principally engaged
in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence
and high-mortality diseases and medical conditions prevalent in the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;). All of our
operations are conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form
of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical
products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National
Medical Products Administration (the &ldquo;NMPA&rdquo;, formerly China Food and Drug Administration, CFDA) based upon demonstrated safety
and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, we
manufactured 19 pharmaceutical products for a wide variety of diseases and medical indications, each of which may be classified into one
of three general categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Basic generic drugs, which are common drugs in the PRC for
which there is a very large market demand;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">First-to-market generic drugs, which are generic Western drugs
that are new to the PRC marketplace; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Modern Traditional Chinese Medicines, which are generally
comprised of non-synthetic, plant-based medicinal compounds of the type that have been widely used in the PRC for thousands of years,
to which we apply modern production techniques to produce pharmaceutical products in different formulations, such as tablets, capsules
or powders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In selecting generic drugs
to develop and manufacture, we consider several factors, including the number of other manufacturers currently producing a particular
drug, the size of the market for that drug, the proposed or required method of distribution, the existing and expected pricing for that
particular drug in the marketplace, the costs of manufacturing that drug, and the costs of acquiring or developing the formula for that
drug. We believe we have historically selected generic drugs for manufacture that have large addressable markets and higher profit margins
relative to other generic drugs manufactured and distributed in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we manufactured
one comprehensive healthcare product and two protective products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently own and operate
two production facilities in Haikou, Hainan Province, PRC, one of which has a construction area of 663.94 square meters. The other factory
has two buildings with production area of 20,282.42 square meters and 6,593.20 square meters. We implement quality control procedures
in this facility in compliance with the PRC&rsquo;s Good Manufacturing Practices, or GMP standards, and applicable NMPA regulations to
ensure consistent quality in our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NMPA promulgated <I>Good
Manufacturing Practices for Pharmaceutical Products</I> (2010 revised version) on February 12, 2011 (effective as of March 1, 2011) (the
&ldquo;Year 2011 GMP&rdquo;). The Year 2011 GMP standards outline the basic principles and standards for the manufacturing of pharmaceutical
products and the management of quality controls in the pharmaceutical products manufacturing industry in the PRC. All of our production
lines: tablets, capsules, dry power, liquid injectables, solid oral solution Cephalosporins (specifically designated), are in full compliance
with the Year 2011 GMP standard. A newly revised Drug Administration Law (the &ldquo;New Law&rdquo;) came into effect on December 1, 2019,
which cancelled the GMP certification but impose the pilot inspection mechanism in the event any production line(s) does not satisfy any
pilot inspection under the New Law, the production on such production line(s) could be suspended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We market and sell our products
through 16 sales offices covering all major cities and provinces in the PRC. To comply with applicable Chinese laws relating to sales
of prescription drugs to certain hospitals and clinics, we also use a distribution system comprised of over 1,000 independent prefecture-level,
city-level, and county-level distributors. Our sales system has further developed and expanded with the expansion of Chinese healthcare
reform, and our 16 provincial offices deliver our products to basic health care institutions as well as tier two and tier three hospitals
through the above mentioned distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate organizational
chart is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Industry Background and Market Opportunities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We have observed the following
trends in China's healthcare industry in recent years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">1.
The level of basic medical insurance has been improved in an all-round way. According to The 2019 Communique on Statistics on the Development
of HealthCare in China (hereinafter referred to as Communique) published by Chinese National Health Insurance Administration on June 6,
2020, more than 1.35 billion people participated in Basic Medical Insurance System (BMIS) in 2019, and the participation rate remained
stable at more than 95%. The reimbursement rate for hospital expenses of Basic Medical Insurance System for Urban Employees (BMISUE) and
Urban and Rural Residences Medical Insurance System (URRMIS) has been raised to more than 60%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">2.
Expenditures on essential medicines have decreased significantly. As per the Communique, the proportion of expenditure on essential medicines
in health institutions at all levels. After the abolition of &ldquo;drug adds-on&rdquo;, in public hospitals, the share of drug revenue
in total income has declined from 46.33% in 2010 to 32.71% in 2018; the average drug costs per outpatient rate as a percentage of total
costs has fell from 51.5% in 2009 to 40.6% in 2019; while drug costs as a percentage of total hospitalization expenses fell from 43.6%
in 2009 to 27.5% in 2019. In Community Health Centres, the proportion of medicines to hospitalization costs was 35.4% in 2019, down 13.9
% from 2010 levels. In township hospitals, the proportion of hospitalization cost of medicines to total expenditure was 38.5% in 2019,
down 14.4% from 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">3.
The capacity of health services in primary-level institutions is growing. In the case of township hospitals, there has been a significant
increase in the number of visits and hospitalizations, with the number of beds per 10,000 agricultural population rising from 10.50 in
2009 to 14.80 in 2019. In 2020, the central government spent RMB50.38 billion on basic public health services, and RMB9.95 billion on
COVID-19 prevention and control for grass-roots medical institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">4.
The System of Graded Diagnosis and Treatment (SGDT) has been steadily advanced. The primary community health service center and the second
and third-level hospitals was open as a medical union in cities, to achieve the sharing of medical and health resources between regions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
General Office of the State Council of China issued The Key Tasks for Deepening the Reform of the Medical and Health System in the Second
Half of 2020 (hereinafter referred to as the Tasks) on July 23, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Tasks pointed out that since the outbreak of COVID-19, our medical and health system has stood the test and played an important role in
winning the battle with this epidemic. In the second half of 2020, the Tasks urged us to promote the deepening of medical reform and the
prevention and treatment of the COVID-19 epidemic, put prevention in a more prominent position, and continue to transfer from a treatment-centred
approach to a population health-centred approach. We continue to reform medical care, medical insurance and medicine, and focus on solving
the problem of &quot;inadequate and overly expensive medical services&quot;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">With
the growth of China&rsquo;s per capita income, people&rsquo;s awareness of health care has been gradually increasing. Medical consumption
expenditure and consumer demand for higher-level health care are expected to continue to grow. In early March 2021, China's vice minister
of Ministry of Human Resources and Social Security said at a press conference that people aged 60 and over had reached 18.1% of the overall
population by the end of 2019, and that the country's elderly population is expected to exceed 300 million in the coming five years. According
to the China Development Research Foundation's <I>China Development Report 2020</I>, Chinese aging populations will peak during 2035 to
2050, and that by 2050, China's elderly population aged 60 and over will be close to 500 million, accounting for more than a third of
the total population. In view of the increased awareness of health care and the ageing society, the increasing industry concentration
and internationalization, and the fact that NMPA initiated policies to encourage mergers and reorganizations among business entities to
seek joint development, we are optimistic about the development of China&rsquo;s pharmaceutical industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Impact from the New Coronavirus Global Pandemic
(&ldquo;COVID-19&rdquo;)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the end of 2019, the COVID-19 outbreak has spread around the world: from January to February 2020 in China, to February to April 2020
in the United States, Italy, Spain and other European and American countries, to April to August in the United States, India, Brazil,
Russia, till the second outbreak in Europe and other regions in August, overseas outbreaks continue to ferment. In December 2020, situation
in the United Kingdom continues to deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
outbreak of COVID-19 has a material and adverse effect on the Company&rsquo;s business operations. These included, but are not limited
to, disruptions or restrictions on our ability to travel or to distribute our products, as well as temporary closures of our facilities
or the facilities of our suppliers or customers in early 2020. The Company reopened its facility and ramped up its operations in the first
quarter 2020. In addition, COVID-19 not only brought a widespread health crisis, it also adversely affected the economies and financial
markets in China and many other countries, resulting in an economic downturn that could significantly impact the Company operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Chinese government has responded positively to the COVID-19 outbreak by introducing a series of policies in a timely manner, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
General Office of the National Health and Wellness Commission of China issued the &ldquo;Notice on Further Improving the Emergency Response
Capacity of Pre-Hospital Medical Care under the Normalization of the Prevention and Control of the COVID-19&rdquo; on July 15, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">China's
National Health and Wellness Commission officially announced the &ldquo;COVID-19 Prevention and Control Program (7th Edition)&rdquo; on
September 16, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the release of COVID-19 vaccine in December 2020, the world is making every effort to accelerate the vaccination progress. However, although
the vaccine has played a positive role in the prevention and control of the epidemic, and the number of new daily incurred cases of COVID-19
has dropped for six weeks in the world, WHO officials say the apparent turning point of the global outbreak has not arrived, and the task
to prevent and control the epidemic remains daunting. Michael Ryan, WHO's head of the health emergency program, spoke on a news conference
on March 1, 2021 local time that it was impossible to end the outbreak this year. At present, the focus is to control the spread of the
new coronavirus and to avoid the virus mutation, and to improve the speed of vaccination at the same time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Consistency Evaluation for Generic Drugs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
&ldquo;consistency evaluation of generic drugs&rdquo; refers to the evaluation of generic drugs that were approved for market, for the
consistency with the quality and efficacy of the original drug. The goal is for generic drugs to achieve the same level of quality and
efficacy as the original drugs and to replace the original drugs in clinical use. This can not only save medical expenses, but also improve
the development of the pharmaceutical industry, and to ensure the safety and effectiveness of public drug use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
State Council issued the Pilot Program for the Central Procurement and Use of Drugs by State Organizations (the &ldquo;Program&rdquo;)
on January 17, 2019. The Program calls for the selection of pilot drugs from generics that have passed the &quot;consistency evaluation&quot;,
and for centralized procurement and use in order to reduce drug prices and reduce patient drug costs. According to documents of the third
batch of national centralized procurement issued in July 2020, generic products are required to pass the NMPA&rsquo;s generic drug consistency
evaluation to be eligible for procurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">NMPA
issued an official document on The Implementation of the Evaluation of the Quality and Efficacy of Chemical Injection Generics on May
14, 2020, requiring consistency evaluation for generics of pharmaceutical injections that are already on the market. According to the
CPM New Drug Research and Development Monitoring Database, a total of 183 chemical injections passed the consistency evaluation in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
company has actively promoted the consistency evaluation process of several key current existing oral products in 2020. We have a product
that passed biological equivalents experiments of consistency evaluation in March 2021. We plan to submit its relevant documentation and
data to NMPA in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The PRC&rsquo;s medical insurance system</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
New Rural Cooperative Medical System (NRCMS) was officially launched in rural areas in 2003. It is a critical illnesses-oriented medical
assistance system for farmers, and has achieved full coverage in 2008. In towns and cities, The Urban Residences Medical Insurance System
(&ldquo;URMIS&rdquo;) has been in operation since 2007. It provides medical security for urban residents through financing organized by
the government, with residents' contributions as the main source of funds and supplemented by appropriate government subsidies. In order
to further expand the coverage of medical insurance and coordinate the economic and social development of urban and rural areas, in January
2016, the State Council issued the Opinions on the Integration of the Basic Medical Insurance System for Urban and Rural Residents (the
Opinion). The Opinion proposes to integrate the NRCMS and URMIS, to establish a unified basic medical insurance system for urban and rural
residents, and further unify the operation of services and information systems to improve the quality and efficiency of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the Communique, 329 million people participated in health insurance for workers and 1,024 million people participated in medical insurance
for urban and rural residents. The total income of the basic medical insurance fund was RMB2442.1 billion, an increase of 10.2% over the
previous year, accounting for about 2.5% of GDP in the current year, The total expenditure was RMB2085.4 billion, an increase of 12.2%
over the previous year, and the cumulative balance was RMB276.97 billion. Experts pointed out that in 2019, the URRMIS has been fully
integrated, the scale of the medical insurance fund has been expanded, and the anti-risk capacity of the medical insurance fund has been
improved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">We believe that the pursuit
of innovation is imperative for providing the basic medical solutions needed by the majority of patients. We are passionate about protecting
human health, and we always adhere to the highest standards of ethics and integrity to fulfill our firm commitment to our customers and
patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we are well-positioned
in a comparatively steadily growing industry in one of the fastest-growing economies in the world. China's per capita GDP exceeds US$10,000
in 2019, which stimulates consumption structure upgrade, and the establishment of a high-quality health care system. We currently manufacture
a number of off-patent branded generic drugs. Our diverse portfolio of products and new product pipelines include products for high-incidence
and high-mortality conditions in the PRC, such as cardiovascular, central nervous system (&ldquo;CNS&rdquo;), infectious, and digestive
diseases. We launched wash-free sanitizers and various types of masks since the outbreak of COVID-19 at year end 2019. In addition, we
continue to explore comprehensive healthcare market after the launch of Noni enzymes in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">Consistency evaluation
of our current existing major products will be the focus of our strategy in the near future. The consistency evaluation of generic drugs
will improve Chinese generic drugs quality and eliminate unqualified enterprises, so that high-quality generic drug companies are expected
to benefit from it. Consistency evaluation, together with the GPO, is optimizing the competitive landscape of the Chinese pharmaceutical
industry. We believe that the market space and growth potential of Chinese generic drugs are huge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">A series of medical reform
policies introduced in recent years has profound and far-reaching impact on pharmaceutical companies. Therefore, early consideration of
the transformation and upgrading, as well as product positioning become very important. Based on our experience in R&amp;D, production
and marketing experiences, and our market insights, we have decided to gradually adjust our strategy to produce generic and innovative
drugs with high value in pharma-economics, good clinical efficacy and market differentiation. These include drugs that treat chronic diseases
prevalent in China, geriatric diseases, cancers, and nutritional products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">In addition, as another direction
of strategic development, we will actively explore connectivity on the Internet. We will take the initiative to learn, participate, and
put our products to the online market, to achieve online and offline connectivity of a complete ecological system.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">Our objective is to leverage
our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical products. We intend to achieve this
objective by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Promoting Our Existing Brands to
Increase Our National Recognition</I>. We intend to support and grow the existing recognition and reputation of our brands and to maintain
our branded pricing strategy through continued sales and marketing efforts through our new, upgraded GMP-compliant production lines. To
achieve this goal, we plan to promote the efficacy and safety profile of our established prescription pharmaceutical products to physicians
at hospitals and clinics in all provinces of PRC through the efforts of our sales force, independent distributors and educational physician
conferences and seminars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Promoting the progress of consistency
evaluation of our current existing main products. </I>We intend to cope with the latest policies and the GPO requirements. We aim to make
efficient use of our existing human and material resources, and strive to create favorable conditions for product sales and international
development through gaining a favorable result in the consistency evaluation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Exploring the market for comprehensive
health products. </I>To advocate a healthy way of life, we intend to explore the market for comprehensive health products and help our
customers not only &lsquo;cure the disease&rsquo;, but also &lsquo;prevent potential diseases&rsquo;, eliminate sub-health, improve physical
fitness, reduce pain, and maintain good health management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Expanding Our Distribution Network
to Increase Market Penetration</I>. We intend to expand our reach beyond our current 16 offices in the PRC to drive additional growth
of our existing and future products. We currently contract with over 1,000 distributors in the PRC and plan to expand on these relationships
to target new markets. We will continue our conservative sales strategy of increased cooperation with customers with reliable accounts
receivable collection performance. In addition, we plan to continue to broaden our marketing efforts outside of major cities in the PRC
and to increase our market penetration in cities and rural areas where we already have a presence. Over the long term, we also intend
to expand our presence beyond the PRC to international markets by working with international pharmaceutical companies to cross-sell our
products.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Acquiring Complementary Products
Lines, Technologies, Distribution Networks and Companies</I>. We intend to selectively pursue strategic acquisition opportunities that
we believe will grow our customer base, expand our product lines and distribution network, enhance our manufacturing and technical expertise
or otherwise complement our business or further our strategic goals. Pursuing strategic acquisitions is a significant component of our
growth strategy. The Company has not identified any strategic acquisition opportunities as of the date of this report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have a product
portfolio of 22 products, including 19 pharmaceutical products that address a wide variety of diseases and medical indications, and the
remaining are comprehensive healthcare and protective products. All of our pharmaceutical products have demonstrated safety and efficacy
in clinical trials sufficient to obtain approval by the NMPA and are sold on a prescription basis. The following table summarizes the
approved indications for our marketed products and the year in which each of such products was first marketed to our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 54%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year of</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commercial</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indication</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Launch</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CerebroproteinHydroloysate Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1996</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gastrodin Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, including vertigo, neuralgia and headaches.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propylgallate for Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ozagrel Sodium for Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute thrombotic cerebral infarction and dyskinesia associated with cerebral infarction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alginic Sodium Diester Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bumetanide for Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue from acute drug poisoning.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2007</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Candesartan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypertension</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-infection and Respiratory Diseases</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roxithromycin Dispersible Tablets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharyngitis and tonsillitis caused by Streptococcus pyogenes; sinusitis, tympanitis, acute and chronic bronchitis caused by acute bacterial infection, Mycoplasma pneumonia and Chlamydia pneumoniae; urethritis and cervical infection caused by chlamydia trachomatis; skin soft tissue infection caused by sensitive bacteria.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1995</FONT></TD></TR>

<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cefaclor Dispersible Tablets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tympanitis, lower respiratory tract infection, urinary tract infections and skin/skin tissue infection.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2002</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cefalexin Capsules</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute tonsillitis caused by sensitive fungi, airway infections, such as pharyngitis, otitis media, nasal sinusitis and bronchitis; pneumonia, respiratory tract infection, urinary tract infections and skin soft tissue infections.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2002</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrographolide</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Detoxification, antibacterial and anti-inflammatory. For sore throat caused by upper respiratory tract infection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2003</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clarithromycin Granules and Capsules</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasopharynx infection, lower respiratory tract infection, skin tissue infection, acute tympanitis and mycoplasma pneumonia caused by clarithromycin susceptible organisms; urethritis and cervical infection caused by chlamydia trachomatis; and the treatment of legionella infection, mycobacterium avium complex (MAC) infection and helicobacter pylori infection.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2004</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naproxen Sodium and PseudophedrineHydrochlorida Sustained Release Tablet</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relieves cold, sinus and flu symptoms, blocked nose caused by anaphylaxis rhinitis, runny nose, fever, sore throat, symptoms of myalgia in the limbs and pain around the joints.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Digestive Diseases</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hepatocyte Growth-promoting Factor for Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious viral hepatitis symptoms caused by various viral hepatitis types (acute, subnormal temperature, chronic serious disease early or middle period of hepatitis).</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiopronin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute and chronic Hepatitis B, and for the relief of drug-induced liver injury.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound Ammonium Glycyrrhetate S for Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liver dysfunction caused by acute and chronic hepatitis; supplemental treatment to toxic/trauma hepatitis, liver cancer; also for the indication of food/drug poisoning, and drug allergy.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omeparzole</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gastroesophageal reflux disease, and other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009</FONT></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; width: 52%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Others</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vitamin B6 for Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vitamin supplement.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granisetron Hydrochloride Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comprehensive Healthcare and Protective Products</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noni Enzyme</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural, healthy and nutritionrich<BR>
a natural, healthy and nutrition-rich food supplement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanitizer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% alcohol wash-free sanitizer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Masks</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KN95 Particulate Respirator, Disposable Medical Mask, Particle Filtering Mask</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the aggregate amount our revenues attributed to our product portfolio by indication group for the years ended December 31, 2020
and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; padding-bottom: 0; font-weight: bold; text-align: center">Twelve Months Ended</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding-bottom: 0; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
    Change</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>%</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 0; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    Category</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
    millions)</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
    millions)</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
    millions)</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>Change</B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0; width: 52%; text-align: left">CNS Cerebral &amp; Cardio Vascular</TD><TD STYLE="padding-bottom: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 1%; text-align: left">$</TD><TD STYLE="padding-bottom: 0; width: 9%; text-align: right">2.03</TD><TD STYLE="padding-bottom: 0; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 1%; text-align: left">$</TD><TD STYLE="padding-bottom: 0; width: 9%; text-align: right">2.35</TD><TD STYLE="padding-bottom: 0; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; width: 9%; text-align: right">-0.33</TD><TD STYLE="padding-bottom: 0; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; width: 9%; text-align: right">-14</TD><TD STYLE="padding-bottom: 0; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0; text-align: left">Anti-Viral/ Infection &amp; Respiratory</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">$</TD><TD STYLE="padding-bottom: 0; text-align: right">5.13</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">$</TD><TD STYLE="padding-bottom: 0; text-align: right">6.33</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; text-align: right">-1.20</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; text-align: right">-19</TD><TD STYLE="padding-bottom: 0; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0; text-align: left">Digestive Diseases</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">$</TD><TD STYLE="padding-bottom: 0; text-align: right">0.40</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">$</TD><TD STYLE="padding-bottom: 0; text-align: right">0.46</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; text-align: right">-0.06</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; text-align: right">-14</TD><TD STYLE="padding-bottom: 0; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0">Other</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">$</TD><TD STYLE="padding-bottom: 0; text-align: right">1.58</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">$</TD><TD STYLE="padding-bottom: 0; text-align: right">1.86</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; text-align: right">-0.28</TD><TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0; text-align: right">-15</TD><TD STYLE="padding-bottom: 0; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the nature of the pharmaceutical
industry, we continually strive to change our product portfolio to respond to changes in market demand. Based on a foundation established
by a number of our widely-recognized prescription products, such as Cefaclor and Roxithromycin, we have launched and will continue to
launch a variety of pharmaceuticals. The core criteria for our selection of potential pipeline products are strong market demand, proven
efficacy, and safety. In an effort to gain an advantage in the marketplace, we often seek to improve the production process of the new
generic products we elect to manufacture or to improve the quality of a proposed product to increase its efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also adjust the delivery
systems and marketing for each of our products based on the product&rsquo;s target patient group. We believe that maintaining a variety
of delivery systems (e.g. tablets, capsules, injectables and dry powders) for certain of our products targeted at different groups enhances
our competitive position in the marketplace. As a result, our sales and marketing personnel work closely with management and our research
and development personnel to determine which of our products can successfully be marketed for more than one delivery system and which
generic drugs in the marketplace may be good candidates for us to manufacture and distribute using different delivery systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Product Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research &amp; development
and innovation represent the core competitive advantage for a company&rsquo;s sustainable growth. For pharmaceutical companies, products
with proprietary intellectual property are not only strategic resources for comprehensive strength, but also important tools to engage
in social responsibility. We have been focusing on the research and development of both first generic drugs and innovative drugs. Additionally,
we also have actively worked to meet unsatisfied medical needs by sticking to a market-oriented approach and continuously improving the
effectiveness and ease of use of our drugs, supported by a well-designed system for intellectual property management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC State Council issued
&ldquo;Opinions on Carrying out Consistency Evaluation on Quality and Efficacy of Generic Drugs&rdquo; on March 5, 2016, requiring all
manufacturers of generic chemical pipeline products to carry out Consistency Evaluations before they may obtain final registration approval.
Drugs failing to meet these requirements may not be re-registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, due to this newly
issued policy, as with all other Chinese generic pharmaceutical companies, the NMPA production approved standards and experimental requirements
for almost all of our pipeline products have undergone major adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company's recent research
and development work is mainly aimed at promoting the consistency evaluation of several major products already on the market, as well
as the continued exploration of comprehensive health product categories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Distribution and Customers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we have a well-established
sales network. As our current pharmaceutical product portfolio is comprised mainly of prescription drugs, our major sales targets are
hospitals. As of December 31, 2020, we also have&nbsp;16 sales offices covering all major provinces of China, and over 1,000 sales representatives
who assist in managing many of our relationships with hospitals, doctors and local drug distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the nature of our products
and current governmental regulations, all of our customers are located in the PRC. We have established long-standing relationships with
most of our key customers through our operating subsidiary, Helpson, which was formed in 1993.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Production Facilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We manufacture and package
our products at our manufacturing facility in the Haikou Free Trade Zone in Haikou, Hainan Province. Our old manufacturing facility, which
was built in 2002, is approximately 8,000 square meters; and our new building, approximately 20,000 square meters, was completed in 2013.
We have production lines with the 2011 version of GMP certificates for different forms of our products including: tablets, capsules, dry
power, liquid injectables, solid oral solution Cephalosporins (specifically designated).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our existing production
lines have met the GMP Standards which became effective as of March 1, 2011. On December 1, 2019 the newly revised Drug Administration
Law (the &ldquo;New Law&rdquo;) came into effect, which cancelled the GMP certification but impose the pilot inspection mechanism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Raw Materials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require a supply of a wide
variety of raw materials to manufacture our products. We employ purchasing staff with extensive knowledge of our products who work with
our product development, and formulations and quality control personnel to source raw materials for our products. Currently, we rely on
numerous suppliers in the PRC and overseas to deliver our required raw materials and believe we have at least three principal suppliers
for each of our most critical raw materials. Historically, we have not had difficulty obtaining raw materials from suppliers. For the
year ended December 31, 2020, our purchases of raw material purchases from our three top suppliers accounted for 20.7%, 17.7%, and 13.5%,
respectively. For the year ended December 31, 2019 suppliers accounted for 22.3%, 20.6% and 5.8%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we have established
a commercially competitive position in the highly-fragmented pharmaceutical industry in China through our core competitive advantages,
as described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We have a highly-efficient commercialization
process for new products, including significant experience with the NMPA registration process.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We have over 20 years of product-development
experience during which time we have implemented processes to efficiently introduce and market new and existing products to the Chinese
market.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We have a market-oriented product portfolio
and product lines.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Our product focus is on developing and
manufacturing medicines that help large patient groups, such as the infectious disease and cardio vascular disease patient groups. Our
diversified GMP-certified manufacturing facility includes various production lines targeting a variety of delivery mechanisms, such as
tablets, capsules, cephalosprine tablets, cephalosprine capsules, liquid-injectables and dry powder injectables, which enables us to effectively
manufacture a broad range of new drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We have product diversification to target specific
sub-markets.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We attempt to differentiate our products
from those of our competitors by changing, and, in many cases, improving certain physical aspects of our products to market to different
market segments. For example, to make our Cefaclor product more patient friendly to children and patients with swallowing problems, we
added an enteric coating to make our tablets easier to swallow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We have a national sales network and a highly-trained
marketing team.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Our experienced sales team has the industry
knowledge and know-how to synergistically combine our strong market insight with a successful commercialization platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We have developed high-quality relationships
with leading hospital and clinic administrators and physicians.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">While sales of our pharmaceutical products
to hospitals are made through our distributors, we believe our long-term relationships with leading hospitals and healthcare clinics throughout
China resulting from our long-term promotional efforts and periodic physician seminars improve the perception of our products in the marketplace
and help us identify and select high-volume drugs to develop into new generic products relatively early in the process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding such favorable
positioning, we are subject to intense competition. There are both local and overseas pharmaceutical enterprises that are engaged in the
manufacture and sale of potential substitute or similar pharmaceutical products in the PRC. These competitors may have more capital, better
research and development resources, better manufacturing and marketing capability, and more experience than we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our profitability may be adversely affected if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of our competitors increases;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors engage in increased price competition; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors develop new products or product substitutes having comparable medicinal applications or therapeutic effects that are more effective, less costly and/or have more perceived benefits than those produced by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, imported products
and China&rsquo;s admission as a member of the World Trade Organization (&ldquo;WTO&rdquo;) creates increased competition. The PRC became
a member of the WTO in December 2001. As a result, competition in the pharmaceutical industry in the PRC intensified generally in two
respects. First, with lower import tariffs, imported pharmaceutical products manufactured overseas may become increasingly competitive
in terms of pricing. Second, we believe that well-established foreign pharmaceutical manufacturers may set up production facilities in
the PRC and compete with domestic manufacturers directly. With the expected increased supply of competitively-priced pharmaceutical products
in the PRC, we may face increased competition from foreign pharmaceutical products, especially in terms of high-end pharmaceutical products,
including certain types of products manufactured by U.S. manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We regard our packaging designs,
trademarks, trade secrets, patent and similar intellectual property as parts of our core competence that are critical to our success.
We rely on patent, trademark and trade secret law, as well as confidentiality agreements with certain of our employees, distributors and
others to protect our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2008, we purchased
the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product from a third party
laboratory. In connection with that acquisition, we obtained the title of the patent. This patent expires in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2012, we acquired another
patent related to a medical formula for the treatment of cerebral/cardio-vascular diseases. This patent expires in 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, we
owned 18 registered trademarks, including marks for eight of the 19 pharmaceutical products we manufacture, including the tradenames Fukexing,
Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang, Shenkaineng, XERONINE, and Aronino, as well as marks for our AFGF logo, our
HPS logo, our two HELPSON logos and four other logos. The registration numbers of the 18 registered trademarks are as follows: No.1500459,
No.1511770, No.1535416, No.1537828, No.1535420, No.1272792, No.1272760, No.1330294, No.1327731, No.1330295, No.3993785, No. 4074317, No.4074321,
No. 4315247, No. 32445705, No. 32437940, No. 34711564, and No. 34711561.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Environmental Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We comply with the Environmental
Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory compliance, we actively ensure
the environmental sustainability of our operations. Penalties may be levied upon us if we fail to adhere to and maintain certain standards.
Such failure has not occurred in the past, and we do not anticipate that it will occur in the future, but no assurance can be given in
this regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Regulations Relating to
Pharmaceutical Industry</I>. The pharmaceutical industry in China is highly regulated. The primary regulatory authority is the NMPA, including
its provincial and local branches. As a developer and producer of medicinal products, we are subject to regulation and oversight by the
NMPA and its provincial and local branches. The Law of the PRC on the Administration of Pharmaceuticals provides the basic legal framework
for the administration of the production and sale of pharmaceuticals in China and covers the manufacturing, distribution, packaging, pricing
and advertising of pharmaceutical products. These regulations set forth detailed rules with respect to the administration of pharmaceuticals
in China. We are also subject to other PRC laws and regulations that are applicable to business operators, manufacturers and distributors
in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Registration and Approval
of Medicine</I>. Pursuant to the PRC Provisions for Drug Registration, a medicine must be registered and approved by the NMPA before it
can be manufactured and sold. The registration and approval process requires the manufacturer to submit to the NMPA a registration application
containing detailed information concerning the efficacy and quality of the medicine and the manufacturing process and the production facilities
the manufacturer expects to use. A series of policies on consistency evaluation and drug review process have been issued in recent years,
and potentially more reforms and adjustments are underway in order to promote the pharmaceutical industry in China in line with the international
standards. In this context, we believe that the uncertainties in the timetables for obtaining NMPA production approvals for products under
research are increasing. If a manufacturer chooses to manufacture a pre-clinical medicine, it is also required to conduct pre-clinical
trials, apply to the NMPA for permission to conduct clinical trials and go through the clinical trials. If a manufacturer chooses to manufacture
a post-clinical medicine, it only needs to go through the clinical trials. In both cases, a manufacturer needs to file clinical data with
the NMPA for approval for manufacturing after clinical trials are completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>New Medicine</I>. If a
new medicine is approved by the NMPA, the NMPA will issue a new medicine certificate to the manufacturer and impose a monitoring period
of one to five years. During the monitoring period, the NMPA will monitor the safety of the new medicine, and will neither accept new
medicine certificate applications for an identical medicine by another pharmaceutical company, nor approve the production or import of
an identical medicine by other pharmaceutical companies. As a result of these regulations, the holder of a new medicine certificate has
the exclusive right to manufacture it during the monitoring period. We currently have the new medicine certificates for our Pusenouke,
Cefaclor dispersible tablets and Roxithromycin dispersible tablets and Bumetanide for injection products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>National Production Standard
and Provisional Standard</I>. In connection with the NMPA&rsquo;s approval of a new medicine, the NMPA will normally direct the manufacturer
to produce the medicine according to a provisional national production standard, or a provisional standard. A provisional standard is
valid for two years, during which time the NMPA closely monitors the production process and quality consistency of the medicine to develop
a national final production standard for the medicine, or a final standard. Three months before the expiration of the two-year period,
the manufacturer is required to apply to the NMPA to convert the provisional standard to a final standard. Upon approval, the NMPA will
publish the final standard for production. The NMPA has no statutory timeline to complete its review and grant approval for the conversion.
In practice, the approval for conversion to a final standard is time-consuming and could take a number of years. However, during the NMPA&rsquo;s
review period, the manufacturer may continue to produce the medicine according to the provisional standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Transitional Period</I>.
Prior to the latter of (1) the expiration of a new medicine&rsquo;s monitoring period or (2) the date when the NMPA grants a final standard
for a new medicine after the expiration of the provisional standard, the NMPA will not accept applications for an identical medicine nor
will it approve the production of an identical medicine by other pharmaceutical companies. Accordingly, the manufacturer will continue
to have an exclusive production right for the new medicine during this transitional period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Continuing NMPA Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical manufacturers
in China are subject to continuing regulation by the NMPA. If the labeling or its manufacturing process of an approved medicine is significantly
modified, a new pre-market approval or pre-market approval supplement will be required by the NMPA. A pharmaceutical manufacturer is subject
to periodic inspection and safety monitoring by the NMPA to determine compliance with regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NMPA has a variety of
enforcement actions available to enforce its regulations and rules, including fines and injunctions, recall or seizure of products, the
imposition of operating restrictions, partial suspension or complete shutdown of production and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pharmaceutical Product Manufacturing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Permits and Licenses for
Pharmaceutical Manufacturers.</I> A pharmaceutical manufacturer must obtain a pharmaceutical manufacturing permit from the NMPA&rsquo;s
relevant provincial branch. This permit is valid for five years and is renewable for an additional five-year period upon its expiration.
Our current pharmaceutical manufacturing permit, issued by the NMPA, will expire on November 8, 2025. We are confident the permit could
be renewed before its expiration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Good Manufacturing Practice.</I>
A pharmaceutical manufacturer must meet the Good Manufacturing Practice standards, or GMP standards, for each of its production facilities
in China in respect of each form of pharmaceutical product it produces. GMP standards include staff qualifications, production premises
and facilities, equipment, raw materials, environmental hygiene, production management, quality control and customer complaint administration.
Prior to December 1, 2019, if a manufacturer meets the GMP standards, the NMPA will issue to the manufacturer a Good Manufacturing Practice
certificate, or a GMP certificate, with a five-year validity period. However, for a newly-established pharmaceutical manufacturer that
meets the GMP standards, the NMPA will issue a GMP certificate with only a one-year validity period. The Year 2011 GMP Standards became
effective on March 1, 2011, and pharmaceutical manufacturers (except for manufacturers of injectables, blood products or vaccines, which
had a three-year grace period) had a five-year grace period to upgrade existing facilities to comply with the revisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our existing production
lines have met the Year 2011 GMP Standards. On December 1, 2019, the newly revised Drug Administration Law (the &ldquo;New Law&rdquo;)
came into effect. One of the major amendments is the cancellation of GMP certification. The New Law eliminated the requirement that drug
administration authorities shall assess drug manufacture enterprises and drug trading enterprises, and issue assessment certificates.
Instead, it requires that drug manufacturing enterprises and drug trading enterprises establish and improve the quality management systems
of manufacture and trade of drugs, and ensure that the process of manufacturing and trading of drugs always meets all legal requirements.
This means a stricter form of supervision is implemented comparing to the prior GMP certificates system and our production lines are subject
pilot inspection under the New Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product Liability and Consumers Protection</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product liability claims may
arise if any of our pharmaceutical products have a harmful effect on a consumer, who may make a claim for damages or compensation as an
injured party. The General Principles of the Civil Law of the PRC, which became effective in January 1987, state that manufacturers and
sellers of defective products causing property damage or injury shall incur civil liabilities for such damage or injuries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Product Quality Law of
the PRC was enacted in 1993 and amended in 2000 to strengthen the quality control of products and protect consumers&rsquo; rights and
interests. Under this law, manufacturers and distributors who produce or sell defective products may be subject to confiscation of earnings
from such sales, revocation of business licenses and imposition of fines, and in severe circumstances, may be subject to criminal liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law of the PRC on the
Protection of the Rights and Interests of Consumers was promulgated on October 31, 1993 and became effective on January 1, 1994 to protect
consumers when they purchase or use goods or services. All business operators must comply with this law when they manufacture or sell
goods and/or provide services to customers. In extreme situations, pharmaceutical product manufacturers and distributors may be subject
to criminal liability if their goods or services lead to the death or injuries of customers or other third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Price Controls</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since October 2015, with the approval of the State
Council, 16 ministries (bureaus) including the Health and Family Planning Commission have established departmental coordination mechanisms
and organized the first batch of pilot national drug price negotiations. Thereafter, the dynamic adjustment of the national health insurance
catalogue began. In the past five years, China has gradually established a dynamic adjustment mechanism for basic medical insurance drugs
and optimized the structure of drugs in the catalogue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the health care negotiations,
the health insurance fund plays a &quot;strategic buyer&quot; role and uses &quot;quantity-for-price&quot; to create a significant drop
in drug costs. The adjustment of the health insurance catalogue focuses on improving the efficiency of the use of health insurance funds
and using limited resources to maximize the clinical benefits of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, the State Administration
of Health Insurance issued the Interim Measures for the Administration of Drug Use in Basic Medical Insurance, which further clarified
the establishment and improvement of the dynamic adjustment mechanism In principle, the catalogue will be adjusted once a year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the State also
organizes centralized procurement of medicines. With a large number of procurement, the State is able to obtain high-quality low-cost
drugs. The General Office of the State Council issued the Opinions of the General Office of the State Council on Promoting the Normal
Institutionalization of Centralized Procurement of Drugs on January 28, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, certain generic
drugs will be selected to enter the centralized procedure after a consistency evaluation, result in a significant price reduction in exchange
for sales volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regulations
relating to pharmaceutical industry in China, we are also subject to the regulations applicable to a foreign invested enterprise in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Foreign Currency Exchange.
</I>Pursuant to the Foreign Currency Administration Rules promulgated in 1996 and amended in 1997 and various regulations issued by the
State Administration of Foreign Exchange, or the SAFE, and other relevant PRC government authorities, Renminbi is freely convertible only
to the extent of current account items, such as trade-related receipts and payments, interests and dividends. Capital account items, such
as direct equity investments, loans and repatriation of investment, require the prior approval from the SAFE or its local counterpart
for conversion of Renminbi into a foreign currency, such as U.S. dollars, and remittance of the foreign currency outside the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments for transactions
that take place within the PRC must be made in Renminbi. Unless otherwise approved, PRC companies other than foreign investment enterprises
(FIEs) must convert foreign currency payments they receive from abroad into Renminbi. On the other hand, FIEs may retain foreign currency
in accounts with designated foreign exchange banks, subject to a cap set by the SAFE or its local counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividend Distribution.
</I>Under the PRC regulations governing dividend distributions by wholly foreign-owned enterprises and Sino-foreign equity joint ventures,
wholly foreign-owned enterprises and Sino-foreign equity joint ventures in the PRC may pay dividends only out of their accumulated profits,
if any, determined in accordance with PRC accounting standards and regulations. Additionally, these foreign-invested enterprises are required
to set aside certain amounts of their accumulated profits each year, if any, to fund certain reserve funds. These reserves are not distributable
as cash dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, we
had 248 employees, among which 237 employees were full-time employees and 11 employees were temporary employees. None of our employees
is represented by a labor union and, in general, we consider our relationship with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by applicable
Chinese law, we have entered into employment contracts with substantially all of our officers, managers and employees. We are working
towards entering into employment contracts with those employees who do not currently have employment contracts with us. The PRC enacted
a new Labor Contract Law, which became effective on January 1, 2008. We have updated our employment contracts and employee handbook and
are in compliance with such law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_002"></A><B>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The following are some material risks, any
of which could have an adverse effect on our business financial condition, operating results, or proepsects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
                                            Related to our Business and our Industry</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            our products do not attain market acceptance among the medical community, our operations
                                            and profitability would be adversely affected;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">If we fail to meet standards pursuant to the newly revised Drug Administration Law, certain production
lines will be suspended and our profitability would be adversely affected;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We may be subject from time to time to product recalls initiated by us or by the NMPA. Product recalls
could impose significant costs on us and adversely affect our ability to generate revenue;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">If we fail to develop new products with high profit margins and our high-profit-margin products are replaced
by competitors&rsquo; products, then our gross will be adversely affected;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Most of our products are off-patent branded generics that can be manufactured and sold by other pharmaceutical
manufacturers in the PRC which may increase the competition we face;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">If we are not able to maintain and enhance our brand recognition to maintain our competitive advantage,
our reputation, business and operating results may be harmed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Reimbursement may not be available for our products, which could diminish our sales;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The growth and success of our business depend on our ability to successfully market our principal products
to hospitals and their selection for medicine purchases;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Our future research and development projects may not be successful;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We cooperate with research institutions and universities in the PRC for the research and development of
certain new products and any failure of such research institutions to meet our timing and quality standards may pose impairment loss on
our financial results and our failure to continue such collaborative arrangement could adversely affect our ability to develop new pharmaceuticals
and our overall business prospects;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We may not be able to obtain regulatory approval for any of the new products and failure to obtain these
approvals could materially harm our business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">New product development in the pharmaceutical industry is time-consuming and costly and has a low rate
of successful commercialization;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We may not be able to successfully identify and acquire new products or businesses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We rely on distributors for all of our revenues and failure to maintain relationships or to otherwise
expand our distribution network would materially and adversely affect our business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We rely on a limited number of distributors for the majority of sales of our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Our operations may be affected if we could not pass the Consistency Evaluation requirement issued by the
State Council for any of our current existing products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD>We face risks related to health pandemics that could impact our sales and operating results;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Our operations may be affected if we could not obtain raw materials from our current key suppliers on
acceptable terms;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We may not be able to effectively manage our employees and distribution network, and our reputation, business,
prospects and brand may be materially and adversely affected by actions taken by our distributors and third party marketing firms;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We have limited insurance coverage and may incur losses resulting from product liability claims, business
interruptions or claims that could be covered by D&amp;O Insurance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Our future liquidity needs are uncertain and we may need to raise additional funds in the future;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The failure to manage growth effectively could have an adverse effect on our business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">If we are unable to attract and retain key personnel, it could adversely affect our ability to develop
and market our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">If infringement or counterfeiting of our intellectual property rights occurs, then our reputation and
business may be adversely affected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks Related to Doing Business in China</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Adverse changes in political and economic policies of the PRC government could have a material and adverse
effect on the overall economic growth of China, which could reduce the demand for our services and materially and adversely affect our
competitive position;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The PRC legal system has inherent uncertainties that could limit our legal protections;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">PRC economic reform policies could result in a total investment loss in our common stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">You may experience difficulties in bringing original actions in the PRC against our company or our management
based on U.S. or other foreign laws;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">As a Foreign Invested Company in China, Helpson&rsquo;s ownership structure may be impacted by the foreign
investment regulation and its measures in China;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Because we receive substantially all of our revenue in Renminbi, which currently is not a freely convertible
currency, we are subject to changes in the PRC&rsquo;s political and economic decisions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We cannot be certain that the Chinese regulatory authorities will not impose more stringent restrictions
on the convertibility of the Renminbi, especially for foreign exchange transactions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Failure to comply with PRC regulations regarding the registration requirements for employee equity incentive
plans may subject us to fines and other legal or administrative sanctions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The enforcement of new labor contract law and its implementation rules and increase in labor costs in
the PRC may adversely affect our business and our profitability;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Dividends payable by us to our foreign investors and gain on the sale of our shares may become subject
to taxes under PRC tax laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks Related to our Common Stock</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The market price for our common stock may be volatile;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">If we issue additional shares of our capital stock, our stockholders will experience dilution in their
respective percentage ownership in the company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">A large portion of our common stock is controlled by a small number of stockholders and as a result, these
stockholders are able to influence and ultimately control the outcome of stockholder votes on various matters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We are likely to remain subject to &ldquo;penny stock&rdquo; regulations and as a consequence there are
additional sales practice requirements and additional warnings issued by the SEC;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD>There is substantial doubt about our ability to continue as a going concern;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We do not anticipate paying cash dividends on our common stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Business and our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The commercial success of our products depends
upon the degree of their market acceptance among the medical community. If our products do not attain market acceptance among the medical
community, our operations and profitability would be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our products depends upon the degree of market acceptance they achieve within the medical community, particularly among physicians and
hospital administrators. Physicians may not prescribe or recommend our products to patients and procurement departments of hospitals may
not purchase our products if physicians or hospital pharmacists do not find our products attractive. The acceptance and use of our products
among the medical community will depend upon a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">perception of physicians, patients and others in the medical
community as to the safety and effectiveness of our products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the prevalence and severity of any side effects;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the pharmacological benefit of our products relative to competing
products and products under development;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the efficacy and potential advantages of our products relative
to competing products and products under development;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the relative convenience and ease of administration of our
products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the methods by which our pharmaceutical products may be delivered
to patients;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the effectiveness of our education, marketing and distribution
efforts and those of our distributors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">publicity concerning our products or competing products and
treatments; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the price of our products and competing products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to meet standards pursuant to
the newly revised Drug Administration Law, the production at certain of our production lines will be suspended and our operations and
profitability would be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our existing production
lines have met the GMP Standards which became effective as of March 1, 2011. On December 1, 2019 the newly revised Drug Administration
Law (the &ldquo;New Law&rdquo;) came into effect. One of the major amendments of the New Law is the cancellation of GMP certification.
The New Law eliminated the requirement that drug administration authorities shall assess drug manufacture enterprises and drug trading
enterprises, and issue assessment certificates. Instead, it requires that drug manufacturing enterprises and drug trading enterprises
establish and improve the quality management systems of manufacture and trade of drugs, and ensure that the process of manufacturing and
trading of drugs always meets all legal requirements. This means a stricter form of supervision is implemented comparing to the prior
GMP certificates system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While all of our existing
product lines are in full compliance with the GMP standards issued in 2011, in the event we fail to continually meet the requirements
of the GMP and receive the deficiency feedback from any pilot inspection under the New Law, the production on such production line(s)
could be suspended and our operations and profitability could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject from time to time to product
recalls initiated by us or by the NMPA. Product recalls could impose significant costs on us and adversely affect our ability to generate
revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our business, we must comply
with a variety of product safety and product testing regulations. In particular, our products are subject to, among other statutes and
regulations, those issued by the NMPA. If the NMPA issues any notices to cease the production, sale and use of any of our products, we
must comply with such requirements. As a result, we may incur significant costs in complying with cessation requirements, and our financial
results could be materially and adversely affected. Furthermore, concerns about potential liability or potential future changes in product
safety regulations may lead us to voluntarily recall or otherwise discontinue selling selected products, which could materially and adversely
affect our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2013, NMPA issued
a nationwide notice (the &ldquo;NMPA Notice&rdquo;) for the cessation of the production, sale and use of Buflomedil effective immediately.
The NMPA Notice was a result of the reevaluation done by the NMPA based on the indications from the recent Chinese and international research
materials, which found that the risks of side effects to the nervous system and the cardiovascular system from Buflomedil have surpassed
its clinical treatment benefits. The NMPA Notice was applicable to all the manufacturers and distributors in China who are in the business
of the production and sale of Buflomedil related products. As a result, we no longer produce Buflomedil after 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recalls may also harm our
reputation, increase our costs and reduce our net sales. Governments and regulatory agencies in the markets where we manufacture and sell
products may enact additional regulations relating to product safety and consumer protection in the future or take other actions that
may adversely impact our business. The NMPA has the authority to revoke drug approvals previously granted and remove previously approved
products from the market for various reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to develop new products with
high profit margins and our high-profit-margin products are replaced by competitors&rsquo; products, then our gross and net profits margins
will be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had gross profit margins
of 17.0% for the year ended December 31, 2020, compared to gross profit margins of 13.6% for the year ended December 31, 2019. The pharmaceutical
market in the PRC remains very competitive, and there may be pressure to reduce sale prices of products without a corresponding decrease
in the cost of sold products. To the extent that we fail to develop new products with high profit margins and our high-profit-margin products
are replaced by our competitors&rsquo; products, our gross profit margins and net profit margins will be adversely affected. In addition,
three of our products are included in the National Essential Drug List (the &ldquo;EDL&rdquo;), which are subject to strict governmental
price controls. Therefore, our gross profit margin and net profit margins could be adversely affected notwithstanding any increase in
our revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our products face substantial competition.
Other companies may discover, develop, acquire or commercialize products earlier or more successfully than we do.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in a highly competitive
environment. Our products compete with other products or treatments for diseases that treat similar medical conditions. Many of our products
may compete against products that have lower prices, superior performance, greater ease of administration or other advantages. We would
face enhanced competition if competitive products are added to the National Medical Insurance Program. Our inability to compete effectively
could reduce sales or margins, which could have a material adverse effect on our results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our competitors are
actively engaging in research and development in areas in which we have products or in which we are developing new product or new indications
for existing products. In the future, we expect that our products will compete with new drugs currently in development, drugs approved
for other indications that may be approved for the same indications as those of our products and drugs approved for other indications
that are used off-label. If alternatives to our products are dispensed or prescribed to patients, the volume of our competing products
sold may decline or we may be required to lower the prices of our competing products to remain competitive, either of which could negatively
impact our sales. In addition, an increasing number of foreign pharmaceutical companies have introduced their pharmaceutical products
into the Chinese market. Competitive products introduced by these companies can also negatively impact our sales and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Large Chinese state-owned
and privately owned pharmaceutical companies and foreign-invested or foreign pharmaceutical companies may have greater clinical, research,
regulatory, manufacturing, marketing, financial and human resources than we do. In addition, some of our competitors may have technical
or competitive advantages over us with respect to the development of technologies and processes. These resources may make it difficult
for us to compete with them to successfully discover, develop and market new products and for our current products to compete with new
products or new product indications that these competitors may bring to market. There may also be significant consolidation in the pharmaceutical
industry among our competitors. Alliances may develop among competitors, and these alliances may rapidly acquire significant market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, in order
to gain market share in China, competitors may significantly increase their advertising expenditures and promotional activities or even
engage in irrational or predatory pricing behavior. In addition, our competitors may engage in inappropriate competition or illegal acts,
such as bribery. Third parties may actively engage in activities designed to undermine our brand name and product quality or to influence
customer confidence in our products. Increased competition may result in price reductions, reduced margins and loss of market share, any
of which could materially adversely affect our profit margins. We may not be able to compete effectively against current and future competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Most of our products are off-patent branded
generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC which may increase the competition we face
and reduce our business profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of our products are off-patent
branded generic pharmaceuticals and are not protected by intellectual property rights. As a result, other pharmaceutical companies may
sell equivalent products at a lower cost, and this might result in a commensurate loss in sales of our branded generic products or require
us to lower our prices to compete. If other pharmaceutical companies sell pharmaceutical products that are similar to our unprotected
products, we may face additional competition and our business and profitability may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business depends in part on our well-known
Helpson brand name, and if we are not able to maintain and enhance our brand recognition to maintain our competitive advantage, our reputation,
business and operating results may be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that market awareness
of our Helpson brand has contributed significantly to the success of our business. We also believe that maintaining and enhancing the
Helpson brand is critical to maintaining our competitive advantage. Although our sales and marketing staff will continue to further promote
our brand to remain competitive, we may not be successful. If we are unable to further enhance our brand recognition and increase awareness
of our products, or if we are compelled to incur excessive marketing and promotion expenses in order to maintain our brand awareness,
our business and results of operations may be materially and adversely affected. Furthermore, our sales and results of operations could
be adversely affected if the Helpson brand or our reputation is impaired by recalls or negative publicity for one of our branded products,
or certain actions taken by our distributors, competitors, third-party marketing firms or relevant regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reimbursement may not be available for our
products, which could diminish our sales or affect our ability to sell our products profitably.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market acceptance and sales
of our products also depend on a large extent on the reimbursement policies of the PRC government. The Ministry of Labor and Social Security
of the PRC or provincial or local labor and social security authorities, together with other government authorities, review the inclusion
or removal of drugs from the national medical insurance catalog or provincial or local medical insurance catalogs for the National Medical
Insurance Program every other year, and catalogs under which a drug will be classified affects the amounts reimbursable to program participants
for their purchases of those medicines. These determinations are made based on a number of factors, including price and efficacy. Generally,
there are two catalogs, the National Insurance Catalogue (&ldquo;NIC&rdquo;) and the EDL on which a product can be included. The products
selected for the EDL generally are selected from the NIC. A consumer can be reimbursed for the full cost of a medicine on the EDL and
can be reimbursed for 80% to 90% of the cost of a medicine listed on the NIC. Our Cefalexin, Clarithromycin and Omeprazole products are
currently included in the EDL. If government authorities decide to remove these products from the medicine catalogs, such removal may
reduce the affordability of our products and change the public perception regarding our products, which, in turn, would adversely affect
the sales of these products and reduce our net revenue. Furthermore, if we are unable to obtain approval from the relevant government
authorities to include our new products in the national, provincial or local medicine catalogs, sales of our new products maybe materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The growth and success of our business depend
on our ability to successfully market our principal products to hospitals and their selection in tender processes used by hospitals for
medicine purchases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future growth and success
significantly depend on our ability to successfully market our principal products to hospitals as prescription medicines. Approximately
80% of the end-customers of our products are hospitals. Hospitals may make bulk purchases of a medicine included in the national and provincial
medicine catalogs only if that medicine is selected under a government-administered tender process. A hospital&rsquo;s interest in a particular
medicine is evidenced by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the inclusion of this medicine on the hospital&rsquo;s formulary,
which establishes the scope of medicines physicians at this hospital may prescribe to their patients, and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the willingness of physicians at a hospital to prescribe
this medicine to their patients.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe effective marketing
efforts are critical in ensuring that hospitals and physicians are interested in purchasing our products. If our marketing efforts are
not effective, hospital administrators may not want to include our products in their formularies or may remove them from their formularies,
or physicians may not be interested in prescribing our products to their patients. As a result, we may find it difficult to maintain the
existing level of sales of our products, and our revenues and profitability may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future research and development projects
may not be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The successful development
of pharmaceutical products can be influenced by many factors. Products that appear to be promising in their early phases of research and
development may fail to be commercially viable for various reasons, such as failing to obtain the necessary regulatory approvals. Additionally,
the research and development process for new products for which we may obtain an approval certificate is long. The process of conducting
basic research and various stages of tests and trials of a new product before obtaining an approval certificate and commercializing the
product may require ten years or longer. A few of our product candidates are in the early stages of pre-clinical study and clinical trials
and we must conduct a significant number of additional clinical trials before we can seek the regulatory approvals necessary to begin
commercial production and sales of these products. We cannot guarantee that our future research and development projects will be successful
or completed within their anticipated time frames or budgets, or that we will receive the necessary approvals from the relevant authorities
for the production of these products, or that these newly-developed products will achieve commercial success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may obtain
approval for a competitive product before the product we are developing is approved. If this occurs, we may be precluded from getting
approval until the competitor&rsquo;s monitoring period expires and realize little to no benefit from our research and development investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if such products can
be successfully commercialized, they may not achieve the level of market acceptance that we expect. Additionally, the pharmaceutical industry
is characterized by rapid changes in technology, constant enhancements of industry know-how and the frequent emergence of new products.
Future technological improvements and continual product developments in the pharmaceutical market may render our existing products obsolete
or affect their viability and competitiveness. Therefore, our future success will largely depend on our development capability, including
our ability to improve our existing products, diversify our product range and develop new and competitively-priced products that meet
the requirements of the changing market. Should we fail to respond to these frequent technological advances by failing to improve our
existing products, develop new products in a timely manner, or have these products reach a desirable level of market acceptance, our business
and profitability will be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cooperate with research institutions
and universities in the PRC for the research and development of certain new products and any failure of such research institutions to
meet our timing and quality standards may pose impairment loss on our financial results and our failure to continue such collaborative
arrangement or enter into such new arrangements could adversely affect our ability to develop new pharmaceuticals and our overall business
prospects</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
collaborating with third parties for the research and development of new products. We have maintained long-term cooperative relationships
with a number of research institutions and universities in the PRC. These research institutions and universities used to collaborate with
us in a number of research projects and certain of our products with approval certificates were developed by such research institutions.
Any failure of such research institutions to meet the required quality standards and timetables set forth in their research agreements
with us, or our inability to enter into additional research agreements with these research institutions on terms acceptable to us in the
future, may have an adverse effect on our ability to develop new medicines and on our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Company may resume
the development of these formulas in the future if sufficient funding and other favorable conditions arise, we cannot guarantee that we
will be able to enter into agreements with new parties on terms acceptable to us. Our inability to enter into such agreements or our failure
to maintain such arrangements could limit the number of new products that we develop and ultimately decrease our sources of future revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to obtain regulatory
approval for any of the new products and failure to obtain these approvals could materially harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All new medicines must be
approved by the NMPA before they can be marketed and sold in the PRC. The NMPA requires successful completion of clinical trials and demonstrated
manufacturing capability before it grants approval. It often takes a number of years before a medicine can be ultimately approved by the
NMPA. In addition, the NMPA and other regulatory authorities may apply new standards for safety, manufacturing, packaging, and distribution
of future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Complying with such standards
may be time-consuming and expensive and could result in delays in obtaining NMPA approval for our future product candidates, or possibly
preclude us from obtaining NMPA approval altogether. For example, due to the enhanced criteria introduced during the implementation process
of the trial of one of our products in the dried powder injectable and granule production lines in our old plant, the clinical trials
lasted longer than originally expected. Furthermore, our future products may not be effective or may prove to have undesirable or unintended
side effects, toxicities or other characteristics that may preclude us from obtaining regulatory approval and prevent or limit their commercial
use. The NMPA and other regulatory authorities may not approve the products that we develop and even if we do obtain regulatory approvals,
such regulatory approvals may be subject to limitations on the indicated uses for which we may market a product, which may limit the size
of the market for such product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>New product development in the pharmaceutical
industry is time-consuming and costly and has a low rate of successful commercialization</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our ability to enhance our existing products and to develop new products. The development process for pharmaceutical products is complex
and uncertain, as well as time-consuming and costly. Relatively few research and development programs produce a commercial product. A
product candidate that appears promising in the early phases of development may fail to reach the market for a number of reasons, such
as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure to demonstrate safety and efficacy in preclinical and clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure to obtain approvals for intended use from relevant regulatory bodies, such as the NMPA;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to manufacture and commercialize sufficient quantities of the product economically; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proprietary rights, such as patent rights, held by others to our product candidates and their refusal to sell or license such rights to us on reasonable terms, or at all.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in any part of the
development process or our inability to obtain regulatory approval of our products could adversely affect our operating results by restricting
or delaying our introduction of new products. Even if we successfully commercialize new products, these products may compete with our
mature products and may result in a reduction in the sales volume of our mature product or vice versa. Failure to develop, obtain necessary
regulatory clearances or approvals for or successfully commercialize or market potential new products or technologies could have a material
adverse effect on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to successfully identify
and acquire new products or businesses</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our own product
development efforts, our growth strategy also relies on our acquisitions of new product candidates, products or businesses from third
parties. Any future growth through acquisitions will be dependent upon the continued availability of suitable acquisition candidates at
favorable prices and favorable terms and conditions. Even if such opportunities present themselves, we may not be able to successfully
identify them. Moreover, other companies, many of which may have substantially greater financial, marketing and sales resources, are competing
with us for the right to acquire such product candidates, products or businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on distributors for all of our revenues
and failure to maintain relationships with our distributors or to otherwise expand our distribution network would materially and adversely
affect our business</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We sell our products exclusively
to pharmaceutical distributors in the PRC and rely on distributors for all of our revenues. We have business relationships with over 1,000
distributors in the PRC. For the year ended December 31, 2020, no customer accounted for more than 10.0% of sales, and three customers
accounted for 52.0%, 11.2%, and 10.2% of accounts receivable. In line with industry practices in the PRC, we enter into written sales
agreements with our distributors. However, such sales agreements are not in substance equivalent to a typical distribution agreement in
the United States. Each sales agreement is more in the form of a sales order and specifies one or several purchases of one or more products
without any continuing obligation to purchase any additional amount of products. In the event certain distributors choose not to continue
their relationship with us after completing their existing sales agreements, they can do so without breaching any contract or agreement,
our financial results could be adversely affected if we cannot find the substantially similar distributors in time under such circumstances.
In addition, some of our distributors may sell products that compete with our products. We compete for desired distributors with other
pharmaceutical manufacturers, many of which may have higher visibility, greater name recognition, financial resources, and broader product
selection than we do. Consequently, maintaining relationships with existing distributors and replacing distributors may be difficult and
time-consuming. Any disruption of our distribution network, including our failure to renew our existing distribution agreements with our
desired distributors, could negatively affect our ability to effectively sell our products and would materially and adversely affect our
business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on a limited number of distributors
for the majority of sales of our products</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on a limited number
of distributors for most of our net revenue. Our top five distributors in the aggregate accounted for 16% and 14% of our net revenues
in 2020 and 2019, respectively. We expect that a relatively small number of distributors will continue to account for a major portion
of our net revenue in the near future. Our dependence on a few distributors may expose us to the risk of substantial losses if a single
large distributor stops purchasing our products, purchases lower quantities of our products or goes out of business and we cannot find
substitute distributors on equivalent terms. If any of our large distributors reduces the quantity of the products they purchase from
us or stops purchasing from us, our net revenue would be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our operations may be affected if we could
not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generic drugs refer to drugs
with the same active ingredient, dosage form, delivery channel and therapeutic effects compared to the original drugs. The &ldquo;Consistency
Evaluation&rdquo; requires currently marketed generic products to prove their consistency in term of quality and therapeutic effect, and
substitutability during clinical trials with original drug. The Consistency Evaluation could enhance the development of pharmaceutical
industry, ensure drug safety and effectiveness, promote the upgrading and restructuring the pharmaceutical industry, and improve international
competitiveness. Both <I>Relevant Matters Related to the Implementation of the Opinions of the General Office of the State Council on
the Consistent Evaluation of the Quality and Efficacy of Generic Drugs</I> (No. 106 of 2016) issued on 26 May 2016, and <I>Announcement
of the General Administration on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs</I> (No. 100 of 2017) issued
on August 28, 2017 require that if a drug has more than 3 manufacturers passed the consistency evaluation, then the drug manufacturers
without consistency evaluation valid status will have no access to participate in the drug Centralized Procurement. NMPA issued an official
document on The Implementation of the Evaluation of the Quality and Efficacy of Chemical Injection Generics on May 14, 2020, requiring
consistent evaluation for generics of pharmaceutical injections that are already on the market. If we fail to complete the consistency
evaluations for our generic drugs per the government&rsquo;s requirements, our business and operation will be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face risks related to health pandemics that could impact our
sales and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be adversely
affected by the effects of a widespread outbreak of contagious disease, including the recent outbreak of respiratory illness caused by
a novel coronavirus first identified in Wuhan, Hubei Province, China. These could include disruptions or restrictions on our ability to
travel, to transport raw materials by our suppliers to us or to distribute our products to our customers. There were temporary closures
of our facilities during the period from February to March 2020 and returned to normal in the second quarter of 2020 due to the outbreak
of the Covid-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any disruption or delay of
our operations and those of our suppliers or customers may adversely impact our sales and operating results. We observed that almost all
Chinese enterprises, including us, have experienced various degrees of operation suspension, staff quarantine, and disruption of transportation
and logistics, and interrupted connection with upstream and downstream entities in 2020 due to the Covid-19 pandemic. In addition, a significant
outbreak of contagious diseases in the human population resulted in a widespread health crisis that could adversely affect the economies
and financial markets of China and many other countries, resulting in an economic downturn that could affect demand for our products and
significantly impact our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our operations may be affected if we could
not obtain raw materials from our current key suppliers on acceptable terms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We need a supply of a wide
variety of raw materials to manufacture our products. Currently, we rely on numerous suppliers in the PRC and overseas to deliver our
required raw materials. We have at least three principal suppliers for each of our most critical raw materials. For the year ended December
31, 2020, three suppliers accounted for 20.7%, 17.7%, and 13.5% of raw material purchases and the year ended December 31, 2019, purchases
from three suppliers accounted for 22.3%, 20.6%, and 5.8% our raw material purchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have not
had difficulty obtaining raw materials from suppliers. However, besides the impact that may be caused by the coronavirus outbreak discussed
above, we cannot predict the impact on our suppliers of the current economic environment and other developments in their respective businesses,
either. Insolvency, financial difficulties or other factors may result in our suppliers not being able to fulfill the terms of their agreements
with us. Furthermore, such factors may render suppliers unwilling to extend contracts that provide favorable terms to us or may force
them to seek to renegotiate existing contracts. Although we believe we have alternative sources of supply for the raw materials used in
our business, termination of our relationships with any of our key suppliers could have a material adverse effect on our business, financial
condition or results of operations in the unlikely event that we are unable to obtain adequate raw materials from other sources in a timely
manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to effectively manage
our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected by
actions taken by our distributors and third party marketing firms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited ability to
manage the activities of our distributors and third-party marketing firms that we contract to promote our products and brand name, which
are independent from us. Our distributors and third-party marketing firms could take one or more of the following actions, any of which
could have a material adverse effect on our business, prospects and brand:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell
our products outside their designated territory, possibly in violation of the exclusive distribution rights of other distributors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
to adequately promote our products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promote
competing products in lieu of our products; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">violate
the anti-corruption laws of China, the United States or other countries.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, although our
company policies prohibit our employees from making improper payments to hospitals or otherwise engaging in improper activities to influence
the procurement decisions of hospitals, we may not be able to effectively manage our employees, as the compensation of our sales and marketing
personnel is partially linked to their sales performance. As a result, we cannot assure you that our employees will not violate the anticorruption
laws of the PRC, the United States and other countries. Such violations could have a material adverse effect on our reputation, business,
prospects and brand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to adequately manage
our employees, distribution network or third-party marketing firms, or their non-compliance with employment, distribution or marketing
agreements could harm our corporate image among hospitals and end users of our products and disrupt our sales, resulting in a failure
to meet our sales goals. Furthermore, we could be liable for actions taken by our employees, distributors or third-party marketing firms,
including any violations of applicable law in connection with the marketing or sale of our products, including China&rsquo;s anticorruption
laws and the Foreign Corrupt Practices Act of the United States, or the FCPA. In particular, if our employees, distributors or third-party
marketing firms make any payments that are forbidden under the FCPA, we could be subject to civil and criminal penalties imposed by the
U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the PRC government
has increased its anti-corruption measures. In the pharmaceutical industry, corrupt practices include, among others, acceptance of kickbacks,
bribes or other illegal gains or benefits by hospitals and medical practitioners from pharmaceutical manufacturers and distributors in
connection with the prescription of certain pharmaceuticals. Our employees, affiliates, distributors or third-party marketing firms may
violate these laws or otherwise engage in illegal practices with respect to their sales or marking of our products or other activities
involving our products. If our employees, affiliates, distributors or third-party marketing firms violate these laws, we could be required
to pay damages or fines, which could materially and adversely affect our financial condition and results of operations. In addition, PRC
laws regarding the types of payments to promote or sell our products that are impermissible are not always clear. As a result, we, our
employees, affiliates, our distributors or third-party marketing firms could make certain payments in connection with the promotion or
sale of our products or other activities involving our products which at the time could be reasonably determined to be legal but are later
deemed impermissible by the PRC government. Furthermore, our brand and reputation, our sales activities or the price of our common stock
could be adversely affected if we become the target of any negative publicity as a result of actions taken by our employees, affiliates,
distributors or third-party marketing firms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited insurance coverage and may
incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nature of our business
exposes us to the risk of product liability claims that is inherent in the research and development, manufacturing and marketing of pharmaceutical
products. Using product candidates in clinical trials also exposes us to product liability claims. These risks are greater for our products
that receive regulatory approval for commercial sale. Even if a product is approved for commercial use by an appropriate governmental
agency, there can be no assurance that users will not claim effects other than those intended resulted from the use of our products. While
no material claim for personal injury resulting from allegedly defective products has been brought against us to date, a substantial claim
or a substantial number of claims, if successful, could have a material adverse impact on our business, financial condition and results
of operations. Such lawsuits may divert the attention of our management from our business strategies, may be costly to defend and may
negatively impact our reputation and our Helpson brand&rsquo;s reputation, and may harm the sales of our other branded products. In addition,
product liability insurance for pharmaceutical products is not available in the PRC. In the event of allegations that any of our products
are harmful, we may experience reduced consumer demand for our products or our products may be recalled from the market. We may also be
forced to defend lawsuits and, if unsuccessful, to pay a substantial amount in damages, legal fees, and other related expenses. In addition,
business interruption insurance available in the PRC offers limited coverage compared to that offered in many other countries. We do not
have any business interruption insurance. Any business disruption or natural disaster could result in substantial costs and diversion
of resources. Lastly, we currently do not have directors and officers insurance. In the event we or any of our directors or officers are
sued under any proceedings or actions that could be covered by a standard D&amp;O insurance, we may incur substantial costs and expenses
to defend such case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future liquidity needs are uncertain
and we may need to raise additional funds in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current operating
plans, we expect our existing resources to be sufficient to fund our existing operations for at least 12 months. However, we may need
to raise additional funds to expand our operations. In addition, we may need to raise additional funds if our expenditures exceed our
current expectations. This could occur for a number of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
decide to devote significant amount of financial resources to the development of products that we believe to have significant commercialization
potential;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we decide to acquire or license rights to additional product candidates or new technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
of our product candidates fail in clinical trials or pre-clinical studies or prove not to be as commercially promising as we expected,
and we are forced to develop or acquire additional product candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our product candidates require more extensive clinical or pre-clinical testing or clinical trials for these product candidates take
longer to complete than we currently expect; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
decide or are required to conduct more high-throughput screening than expected against current or additional disease targets to develop
additional product candidates.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to raise additional
funds in the future is subject to a variety of uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
future financial condition, results of operations and cash flows;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
market conditions for capital-raising activities by pharmaceutical companies; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic,
political and other conditions in China and elsewhere.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
our revenues will be sufficient to meet our operational needs and capital requirements. If we need to obtain external financing, we cannot
assure you that financing will be available in amounts or on terms acceptable to us, if at all. Our future liquidity needs and other business
reasons could require us to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity or equity-linked
securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased
debt service obligations and could result in operating and financing covenants that would restrict our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The failure to manage growth effectively
could have an adverse effect on our business, financial condition and results of our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rapid market growth of
our pharmaceutical products may require us to expand our employee base for managerial, operational, financial and other purposes. As of
December 31, 2020, we had 248 employees. Our future development will impose significant responsibilities upon the members of management
to identify, recruit, maintain, integrate and motivate new employees. Aside from the increased difficulties in the management of human
resources, we may also encounter working capital issues, as we need increased liquidity to finance the purchases of raw materials and
supplies, drug formulas for new products, investment in research and development, acquisition of new businesses and technologies, and
the hiring of additional employees. For effective growth management, we will be required to continue improving our operations, management,
and financial systems and control. Our failure to manage growth effectively may lead to operational and financial inefficiencies that
will have a negative effect on our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend upon key employees and consultants
in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability
to develop and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent upon
the principal members of our management team, especially Ms. Zhilin Li, our Chairman, President and Chief Executive Officer. The loss
of Ms. Li&rsquo;s services would adversely affect our ability to develop and market our products. We also depend in part on the continued
services of our key scientific personnel and our ability to identify, hire and retain additional personnel, including marketing and sales
staff. We face intense competition for qualified personnel, and the existence of noncompetition agreements between prospective employees
and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we attempt
to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater resources
and more experience than we have, making it difficult for us to compete successfully for key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our employees and
consultants were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors,
or at universities or other research institutions. Although there is currently no claim against us, we may be subject to claims that these
employees or consultants have, inadvertently or otherwise, used or disclosed trade secrets or other proprietary information of their former
employers. It may be necessary to for us to litigate and defend against these claims. Even if we successfully defend against these claims,
litigation could result in substantial costs and be a distraction to our management. If we fail to defend such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights or personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Power shortages, natural disasters, terrorist
acts or other calamities could disrupt our production and have a material adverse effect on our business, financial position and results
of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our products are produced
at our manufacturing facility in Hainan, China. A significant disruption at that facility, even on a short-term basis, could impair our
ability to timely produce and ship products, which could have a material adverse effect on our business, financial position and results
of operations. Our manufacturing operations are vulnerable to interruption and damage from natural and other types of disasters, including
earthquake, fire, floods, environmental accidents, power loss, communications failures and similar events. If any disaster were to occur,
our ability to operate our business at our facilities would be seriously impaired. For example, a once-in-forty-year 16 grade super typhoon
Rammasun hit Haikou on July 18, 2014, which caused us approximately $2.3 million (RMB14.2 million) in losses. Part of a warehouse was
flooded, some damage was caused to our new facility, and the water and electricity supply was suspended for several days, causing a brief
halt to our production activities and a delay in our obtaining GMP certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we do not maintain
any insurance other than property insurance for some of our buildings, vehicles and equipment. Accordingly, unexpected business interruptions
resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources. Our production
process requires a continuous supply of electricity. We have encountered power shortages historically due to restricted power supply to
industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity
supply network. Because the duration of those power shortages was brief, they had no material impact on our operations. Longer interruptions
of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss
of production in progress. Any major suspension or termination of electricity or other unexpected business interruptions could have a
material adverse impact on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot guarantee the protection of our
intellectual property rights, and if infringement or counterfeiting of our intellectual property rights occurs, then our reputation and
business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To protect the brand names
of our products, we have registered and applied for registration of certain of our trademarks in the PRC. Currently eight of the 19 pharmaceutical
products we manufacture are marketed under a brand registered as a trademark in China. We also purchased a pharmaceutical compound from
a third party that we are seeking to develop into a further product. To date, we have not experienced any infringements of our trademarks
for sales of pharmaceutical products or our exclusive patent license, and we are not aware of any infringement of our intellectual property
rights. However, there is no guarantee that there will not be any infringements of our brand name or other registered trademarks or counterfeiting
of our products in the future. There is no guarantee that there will not be any third-party infringement of our patents. Should any such
infringement or counterfeiting occur, our reputation and business may be adversely affected. We may also incur significant expenses and
substantial amounts of time and effort to protect our intellectual property rights in the future. Such diversion of our resources may
adversely affect our existing business and future expansion plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Litigation may be necessary
in the future to enforce our intellectual property rights or to determine the validity and scope of the intellectual property rights of
others. However, because the validity, enforceability and scope of protection of intellectual property rights in the PRC are uncertain
and still evolving, we may not be successful in prosecuting these cases. In addition, any litigation or proceeding or other efforts to
protect our intellectual property rights could result in substantial costs and diversion of our resources and could seriously harm our
business and operating results. Furthermore, the degree of future protection of our proprietary rights is uncertain and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. If we are unable to protect our trade names, trade secrets
and other propriety information from infringement, our business, financial condition and results of operations may be materially and adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Doing Business in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adverse changes in political and economic
policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could reduce the
demand for our services and materially and adversely affect our competitive position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conduct substantially all
of our business and have historically derived all of our revenues in China. Accordingly, our business, financial condition, results of
operations and prospects are affected significantly by economic, political and legal developments in China. The Chinese economy differs
from the economies of most developed countries in many respects, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
degree of government involvement;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
level of development;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
growth rate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
control of foreign exchange;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">access
to financing; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
allocation of resources.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Chinese economy
has experienced significant growth in the past 30 years, growth has been uneven, both geographically and among various sectors of the
economy. The Chinese economy has also experienced certain adverse effects due to the recent global financial crisis. The Chinese government
has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures benefit the
overall Chinese economy, but may also have a negative effect on us. For example, our operating results and financial condition may be
adversely affected by government control over capital investments or changes in tax regulations that are applicable to us, and by government
policies or guidance aimed at curtailing the perceived over-capacity of certain industry sectors, such as pharmaceutical companies. The
Chinese government has implemented certain measures, including interest rate increases, to control the pace of economic growth. These
measures may cause decreased economic activity in China, which could in turn reduce the demand for our products and materially and adversely
affect our operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&rsquo;s economy has
been transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has implemented
measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the
establishment of sound corporate governance in business enterprises, a substantial portion of the productive assets in China is still
owned by the Chinese government. The continued control of these assets and other aspects of the national economy by the Chinese government
could materially and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chinese government also
exercises significant control over China&rsquo;s economic growth through the allocation of resources, controlling payment of foreign currency-denominated
obligations, setting monetary policy and providing preferential treatment to particular industries or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any adverse change in the
economic conditions or government policies in China could have a material and adverse effect on overall economic growth and the level
of investments in health industries in China, which in turn could lead to a reduction in demand for our products and consequently have
a material and adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The PRC legal system has inherent uncertainties
that could limit the legal protections available to us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC legal system is a
civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal cases have little precedential
value. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing commercial matters.
The overall effect of legislation enacted over the past 20 years has significantly enhanced the protections afforded to foreign-invested
enterprises in China. However, these laws, regulations and legal requirements are relatively recent and are evolving rapidly, and their
interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available to foreign investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The practical effect of the
PRC legal system on our business operations in China can be viewed as two separate but intertwined considerations. First, as a matter
of substantive law, the Foreign Invested Enterprise laws provide significant protection from government interference. In addition, these
laws guarantee the full benefit of corporate articles and contracts to Foreign Invested Enterprise participants. These laws, however,
do impose standards concerning corporate formation and governance that are not qualitatively different from the corporation laws found
in the United States. Similarly, PRC accounting laws mandate accounting practices that may not be consistent with the U.S. generally accepted
accounting principles. PRC accounting laws require that an annual &ldquo;statutory audit&rdquo; be performed in accordance with PRC accounting
standards and that the account books of a foreign invested enterprise be maintained in accordance with PRC accounting laws. Article 14
of the PRC Wholly Foreign-Owned Enterprise Law requires a wholly foreign-owned enterprise to submit certain periodic fiscal reports and
statements to designated financial and tax authorities. If a foreign-invested enterprise refuses to keep account books in China, the financial
and tax authorities may impose a fine on it, and the industry and commerce administration authority may order it to suspend operations
or may revoke its business license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Second, while the enforcement
of substantive rights may be less clear than United States procedures, foreign-invested enterprises and foreign wholly-owned enterprises
are PRC registered companies that enjoy the same status as other PRC registered companies in business-to-business dispute resolutions.
The PRC legal infrastructure, however, is significantly different in operation from its United States counterpart, and may present a significant
impediment to the operation of a foreign invested enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRC economic reform policies or nationalization
could result in a total investment loss in our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since 1979, the PRC government
has been reforming its economic policies. Because many reforms are unprecedented or experimental, they are expected to be refined and
improved over time. Other political, economic and social factors, such as political changes, changes in the economic growth rates, unemployment
or inflation, or in the disparities in per capita wealth between regions within China, could lead to further readjustment of the reform
measures. This refinement and readjustment process may negatively affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the PRC government
owns the majority of productive assets in China, in the past several years the government has implemented economic reform measures that
emphasize decentralization and encourage private economic activity. Because these economic reform measures may be inconsistent or ineffectual,
there are no guarantees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be able to capitalize on economic reforms;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC government will continue its pursuit of economic reform policies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The economic policies, even if pursued, will be successful;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic policies will not be significantly altered from time to time; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business operations in China will not become subject to the risk of nationalization.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the last few years, China&rsquo;s
economy has registered high growth rates. Recently, there have been indications that rates of inflation have increased. In response, the
Chinese government recently has taken measures to curb this excessively expansive economy. These measures have included restrictions on
the availability of domestic credit, reducing the purchasing capability of some of its customers, and limited recentralization of the
approval process for purchases of certain foreign products. These austere measures alone may not succeed in slowing down the economy&rsquo;s
excessive expansion or control inflation, and may result in severe dislocations in the Chinese economy. The PRC government may adopt additional
measures to further combat inflation, including the establishment of freezes or restraints on certain projects or markets. These measures
may adversely affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no guarantee that
the reforms to China&rsquo;s economic system will continue or that we will not be adversely affected by changes in China&rsquo;s political,
economic, and social conditions and by changes in policies of the PRC government, such as changes in laws and regulations, measures which
may be introduced to control inflation, changes in the rate or method of taxation, imposition of additional restrictions on currency conversion
and remittance abroad, and reduction in tariff protection and other import restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments or bringing original actions in the PRC against our company or our management based
on U.S. or other foreign laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating subsidiary,
Helpson, is incorporated under the laws of the PRC and substantially all of our assets are located in the PRC. Additionally, substantially
all of our directors, executive officers and managers reside within the PRC, and substantially all assets of these persons are located
within the PRC. As a result, it may not be possible to effect service of process within the United States or elsewhere outside the PRC
upon certain of our directors, executive officers or managers, including with respect to matters arising under U.S. federal securities
laws or applicable state securities laws. Moreover, the PRC does not have treaties providing for the reciprocal recognition and enforcement
of judgments of courts with the United States, the United Kingdom, Japan or many other countries. As a result, recognition and enforcement
in the PRC of judgments of a court in the United States and any of the other jurisdictions mentioned above in relation to any matter may
be difficult or impossible. Furthermore, an original action may be brought in the PRC against us, our directors, executive officers or
managers only if the actions are not required to be arbitrated by PRC law under Helpson&rsquo;s articles of association, and only if the
facts alleged in the complaint give rise to a cause of action under PRC law. In connection with any such original action, a PRC court
may impose civil liability, including monetary damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a Foreign Invested Company in China,
Helpson&rsquo;s ownership structure may be impacted by the foreign investment regulation and its measures in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2019, Catalogue
of Encouraging Foreign Investment Industries (2019 Edition) (the &ldquo;2019 Encouraged Catalogue&rdquo;) and Special Administrative Measures
for Foreign Investment Access (Negative List) (2019 Edition) (the &ldquo;2019 Negative List&rdquo;) were jointly released by China&rsquo;s
Ministry of Commerce and the National Development and Reform Commission and became effective on July 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Decree
No. 723 of the State Council of the People's Republic of China issued on December 26, 2019, the Regulations on the Implementation of the
Foreign Investment Law of the People's Republic of China came into force on January 1, 2020. On June 23, 2020, the National Development
and Reform Commission of China and the Ministry of Commerce issued Decrees No. 32, the Special Measures for the Administration of Foreign
Investment Access (Negative List) (2020 Edition), and and No. 33, the Special Management Measures for Foreign Investment Access in Free
Trade Pilot Zones (Negative List) (2020 Edition), effective July 23, 2020. =. As per these policies, the national negative list of foreign
investment access was reduced from 40 to 33, and the negative list of foreign investment access in the FTZ was reduced from 37 to 30.
On December 28, 2020, the National Development and Reform Commission and the Ministry of Commerce publicly released the Directory of Industries
to Encourage Foreign Investment (Encouraged Catalogue) (2020 Edition). Industries listed in the 2020 Encouraged Catalogue are the encouraged
industries. On the other hand, industries listed in the 2020 Negative List are subject to special management measures. For example, establishment
of wholly foreign-owned enterprises is generally allowed in industries outside of the 2020 Negative List. Also, foreign investors are
not allowed to invest in industries that are expressly prohibited in the 2020 Negative List. The industries that are not expressly prohibited
in the Negative List are still subject to government approvals and certain special requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of pharmaceutical
manufacturing industry including the segments under which the Company conducts its business is not included in the 2020 Negative List.
Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and
private retailers located throughout the PRC. The Company believes Helpson&rsquo;s business is not subject to any ownership restrictions
prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement
with Helpson&rsquo;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005
and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day.
Helpson received its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. However, in the event
the 2020 Negative List is amended in the future to include any of the business Helpson is operating, our ownership structure could be
subject to change to the extent our structure is not given any &ldquo;grandfather&rdquo; protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we receive substantially all of
our revenue in Renminbi, which currently is not a freely convertible currency, and the PRC government controls the currency conversion
and the fluctuation of the Renminbi, we are subject to changes in the PRC&rsquo;s political and economic decisions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We receive substantially all
of our revenues in Renminbi, which currently is not a freely-convertible currency. The PRC government may, at its discretion, restrict
access in the future to foreign currencies for current account transactions. Any future restrictions on currency exchanges may limit our
ability to use revenue generated in Renminbi to fund any future business activities outside China or to make dividend or other payments
in U.S. dollars. Although the Chinese government introduced regulations in 1996 to allow greater convertibility of the Renminbi for current
account transactions, significant restrictions still remain, including primarily the restriction that foreign-invested enterprises may
only buy, sell or remit foreign currencies, after providing valid commercial documents, at those banks authorized to conduct foreign exchange
business. In addition, conversion of Renminbi for capital account items, including direct investment and loans, is subject to governmental
approval in China, and companies are required to open and maintain separate foreign exchange accounts for capital account items.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be certain that the Chinese regulatory
authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially with respect to foreign exchange
transactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fluctuation in the value of
the Renminbi may have a material and adverse effect on your investment. The change in value of the Renminbi against the U.S. dollar is
affected by, among other things, changes in PRC&rsquo;s political and economic conditions. From 1995 until July 2005, the People&rsquo;s
Bank of China intervened in the foreign exchange market to maintain an exchange rate of approximately Renminbi 8.3 per U.S. dollar. On
July 21, 2005, the PRC government changed this policy and began allowing modest appreciation of the Renminbi versus the U.S. dollar. Under
the new policy, the Renminbi was permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies.
This change in policy caused the Renminbi to appreciate approximately 21.5% against the U.S. dollar over the following three years. As
a consequence, the Renminbi has fluctuated sharply since July 2008 against other freely traded currencies, in tandem with the U.S. dollar.
It is difficult to predict how long the current situation may last and when and how it may change again. There is significant international
pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more
significant appreciation in the value of the Renminbi against the U.S. dollar. Significant revaluation of the Renminbi may have a material
adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from securities offering
into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount
we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments
for dividends on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative
effect on the U.S. dollar amount available to us. In August 2015, the PRC Government devalued its currency by approximately 3%, represented
the largest yuan depreciation for 20 years. Concerns remain that China&rsquo;s slowing economy, and in particular its exports, will need
a stimulus that can only come from further cuts in the exchange rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, appreciation
or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms
without giving effect to any underlying change in our business or results of operations. The income statements of our operations are translated
into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens against foreign currencies,
the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for
our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies, the translation of these foreign
currency denominated transactions results in increased revenue, operating expenses and net income for our international operations. We
are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars
in consolidation. If there is a change in foreign currency exchange rates, the conversion of the foreign subsidiaries&rsquo; financial
statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component of other comprehensive income.
Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered
into any hedging transactions. While we may enter into hedging transactions in the future, the availability and effectiveness of these
transactions may be limited, and we may not be able to successfully hedge our exposure at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to the environmental protection
laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing process
may produce by-products, such as effluent, gases and noise, which are harmful to the environment. We are subject to multiple laws governing
environmental protection, such as &ldquo;The Law on Environmental Protection in the PRC&rdquo; and &ldquo;The Law on Prevention of Effluent
Pollution in the PRC,&rdquo; as well as standards set by the relevant governmental bodies determining the classification of different
wastes and proper disposal. We have properly attained a waste disposal permit for our manufacturing facility, which details the types
and concentration of effluents and gases allowed for disposal. We are responsible for periodically renewing this waste disposal permit.
There is no assurance that we will obtain a renewal of the waste disposal permit when the current permit expires in November 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China is experiencing substantial
problems with environmental pollution. Accordingly, it is likely that the national, provincial and local governmental agencies will adopt
stricter pollution controls. There is no guarantee that future changes in environmental laws and regulations will not impose costly compliance
requirements on us or otherwise subject us to future liabilities. Our business&rsquo;s profitability may be adversely affected if additional
or modified environmental control regulations are imposed upon us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with PRC regulations regarding
the registration requirements for employee equity incentive plans may subject our PRC citizen employees or us to fines and other legal
or administrative sanctions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 28, 2007, the SAFE
promulgated the Application Procedure of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Holding
Plan or Share Option Plan of Overseas-Listed Company, which were superseded by Notice from SAFE regarding Issues related to Domestic Individual
Participating Offshore Public Company Equity Incentive Plan promulgated on February 15, 2012 (&ldquo;SAFE #7&rdquo;) or the Share Option
Rule. Under the Share Option Rule, PRC citizens who are granted stock options or other employee equity incentive awards by an overseas
publicly-listed company are required, through a PRC agent who may be a PRC subsidiary of such overseas publicly-listed company, to register
with the SAFE and complete certain other procedures related to the share options or other employee equity incentive plans. We and our
PRC citizen employees who are granted share options or other equity incentive awards under our 2010 Long-Term Incentive Plan, or PRC optionees,
are subject to the Share Option Rule. If we or our PRC optionees fail to comply with these regulations, we or our PRC optionees may be
subject to fines and legal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The enforcement of new labor contract law
and its implementation rules and increase in labor costs in the PRC may adversely affect our business and our profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China adopted the PRC Employment
Contract Law, or the new Labor Contract Law, effective January 1, 2008 and the implementation rules effective September 18, 2008. The
new Labor Contract Law and its implementation rules impose more stringent obligations on employers for, among others, entering into written
employment contracts, hiring temporary employees, dismissing employees, setting compensations for dismissal and protecting certain sick
or disabled employees from dismissal and setting forth detailed requirements relating to the contents of the employment contracts. The
implementation of the new Labor Contract Law may increase our operating expenses, in particular our personnel expenses, as the continued
success of our business depends significantly on our ability to attract and retain qualified personnel. In the event that we decide to
terminate some of our employees or otherwise change our employment or labor practices, the new Labor Contract Law may also limit our ability
to effect those changes in a manner that we believe to be cost-effective or desirable, which could adversely affect our business and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRC regulation of loans and direct investment
by offshore holding companies to PRC entities may delay or prevent us from using the proceeds we receive from securities offerings to
make loans or additional capital contributions to our PRC operating subsidiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In utilizing the proceeds
we receive from a securities offering, as an offshore holding company with a PRC subsidiary, we may make loans to our PRC subsidiary,
or we may make additional capital contributions to our PRC subsidiary. Any loans to our PRC subsidiary are subject to PRC regulations
and approvals. For example, loans to our PRC subsidiary Helpson, which is a foreign-invested enterprise, to finance its activities cannot
exceed statutory limits and must be registered with the State Administration of Foreign Exchange in China, or SAFE, or its local counterpart.
Loans by us to domestic PRC enterprises must be approved by relevant government authorities and must also be registered with the SAFE
or its local counterpart. Any capital contributions to our PRC subsidiary must be approved by the Ministry of Commerce in China or its
local counterpart. On August 29, 2008, SAFE promulgated Circular 142, a notice regulating the conversion by a foreign-invested company
of foreign currency into Renminbi by restricting how the converted Renminbi may be used. The notice requires that Renminbi converted from
the foreign currency denominated capital of a foreign-invested company may only be used for purposes within the business scope approved
by the applicable governmental authority and may not be used for equity investments within the PRC unless specifically provided for otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, SAFE strengthened
its oversight over the flow and use of Renminbi funds converted from the foreign currency-denominated capital of a foreign-invested company.
The use of such Renminbi may not be changed without approval from SAFE, and may not be used to repay Renminbi loans if the proceeds of
such loans have not yet been used. Violations of Circular 142 may result in severe penalties, including substantial fines as set forth
in the Foreign Exchange Administration Rules. We cannot assure you that we will be able to obtain these government registrations or approvals
on a timely basis, if at all, with respect to our future loans or capital contributions to our direct or indirect subsidiaries. If we
fail to receive such registrations or approvals, our ability to use the proceeds from a securities offering and to capitalize our PRC
operations may be negatively affected, which could materially and adversely affect our liquidity and ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The 2006 M&amp;A Rule establishes more complex
procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth
through acquisitions in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2006, six PRC
regulatory agencies, namely, the Ministry of Commerce, the State Assets Supervision and Administration Commission, or SASAC, the State
Administration for Taxation, the State Administration for Industry and Commerce, the CSRC and SAFE, jointly adopted the Regulations on
Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the 2006 M&amp;A Rule, which became effective on September 8,
2006. The 2006 M&amp;A Rule establishes additional procedures and requirements that could make some acquisitions of PRC companies by foreign
entities, such as our company, more time-consuming and complex, including requirements in some instances that the approval of the Ministry
of Commerce shall be required for transactions involving the shares of an offshore listed company being used as the acquisition consideration
by foreign entities, including Sino-foreign joint ventures. In the future, we may grow our business in part by acquiring complementary
businesses. Complying with the requirements of the 2006 M&amp;A Rule to complete such transactions could be time-consuming, and any required
approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability to complete such transactions,
which could affect our ability to expand our business or maintain our market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our China-sourced income is subject to PRC
withholding tax under the new Enterprise Income Tax Law of the PRC, and we may be subject to PRC enterprise income tax at the rate of
25% when more detailed rules or precedents are promulgated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Nevada holding company
with substantially all of our operations conducted through our operating subsidiary in China. Under the new PRC Enterprise Income Tax
Law, or the new EIT Law, and its implementation rules, both of which became effective on January 1, 2008, China-sourced income of foreign
enterprises, such as dividends paid by a PRC subsidiary to its overseas parent, is generally subject to a 10% withholding tax. The new
EIT Law, however, also provides that enterprises established outside China whose &ldquo;de facto management bodies&rdquo; are located
in China are considered &ldquo;tax resident enterprises&rdquo; and will generally be subject to the uniform 25% enterprise income tax
rate as to their global income. Under the implementation rules, &ldquo;de facto management bodies&rdquo; are defined as the bodies that
have, in substance, overall management control over such aspects as the production and business, personnel, accounts and properties of
an enterprise. In April 2009, the PRC tax authority promulgated the Notice on Determination of Tax Resident Enterprises of Chinese-controlled
Offshore Incorporated Enterprises in accordance with Their De Facto Management Bodies, or Circular 82, to clarify the criteria for determining
whether the &ldquo;de facto management bodies&rdquo; are located within the PRC for enterprises incorporated overseas with controlling
shareholders being PRC enterprises. As all of the our operational management is currently based in the PRC, and we expect them to continue
to be located in China, our company may be deemed a PRC resident enterprise and therefore subject to the PRC enterprise income tax at
a rate of 25% on our worldwide income, which excludes the dividends received directly from another PRC resident enterprise. Due to the
lack of clear guidance on the criteria pursuant to which the PRC tax authorities will determine our tax residency under the new EIT Law,
it remains unclear whether the PRC tax authorities will treat us as a PRC resident enterprise. Therefore, we are unable to confirm whether
we are subject to the tax applicable to resident enterprises or non-resident enterprises under the new EIT Law. Furthermore, in connection
with the new EIT Law and Tax Implementation Regulations, the Ministry of Finance and State Administration of Taxation jointly issued,
on April 30, 2009, the Notice on Issues Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular
59, which became effective retrospectively on January 1, 2008. It is uncertain to us as to how it will be implemented and the respective
tax base and the tax exposure cannot be determined reliably at this stage. In case we are required to pay the income tax on capital gains
by the relevant PRC tax authorities, our financial conditions and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dividends payable by us to our foreign investors
and gain on the sale of our shares may become subject to taxes under PRC tax laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the new EIT law and
its implementation rules, to the extent that we are considered a &ldquo;resident enterprise&rdquo; which is &ldquo;domiciled&rdquo; in
China, PRC income tax at the rate of 10% is applicable to dividends payable by us to investors that are &ldquo;non-resident enterprises&rdquo;
so long as such &ldquo;non-resident enterprise&rdquo; investors do not have an establishment or place of business in China or, despite
the existence of such establishment or place of business in China, the relevant income is not effectively connected with such establishment
or place of business in China. Similarly, any gain realized on the transfer of our shares by such investors is also subject to a 10% PRC
income tax if such gain is regarded as income derived from sources within China and we are considered a &ldquo;resident enterprise&rdquo;
which is domiciled in China for tax purposes. Additionally, there is a possibility that the relevant PRC tax authorities may take the
view that our purpose is that of a holding company, and the capital gain derived by our overseas stockholders would be deemed China-sourced
income, in which case such capital gain may be subject to PRC withholding tax at the rate of up to 10%. If we are required under the new
EIT law to withhold PRC income tax on our dividends payable to our foreign stockholders who are &ldquo;non-resident enterprises&rdquo;,
or if you are required to pay PRC income tax on the transfer of our shares under the circumstances mentioned above, the value of your
investment in our shares may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The strengthened scrutiny over acquisition
transactions by the PRC tax authorities may have a negative impact on our acquisition strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the new
EIT Law, the Ministry of Finance and State Administration of Taxation jointly issued, on April 30, 2009, the Notice on Issues Concerning
Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59. On December 10, 2009, the State Administration
of Taxation issued the Notice on Strengthening the Management on Enterprise Income Tax for Non-resident Enterprises Equity Transfer, or
Circular 698. Both Circular 59 and Circular 698 became effective retrospectively on January 1, 2008. By promulgating and implementing
these circulars, the PRC tax authorities have strengthened their scrutiny over the direct or indirect transfer of equity interest in a
PRC resident enterprise by a non-resident enterprise. For example, Circular 698 specifies that the PRC State Administration of Taxation
is entitled to redefine the nature of an equity transfer where offshore vehicles are interposed by abusing corporate structures for tax-avoidance
purposes and without reasonable commercial intention. We may pursue acquisitions as one of our growth strategies, and may conduct acquisitions
involving complex corporate structures. We cannot be assured that the PRC tax authorities will not, at their discretion, adjust the capital
gains thus causing us to incur additional acquisition costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market price for our common stock may
be volatile which could result in a complete loss of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price for our common
stock is highly volatile and subject to wide fluctuations in response to factors including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
or anticipated fluctuations in our quarterly operating results;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
of new products by us or our competitors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in financial estimates by securities analysts;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
in the pharmaceutical market;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in the economic performance or market valuations of other companies involved in pharmaceutical production;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic,
regulatory and political developments;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addition
or departure of key personnel, or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential litigation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the securities
markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may issue additional shares of our capital
stock to raise additional cash for working capital; if we issue additional shares of our capital stock, our stockholders will experience
dilution in their respective percentage ownership in the company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue additional shares
of our capital stock to raise additional cash for working capital. There is no anti-dilution protection or preemptive rights in connection
with our common stock. Thus, the percentage ownership of existing holders of common stock may be diluted in their respective percentage
ownership in us if we issue additional shares of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A large portion of our common stock is controlled
by a small number of stockholders and as a result, these stockholders are able to influence and ultimately control the outcome of stockholder
votes on various matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A large portion of our common
stock is held by a small number of stockholders. For instance, Zhilin Li, our Chief Executive Officer, holds 26.4%, and Heung Mei Tsui,
a member of our Board of Directors, holds 20.4% of our common stock, respectively, as of the date hereof. As a result, these two stockholders
are able to significantly influence the outcome of stockholder votes on various matters, including the election of directors and other
corporate transactions including business combinations. In addition, the occurrence of sales of a large number of shares of our common
stock, or the perception that these sales could occur, may affect our stock price and could impair our ability to obtain capital through
an offering of equity securities. Furthermore, the current ratios of ownership of our common stock reduce the public float and liquidity
of our common stock which can in turn affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are likely to remain subject to &ldquo;penny
stock&rdquo; regulations and as a consequence there are additional sales practice requirements and additional warnings issued by the SEC.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time we have net
tangible assets of $5,000,000 or less and the trading price of our common stock is below $5.00 per share, the open-market trading of our
common stock will be subject to the &ldquo;penny stock&rdquo; rules of the SEC. The &ldquo;penny stock&rdquo; rules impose additional
sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors
(generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For
transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and
have received the purchaser&rsquo;s written consent to the transaction before the purchase. Additionally, for any transaction involving
a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the SEC relating
to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative
and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited
market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability of broker-dealers to sell the common
stock and may affect a stockholder&rsquo;s ability to resell the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that our common stock will qualify for exemption from the &ldquo;penny stock&rdquo; rules. In any event, even if our common stock is exempt
from such rules, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person
from participating in a distribution of a &ldquo;penny stock&rdquo; if the SEC finds that such a restriction would be in the public interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders should be aware
that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse.
Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter
or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii)
boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive
and undisclosed bid-ask differential and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters
and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices
and with consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are responsible for the indemnification
of our officers and directors under certain circumstances which could result in substantial expenditures, which we may be unable to recoup.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide for the
indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney&rsquo;s fees and other
expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of
us. This indemnification policy could result in substantial expenditures, which we may be unable to recoup.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have identified material weaknesses in
our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial reports, affect
the ability of our auditors to attest to the effectiveness of our internal controls should we become an accelerated filer in the future,
and weaken investors&rsquo; confidence in our financial reporting.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As directed by Section 404
of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring public companies in their annual reports to include a report of management
on the reporting company&rsquo;s disclosure controls and procedures and internal controls over financial reporting. We became subject
to this requirement commencing with our fiscal year ended December 31, 2007 and a report of our management is included under Item 9A.
&ldquo;Controls and Procedures&rdquo; of this Annual Report on Form 10-K. As set forth in such report, our management has concluded that
our internal controls over financial reporting were not effective as of December 31, 2020, and there existed a material weakness in our
internal control over financial reporting as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we are taking appropriate
actions to remediate such material weakness; however, such measures may not be sufficient to address the material weaknesses identified
or ensure that our controls and procedures are effective. We may also discover other material weaknesses in the future. Any failure to
maintain or implement required new or improved controls, or any difficulties we encounter in the implementation of such controls, could
cause us to fail to meet our periodic reporting obligations or result in material misstatements in our financial statements and affect
the ability of our auditors to attest to the effectiveness of our internal control over financing reporting to the extent we become an
accelerated filer in the future. In addition, substantial costs and resources may be required to rectify any internal control deficiencies.
If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price
of our common stock could decline significantly, and our business and financial condition could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is substantial doubt about our ability to continue as a
going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditors have indicated
in their report on our financial statements for the years ended December 31, 2020 and 2019 that conditions exist that raise substantial
doubt about our ability to continue as a going concern as discussed in Note 1 to the financial statements. The Company incurred recurring
losses from operations, has net current liabilities and an accumulated deficit that raise substantial doubt about its ability to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To alleviate the conditions
that raise substantial doubt about the Company&rsquo;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&rsquo;s existing fixed
assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to generate
enough cash or obtain additional sufficient funding, we would need to scale back or eliminate our business plan, reduce our operating
costs and headcount, or discontinue or curtail our operations. Accordingly, our business, prospects, financial condition and results of
operations could be materially and adversely affected, and we may be unable to continue as a going concern. If we are unable to continue
as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited
consolidated financial statements, and it is likely that investors will lose all or a part of their investment. Our financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not anticipate paying cash dividends
on our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not rely on an
investment in our common stock to provide dividend income, as we have not paid any cash dividends on our common stock and do not plan
to pay any in the foreseeable future. Accordingly, investors must rely on sales of our common stock after price appreciation, which may
never occur, as the only way to realize any return on their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restrictions on the Use of Rule 144 by Shell
Companies or Former Shell Companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, the SEC has
taken the position that Rule 144 under the Securities Act, as amended, is not available for the resale of securities initially issued
by companies that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical compliance
with the requirements of Rule 144. The SEC has codified and expanded this position in its amendments effective on February 15, 2008 and
applies it to securities acquired both before and after that date by prohibiting the use of Rule 144 for resale of securities issued by
shell companies (other than business transaction related shell companies) or issuers that have been at any time previously a shell company.
The SEC has provided an important exception to this prohibition, however, if the following conditions are met: the issuer of the securities
that was formerly a shell company has ceased to be a shell company; the issuer of the securities is subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act; the issuer of the securities has filed all Exchange Act reports and material required to be
filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials),
other than Form 8-K reports; and at least one year has elapsed from the time that the issuer filed current Form 10 type information with
the SEC reflecting its status as an entity that is not a shell company. As such, due to the fact that we had been a shell company prior
to October 2005, holders of &ldquo;restricted securities&rdquo; within the meaning of Rule 144, when reselling their shares pursuant to
Rule 144, shall be subject to the conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_003"></A><B>ITEM 1B. UNRESOLVED STAFF COMMENTS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_004"></A><B>ITEM 2. PROPERTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no private land ownership
in the PRC. All land is either owned by the government of the PRC on behalf of all Chinese citizens or collectively owned by farmers.
However, land use rights may be allocated by the PRC State Land Administration Bureau or its authorized branches. Helpson was granted
land use rights by the PRC government for approximately 22,936 square meters of land located on Plot C09-2 in the Haikou Bonded Zone,
Hainan Province, PRC in 2003. These land use rights will expire on September 10, 2063.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson owns two production
facilities in Haikou, Hainan Province, PRC, one of which has a construction area of 663.94 square meters and is located on the 6th floor
of Standard Plant Building B, Jinpan Industrial Development Zone. The other factory, located on Plot C09-2 in the Haikou Bonded Zone,
has two buildings with production area of 20,282.42 square meters, certificate number HK477872, and 6,593.20 square meters, certificate
number HK122889.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Helpson rents
offices located on the second floor of the Jiahai Building owned by Hainan Zhongfu Foreign Export Personnel Service Center (the &ldquo;Center&rdquo;)
as its principal executive offices. Monthly rent at this facility is RMB 5,580 (approximately $843). The original term of the lease was
3 years, from December 1, 2010 to November 30, 2013. On December 31, 2011, this lease was superseded by a new lease, for a term of nine
years, for office spaces on the second floor and the entire third floor at a monthly rent of RMB 20,000 (approximately $2,941), with a
5% increase every two years from the fourth year until the end of the term (the &ldquo;2011 Lease&rdquo;). On May 2, 2018, the 2011 Lease
was superseded by a new lease, for a term of three years ending June 30, 2021, for office spaces on the second and third floor at a monthly
rent of RMB 16,000 (approximately $2319), and RMB 30,000 (approximately $4,349), respectively. The aggregate area of the office space
rented by Helpson is 1,686 square meters (16,812 square feet).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that all our properties
have been adequately maintained, are generally in good condition, and are suitable and adequate for our business. However, we anticipate
a possible need for expansion and additional space as our production increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mortgaged Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson entered into an eight-year
construction loan facility dated June 21, 2013. The total loan facility amount is RMB80,000,000 (approximately $12.3 million), which had
been fully utilized through May 7, 2014. We have incrementally repaid the principle of RMB66 million (approximately $10.1 million) of
the construction loan per the repayment schedule as of January 10, 2021. The proceeds of the loan were used for and are collateralized
by the construction of the Company&rsquo;s new production facility and the included production line equipment and machinery. Upon the
Company&rsquo;s receipt of the ownership certificate over the new factory, the mortgage was formally placed on the new facility in the
second quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loans referred to above
are set forth in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 19%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Amount of the Line of Credit</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lending Institution</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contract Period</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest Rate</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 19%; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Properties under</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mortgage</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB 80 million<BR>
(Approximately $13 million)</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank of China</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -10pt">July 11, 2013</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -10pt">to July 10, 2021</P></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interest rate is 5.39%, based upon 110% of the PRC government&rsquo;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helpson&rsquo;s new factory: 20,282.42 square meters&nbsp;&nbsp;(Certificate #: HK477872) and the production line equipment and machinery in the new factory</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_005"></A><B>ITEM 3. LEGAL PROCEEDINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. However, we are
currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_006"></A><B>ITEM 4. MINE SAFETY DISCLOSURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aa_007"></A><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_008"></A><B>ITEM 5. MARKET FOR REGISTRANT&rsquo;S COMMON
EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares began trading on
the NYSE American (Formerly known as NYSE Amex, NYSE MKT) on September 30, 2009 under the symbol &ldquo;CPHI&rdquo;. Prior to September
30, 2009, our shares traded on the OTC Bulletin Board under the symbol &ldquo;CPHI.OB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2021, there
were approximately 135 shareholders of record of our common stock and an indeterminate number of beneficial holders who held our common
stock in street name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is Equinity Trust Company, with offices located at 3200 Cherry Creek South Drive, Suite 430, Denver, Colorado 80209.
Their telephone number is (303) 282-4800 and fax number is (303) 282-5800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid or declared
any dividend on our common stock and we do not anticipate paying cash dividends in the foreseeable future. As a result of our holding
company structure, we would rely entirely on dividend payments from our subsidiaries, Onny Investment Ltd. and Hainan Helpson Medial &amp;
Biotechnology Co., Ltd., for our cash flow to pay dividends on our common stock. The PRC government imposes controls on the conversion
of Renminbi into foreign currencies and the remittance of currencies out of the PRC, which may also affect our ability to pay cash dividends
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Securities Authorized for Issuance under Equity
Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>securities to be</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>issued upon</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercise of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>outstanding</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>options, warrants</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and rights</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted-average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercise price of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>outstanding</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>options, warrants</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and rights</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of securities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>remaining available for</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>future issuance under</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>equity compensation</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>plans (excluding</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>securities reflected</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>in column (a))</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">(a)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">(b)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">(c)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Equity compensation plans not approved by security holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 1.5pt">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,825,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Totals</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,825,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_009"></A><B>ITEM 6. SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a &ldquo;smaller reporting
company&rdquo; as defined in Item 10 of Regulation S-K, we are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_010"></A><B>ITEM 7. MANAGEMENT&rsquo;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The statements contained in this report with respect
to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking
statements can be identified by the use of forward-looking terminology, such as &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;expect&rdquo;,
&ldquo;plan&rdquo;, &ldquo;intend&rdquo;, &ldquo;seek&rdquo;, &ldquo;estimate&rdquo;, &ldquo;project&rdquo;, &ldquo;could&rdquo;, &ldquo;may&rdquo;
or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes
to caution the readers that any such forward-looking statements contained in this report reflect our current beliefs with respect to future
events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory,
technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and
other factors, some of which are described in this report including in &ldquo;Risk Factors&rdquo; in Item 1A and some of which are discussed
in our other filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions.
No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing
our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">These risk factors should be considered in connection
with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral
forward-looking statements made in connection with this report that is attributable to our company or persons acting on our behalf are
expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely
on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&rsquo; expectations or estimates or
to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or
to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview &amp; Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We are principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;). All of our operations are conducted
in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical products are sold on a prescription
basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the
&ldquo;NMPA&rdquo;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The 2019 Statistical Communique on the Development
of China's Health and Health Industry shows that by the end of 2019, the total number of medical and health institutions in China reached
1,007,545, which represented an increase of 1,345 hospitals and 10,751 primary health care institutions compared with the condition in
the previous year. There are 8.807 million beds in the national health care institutions by the end of 2019. Public and private hospitals
accounted for 72.5% and 27.5%, respectively, for the beds in all hospitals. The number of beds in health facilities per 1,000 population
increased from 6.03 in 2018 to 6.30 in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Drug consistency evaluation is a drug quality
requirement in China's 12th Five-Year Plan for Drug Safety, that is, the State requires generic drugs to be consistent with the quality
and efficacy of their corresponding original drugs. China's consistency evaluation of generic drugs had continued to proceed in 2020.
The supporting policies from central and provincial governments have been constantly issued, including polices regarding consistency evaluation
for injectable products. We have always taken the task of facilitating the consistency evaluation as our top priority, and worked on them
actively. However, due to the continuous dynamic changes of the detailed policies, future market, expected investment, and return of investment
(&ldquo;ROI&rdquo;) for each drug&rsquo;s consistency evaluation, the whole industry, including us, has been making slow progress in terms
of the consistency evaluation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We have taken a more cautious and flexible attitude
towards the initiating and progressing of an existing product&rsquo;s consistency evaluation and to cope with the changing macro environment
of drug sales in China. On the one hand, since &quot;4 + 7&quot; (refers to 11 selected pilot cities, including 4 municipalities and 7
other cities) trial Centralized Procurement (&ldquo;CP&rdquo;) activities initiated in 2018, four rounds of CPCP activities had been carried
out by March 2021, which significantly reduced the price of the drugs that won the bids. On the other hand, the consistency evaluation
has been adopted as one of the qualification standards for participating in the CP activities. As a result, we need to balance at least
the two factors above before making decisions for any products . We have a product that passed biological equivalents experiments of consistency
evaluation in March 2021. We plan to submit relevant documentation and data to NMPA in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In addition, we continue to explore in the field
of comprehensive healthcare. Comprehensive healthcare is a general concept proposed according to the development of the times, social
needs and changes in disease spectrum. According to the Outline of &quot;Healthy China 2030&quot; issued by Chinese government in October
2016, the total size of China's health service industry will reach more than RMB 8 trillion by 2020 and RMB 16 trillion by 2030. This
industry focuses on people's daily life, aging and disease, pays attention to all kinds of risk factors and misunderstandings affecting
health, and calls for self-health management, and advocates the comprehensive care of the entire process of life. It covers all kinds
of health-related information, products and services, as well as actions taken by various organizations to meet the health needs. We launched
Noni enzyme, a natural, healthy and nutrition-rich food supplement at the end of 2018, and wash-free sanitizer and masks in 2020 to address
the market needs caused by COVID-19 in China. In addition, we also actively responded to the market demand for COVID-19 related products,
and completed a one-time COVID-19 tester export transaction in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We will continue to optimize our product structure
and actively respond to the current health needs of human beings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Trends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">As a generic drug company we are presented with
a huge domestic market. We believe that through further upgrades and consistency evaluations, we will be able to meet the European and
American production standards, which enables us to export our products to overseas markets. In the future, cost management and control
ability will gradually become an important factor in determining the competitiveness of generic pharmaceutical enterprises. Although price
control leads to a decline in the profitability, the winning enterprises in centralized procurement have a good chance of achieving price-for-volume
in order to increase its market share and support its continuous innovation transformation. As a separate note, consumption upgrading
in China drives the increase of optional consumption. With the improvement of residents' quality of life, the healthcare demand is also
changing. We believe that there are a large number of unmet demands in comprehensive healthcare and Internet healthcare sectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In addition, the Office of the State Council issued
&ldquo;<I>Pilot Plan for Marketing Authorization Holders</I>&rdquo; on May 24, 2016, allowing eligible drug research and development institutions
and scientific researchers to become Marketing Authorization Holders (&ldquo;MAH&rdquo;) by obtaining drug marketing authorization and
drug approval numbers from the State Council. This policy uses a management model of separating drug marketing authorization and drug
production licenses, thereby allowing an MAH to produce pharmaceuticals itself or to consign production to other pharmaceutical manufacturers.
This policy not only transitions our production practices to meet the European and United States standards by separating drug approval
and production qualifications, and therefore changing the existing model of bundling drug approval numbers to pharmaceutical manufacturers
in China, but also serves as a supplement to the ongoing consistency evaluations policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In general, demand for pharmaceutical products
is still experiencing steady growth in China. We believe the ongoing generic drug consistency evaluations and reform of China&rsquo;s
drug production registration and review policies will have major effects on the future development of our industry and may change its
business patterns. We will continue to actively adapt to the national policy guidance and further evaluate market conditions for our existing
products, and competition in the market in order to optimize our development strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations for the Fiscal Year ended
December 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Revenue was both $10.9 million for the years ended
December 31, 2020, and 2019, respectively. This was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter
of 2020 that offsets the sales decrease of our current existing products in 2020 as compared to 2019. Because of the market demand for
COVID-19 related products, we received an export order for diagnostic test, which we purchased from a third party. This one-time business
contributed approximately $1.7 million to our revenue in 2020. This is a milestone of our continuous efforts to explore various niche
markets, products and regions based on our experiences and abilities. Except for revenue from the export of COVID-19 tester, sales of
our existing products decreased in 2020 compared to the condition in 2019. The main reason for this decline was that the negative impact
on our sales caused by temporarily suspended operations, staff quarantine, and significantly declined outpatient volume at the primary
hospitals caused by COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Set forth below are our revenues by product category
in millions (USD) for the years ended December 31, 2020 and 2019, excluding the one-time revenue from the trading of COVID-19 testers
for the year ended December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended<BR> December 31,</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Net Change</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>%</B></TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Product Category</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in millions)</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in millions)</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">(in&nbsp;millions)</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">CNS Cerebral &amp; Cardio Vascular</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-0.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-14</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Anti-Viral/ Infection &amp; Respiratory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-19</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Digestive Diseases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-14</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.86</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-0.28</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-1.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-17</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The most significant revenue decrease in terms
of dollar amount was in our &ldquo;Anti-Viral/ Infection &amp; Respiratory&rdquo; product category, which generated $5.13 million in sales
revenue in 2020 compared to $6.33 million in 2019, a decrease of $1.20 million. This decrease was mainly due to a decrease in sales of
our Roxithromycin caused by the implementation of the centralized procurement policy by the Chinese government, a stricter drug pricing
control policy, as well as market fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Sales in &ldquo;CNS Cerebral &amp; Cardio Vascular&rdquo;
product category was $2.03 million in sales revenue in 2020, which represented a decrease of $0.33 million compared to $2.35 million in
2019. This decrease was mainly due to a decrease in sales of our Ozagrel caused by the implementation of centralized procurement policy,
a stricter drug centralized procurement policy, as well as market fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Sales revenue in the &ldquo;Other&rdquo;
category was $1.58 million in 2020, which represented a decrease of $0.28 million compared to $1.86 million in 2019. This decrease was
mainly due to the sales decrease of Vitamin B6 in this year, caused by the implementation of centralized procurement policy, a stricter
drug centralized procurement policy, as well as market fluctuation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our &ldquo;Digestive Diseases&rdquo; category
generated $0.40 million of sales in 2020, which represented a decrease of $0.06 million compared to $0.46 million in 2019. This decrease
was mainly due to a decrease in sales of our Omeprazole, caused by the implementation of centralized procurement policy, a stricter drug
centralized procurement policy, as well as market fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Year Ended December 31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><B>Product Category</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2019</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">CNS Cerebral &amp; Cardio Vascular</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Anti-Viral/ Infection &amp; Respiratory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Digestive Diseases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">For the year ended December 31, 2020, revenue
breakdown by product category experienced certain variances compared with that of the prior year. Sales in the &ldquo;Anti-Viral/Infection
&amp; Respiratory&rdquo; product category represented 56% and 58% of total sales in the years ended December 31, 2020 and 2019, respectively.
The &ldquo;CNS Cerebral &amp; Cardio Vascular&rdquo; category represented 22% of total revenue in 2020, compared to 21% in 2019. The &ldquo;Digestive
Diseases&rdquo; category represented 5% and 4% of total revenue in 2020 and 2019, respectively. The &ldquo;Other&rdquo; category represented
both 17% of revenues in 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cost of Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">For the year ended December 31, 2020, our cost
of revenue was $9.0 million, or 82.0% of total revenue, which represented a decrease of $0.4 million from $9.4 million, or 86.4% of total
revenue, in 2019. This was mainly due to the impact of the one-time COVID-19 tester transaction and the government relief for employees&rsquo;
social insurance in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Gross Profit and Gross Margin</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Gross profit for the year ended December 31, 2020
was $2.0 million, compared to $1.5 million in 2019. Our gross profit margin in 2020 was 18.0% compared to 13.6% in 2019. This increase
in our gross profit margin was mainly due to the impact of the one-time COVID-19 tester transaction and the government relief for employees&rsquo;
social insurance in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Selling Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our selling expenses for the year ended December
31, 2020 were $2.2 million, a decrease of $0.2 million compared to $2.4 million for the year ended December 31, 2019.&nbsp;Selling expenses
accounted for 20.4% of the total revenue in 2020 compared to 21.5% in 2019. &nbsp;This decrease was mainly due to emergency quarantine
measures which reduced business travel and marketing activities due to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our general and administrative expenses for the
year ended December 31, 2020 were $1.8 million, as compared to $2.3 million in 2019. General and administrative expenses accounted for
16.8% and 21.0% of our total revenues in 2020 and 2019, respectively. This decrease was mainly due to lower travel and office costs due
to the impact of COVID-19, as well as offsets for administrative costs from government subsidies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our research and development expenses for the
year ended December 31, 2020 was $0.38 million, compared to $0.23 million in 2019. Research and development expenses accounted for 3.5%
and 2.1% of our total revenues in 2020 and 2019, respectively. These expenditures were mainly spent on the consistency evaluation of our
existing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impairment Loss </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">There was no impairment loss for the year ended
December 31, 2020. However, we recognized $17.02 million impairment loss for the year ended December 31, 2019, among which, there was
an impairment loss for the advances made to laboratories for the year December 31, 2019 in the amount of $17,015,117. As a pharmaceutical
company, we have been focusing on the development and maintenance of our intangible assets, mainly in the form of medical formulas. The
consistency evaluations discussed under the &ldquo;Business Overview &amp; Recent Developments&rdquo; section hereof is expected to have
a significant impact on all generic products not only in our pipeline, but also throughout the existing Chinese market. After evaluating
the detailed rules under this policy, in addition to the potential ROI and our recent cash flow position, our management made certain
assessments regarding the impairment of our intangible assets, and identified four formulas that would likely to be unable to generate
positive cash flow in the foreseeable future and therefore recognized impairment loss on them accordingly as of December 31, 2019. The
management determined to impair all advances at December 31, 2019, but may resume the development of these formulas in the future if sufficient
funding and other favorable conditions arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Bad Debt Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our bad debt expenses for the year ended December
31, 2020 was $115,186, as compared to $3,153 in 2019. This increase was mainly due to the write-off of accounts receivable from some customers
who ceased operations due to the COVID-19 outbreak in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In general, our normal customer credit or payment
terms are 90 days. This has not changed in recent years. Due to the peculiar environment affecting the Chinese pharmaceutical market,
deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are common.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The amount of net accounts receivable that were
past due (or the amount of accounts receivable that were more than 180 days old) was $0.06 million and $0.15 million as of December 31,
2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The following table illustrates our accounts receivable
aging distribution in terms of the percentage of the total accounts receivable as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><B>December 31,</B></TD><TD STYLE="white-space: nowrap; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><B>December 31,</B></TD><TD STYLE="white-space: nowrap; text-align: center"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><B>2019</B></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">1 - 180 Days</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.38</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.14</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">180 - 360 Days</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.69</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">360 - 720 Days</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.59</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&gt; 720 Days</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">96.98</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">95.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bad debt allowance estimate practice is that
we consider accounts receivable balances aged within 180 days current, except for any individual uncollectible account assessed by management.
We account for the following respective percentage as bad debt allowance based on age of the accounts receivables: 10% of accounts receivable
that are between 180 days and 365 days old, 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts
receivable that are greater than 720 days old.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize bad debt expenses per actual write-offs
as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that
of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is
lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances
were $18.2 million and $17.6 million as of December 31, 2020 and December 31, 2019, respectively. The changes in the allowances for doubtful
accounts during the years ended December 31, 2020 and 2019 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center"><B>For the Fiscal Years Ended</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December 31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2019</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Balance, Beginning of Period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,575,100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,815,017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Bad debt expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts receivable written off</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(687,715</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,147,922</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(243,070</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Balance, End of Period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,150,493</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,575,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Loss from Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating loss for the year ended December
31, 2020 was $2.6 million, compared to an operating loss of $20.4 million in 2019. The decrease in loss from operations was mainly a result
of the decrease in impairment of long term assets as discussed under the heading &ldquo;<B><I>Impairment Loss</I></B>&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net interest expense was both $0.29 million for
the year ended December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Loss for year ended December 31, 2020 was
$2.9 million, compared to net loss of $20.7 million for the year ended December 31, 2019. The decrease in net loss was mainly a result
of the decrease in impairment of long term assets as discussed under the heading &ldquo;<B><I>Impairment Loss</I></B>&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2020, loss per
basic and diluted common share was $0.07, compared to loss per basic and diluted share of $0.48 for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of basic and diluted weighted-average outstanding shares used to calculate loss per share was </FONT>43,623,273 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
2020, as compared to 43,579,557 for 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal source of liquidity is cash generated
from operations and bank lines of credit.&nbsp;In addition to the aggregated advance of $724,963 from our CEO in 2019, we received some
temporary advances from and made several repayments to her in 2020. As of December 31, 2020, the aggregated advance from our CEO was
$740,316 for use in operations. Our cash and cash equivalents were $1.0 million, representing 4.5% of our total assets, as of December
31, 2020, as compared to $1.1 million, representing 4.8% of our total assets as of December 31, 2019. All of the $1.0 million of cash
and cash equivalents as of December 31, 2020 are considered to be reinvested indefinitely in the Company&rsquo;s Chinese subsidiary,
Helpson and is not expected to be available for payment of dividends or for other payments to its parent company or to its shareholders.
In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately
$1.4 million), of which RMB 8,000,000 (approximately $1.2 million) have been advanced at December 31, 2020. The loan bears interest at
a rate of 4.25% per annum. Advances on the line of credit shall be repaid in installments semi-annually for two years from the date of
the advance; the first repayment of RMB 500,000 (approximately $0.07 million) was made on October 20, 2020, and the second repayment
of RMB 300,000 (approximately $0.06 million) was made in January 2021. &nbsp;The Company has an additional RMB 2,000,000 (approximately
$0.3 million) available under the line, subject to a risk review and approval by the third party guarantee company. On June 30, 2020
the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.3 million),
all of which have been advanced. The loan bears interest at a rate of 4.05% per annum. In addition, we entered into an eight-year construction
loan facility on September 21, 2013. The total construction loan facility amount was RMB 80 million (approximately $13 million), which
had been fully utilized through May 7, 2014. As of December 31, 2020, the construction loan installments to be repaid within the next
12 months are approximately $2.3 million. On July 10, 2020, we repaid such principal and accumulatively repaid the principal of RMB 65
million (approximately $9.2 million) of the construction loans per the payback schedule. The total balance of the construction loan facility
is RMB 15 million ($2.3 million) as of December 31, 2020, which is all due within 12 months, and a repayment of RMB 1 million (approximately
$0.15 million) was made in January 2021. The Company also obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from
China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $344,098), and the remaining of RMB 856,660
(approximately $125,793) in October under this line. The loan bears interest at a rate of 4.50% per annum. The line of credit is due
in one year on the anniversary date of the advance. These factors raised substantial doubts about the Company&rsquo;s ability to continue
as a going concern. Cash flow generated from operating activities and lines of credit were used to fund our daily operating expenses
as well as the repayment of our loan facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net accounts receivable was $0.5 million and
$0.6 million as of December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total inventory was $3.7 million and $3.6 million
as of December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our current operating plan, management
believes that cash provided by operations, in addition to the newly obtained lines of credit in April, June, and September 2020 will be
sufficient to meet our working capital needs and our anticipated capital expenditures for the next twelve months, there can be no assurance
that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as
a going concern. We may seek debt or equity financing as necessary when we believe the market conditions are the most advantageous to
us and/or reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives.&nbsp;&nbsp;Although
our Chairperson and Chief Executive Officer had advanced funds for working capital during 2020 and 2019, there can be no assurances that
this will be the case in the future. There can be no assurance that any additional financing will be available on acceptable terms, if
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used by operating activities was $0.04
million in the year ended December 31, 2020, compared to net cash flow of $0.61 million provided by operating activities in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, our net accounts receivable
was $0.5 million, a decrease of $0.1 million from $0.6 million as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of December 31, 2020, total inventory was $3.7
million, stayed close to $3.6 million as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, net cash
used in investing activities was $0.87 million, compared to $0.13 million for the year ended December 31, 2019. The increase was mainly
due to the purchase of mask production lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flow generated from financing activities
was $0.62 million in the year ended December 31, 2020; compared to $1.7 million cash used in the year ended December 31, 2019. This change
was mainly because of a few credit lines we entered in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to relevant PRC laws, companies registered
in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income,
as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account
balances reach fifty percent (50%) of the companies&rsquo; registered capital prior to their remittance of funds out of the PRC.&nbsp;&nbsp;Allocations
to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans,
advances or cash dividends.&nbsp;For the years ending December 31, 2020 and 2019, Helpson&rsquo;s net assets totaled $5,777,000 and $7,189,000,
respectively.&nbsp;&nbsp;Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson&rsquo;s net assets
that was designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends,
was 50% of Helpson&rsquo;s registered capital, which is $8,145,000 for each of the fiscal years ended December 31, 2020 and 2019.&nbsp;Since
the amount that Helpson must set aside for the statutory surplus fund only accounts for 141% and 113%, respectively, of its total net
assets, this reserve does not have a major impact on our liquidity.&nbsp;&nbsp;There were no allocations to the statutory surplus reserve
accounts during the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese government also imposes controls on
the conversion of RMB into foreign currencies and the remittance of currencies out of China.&nbsp;Our businesses and assets are primarily
denominated in RMB.&nbsp;All foreign exchange transactions take place either through the People&rsquo;s Bank of China or other banks authorized
to buy and sell foreign currencies at the exchange rates quoted by the People&rsquo;s Bank of China.&nbsp;Approval of foreign currency
payments by the People&rsquo;s Bank of China or other regulatory institutions requires the submission of a payment application form together
with certain invoices and executed contracts.&nbsp;The currency exchange control procedures imposed by Chinese government authorities
may restrict Helpson, our Chinese subsidiary, from transferring its net assets to our parent company through loans, advances or cash dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we did not have any off-balance
sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management's discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with
United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting
policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained
in Note 1 to our consolidated financial statements, &ldquo;Organization and Significant Accounting Policies&rdquo;, is incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_011"></A><B>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_012"></A><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated balance sheets,
as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, stockholders&rsquo; equity
and cash flows for each of the two years in the period ended December 31, 2020 and 2019, together with the related notes and the report
of our independent registered public accounting firms, are set forth on the &ldquo;F&rdquo; pages of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_013"></A><B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_014"></A><B>ITEM 9A. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain disclosure controls
and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information that would be required
to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period specified in the SEC&rsquo;s
rules and forms, and that such information is accumulated and communicated to our management, including to our Chief Executive Officer
and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Rule 13a-15
under the Exchange Act, our management, including our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness
of the design and operation of our disclosure controls and procedures as of December 31, 2020. Based on that evaluation, our Chief Executive
Officer and interim Chief Financial Officer concluded that as of December 31, 2020, our disclosure controls and procedures were not effective
to satisfy the objectives for which they are intended due to the material weakness in our internal control over financial reporting discussed
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s Report on Internal Control
over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is
defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&rsquo;s
principal executive and principal financial officers, or persons performing similar functions, and effected by a company&rsquo;s board
of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes
those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of a company; (ii) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles and that receipts and expenditures
of a company are being made only in accordance with authorizations of management and directors of a company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company&rsquo;s assets that could
have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any system of internal control,
no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and
misstatements due to error or fraud may occur and not be detected in a timely manner. Also, because of changes in conditions, internal
control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance
with respect to financial statement preparation. In addition, the design of any system of controls is based in part on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under
all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree
of compliance with policies or procedures. Therefore, any current evaluation of controls cannot and should not be projected to future
periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assessed our internal
control over financial reporting as of the year ended December 31, 2020. In making this assessment, management used the criteria set forth
in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the report entitled &ldquo;Internal Control-Integrated
Framework.&rdquo; The 2013 COSO framework summarizes each of the components of a company&rsquo;s internal control system, including (i)
the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication, and (v) monitoring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on management&rsquo;s
assessment using the COSO criteria, management has concluded that our internal control over financial reporting was not effective as of
December 31, 2020, to allow our management, employees and consultants, in the normal course of performing their assigned functions, to
prevent or detect misstatements on a timely and reasonable basis and to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting
principles (&ldquo;U.S. GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A material weakness is a control
deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the
annual or interim financial statements will not be prevented or detected. Our Chief Executive Officer and interim Chief Financial Officer
has determined there existed a material weakness in our internal control over financial reporting as of December 31, 2020, with respect
to our lack of accounting financial reporting personnel knowledgeable in US GAAP. As of the date of this report, we are undertaking steps
to address the aforementioned material weaknesses by obtaining education and training for our personnel regarding the proper accounting
under U.S. GAAP and reviewing the processes to correct the identified weaknesses. Notwithstanding these material weaknesses, management
has concluded that our consolidated financial statements included in this annual report are fairly stated in all material respects in
accordance with U.S. GAAP for each period presented herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we are a smaller reporting
company, this Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Internal Controls over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules
13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_015"></A><B>ITEM 9B. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aa_016"></A><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_017"></A><B>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Listed below are the names
and ages of all our directors and executive officers at March 22, 2021, along with their positions, offices and term:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, Chief Executive Officer and interim Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heung Mei Tsui</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene Michael Bennett</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yingwen Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baowen Dong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our independent directors
hold offices until our next annual meeting of the stockholders, at which a successor will be duly elected and qualified or until his or
her earlier resignation, removal from office, death or incapacity. Non-independent directors will hold office for a term of three (3)
years or when their respective successors shall have been elected and shall qualify, or upon their prior death, resignation or removal.
Directors may be re-elected for successive terms. Officers serve at the discretion of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth biographical
information regarding the above directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Zhilin Li</I></B> is
the Chairman, President, Chief Executive Officer and interim Chief Financial Officer of our company. She has served as a director since
2006 and as the President and Chief Executive Officer since 2005. She was a founder of Helpson, and served as Chairman and Chief Executive
Officer of Helpson from 1993 to 2005. Ms. Li was formerly the president of Haikou Bio-Engineering Institute as well as the vice president
of Sichuan Institute of Biology. She graduated from Sichuan University with a degree in biology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Heung Mei Tsui</I>&nbsp;</B>has
served as a director of the Company since April 28, 2009. Previously, Ms. Tsui served as a member of our board from October 2005 to February
2008. Ms. Tsui has been a self-employed businesswoman engaged in strategic investments and was previously engaged in the pharmaceutical
chemical raw material import/export business. Ms. Tsui graduated from Hunan Financial&amp; Economic College in 1982.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Gene Michael Bennett</I></B>
has served as our independent director since February 2008. Presently, Mr. Bennett is Chairman of the board of directors for Bonita Healthcare
Ltd, Houston, Texas, USA, and Chairman of the Board of Redwood Senior Living Inc. located in Alameda County, California, USA. From 2013
through 2015 Mr. Bennett served as part-time CFO for Kang Jia Fu, Royal Traditional Health Investment Management Co. Ltd, located in Wuxi,
Jiangsu Province, China and advisor to Swiss Capital Asia, located in Hong Kong. From 2009 through 2013, Mr. Bennett served as the CEO
of American General Business Association, located in Beijing, China. Mr. Bennett was a partner of Nexis Investment Consulting Corporation
based in Beijing from 2004-2009. He was a partner of ProCFO Company based in California which provided contract chief financial officer
service for firms during 2000-2004. During 1998-2000, he was a basic law, accounting and tax professor at University of Hawaii, and an
accounting, tax and audit professor at Chaminade University of Honolulu, Hawaii, USA. In addition, he previously served as the chief financial
officer and member of the board of directors of Argonaut Computers in Southern California. Mr. Bennett worked as an accounting and audit
professor at Chapman University and an accounting, tax, and audit professor at California State University at Fullerton. He also acted
as chief financial officer and a board member of the National Automobile Club. Mr. Bennett graduated from Michigan State University with
an MBA in Finance and BA in Accounting. He obtained his CPA license from the State of Colorado, which is currently inactive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Yingwen Zhang</I></B>
has served as our independent director since February 2008. He also currently serves as a consultant of Shanghai Reseat Medical Tech Co.
Ltd., a medical device producer. He acted as Senior Consultant and Chairman of HSE (Health Safe and Environment) Committee of SINOFERT
Holdings Limited (HKG: 0297) of SINOCHEM Group from October 2005 to June 2009. He served as an independent director of a public company,
Chongqing New Energy Co., Ltd. (SH.600847), from 2007 to 2018. Additionally, Mr. Zhang was appointed as the Commercial Counselor of the
China Embassy in Malaysia from March 2000 through October 2005. Prior to that, from 1988 to 2000, Mr. Zhang was appointed as the Director-General
to Sichuan Provincial Foreign Trade and Economic Cooperation Bureau (the Commercial Bureau of Sichuan Province, China). In his early career
he was a chemical engineer and senior economist, and then became a senior manager for several chemical corporations in China. From 1983
to 1988, Mr. Zhang served as vice CEO and then CEO of a large nature gas-chemical state owned enterprise (SOE) in the PRC affiliated with
the SINOPEC Group. Mr. Zhang graduated from the Chemical Engineering Department of Tianjin University in 1967.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Baowen Dong</I></B>
has served as our independent director since February 2008. Mr. Dong participated on the expert team of the Sichuan University from 2003
to 2008, doing teaching evaluation and assessment work in Engineering and Medical Science faculty. In the past few years, Mr. Dong has
focused on the research of China&rsquo;s Health Care Reform. Previously, he concentrated on biomedical and medical information researches.
Mr. Dong has had different roles in areas of teaching and research, including serving as a department head and a professor, at Sichuan
University from 1974 to 2001. Additionally, Mr. Dong was engaged in the field of communication technology from 1966 to 1974. Mr. Dong
graduated from Xidian University in 1966.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among our directors or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director or Officer Involvement in Certain
Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, our directors
and executive officers were not involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Securities
Exchange Act of 1934, as amended, requires our directors, executive officers and persons who own more than 10% a registered class of our
equity securities (&ldquo;Reporting Persons&rdquo;), to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the
SEC. The Reporting Persons are also required by SEC rules to furnish us with copies of Section 16(a) forms they file. Based upon a review
of the filings made on their behalf during the fiscal year ended December 31, 2020 as well as an examination of the SEC&rsquo;s EDGAR
system Form 3, 4, and 5 filings (including amendments to such forms) and our records, we believe that, during the year ended December
31, 2020, the Reporting Persons met all applicable Section 16(a) filing requirements except that Ms. Zhilin Li did not timely file a Form
4 to report her acquisition of 2,000,000 shares of the Company&rsquo;s common stock on December 23, 2020, which Form 4 was subsequently
filed on January 8, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2008, we adopted
a code of business conduct and ethics for all directors and employees (including officers) within the meaning of the regulations adopted
by the SEC under Section 406 of the Sarbanes-Oxley Act of 2002. The code has been designed to deter wrongdoing and promote (i) honest
and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships,
(ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and
in other public communications made by us, (iii) compliance with applicable governmental laws, rules and regulations, (iv) the prompt
internal reporting of violations of the code to an appropriate person or persons, and (v) accountability for adherence to the code. The
application of the code to the persons it applies to may only be waived by our Board of Directors in accordance with SEC regulations and
the Sarbanes-Oxley Act of 2002. A copy of the code is available on our website at <U>www.chinapharmaholdings.com</U> or may be obtained
by sending a written request to our corporate secretary at China Pharma Holdings, Inc., Second Floor, No. 17, Jinpan Road, Haikou, Hainan
Province, China 570216.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2008, we established
an audit committee, which currently consists of our three independent directors: Gene Michael Bennett, Yingwen Zhang and Baowen Dong.
Mr. Bennett, the Chairman of the Audit Committee, is an &ldquo;audit committee financial expert&rdquo; as defined in Item 401(d)(5) of
Regulation S-K promulgated under the Securities Act. The audit committee carries out its responsibilities in accordance with the terms
of its Audit Committee Charter, a copy of which attached as Exhibit 99.1 to our Annual Report on Form 10-K filed on March 17, 2009, and
available on our website at <U>www.chinapharmaholdings.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="aa_018"></A><B>ITEM 11. EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary of Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer and principal
financial officer during the last two fiscal years in all capacities to our Company and our subsidiaries. No other executive officer received
compensation in excess of $100,000 during the fiscal year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aa_019"></A><B>SUMMARY COMPENSATION TABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Non-Equity</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Nonqualified</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Name and</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Incentive Plan</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Deferred</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">All Other</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">principal</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Salary</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Bonus</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ended</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Earnings ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Zhilin Li</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: center">&nbsp;</TD><TD STYLE="width: 7%; text-align: center">2020</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">225,600</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">16,000</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">241,600</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Chairman, Chief</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">President and interim Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Zhilin Li</I></B>.
Hainan Helpson Medical &amp; Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (&ldquo;Helpson&rdquo;),
entered into an employment agreement with Ms. Zhilin Li, our Chairman of the Board and Chief Executive Officer. Upon the expiration of
the original agreement, Helpson renewed the agreement with Ms. Li on the same terms as the original agreement. The new employment agreement
will expire on June 30, 2025. Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson&rsquo;s
Chief Executive Officer for a term of five years at an annual salary of RMB800,000. Helpson may adjust Ms. Li&rsquo;s compensation based
upon her production and operating achievement and her technical ability and working performance. Ms. Li&rsquo;s total annual cash compensation
for the fiscal year ended December 31, 2020, when aggregated with her compensation from our U.S. holding company level, was $241,600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payments upon Termination or Change-in-Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>PRC Law. </I>Under the
applicable laws of the PRC, we must pay severance to all employees who are Chinese nationals and who are terminated with or without cause,
or whose employment agreement with us expires and we choose not to continue their employment. The severance benefit required to be paid
under the laws of the PRC equals the average monthly compensation paid to the terminated employee (including any bonuses or other payments
made in the 12 months prior to the employee&rsquo;s termination) multiplied by the number of years the employee has been employed with
us, plus an additional month&rsquo;s salary if 30 days&rsquo; prior notice of such termination has not been given. However, if the average
monthly compensation to be received by the terminated employee exceeds three times the average monthly salary of the employee&rsquo;s
local area, as determined and published by the local government, such average monthly compensation shall be capped at three times the
average monthly salary of the employee&rsquo;s local area. Except as described above, our executive officer does not have any other agreement
or arrangement under which she may be entitled to severance payments upon termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discussion of Summary Compensation and Grants
of Plan-based Awards Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of certain material
terms of our existing compensation plans and arrangements is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 12, 2010, our
Board of Directors adopted, and on December 22, 2010 our shareholders approved the 2010 Long-Term Incentive Plan (the &ldquo;2010 Incentive
Plan&rdquo;). On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &ldquo;Amendment&rdquo;),
pursuant to which the term of the 2010 Incentive Plan shall be extended to December 31, 2029. The Amendment was adopted by the shareholders
on December 19, 2019. The 2010 Incentive Plan gave us the ability to grant stock options, restricted stock, stock appreciation rights
and performance units to employees, directors and consultants, or those who will become employees, directors and consultants of our company
and/or our subsidiaries. The 2010 Incentive Plan currently allows for equity awards of up to 4,000,000 shares of common stock. As of March
20, 2021, 2,175,000 shares of restricted stock were outstanding, and no options were outstanding. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning cash and non-cash compensation earned by or paid to our directors during the year ended December 31, 2020.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTOR COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees <BR> Earned <BR> or <BR> Paid in <BR> Cash <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock <BR> Awards <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option <BR> Awards <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Equity <BR> Incentive <BR> Plan <BR> Compensation <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Qualified <BR> Deferred <BR> Compensation <BR> Earnings <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All <BR> Other <BR> Compensation <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left">Heung Mei Tsui</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">16,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">16,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gene Michael Bennett</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yingwen Zhang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,799</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Baowen Dong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,799</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors will also be
reimbursed for all of their out-of-pocket expenses in traveling to and attending meetings of our Board of Directors and committees on
which they serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Zhilin Li, our Chairman,
President and Chief Executive Officer, was also compensated for serving on our board of directors as set forth in the Summary Compensation
Table appearing earlier in this Item 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Engagement Letters</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 29, 2020 we renewed
the engagement letters with each of our three independent directors. Pursuant to the renewed engagement letters, entered into on the same
terms and conditions as the previous engagement letters and for a term of one year, each of Mr. Zhang and Mr. Dong is entitled to receive
annual compensation of RMB40,000 (approximately $5,799), payable quarterly and Mr. Bennett is entitled to receive annual compensation
of $16,000, payable quarterly, and a warrant to purchase 5,000 shares of common stock at an exercise price of $0.44 per share. As of the
date of this report, no warrants have been issued to Mr. Bennett.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_020"></A><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information as of March 22, 2021, with respect to the beneficial ownership of our common stock, the sole outstanding class of
our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director, (iii) each
executive officer and (iv) all executive officers and directors as a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2021, an
aggregate of 45,579,557 shares of our common stock were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owners(1)(2)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount and Nature of Beneficial</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ownership</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of Class(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: justify">Directors and Executive Officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Zhilin Li <BR>President, Chief Executive Officer, <BR>Interim Chief Financial Officer <BR>and Chairman of the Board</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,050,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">26.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Heung Mei Tsui <BR>Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,312,651</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Yingwen Zhang <BR>Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Gene Michael Bennett (4) <BR>Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Baowen Dong <BR>Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">All directors and executive officers as a group (5 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,362,651</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46. 87</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
less than 1%.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly,
through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to
which such person has the right to acquire such voting and/or investment power within 60 days.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China
Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People&rsquo;s Republic of China 570216.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the percentage of common stock owned by the beneficial owners, (a) the numerator is the number of shares of common stock
beneficially owned by such owner, including shares the owner may acquire, within 60 days of March 22, 2021, upon the exercise of the
options or warrants, if any, held by the owner; and (b) the denominator is the sum of (i) the total 45,579,557 shares of common stock
outstanding as of March 20, 2021, and (ii) the number of shares underlying any options or warrants, which such owner has the right to
acquire upon the exercise of such options or warrants within 60 days of March 22, 2021 (for those who have options or warrants).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of his engagement letters, Mr. Bennett is entitled to receive warrants to purchase an aggregate of 65,000 shares of our
common stock (5,000 shares in each of year between 2008 to 2020 fiscal years). As of the date of this report no such warrants were issued.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="aa_021"></A><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Tsui, one of our directors,
has made various loans to the Company. The balance of such loans from Ms. Tsui remained $1,354,567 as of December 31, 2020 and 2019. The
loans bear interest at a rate of 1% per annum and principal and interest were payable by December 31, 2021, pursuant to a loans extension
confirmation letter executed by the Company and Ms. Tsui in 2020. We recognized interest expense of $125,487 and $111,941 for the years
ended December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company received net advances
totaling $686,317 and $667,440 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer as of December 31, 2020
and 2019, respectively. On July 8, 2019 the Company entered into a loan agreement to borrow cash of RMB 4,770,000 ($691,459) with its
Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within
one year of the loan agreement. Total interest expense related to the loan for the year ended December 31, 2020 was $46,764.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Independence of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has
determined that Messrs. Gene Michael Bennett, Baowen Dong and Yingwen Zhang are &ldquo;independent directors&rdquo; as defined in the
listing standards of NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_022"></A><B>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Audit Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate fees billed
by <FONT STYLE="background-color: white">B F Borgers CPA PC, </FONT>our principal accountant , for professional services rendered for
the audit of our annual financial statements included in our Annual Reports on Form 10-K, for the reviews of the financial statements
included in our Quarterly Reports on Form 10-Q, and for services in connection with statutory and regulatory filings or engagements were
approximately $100,000 for the fiscal year ended December 31, 2020, and $110,000 for the fiscal year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Audit-Related Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur any audit-related
fees during the fiscal years ended December 31, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Tax Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged our principal
accountant to render tax services to us in the year ended December 31, 2020 for $5,400.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>All Other Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not engage our principal
accountant to render services to us during the last two fiscal years, other than as reported above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Approval Policies and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Sarbanes-Oxley Act
of 2002, all audit and non-audit services performed by our auditors must be approved in advance by our Audit Committee to assure that
such services do not impair the auditors&rsquo; independence from us. In accordance with its policies and procedures, the Audit Committee
pre-approved the audit service performed by <FONT STYLE="background-color: white">B F Borgers CPA PC</FONT>, for our consolidated financial
statements as of and for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aa_023"></A><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="aa_024"></A><B>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The following documents
are filed as part of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following financial statements
of China Pharma Holdings, Inc. and Reports of Independent Registered Public Accounting Firms are presented in the &ldquo;F&rdquo; pages
of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">Report of B F Borgers CPA PC, Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Consolidated Balance Sheets - as of December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Consolidated Statements of Operations and Comprehensive Loss - for the years ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Consolidated Statements of Shareholders&rsquo; Equity - for the years ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Consolidated Statements of Cash Flows - for the years ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the Exhibit Index following
the signature page of this report, which Index is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aa_025"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 26, 2021</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHINA PHARMA HOLDINGS, INC.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Zhilin Li</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Zhilin Li</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(principal executive officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 25%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 53%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 18%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Zhilin Li</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the Board, President, Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 26, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Zhilin Li</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(principal executive officer) and interim Chief Financial Officer<BR>
(principal financial officer and principal accounting officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Heung Mei Tsui</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 26, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Heung Mei Tsui</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Gene Michael Bennett</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 26, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Gene Michael Bennett</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Yingwen Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 26, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yingwen Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Baowen Dong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 26, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Baowen Dong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aa_026"></A><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index to Annual Report on Form 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Fiscal Year Ended December 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/cphi8kex31010413.htm" STYLE="-sec-extract: exhibit">Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on December 31, 2012).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/cphi8kex32010413.htm" STYLE="-sec-extract: exhibit">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on December 31, 2012).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/f10k2018ex10-1_chinapharma.htm">Offer Letter dated December 12, 2018 from the Company and accepted by Ms. Heung Mei Tsui for Ms. Tsui serving as a director of the Company (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 28, 2019).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/f10k2018ex10-2_chinapharma.htm">Offer Letter dated December 12, 2018 from the Company and accepted by Ms. Zhilin Li for Ms. Li serving as a director of the Company (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 28, 2019).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054915000090/cphi10kex102123114.htm">Form of Independent Director Engagement Letter (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 30, 2015).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054916000541/ex101.htm">Employment Agreement dated July 1, 2015 between Hainan Helpson Medical &amp; Biotechnology Co., Ltd. and Zhilin Li (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 30, 2016).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/f10k2019ex10-5_chinapharma.htm">Loans Extension Confirmation Letter between the Company and Heung Mei Tsui confirming the extension of the loans (incorporated by reference to Exhibit 10.5 to our Annual Report on Form 10-K filed on March 30, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054910000706/cphi14a111210.htm">2010 Long-Term Incentive Plan of the Company (incorporated by reference to the Definitive Proxy Statement on Schedule 14A filed on November 12, 2010).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054911000554/cphi8kex101060111.htm">Form of Restricted Stock Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.8</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054911000554/cphi8kex102060111.htm">Form of Non-Qualified Stock Option Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.9</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390019022241/def14a1119_chinapharma.htm">First Amendment to the 2010 Long-Term Incentive Plan of China Pharma Holdings, Inc. (incorporated by reference to our Proxy Statement on Schedule 14A filed on November 6, 2019).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex10-10_chinapharm.htm">Loans Extension Confirmation Letter, dated December 31, 2020, between the Company and Heung Mei Tsui confirming the extension of the loans.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054908000562/cphs1ex141071108.txt">Code of Business Conduct and Ethics (incorporated by reference to the Registration Statement on Form S-1 filed on July 11, 2008).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054911000201/ex211.htm">Subsidiaries of the Company (incorporated by reference to our Annual Report on Form 10-K filed on March 3, 2011).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex23-1_chinapharm.htm" STYLE="-sec-extract: exhibit">Consent of the Independent Accounting Firm.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex31-1_chinapharm.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex31-2_chinapharm.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex32-1_chinapharm.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interactive data files pursuant to Rule 405 of Regulation S-T</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Exhibits filed herewith.</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="aa_027"></A><B>CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

<TR STYLE="background-color: rgb(204,238,255)">

    <TD STYLE="text-align: justify; vertical-align: top; width: 90%; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Report of B F Borgers, CPA PC, Independent Registered Public Accounting Firm</A></FONT></TD>

    <TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>

<TR STYLE="background-color: White">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>

    <TD>&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">Consolidated Balance Sheets as of December 31, 2020 and 2019</A></FONT></TD>

    <TD>&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>

<TR STYLE="background-color: White">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>

    <TD>&nbsp;</TD>

    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2020 and 2019</A></FONT></TD>

    <TD>&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>

<TR STYLE="background-color: White">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>

    <TD>&nbsp;</TD>

    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">Consolidated Statements of Stockholders&rsquo; Equity for the Years Ended December 31, 2020 and 2019</A></FONT></TD>

    <TD>&nbsp;</TD>

    <TD STYLE="text-align: center; vertical-align: bottom">F-6</TD></TR>

<TR STYLE="background-color: White">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>

    <TD>&nbsp;</TD>

    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">

    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019</A></FONT></TD>

    <TD>&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">

    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>

    <TD>&nbsp;</TD>

    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">Notes to Consolidated Financial Statements</A></FONT></TD>

    <TD>&nbsp;</TD>

    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-8</FONT></TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 56; Options: NewSection; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC

ACCOUNTING FIRM</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">To the shareholders and the board of directors of<BR>

China Pharma

Holdings, Inc.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Opinion on the Financial Statements</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We have audited the accompanying consolidated

balance sheets of China Pharma Holdings, Inc. and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of December 31,

2020 and 2019, the related consolidated statements of operations and comprehensive income (loss), stockholders&rsquo; equity, and

cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as

the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the

financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the

two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Going concern uncertainty</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying financial statements have

been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the

Company incurred recurring losses from operations, has net current liabilities and an accumulated deficit that raise substantial

doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described

in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Basis for Opinion</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">These financial statements are the responsibility

of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based

on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)

and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable

rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We conducted our audits in accordance with

the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether

the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,

nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required

to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the

effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our audits included performing procedures

to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures

that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures

in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made

by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a

reasonable basis for our opinion.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Critical Audit Matters</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The critical audit matter communicated

below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required

to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated

financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical

audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not,

by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts

or disclosures to which it relates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Valuation of long-lived assets</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As described in Note 1
of the Company&rsquo;s financial statements, the Company performs an annual impairment assessment of&nbsp;its long-lived assets, including
property, plant, and equipment, intangible assets, and operating lease right-of-use assets, or more frequently if events or circumstances
indicate that the carrying values may not be recoverable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 57; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Auditing the recoverability
of&nbsp;long-lived assets involved complex judgment due to the significant estimation required in determining the future cash flows of
the long-lived assets. Specifically, the cash flow forecasts were sensitive to significant assumptions about future market and economic
conditions. Significant assumptions used in the Company&rsquo;s recoverability estimates included sales volume, pricing, cost of raw
materials and labor, marketing spending, general and administrative expenses, and tax rates, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We obtained an understanding
of the controls over the Company&rsquo;s annual impairment assessments for long-lived assets and tested the estimated future cash flows
of the long-lived assets based on our risk assessments. Our audit procedures included, among others, comparing significant inputs to
observable third party and industrial sources, and evaluating the reasonableness of management&rsquo;s projected financial information
by comparing to observable average industry historical trends and projections, and other internal and external data. We performed sensitivity
analyses of significant assumptions to evaluate the change in the recoverability of the long-lived assets and assessed the historical
accuracy of management&rsquo;s estimates. We also assessed the Company&rsquo;s disclosure of its annual impairment assessments included
in Note 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">/s/ B F Borgers CPA PC</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have served as the Company&rsquo;s auditor since 2016.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Lakewood, Colorado</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">March 26, 2021</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>



<!-- Field: Page; Sequence: 58; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>







<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_002"></A>CHINA PHARMA HOLDINGS, INC.</P>



<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONSOLIDATED BALANCE SHEETS</P>







<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">December&nbsp;31,</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">December&nbsp;31,</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">ASSETS</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Current Assets:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="width: 76%; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">957,653</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,074,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Restricted cash</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,908</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Banker&rsquo;s acceptances</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,756</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Trade accounts receivable,

    less allowance for doubtful accounts of $18,150,493 and $17,575,100, respectively</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">501,892</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">635,371</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other receivables, less

    allowance for doubtful accounts of $27,289 and $22,729, respectively</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,643</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Advances to suppliers</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,238</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">404</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Inventory</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,705,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,588,824</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">73,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">77,120</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Total Current Assets</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,321,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,579,005</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Property, plant and equipment, net</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,564,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,313,827</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Operating lease right of use asset</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,687</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,779</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Intangible assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">182,146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">205,611</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,117,991</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,235,222</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Current Liabilities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Trade accounts payable</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,234,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,366,330</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Accrued expenses</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,880</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payables</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,748,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,560,332</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Advances from customers</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">719,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">505,398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Borrowings from related parties</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,134,428</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,071,986</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Operating lease liability, current portion</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,306</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Current portion of construction loan facility</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,298,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,150,168</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Current portion of lines of credit</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,038,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Bankers&rsquo; acceptance notes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">109,908</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Total Current Liabilities</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,403,676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,045,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Non-current Liabilities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Construction loan facility</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,150,168</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Lines of credit, net of current portion</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">904,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Operating lease liability, net of current portion</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,701</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Deferred tax liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">805,556</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">753,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,113,460</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,997,621</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Commitments and Contingencies (Note 9)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Stockholders&rsquo; Equity:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Preferred stock, $0.001 par

    value; 5,000,000 shares authorized; no shares issued or outstanding</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Common stock, $0.001 par

    value; 95,000,000 shares authorized; 45,579,557 shares and 43,579,557 shares issued and outstanding, respectively</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Additional paid-in capital</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,452,684</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Retained deficit</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,839,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,972,402</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,345,446</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,576,219</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Total Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,004,531</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,237,601</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,117,991</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,235,222</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part

of these consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 59; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>







<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_003"></A>CHINA PHARMA HOLDINGS, INC.</P>



<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONSOLIDATED STATEMENTS OF OPERATIONS</P>



<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AND COMPREHENSIVE INCOME (LOSS)</P>







<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">For the Years Ended </TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,866,449</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,923,936</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Cost of revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,913,543</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,441,752</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Gross profit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,952,906</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,482,184</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Operating expenses:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Selling</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,215,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,352,610</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">General and administrative</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,822,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,289,520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Research and development</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,964</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,637</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Bad debt</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Impairment loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,015,117</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,531,199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,890,037</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,578,293</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,407,853</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Other income (expense):</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Interest income</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,527</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(294,159</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(321,718</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Net other expense</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(288,484</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(294,191</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Loss before income taxes</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,866,777</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,702,044</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Income tax benefit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Net loss</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,866,777</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,702,044</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Other

    comprehensive income - foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">769,227</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">259,130</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Comprehensive income (loss)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,097,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,442,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Loss per share:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Basic and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.07</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.48</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Weighted average shares outstanding</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,623,273</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,579,557</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part

of these consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 60; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>







<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_004"></A>CHINA PHARMA HOLDINGS, INC.</P>



<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo; EQUITY</P>







<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Accumulated</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Additional</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Other</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Total</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: center; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Paid-in</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Retained</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Comprehensive</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="width: 28%; font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Balance, December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">43,579,557</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">43,580</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">23,590,204</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(5,270,358</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11,835,349</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,198,775</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net loss for the year</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,702,044</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,702,044</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(259,130</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(259,130</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Balance, December 31, 2019</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,579,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,972,402</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,576,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,237,601</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net loss for the year</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,866,777</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,866,777</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,227</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,227</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Conversion of Officer wages to common stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">862,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">864,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Balance, December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,579,557</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,580</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,452,684</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(28,839,179</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,345,446</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,004,531</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part

of these consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 61; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_005"></A>CHINA PHARMA HOLDINGS, INC.</P>



<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONSOLIDATED STATEMENTS OF CASH FLOWS</P>







<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; vertical-align: bottom">For the Years Ended</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash Flows from Operating Activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="width: 76%; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,866,777</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(20,702,044</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Depreciation and amortization</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,679,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,928,799</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Inventory write off</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">253,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Bad debt expense</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Impairment loss</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,015,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Trade accounts and other receivables</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(613,678</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(478,918</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Advances to suppliers</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,708</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(361</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Inventory</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">807,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,999,978</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Trade accounts payable</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(214,015</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">324,180</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Other payables and accrued expenses</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,217</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Change in bankers&rsquo; acceptance notes payable</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,160</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158,728</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Advances from customers</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,875</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in">Prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,311</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,375</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net Cash Provided by Operating Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,260</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">608,312</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash Flows from Investing Activities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(867,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(136,003</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net Cash Used in Investing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(867,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(136,003</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash Flows from Financing Activities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Payments of construction term loan</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,174,669</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,174,399</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Proceeds from lines of credit</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,856,066</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Payments of line of credit</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72,489</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Borrowings and interest from related party</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,908</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">691,459</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Repayments to related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(191,639</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(245,830</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net Cash Used in Financing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">624,177</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,728,770</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Effect of Exchange Rate Changes on Cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58,156</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19,179</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net Decrease in Cash, Cash Equivalents and Restricted Cash</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(227,234</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,275,640</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash and Cash Equivalents at Beginning of Period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,184,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,460,527</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash, Cash Equivalents and Restricted Cash at End of Period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">957,653</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,184,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Cash and Cash Equivalents</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">957,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,074,979</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Restricted cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">109,908</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash, Cash Equivalents and Restricted Cash at End of Period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">957,653</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,184,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplemental Cash Flow Information:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Cash paid for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Cash paid for interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">237,530</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">299,164</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplemental Noncash Investing and Financing Activities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accounts receivable collected with banker&rsquo;s acceptances</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">687,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">869,625</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Conversion of officer wages to common stock</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">864,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Inventory purchased with banker&rsquo;s acceptances</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">682,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">843,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Right-of-use assets obtained in exchange for operating lease obligations</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,644</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

</TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part

of these consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P><!-- Field: Page; Sequence: 62; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>CHINA PHARMA HOLDINGS, INC.</B></P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL

STATEMENTS</B></P>



<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></P>



<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 1 &ndash; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Organization and Nature of Operations

&ndash;&nbsp;</I></B>China Pharma Holdings, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), owns 100% of Onny Investment

Limited (&ldquo;Onny&rdquo;), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology

Co., Ltd (&ldquo;Helpson&rdquo;), a company organized under the laws of the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;).

China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Onny acquired 100% of the ownership in

Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&rsquo;s three former shareholders. The transaction

was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for

Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing

its Wholly Foreign Owned Enterprise (&ldquo;WFOE&rdquo;) status on June 21, 2005.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Helpson is principally engaged in the development,

manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality

diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities

are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules,

and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been

approved for at least one or more therapeutic indications by the National Medical Products Administration (the &ldquo;NMPA&rdquo;,

formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Liquidity and Going Concern</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had

cash and cash equivalents of $0.96 million and an accumulated deficit of $28.6 million. The Company&rsquo;s Chairperson, Chief

Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.7 million as of December 31, 2020 to provide

working capital and enable the Company&rsquo;s required payments related to its construction loan facility. The Company anticipates

operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing

products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about

its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate

the conditions that raise substantial doubt about the Company&rsquo;s ability to continue as a going concern, management plans

to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company

is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes

that the Company&rsquo;s existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8,

during 2020 the Company obtained lines of credit from three banks for an aggregate amount of RMB 19,700,000 (approximately $3.0

million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months,

there is no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about

its ability to continue as a going concern.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the requirements of Accounting

Standards Codification (ASC) 205-40, <I>Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern</I>

management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about

the Company&rsquo;s ability to continue as a going concern within one year after the date that the financial statements are issued.

This evaluation initially does not take into consideration the potential mitigating effect of management&rsquo;s plans that have

not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,

management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&rsquo;s

ability to continue as a going concern. The mitigating effect of management&rsquo;s plans, however, is only considered if both

(1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements

are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise

substantial doubt about the entity&rsquo;s ability to continue as a going concern within one year after the date that the financial

statements are issued.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under ASC 205-40, the strategic alternatives

being pursued by the Company cannot be considered probable at this time because none of the Company&rsquo;s current plans have

been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable

of being effectively implemented as none of the plans are entirely within the Company&rsquo;s control. Accordingly, substantial

doubt is deemed to exist about the Company&rsquo;s ability to continue as a going concern within one year after the date these

financial statements are issued.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 63; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying consolidated financial

statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities

in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and

classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of

the uncertainties described above.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Consolidation and Basis of Presentation&nbsp;</I></B>&ndash;

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted

in the United States of America (&ldquo;U.S. GAAP&rdquo;) and are expressed in United States dollars. They include the accounts

and operations of the Company including its wholly-owned subsidiaries. All significant intercompany balances and transactions have

been eliminated in the consolidation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Helpson&rsquo;s functional currency is

the Chinese Renminbi. Helpson&rsquo;s revenue and expenses are translated into United States dollars at the average exchange rate

for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses

from translating Helpson&rsquo;s financial statements are included in accumulated other comprehensive income, which is a component

of stockholders&rsquo; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency

of the entity that is party to the transaction are included in the results of operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Accounting Estimates&nbsp;</I>-&nbsp;</B>The

methodology used to prepare the Company&rsquo;s financial statements is in conformity with U.S. GAAP, which requires the management

of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures

of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses

during the reporting periods. Therefore, actual results could differ from those estimates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Cash and Cash Equivalents&nbsp;</I></B>&ndash;

Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term

banker&rsquo;s acceptances notes purchased with maturities of three months or less.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Restricted Cash</I>&nbsp;</B>&ndash;<B>&nbsp;</B>Restricted

cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker&rsquo;s acceptance notes

issued by the Company as discussed in Note 7.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Trade Accounts Receivable and Allowance

for Doubtful Accounts &ndash;&nbsp;</I></B>Trade accounts receivables are carried at the original invoiced amounts less an allowance

for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer

accounts and an estimation of the overall economic conditions affecting the Company&rsquo;s customer base. The Company reviews

a customer&rsquo;s credit history before extending credit to the customer. If the financial condition of its customers were to

deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision

is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled

$115,186 and $3,153 for the years ended December 31, 2020 and 2019, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Trade accounts
receivable that has been fully allowed for and determined to be uncollectible are charged against the allowance in the period the
determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $687,715 and $0
against the allowance for the years ended December 31, 2020 and 2019, respectively. Customer balances outstanding for more than one
year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Advances to Suppliers and Advances

from Customers</I></B>&nbsp;&ndash; Common practice in the PRC is to make advances to suppliers for materials and to receive advances

from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received.

Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews

a supplier&rsquo;s credit history and background information before advancing a payment. If the financial condition of its suppliers

were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize

bad debt expense in the period they are considered unlikely to be collected.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Inventory&nbsp;&ndash; </I></B>Inventory

consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost

is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct

labor and an allocated portion of the Company&rsquo;s production overhead. The Company writes down excess and obsolete inventory

to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and

work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary

course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory

item is written down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost.

Provisions for inventory write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories

are carried at this lower cost basis until sold or scrapped.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 64; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Leases &ndash; </I></B>At lease commencement,

the Company records a lease liability based on the present value of lease payments over the expected lease term including any options

to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments

using an incremental borrowing rate as the Company&rsquo;s leases do not provide an implicit interest rate. The Company&rsquo;s

incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount

equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use

lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor

prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&ldquo;Short-Term

Leases&rdquo;). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the

leases on the condensed balance sheet.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">After lease commencement, the Company measures

its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate

determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any

unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense

and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line

basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Valuation of Long-Lived Assets</I></B>&nbsp;&ndash;

The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate

that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to

be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate

that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the

projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the

Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2020 and 2019

the Company evaluated its long-lived assets and determined that necessary impairment adjustments were $0 and $17,015,117, respectively.&nbsp;In

2019, the Company wrote off the remaining four advances for intangible assets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Property, Plant and Equipment</I></B>&nbsp;&ndash;

Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements

are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation

relating to office equipment was included in general and administrative expenses, while all other depreciation was included in

cost of revenue.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Revenue Recognition</I></B>&nbsp;&ndash;

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects

the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires

disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The

Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide no significant

distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange

for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the

promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether

they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable

consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or

as) the Company satisfies each performance obligation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company only applies the five-step

model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods

or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception,

the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance

obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective

performance obligation when (or as) the performance obligation is satisfied. The Company&rsquo;s contracts are fixed price and

reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company&rsquo;s

performance obligations are transferred to customers at a point in time, typically upon buyer&rsquo;s designated carrier or the

buyer picks up the goods at the Company&rsquo;s warehouse.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For all reporting periods, the Company

has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected

length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received

advance deposits for orders less than one year. These advances total $719,786 and $505,398 and are recorded as a liability on the

accompanying balance sheet as &ldquo;Advances from customers&rdquo; at December 31, 2020 and 2019, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 65; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Cost of Revenues</I></B>&nbsp;&ndash;

Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture

and delivery of products.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Research and Development</I></B>&nbsp;&ndash;

Research and development expenditures are recorded as expenses in the period in which they occur.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Basic and Diluted Loss per Common

Share&nbsp;</I>-&nbsp;</B>Basic loss per common share is computed by dividing net loss by the weighted-average number of common

shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common

shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There were no potentially dilutive common

shares outstanding during the years ended December 31, 2020 and 2019, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Credit Risk</I></B>&nbsp;&ndash;

The carrying amount of accounts receivable included in the balance sheet represents the Company&rsquo;s exposure to credit risk

in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs

ongoing credit evaluations of each customer&rsquo;s financial condition. The Company maintains allowances for doubtful accounts

and such allowances in the aggregate have not exceeded management&rsquo;s estimates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has its cash in bank deposits

primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy

of protecting depositors&rsquo; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which

contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not

subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where

the Company has accounts declare bankruptcy.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Interest Rate Risk</I></B>&nbsp;&ndash;

The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing

debts and viability of securing future debt instruments within the PRC.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Reclassification</I></B>&nbsp;&ndash;

Certain amounts in the prior period presented have been reclassified to conform to the current year presentation. There was no

impact on previously reported assets, net loss or total cash flows.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2016, the Financial Accounting

Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-13,&nbsp;<I>Financial Instruments

&ndash; Credit Losses (Topic 326)</I>, which introduces new guidance for the accounting for credit losses on instruments within

its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial

instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting

model for purchased financial assets with credit deterioration since their origination.&nbsp;The pronouncement will be effective

for public business entities that are SEC filers in fiscal years beginning after&nbsp;December 15, 2022, including interim periods

within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&nbsp;December

15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will have a material

impact on its financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2019, the FASB issued ASU 2019-12,

<I>&ldquo;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&rdquo;. </I>The amendment simplifies the accounting

for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification (&ldquo;ASC&rdquo;)

740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application, among other

things. The guidance is effective for interim and annual reporting periods beginning within 2021 with early adoption permitted.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">From time to time, the FASB or other standards

setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise

discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected

to have a material impact on its consolidated financial statements upon adoption.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 66; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 2 &ndash; INVENTORY</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Inventory consisted of the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,081,745</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,113,994</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Work in process</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">662,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">314,231</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Finished goods</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">960,375</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,160,599</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Inventory</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,705,119</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,588,824</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 3 &ndash; PROPERTY, PLANT AND EQUIPMENT</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Property, plant and equipment consisted of the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Permit of land use</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">431,681</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">403,755</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Building</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,024,303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,375,817</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plant, machinery and equipment</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,018,708</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,309,262</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Motor vehicle</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">259,175</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">217,058</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left">Total</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,063,527</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,614,226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,499,327</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,300,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property, plant and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,564,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,313,827</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Depreciation is computed on a straight-line basis over the estimated

useful lives of the assets as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; width: 82%"><B>Asset</B></TD>

    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 1%"></TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"><B>Life - years</B></TD>

    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><B>&nbsp;</B></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Permit of land use</TD>

    <TD STYLE="text-align: right">&nbsp;</TD>

    <TD STYLE="text-align: center">40 - 70</TD>

    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Building</TD>

    <TD STYLE="text-align: right">&nbsp;</TD>

    <TD STYLE="text-align: center">20 - 49</TD>

    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Plant, machinery and equipment</TD>

    <TD STYLE="text-align: right">&nbsp;</TD>

    <TD STYLE="text-align: center">5 - 10</TD>

    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Motor vehicle</TD>

    <TD STYLE="text-align: right">&nbsp;</TD>

    <TD STYLE="text-align: center">5 - 10</TD>

    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Office equipment</TD>

    <TD STYLE="text-align: right">&nbsp;</TD>

    <TD STYLE="text-align: center">3 - 5</TD>

    <TD>&nbsp;</TD></TR>

</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Depreciation relating to office equipment

was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years

ended December 31, 2020 and 2019, depreciation expense was $2,643,820 and $2,871,134, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>NOTE 4 - INTANGIBLE ASSETS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Intangible assets represent the cost of

medical formulas approved for production by NMPA. The Company did not obtain NMPA production approval for any new medical formulas

during the years ended December 31, 2020 and 2019 and no costs were reclassified from advances to intangible assets during the

years ended December 31, 2020 and 2019, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Approved medical formulas are amortized

from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen

years.&nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could

occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization

expense relating to intangible assets was $35,650 and $57,665 for the years ended December 31, 2020 and 2019, respectively, which

was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of

their amortization period.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 67; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company evaluates each approved medical

formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial

statement. The Company&rsquo;s evaluation is based on an estimated undiscounted net cash flow model, which considers currently

available market data for the related drug and the Company&rsquo;s estimated market share. If the carrying value of the medical

formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over

the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss

was recognized during the years ended December 31, 2020 and 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Intangible assets consisted solely of NMPA

approved medical formulas as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Gross carrying amount</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,173,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,839,117</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,991,672</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,633,506</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net carrying amount</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">182,146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">205,611</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The estimated aggregate annual amortization expense for each

of the next five years and thereafter is as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: left">Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">37,685</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2022</TD><TD STYLE="text-align: left">&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2023</TD><TD STYLE="text-align: left">&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2024</TD><TD STYLE="text-align: left">&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">2025</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,406</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">182,146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 5 &ndash; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In order to expand the number of medicines

the Company manufactured and marketed, it entered into contracts with independent laboratories and others for the purchase of medical

formulas and assistance with the NMPA approval process.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under the new regulations and policy environment,

the criteria for formulations&rsquo; development are more stringent. The Company must supplement and improve the corresponding

processes and standards to meet the latest requirements of NMPA in accordance with the requirements of consistency evaluation.

As a result, the Company anticipates an extended timeline on the approval process for its current pipeline products.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If a medical product is not approved by

the NMPA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required

under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula,

or the Company can require to apply those payments to another medical formula with the same laboratory. As a result of the refund

right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production

approval by the NMPA are recorded as advances for purchases of intangible assets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To date, no formula has failed to receive

NMPA production approval nor has the Company been informed or been made aware of any formula that may fail to receive such approval.

However, there is no assurance that the medical products will receive production approval, and if the Company does not receive

such approval, it will enforce its contractual rights to receive a refund from the laboratory or have the payments applied to another

medical formula with the same laboratory.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year ended December 31, 2019,

the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and

determined that the advances made by the Company for four formulas were impaired. As a result, the Company recognized an impairment

loss for the advances made to these laboratories for the year ended December 31, 2019 in the amount of $17,015,117. The management

determined to impair all remaining advances at December 31, 2019, but may resume the development of these formulas in the future

if sufficient funding and other favorable conditions arise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 68; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>NOTE 6 &ndash; RELATED PARTY TRANSACTIONS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A member of the Company&rsquo;s board of

directors (&ldquo;Board&rdquo;) had advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2020 and 2019

which are recorded as &ldquo;Other payables &ndash; related parties&rdquo; on the accompanying consolidated balance sheets. The

advances bear interest at a rate of 1.0% per year.&nbsp;Total interest expense for the years ended December 31, 2020 and

2019 was $13,546 and $13,546, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received advances totaling $163,825
during the year ended December 31, 2020 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer; and paid back
$191,639&nbsp;to her in the same period. Total amounts owed were $740,316 and $724,963&nbsp;and are recorded as &ldquo;Borrowings from
related parties&rdquo; on the accompanying consolidated balance sheets as of December 31, 2020 and December 31, 2019, respectively. On
July 8, 2019 the Company entered into a loan agreement for cash of RMB 4,770,000 ($674,405) with its Chairperson, Chief Executive Officer
and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement.
The due date of the loan agreement was extended to July 10, 2021. Total interest expense related to the loan for the years ended December
31, 2020 and 2019 was $43,083&nbsp;and $12,393, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Compensation payable to the Chairperson,

Chief Executive Officer and Interim Chief Financial Officer is included in &ldquo;Other payables&rdquo; in the accompanying consolidated

balance sheets totaling $1,658,706 and $2,307,986 as of December 31, 2020 and 2019, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 23, 2020 the Board approved

the issuance of 2,000,000 shares of common stock from the Company&rsquo;s 2010 Long-Term Incentive Plan, as amended for the partial

conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer.

The shares were issued at a market price of $0.43 per share based on the average of the closing prices during the five trading

days prior to the issuance date, and higher than the closing price of $0.42 per share on the issuance date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>NOTE 7 &ndash; BANKER&rsquo;S ACCEPTANCE

NOTES PAYABLE</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In April 2016, the Company entered into

a Banker&rsquo;s Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker&rsquo;s

acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the

bank an amount equal to the amounts represented by the banker&rsquo;s acceptance notes issued to the third parties. The amount

of these deposited balances is shown as &ldquo;Restricted cash&rdquo; on the accompanying balance sheets as of December 31, 2020

and 2019. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately

$4.5 million) or the amount of cash available to deposit against the banker&rsquo;s acceptance notes. In addition, the agreement

calls for the payment of fees equal to 0.05% of the note amount to the bank. As of December 31, 2020 and December 31, 2019, the

Company had outstanding banker&rsquo;s acceptance notes in the amount of $0 and $109,908, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>NOTE 8 &ndash; CONSTRUCTION LOAN FACILITY

AND LINES OF CREDIT</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Construction Loan Facility</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company obtained a construction loan

facility dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility is for an

eight-year term, which commenced on July 11, 2013, the initial draw-down date.&nbsp;The proceeds of the loan were used for and

are collateralized by the construction of the Company&rsquo;s new production facility and the included production line equipment

and machinery. The loan bears interest based upon 110% of the PRC government&rsquo;s eight-year term rate effective on the actual

draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from

the draw-down date and its subsequent anniversary dates.&nbsp;The interest rate has remained at 5.39% on the anniversary

dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years.

Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due

within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over

the next five years through July 11, 2021 on the identical terms as described above for 2015. The Company has made all required

payments due under the loan. As of December 31, 2020, the Company had no additional amounts available to it under this facility.

During the years ended December 31, 2020 and 2019, the Company made principal payments in the amount of $2,174,669 (RMB 15,000,000)

and $2,174,399 (RMB 15,000,000), respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 69; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Lines of Credit</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately
$1.4 million), of which RMB 5,000,000 (approximately $0.7 million) were advanced in April, and RMB 3,000,000 (approximately $0.4 million)
were advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from
the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain
land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company&rsquo;s
Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has an additional RMB 2,000,000
(approximately $0.3 million)</FONT>&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif">available under the line, subject to
a risk review and approval by the third party guarantee company. Total interest expense under this facility for the years ended December
31, 2020 and 2019 was RMB189,892</FONT> (<FONT STYLE="font-family: Times New Roman, Times, Serif">$29,103)</FONT> &nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">and
$0, respectively. The Company repaid RMB 500,000 (approximately $0.07 million) and RMB 300,000 (approximately $0.05 million) to Postal
Savings Bank of China in October 2020, and January 2021, respectively, as per the payment schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2020 the Company obtained a line of
credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million) of which RMB 8,500,000 have been
advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the
line of credit. In addition, the Company&rsquo;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of
credit and pledged personal assets as collateral for the loan. Total interest expense for the years ended December 31, 2020 and 2019 was
RMB166,388 ($25,500) and $0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an
advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October under
this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the
advance. In addition, the Company&rsquo;s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit
and pledged personal assets as collateral for the loan. Total interest for the year ended December 31, 2020 was RMB33,723 ($5,168).</FONT>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Principal payments required for the remaining

terms of the loan facility and the lines of credit for the years ended December 31, are as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Year</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lines of Credit</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Construction Loan Facility</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 63%; text-align: left">2021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,298,886</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,038,345</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,337,231</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left">2022</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">904,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">904,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,298,886</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,942,573</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,241,459</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Fair Value of Construction Loan Facility

and Lines of Credit</I></B> &ndash; Based on the borrowing rates currently available to the Company for bank loans with similar

terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2020 and December 31,

2019 approximated their fair value because the underlying instrument bears an interest rate that approximated current market rates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 9 - LEASES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has leases for certain office

and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts.

Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates

to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed

by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company&rsquo;s

incremental borrowing rate at the initial measurement date. For the years ended December 31, 2020 and 2019, operating lease cost

was $96,552 and $90,306, respectively and cash paid for amounts included in the measurement of lease liabilities for operating

cash flows from operating leases was $102,624 and $95,985, respectively. As of December 31, 2020 and December 31, 2019, the Company

reported operating lease right of use assets of $49,687 and $136,779, respectively and operating use liabilities of $52,070 and

$140,007, respectively. As of December 31, 2020, its operating leases had a weighted average remaining lease term of 0.52 years

and a weighted average discount rate of 4.75%.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 70; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Minimum lease payments for the Company&rsquo;s operating lease

liabilities were as follows for the years ended December 31:</P>



<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">52,814</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total undiscounted cash flows</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,814</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(744</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,070</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Operating lease liabilities, current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">52,070</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Company has leases with terms of less than one year for

certain provincial sales offices that are not material.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 10 - INCOME TAXES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Deferred income tax assets and liabilities

are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected

to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in

income in the period that includes the enactment date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Liabilities are established for uncertain

tax positions expected to be taken in income tax returns when such positions are judged to meet the &ldquo;more-likely-than-not&rdquo;

threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are

included as a component of other expenses. Through December 31, 2020, the Company has not identified any uncertain tax positions

that it has taken. U.S. income tax returns for the years ended December 31, 2017 through December 31, 2020 and the Chinese income

tax return for the year ended December 31, 2020 are open for possible examination.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Under the current tax law in the PRC, the Company is and will

be subject to the enterprise income tax rate of 25%.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There was no provision for income taxes

for the years ended December 31, 2020 and 2019, respectively due to continued net losses of the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Following is a reconciliation of income

taxes calculated at the federal statutory rates to the provision for income taxes:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Years Ended <BR>

December&nbsp;31,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">(Benefit) tax at statutory rate of 25%</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(716,694</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,175,512</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Prior year refund received</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other, primarily the difference in U.S. tax rates</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">708,504</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,167,409</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income tax expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 71; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The temporary differences which give rise

to the deferred income tax assets and liability are as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred income tax assets:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Allowance for doubtful trade receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,537,623</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,393,775</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Allowance for doubtful other receivables</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Inventory obsolescence reserve</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568,182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,528,482</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenses not deductible in current year</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160,601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,085,520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advances for intangible assets impairment</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,441,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,765,906</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lease liability, net</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">807</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">PRC net operating loss carry forward</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,542,576</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,682,671</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">U.S. net operating loss carry forward</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,409,380</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,296,813</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total deferred income tax assets</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,667,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,759,656</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27,667,153</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(30,759,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net deferred income tax asset</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred income tax liability:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Intangible assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">805,556</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">753,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had

net operating loss carryforwards for PRC tax purposes of approximately $37.8 million which are available to offset any future taxable

income through 2026. Approximately $23.1 million of loss carryforwards expired in December 2020. The Company also has net operating

losses for United States federal income tax purposes of approximately $6.7 million of which $5.1 million are available to offset

future taxable income, if any, through 2039, and $1.6 million are available for carryforward indefinitely subject to a limitation

of 80% of taxable income for each tax year.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Recent U.S. federal tax legislation, commonly

referred to as the Tax Cuts and Jobs Act (the &ldquo;U.S. Tax Reform&rdquo;), was signed into law on December&nbsp;22, 2017. The

U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal

corporate income tax rate from 35% to 21% for taxable years beginning after December&nbsp;31, 2017; limiting and/or eliminating

many business deductions; migrating the U.S. to a territorial tax system with a&nbsp;one-time&nbsp;transition tax on a mandatory

deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally

eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management
considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level
of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible
or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December
31, 2020 and 2019. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $27,666,557</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">and
$30,738,262 as of December 31, 2020 and 2019, respectively.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company also incurred various other

taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any

unpaid amounts are reflected on the balance sheets as accrued taxes payable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 11 &ndash; FAIR VALUE MEASUREMENTS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Fair value is defined as the exchange price

that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market

for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value,

a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable

inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &ndash;

Quoted prices in active markets for identical assets or liabilities; Level 2 &ndash; Observable inputs other than Level 1 including

quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated

by observable market data; and Level 3 &ndash; Unobservable inputs supported by little or no market activity for financial instruments

whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments

for which the determination of fair value requires significant management judgment or estimation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 72; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company uses fair value to measure

the value of the banker&rsquo;s acceptance notes it holds at December 31, 2020 and 2019.&nbsp;The banker&rsquo;s acceptance notes

are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at

fair value:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="10" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Fair Value Measurements at</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center"><B>December&nbsp;31,</B></TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Reporting Date Using</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Description</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&rsquo;s acceptance notes</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">53,736</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">53,736</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">53,736</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">53,736</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="10" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Fair Value Measurements at</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center"><B>December&nbsp;31,</B></TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Reporting Date Using</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Description</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&rsquo;s acceptance notes</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">45,756</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">45,756</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,756</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,756</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>NOTE 12 - STOCKHOLDERS&rsquo; EQUITY</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company is authorized to issue 95,000,000

shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be

issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely

by the Company&rsquo;s Board.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">According to relevant PRC laws, companies

registered in the PRC, including the Company&rsquo;s PRC subsidiary, Helpson, are required to allocate at least 10% of their after

tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until

the reserve account balances reach 50% of the company&rsquo;s registered capital prior to their remittance of funds out of the

PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company

in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000

for each of the fiscal years ended December 31, 2020 and 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>Employee Stock Options</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>2010 Incentive Plan</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 12, 2010, the Company&rsquo;s

Board adopted the Company&rsquo;s 2010 Incentive Plan (the &ldquo;Plan&rdquo;), which was then approved by stockholders on December

22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &ldquo;Amendment&rdquo;),

pursuant to which the term of the 2010 Incentive Plan shall be extended to December 31, 2029. The Amendment was adopted by the

shareholders on December 19, 2019. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation

rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants

of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock.

Through December 31, 2019, there were 175,000 shares of restricted stock granted and outstanding under the Plan. No options

were outstanding as of December 31, 2019 under the Plan.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 23, 2020 the Board approved

the issuance of 2,000,000 shares of common stock from the Company&rsquo;s 2010 Long-Term Incentive Plan, as amended for the partial

conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer

as discussed in Note 6. There were no securities issued from the Plan during the year ended December 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company recognized no compensation

expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended

December 31, 2020 and 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, there was no remaining

unrecognized compensation expense related to stock options or restricted stock grants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 73; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>NOTE 13 &ndash; REVENUE</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes the Company&rsquo;s

revenues disaggregated by revenue source and geography based on the Company&rsquo;s PRC based business locations:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended </TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Domestic Pharmaceuticals</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,132,216</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,923,936</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">COVID 19 Testers Exported to Puerto Rico</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,734,233</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,866,449</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,923,936</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>NOTE 14 &ndash; RISKS &amp; UNCERTAINTIES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Current vulnerability
due to certain concentrations</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the year ended December 31, 2020, one customer accounted for 16.0% of sales and three customers respectively accounted for 52.0%,
11.2% and 10.2% of accounts receivable. Three suppliers respectively accounted for 20.7%, 17.75 and 13.5%</FONT>&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif">of
raw material purchases, and three different products respectively accounted for 32.6%, 19.9% and 16.0% of revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the year ended December 31, 2019, no

customer accounted for more than 10% of sales and two customers accounted for 49.6% and 10.7% of accounts receivable. Three suppliers

accounted for 22.3%, 20.6% and 5.8% of raw material purchases, and three different products accounted for 33%, 21% and 17% of revenue.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Nature of Operations</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Impact from the New Coronavirus Global

Pandemic (&ldquo;COVID-19&rdquo;) </B>- The current outbreak of COVID-19 could have a material and adverse effect on the Company&rsquo;s

business operations. These could include disruptions or restrictions on the Company&rsquo;s ability to distribute its products,

as well as temporary closures of its facilities or the facilities of the suppliers or customers. Any disruption or delay of the

Company&rsquo;s suppliers or customers would likely impact the Company&rsquo;s sales and operating results. In addition, COVID-19

has resulted in a widespread health crisis that could adversely affect the economies and financial markets of China and many other

countries, resulting in an economic downturn that could significantly impact our operating results.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Economic environment - </B>Substantially

all of the Company&rsquo;s operations are conducted in the PRC, and therefore the Company is subject to special considerations

and significant risks not typically associated with companies operating in the United States of America. These risks include, among

others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company&rsquo;s

results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes

in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad,

and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely

affect the Company&rsquo;s operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Foreign Currency Risk</B> &ndash; The

Company is exposed to foreign currency risk related to its operations. All of the Company&rsquo;s revenue and the majority of expenses

are denominated in the PRC&rsquo;s currency of Renminbi (RMB), which must be converted into other currencies before remittance

out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval

of the PRC government. The Company has not entered into any forward contracts or derivative instruments mitigating this risk.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Credit

Risk</B> &ndash; The carrying amount of accounts receivable included in the balance sheet represents the Company&rsquo;s

exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to

credit risk. The Company performs ongoing credit evaluations of each customer&rsquo;s financial condition. The Company

maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded management&rsquo;s

estimates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has its cash in bank deposits

primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy

of protecting depositors&rsquo; interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which

contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not

subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where

the Company has accounts declare bankruptcy.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 74; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>NOTE

15 - CONDENSED PARENT COMPANY ONLY FINANCIAL STATEMENT</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The condensed parent company only financial information for

China Pharma Holdings Inc. is presented below:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Condensed Comparative Balance Sheets</B></FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">21,187</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,095</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Current Assets</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,187</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,095</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Intercompany receivables</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,746,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,084,779</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Investment in subsidiary</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,705,241</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,705,241</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,473,207</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,793,115</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities - other payables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,752,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,401,344</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,720,217</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,391,771</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,473,207</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,793,115</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The parent company had no&nbsp;contingencies, long-term obligations and guarantees as of December 31, 2020&nbsp;and 2019.</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<!-- Field: Page; Sequence: 75; Value: 1 -->

    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHINA

PHARMA HOLDINGS, INC.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>





<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Condensed Comparative Schedule of Operations</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"> December&nbsp;31,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">536,035</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">522,386</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(536,035</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(522,386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Condensed Comparative Schedule of Cash Flows</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"> December&nbsp;31,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>

    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>

    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(536,035</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>

    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(522,386</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216,127</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">220,311</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Operating Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(319,908</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(302,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Investing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash Flows from Financing Activities:</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Change in intercompany receivables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">338,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">300,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Financing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">338,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">300,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net Decrease in Cash and Cash Equivalents</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>

    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,075</TD><TD STYLE="text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,095</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,170</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at End of Period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,187</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,095</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>

</TABLE>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">F-21</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>















</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>2
<FILENAME>f10k2020ex10-10_chinapharm.htm
<DESCRIPTION>LOANS EXTENSION CONFIRMATION LETTER, DATED DECEMBER 31, 2020, BETWEEN THE COMPANY AND HEUNG MEI TSUI CONFIRMING THE EXTENSION OF THE LOANS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Loans Extension Confirmation Letter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the loans from Ms. Heung
Mei Tsui to China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), the principal and accumulated interest totaled USD1,480,054 and USD1,354,567
respectively as of December 31, 2020 and 2019. Due to the fact the Company temporarily did not have enough balance in its oversea account
to repay the loans, both Ms. Tsui and the Company agreed to extend the loans to December 31, 2021, by which date the Company shall repay
the principal and accumulated interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender:&nbsp;</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Heung Mei Tsui</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower:</FONT>&nbsp;</TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Pharma Holdings, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li, President &amp; CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;December 31, 2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>f10k2020ex23-1_chinapharm.htm
<DESCRIPTION>CONSENT OF THE INDEPENDENT ACCOUNTING FIRM.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in Registration
Statement on Form S-3 (File No.: 333-251973) and Form S-8 (File No.: 333-251545) of our report dated March 26, 2021 relating to the consolidated
financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the years ended December 31, 2020 and 2019 appearing
in this Annual Report on Form 10-K of China Pharma Holdings, Inc. for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>/s/ </B><FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lakewood, CO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10k2020ex31-1_chinapharm.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Zhilin Li certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">a) Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">c) Evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">d) Disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent function):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">a) all significant deficiencies and
material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Zhilin Li </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10k2020ex31-2_chinapharm.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Zhilin Li, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">a) Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">c) Evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">d) Disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent function):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">a) all significant deficiencies and
material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(principal financial officer and <BR>
principal accounting officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>f10k2020ex32-1_chinapharm.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby certifies, in her capacity
as principal executive officer of China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), for the purposes of 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The Company&rsquo;s Annual Report on Form
10-K for the fiscal year ended December 31, 2020 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: March 26, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification accompanies each Report pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed
filed by the Company for purposes of &sect;18 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement required
by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 2P# 2(  A$! Q$!_\0
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MS#S_ /)O\C^C[_B)B_;]_P">?P9_\-WI_P#\L*/^(F+]OW_GG\&?_#=Z?_\
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M-\ 6>/M?@W5K36K_ /L[PO>\'_3_  Z#VY&.?S._;2^-7P]_:._:H^)WQO\
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M?$CP5#\,_@OX0^&%U9^+-9M9_#FO#PA;&T^U?V397W''!_M'KV'I];?LV_\
M!6+X#_!'X??\$Z_!VI?"GXJ2G]BGQK\4?'_B<^'QX7\CQ=J'CS2[[1[33/#P
MO+]396/^F_VA_P 3 CIP<UP/#\0QH8>M&O4E+?D<WO&-=I.[5^:3A&7O/>+T
M4"^;!WZ>MEU<?+I9VT[]SX1^!/\ P3?_ &A/CY?/IOAC5?A=IMS<?%_Q!\#-
M&CU#Q;_R$OB1X;/_ !-K7[)]A_M&QT/[=:7>GG4,_P!:V/@__P $R_C]\9/"
M_P 5/&&D^,/@WX1T3X)_%_1_@C\2[SQQXRNM#M_!_C"\NOL5W=>(3]A_T+0]
M._Z"'X>M?6W[)_\ P4E_98_9OU ^+4^%'QGF^)<G[9OC'XY77BS2[[PO<?;/
MA1XQNKS5QX8M-)O;_P#L^RUO[==_V<;\@?\ 'GUKRSQM^WY\&?$G[/G[>'P-
MTWP;\8+/Q'^U1\<[GXM6'C34!H4&EGP_H]W]M_X0WQM:V5\?^)X.<ZACOD$'
MKV0CGU_W=>22:5WUUUWEM;5.]TOLO8Y*E/ 3_BX=?U\MSG?!_P#P2(^/WC+0
MO"OBVP^*_P"SI#X3^('QMU?X!^!-8D^(UWCQ5XXT?5+W1Q]DM/[#YLM1^Q_\
M2H Y&!ZC/ _&;_@F'^T5\#_A7\3OBGXFU[X3ZW;?!KXTZ?\ !#XE^&_!_BVZ
MU77-!\0>)-5L[/P]=_9/L.FC[#J/VOOC->W_  '_ ."AG[/'@#]F?]BOX,^,
M/!GQ<UOQ)^S7^U5IW[4$NOZ'=>#;?2M2.CYO+33/]-ON/[.L2-.'IUYS7?\
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M[^P^%_PJ\'_%_P 6^,/"_B/5/$?AS3?"_CS5/L?AZU_T+0SJ'V[4; VFH?\
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MQ-NW]E7@&.E?HW^T!IO@*;]CG]L#PEKWC_X#^)_&&H?"#]F#QOX7_P"$;NO
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M4W-Q_P ^=Q_WZ%)BZ_Y\Y_R%'UC"?]!*_P#)?\SE^KU?Y7]S_P A]%-S<?\
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M?$C_ ,./K_\ A7[YIT/U_H*?7H4<]SU4U?&337GMTZIO\3SO[$RO_H%7W(_
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MO^A0^)'_ (<?7_\ "C_B&V_X)G?]"A\2/_#CZ_\ X5^^U%5_;N>_]!E3^O\
MMT/[#RS_ *!5_P" H_ G_B&V_P""9W_0H?$C_P ./K_^%'_$-M_P3._Z%#XD
M?^''U_\ PK]]J*G^W<]_Z"ZGW_\  #^P\L_Z!5_X"C\"?^(;;_@F=_T)_P 2
M/_#CZ_\ _$_7_)XK77_!N)_P3?LXY?L/@;XAWBFU\R6VD^(VO?OKFSN;,VGY
M 7?'I^5?O_39>_\ UQ/]:I<09W?7%S?DY*S]=$#R7*[?[M'9]%V/XC?^"M/_
M  28_8__ &1$_8ZU'X+>"?'%M)\=_P!L+X??"OQE'>?$#59P/#^M6K=">I!7
MIUZ>H-?K=#_P;B?\$UVN1/\ \(7X_AU.TN;B87/_  L+7O)F^V#-UZ]NOXGN
M!7*_\' '_(,_X)I9_P"DB'P<_G)7]"P^:^DR.-EM^MR.OOR:]7$<1YU]1PT?
MK=33G>K3;M.*2;:ULFUK:][MW2/&PF3Y7]>Q'^S+7R\GM9'X1_\ $-M_P3._
MZ%#XD?\ AQ]?_P *P?$7_!O!_P $J?"&FWFL>*=)\<>'])TZU^TW>H:Q\5M3
ML;&" <'-W>]LC! ).>,9%?T*5^"W_!QAX>6]_P""4G[4WB![K4-*U3P_IV@Z
MIH^IZ1X@O-)O_(&JV(NK8-9D!1]X[2K%^&4@*0WE+.\Z?_,74_\  [?^VGL_
MV'E?_0*ON1YWJO\ P0 _X)'Z%IZ:SK<7C#1-)N/LYM-3U3XK:I8V5[]LM3>6
MGV.[O<+>DV(R/[//(ZX-4M4_X()?\$@-"@L[S6[S7M'LM0B@NM,O-4^-%W8V
M6L6]Y:"\%SI-U?78%[9&RSG^SFP,?>.17Q7^U7XEEU7]HC_@CE\+/&=YK&F_
ML_77["WQ@^(6F:?)KUU-I7C?XH67P0LKK2;7Q#=XYOM.O0+_ $G))/(&!@#\
M<OV:_BA\:?B]X7_9RTK]I/6-8MO#>A_\$J_VT/%'P@_X2B_NH-*U+Q!H]WXD
M'A[5+/\ Y_=;T[_1-/TG'MS2_MO/?^@NI_X'^MC;^P\J_P"@9?@?TQZQ_P $
M#?\ @D!X=O=,TW7[[6-#O]:MK>_T:TU/XV7-E-JVG7FTVEUI=I>WH-Y9G) O
MU$@SU=0<UHG_ (-]/^"4"ZA9:2VE^.XM7U&TN;_2]/G^)NO07FHPV8S<C2K4
MKF]O-//!L=-4L"0=A&2OY$^$/^"<?QI_;'_8D_8:_;2^*_[4MQ\%M-T3]B3P
MOX"^,FN^/[[58-;\$Z?X.\8ZSK-KXITJU PNM^([ :3I^6QJA-Z%ZD _:NN_
M\%,?AG^S3^TNGQ'_ &D?"7C@_%GQS\+O!_C:V\)7,ER=)_9P_9NUC7O#7PV\
M$ZG:V9&+WXP^--<U;2?%_BW^S\YTD]0<&C^W,]_Z"Y_^!$5,CRO_ *!EYJVW
M;T/LRS_X-P/^"8E];PWEMX1^(\UM/&)89!\1]>Z9'/\ ];'T[&IO^(;;_@F=
M_P!"A\2/_#CZ_P#X5^ZOAB[M+W0-&U"QO;;4;/4+&VOK74;,?N-3@O;<72ZF
MIZG^T=XOO3+#!R>>AI?V[GO_ $%U/_ K_H1_8>6?] J_\!1^!/\ Q#;?\$SO
M^A0^)'_AQ]?_ ,*/^(;;_@F=_P!"A\2/_#CZ_P#X5^^U%']NY[_T%U/O_P"
M']AY9_T"K_P%'X$_\0VW_!,[_H4/B1_X<?7_ /"C_B&V_P""9W_0H?$C_P .
M/K_^%?OM11_;N>_]!=3[_P#@!_8>6?\ 0*O_  %'X$_\0VW_  3._P"A0^)'
M_AQ]?_PH_P"(;;_@F=_T*'Q(_P##CZ__ (5^^U%5_;N>_P#094_K_MT/[#RS
M_H%7_@*/P*_XAMO^"9O_ $*'Q)_\.-K]=+X'_P"#>C_@FMX'U.SURR^%GBOQ
M%K6ER_:K"X\8>/->O[(7'J;0<>I[\?3C]T**B>?Y\]*>,J26[]]J_=/EM=/9
MI@LHRRG9K#I?+SOWT/#? ?PM\,?"CP-I7A#P7X*T?1] T7$=AX;\,O\ 9[(9
MN/\ CXNKF^VF\;^([@3R05Z!?0#?ZU:XC-E]O)&\S(UM&(]V?W.TC.8\9SDY
M##TKKI9$"[=GT]O?GKV_IQ51I$!^Y^1('^?SKG>)E/WL0N:3U]YWU;UWO_7W
M+U*>.PN'7LW%.UK:7T7HE8OT445RBLNR"HY2&4(>YXX]?_K_ -<\5C:O=36:
M0M;QR7-S)F*.S@EM("<];O%V,?Z#]X^F<E>P\XO?BGX \&R1Z5XO^)GA?3M1
M1VDE'B'7M T^YE)+%K86^]"/L/!^7:0V2Q.?EBKA\=B%;#7>G1-^6B46_N.6
MIC<%AZGLJK2?F^OGJM.IZUY7LWY?_6JU7B?_  T+\%/^BN?#?_PK=(_^6%'_
M  T+\%/^BN?#?_PK=(_^6%<^'R?.J%_]FG=_W*CW]8,7]HY?_P!!$?O7^9[9
M17BG_#0OP1_Z*_\ #;_PK=(_^6%)_P -"_!3_HKGPW_\*W2/_EA71_9^>_\
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M3_Y /[1R_P#Z"(_>O\SVFF.2=V>T1'X<UXS_ ,-!_!3_ **]\-/_  LM _\
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M=:%:78Y ;0[IM/!Z$@\ YKF_$'["?[*_CWPM\,?!FN_!_P )Z]X/^$_AR_\
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M_17/AO\ ^%;I'_RPI?\ AH7X(_\ 17_AM_X5ND?_ "PH_L_/?^@27_@NK_\
M*@_M' ?]!$?O7^9[737^Z?P_F*\/F_:&^"ZR0[?C!\--@'[Q/^$MT?,GT_T\
M_P"3WK8T;XM^"O%HDC\*^,/".L7#2PI%%:^(M-N>N2<*GS,21PH!//')J_J&
M<)7K8>2BM6W&<;;]XQTW*AF&"J5/9+$J[Z-K\[L]1VI_SU/YU9KD8KQXI+^%
M_M$T.G_O;J[N(A!@XZ6G^3C]:ZZH4/9W]/\ @OJ_QL=G)2AK3=^VM[_??N%%
M%%69V79?<O\ (*K7%R8$=_+WGRCY7/,T_.+;\<=_?T.;#$@$C_/-8]V7D'V8
MH_E3Y_TCC]S/G_CVXZ9&<#&,G&>]4G?$*&NJ7_!?W$7_ -F]IY7_ #Z>J_X)
M_/9_P6[_ ."G7B7]E+PA9?"_X.ZGH]C\1M=TN_E\8ZA./.U7PKIMV+/[&=*7
M."^HYNU+\;E50,'BOX4O'G[5'Q4\<>)KS6+_ ,5>(-2N;C_2O^)YKVJ:KY-Q
M>?\ 'W=6G^G=#S_G-?L7_P '$>L7EQ^V;\2$N(9$$>B^%]+&)?\ 7"S%X1QT
M[C]/I7\]4<D/E_)#Q_QZ^9T_TC_ZY'OZ>]?T3P?D>5_V-@*OU>^*E:3;L^9M
M7O=I]U;HE:WG^%<09CBYYIB+8BUG:RNK).VBT]--SUG_ (7=\3_^@W_Y%U/_
M .3JF_X7C\3O^@W_ .1=4_\ DZO(Z*^T^HX2F_\ =8]MHO\ ]M_X!X/UW$_]
M!3^^7^9ZY_PO'XG?]!O_ ,BZI_\ )U'_  O'XG?]!O\ \BZI_P#)U>1T55/"
MX3VG[S"QM_AC;T^'T#Z[BG_S$M_^!?YGKG_"\?B=_P!!O_R+JG_R=1_PO'XG
M?]!O_P BZI_\G5Y!)(D,;S/YA2./S9?+B\_'.,?X\>U?5'A_]BO]IGQ)9^#[
MFP^'4=F_Q T;^WO!.C^(/$>@^'/$?BK1_P#G[TGP]K5]_:%Z,_\ ,/\ [,KD
MQ<<NINRPT;WMM'OII:YI]8S#^9_^3?YGFW_"\?B=_P!!O_R+JG_R=1_PO'XG
M?]!O_P BZI_\G5YWKWA[Q#X3U2\T3Q;H.L>%=8T^_P!0TNZTOQ)876AWT.H:
M/=?9+NU^R7OO_/'TQX_WD/VF']]#Y7F^9'TX_P#U>WU%)8?!O[,?_ 8?Y&_U
MS&>?_D_^1ZY_PO'XG?\ 0;_\BZI_\G4?\+Q^)W_0;_\ (NJ?_)U>/QR));_:
M4FC^S?Z1YLGF\P?8_7'T_''84LS);QN\WR)'+Y7X_9?MG3OT_E1RY?#[,'_V
M[!W_  M^@OK./GU:\KO;IU/7_P#A>/Q._P"@W_Y%U3_Y.J'_ (7G\3O^@W_Y
M&U;_ .3ZZ[X?_LI_'OXH?"GQM\;_  'X&_M[X7?#?[/_ ,)QXH_M[2K&#0?M
M8_T0?9+V^^WWO3_'C%?/VW_2/L_/G?:OLOE\?\?&,Y^O^>E:4Z675/LP^48>
M?E_2U-\/B<70M[5M_.1ZG_PN[XG_ /0;_P#(NI__ "=5JW^/7Q.M][IK<?G>
M5Y4,GFZI^YZ_]/V/U].]>40V\UQ=0V<)CFN;B[^R^1'+_J;C_I[X_P!"_P _
MBS[/<K;I<O#<6RR?ZJ.XB\B^O/\ 2A9_9;2T_P"7WH#_ "ZY%?4LNJ=()^2A
M_EL='URKB/W5-M?>O7M\M3V.U^/OQ%L?M/V/4MGVS2_LLOF76J3_ /$P_P"@
MI_Q_=>_7OSQ6;;_&SXB6O[F#6O\ 1KB+RK^WN)=4G^V7'_/U_P ?W85Y=<PO
M;3/;3>6C1C_GI^X_Y_/LGVO_ )_OL7_,/Y_Q9+'=6\=A->6>H:9#JEA]OL)-
M4M;K2OM>G_\ /U_IO^>G6KJ8;!3I>RJJ-NFD7^G:QC"A6I575IM^>K]>_J>J
M_P#"\?B5_P!!O_R+JO\ \G4W_A=WQ/\ ^@W_ .1=3_\ DZO([BXAMXT>:>/8
M\7F?N_W_ )/_ $ZWG_/E?>FG]_<U99?*A>Y=XX8?])\J227R/MEQ96OVS[+:
M=/MM]_U#].]!6?U++NT/NC_\B7_:%3O+[W_F>I_\+N^)_P#T&_\ R+J?_P G
M4?\ "[OB?_T&_P#R+J?_ ,G5Y&\R1R7,,R7$,EG%]JNOM$5U!]C_ .G6\_Z?
ML?\ ,/Z=L5-\W]G/JOV:\2RMXK>ZOY)+:Z@GTVWO?]#M+K5K3G^Q;'4;[.?[
M1YK*V4T_W=3#0OTT@NGI^!I>MB/WB<E\W_G_ %<]6_X7=\3_ /H-_P#D74__
M ).J;_A>/Q._Z#?_ )%U3_Y.J[\$_P!GOXP?M&>-/^%=?!;PK;^-_'/]EZAK
M7_"/V^LZ78WT^GZ/:_;+NZM/MM]_SX^_X>GF_C;PGKWPYUS6_#'C:VM]$USP
M_=?9=9L[B_M;C['<?\^OVL=N_P"OI6E">2_] T?NC^J#V6,_F?WO_P"2.[_X
M7C\3O^@W_P"1=4_^3J/^%X_$[_H-_P#D75/_ ).KR.3?%'#--;7$,-Q:_:HK
MB2UNX(/L]G_R\YS^O:O7?%WP%^+O@/P#\-/BIXM\&:AI7PZ^,']HS?#3QAYM
MK/I7B3['_P ??V2[_P"7+_N(UR^VRZIBO8T8QU>BY8_AIK\DP;Q5):N3?J[?
MGV]?D)_PO'XG?]!O_P BZI_\G4?\+Q^)W_0;_P#(NJ?_ "=7D<?[SS=CQO\
M9^H$O^?PY_ER5W_5<)_T#+_P&/\ \B8O%5^[_P# G_F>N?\ "\?B=_T&_P#R
M+JG_ ,G4?\+Q^)W_ $&__(NJ?_)U>1T4OJN$_P"@9?\ @,?_ )$\YYABM?\
M:5U_F_S/78_CM\2X]^_6(WQZRZIU^HON?>N_^&O[6GQI^&_B32M>\/>-?$&G
M7]OJEO+#>6FLZIY%GUS=&T^W8_E7S'3&C>17A2;R3)^Y^T<_N?3IQT_GS58_
M*LOKTL!2JX96Q>]HI.VSV7:Y?]HXN@\/5I8AM^K[]-=GL?Z07_!'C_@I'J7[
M:?PMM_"7Q'N+;5_BMX'EL(YK^VD\C_A)-!:[-J=?N[08&ZP-L2Q/+'D\YK]X
M:_@=_P"#:#5=1C_:UTW35N=D=Q\*O'^GW5O_ ,]K?1S9W=G=$#WNQ[]*_OB
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M?C_3\?K3]G+]A/\ 8P\4>"_^"<'A[6_V;]/O/$/[7_[+?QH\1>+?%'F^*/\
MB6^,/!^E7=[:71'V[@\]..W%?S>>!OVG/VA_A/\ #_6_@GX#^-OBSP9\-_'$
M6?%O@>WNK6?2KS_K[NOI]>_;BNUT3]NS]L/P_I?@:Y\*_M%?%S04^ ]A<:#X
M)DL[^V^P^#]/O/\ C[M?A[_S^V&HCVX(Z5EB<KQ]5_[+F'U1)MM7:NOJ=DNN
M\M]O*\@]O2H?Q</IWW]?PT/TM^"W[+'[*/Q@_89^-/B'2/ACX3\/?&S]C?XM
M6'_"\[B2_P!>@U7XJ? _1]=O+RTUZT_XGF?MVGWV/#_TLP#BNJ\'_LU_L?\
MA/\ 9(^!7[6WQ:\$ZQ?^#_VE/&_Q(-_XL\'Z-KWBK7/@_P#\(W:_8_AE_9&D
MV=]_H7_'V1JP]LU^&]K\4/B%9V?Q(O\ 0?'VIPP_%B7_ (NA9V>J7-C8^)-0
MO+K^V+NZ\1#_ )_M1^U_\3;'..E=_P""_P!K3]I/X9_#?7_@;\.?C?XP\*_"
MKQI%]OO_  ?X?E^W:'#I_P#R]W5I]NL/]"_I[<XC^Q\P5O99BW]_;7KWUN^C
MUZ"_M'"_]"^WG=H_7WQ1^QG^RIXF_8+UCXS? 'P[X3\<^.?A78>#K_X^^%_B
MY%KW@[XF>&[C6->L]8M/BAX3TG[=_IMCXAL1_P (_I.G]?[)O+^OO+QW^SE^
MSG\=/^"MGP-_9I^(7[.7@^?X,_\ #&]AXIB@T^+7;&>;4/\ A75GXD^T\7V,
M"^N\9QGCGG)/\OTG[1WQXUCP7K?@.]^)?BC_ (1CQ!I>G^'+JSU36;6"#4M.
MT>Z^V:3=7?\ V#KZT TGTZUZ+'^WQ^V>_C#P!X[C_:!^)<?CGX?^$C\*M!\:
M1WUK_P )5IWA<VOV3[+I/_/[8FQS8'^7-9O*,XNG_:,M+]7UM;1:/;K=KI:[
MN+'X;MU6EE]VQ^\/P'_9'_8O^)'P\_81^(,W[+'AVUU;X[_M8_$_]E?QQH\L
M_BC/B_X;>$+K6K*S\5,/MP^Q?$33OL5KM)P"5;GBO)U_87_8C_9]^%_QL^-/
MQ(\#:AXJ^'OAO]MS4/@/JFCZ?H/BGXCWWPW^%^CW7_(4\/>'M%O?[0T7XC?8
M?^8AJ/?O7X[:3^WA^U=X9M_!.E:5^T?\1-*\-^!_B#J&LZ/]GN;6"X\$_$#Q
M)G.O6G/34>?^)ATYZ8S3_#7[;G[9'@?4?BO-HO[0/Q,TW7OBS=7%K\4/[4O]
M+OM*\>'_ (\_[4^R7O\ R^ZC8_\ ,0/XU"R?/KOV>8M[VUD]+W2ULMM-%Y)V
M-L1F&5T+/ZNKV\M[=[?U<_:']DW]CO\ 9%\<?L]_!;XE^*_V>+?XF7GQ,_X*
M&^(/V??#EYXTU37M#OIOV?[RZ/\ 9/BCQ#X>^W?VA9^*].L;NTYU&DTGX3_"
M_P"!_P"QU_P7?MM'^"?A_P 3^(_@_P#M%^&/A5X$N-5T;5+[73\,/^$ILAI'
M]JW=[?$V5AIU]D\'K9XQSFOQ$\-_MJ?M/_#WPKX8\)>$OVA/'GAOP]X+\96_
MC+P;H=O+]H@_X61>77^B:I]K''_/W^M36_[9'[2'AMOC3>?\+O\ B@C_ !\N
MOM7Q^CM[^UO['Q5XQO.?M7V3_P#5]*'D>:5+>UQ334E+233=G>SUO9]=DUN3
MA\92KTG4I8=6_+4_0C_@@9:I'_P5)^&NI167]IZI<?#CXH2ZKJ&C_O['3?\
MBE_^/7/M_7BO@_XC?"OQ5XP_:,_:*U7_ (16\UO1/#?Q:N/B#\0;CQ!I]U!8
M6?A^S\>6=G_97VOU^PW?_P!;U\B^$/QP^*G[.^O_ /">? WXE^)/A7XJU6UN
M-!T?Q)X3U2T_X2JTU"\)^UB[M/3\.?:NM\7?M??M/^*O"?B3PCXG^-GQ(O\
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MZR7TSZ\_C]>]&+C_ )[VG_DI_P#%5[3_ ,,__$+_ * ]Q_X(M2_^0:/^&?\
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MR36>^//_ "U]_P#/\OK*//C:Y>#4K=[;4+K^U+^WN(K7^U9KB\M?L?\ 9?\
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M( RV./7J">_'/%?T)2(LMW(LB(RE[;J#G_CY!Y['^G->C7Q5=8;#VJ5/M_\
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MF0",L*/;8C_GY4_\&U/_ )(/98?^2G_X##_(V/\ A!? O_0E>$/_  1Z)_\
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MS;/7G)!ST-9JO37_ "Y;VZ>G8]!4_P#I_;UM]VQ_(9I?QI^,MW_P27_X(0^
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M8>([*[NAXK.HY_M4D =@9^L4O^@=_<P^KK_H)7H??/P>^)GA+XS?"SP!\6O
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MRW_AY1^Q)_T==\%?_!T/\_\ ZC[9_P L'_A:/Q#_ .@S>?\ ?E:/^%H_$/\
MZ#-Y_P!^5H_XA;A_^ABO_ 8_Y!_KOC_^?"/]4#_AY/\ L2?]'7?!?_P<#_'_
M #@^V6_\/*/V)/\ HZ[X*_\ @Z'^?_U'VS_E@_\ "T?B'_T&;S_ORM'_  M'
MXA_]!F\_[\K5_P#$+\+_ -#%_P#@$/\ (/\ 7?'_ //A'^I]_P /*/V)/^CK
MO@K_ .#H?Y__ %'VR[_AY/\ L2?]'7?!?_P<#_'_ #@^V?\ *_\ ^%H_$/\
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M?]^5KB_XA;A_^AE_Y+'_ "-WQQC_ /H'74_U/?\ AY3^Q+_T=;\&/_!U<_\
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ME<:]:Z/H]_:^'-*O-8L[7[9=Z#I.K:UD?;OL/_ZS7]+_ /P4!_9]\._M!_\
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MG\IWPH_9O^*_Q^\/_%KQ5\$_!EYXST'X,:#K'Q!^(VH1ZS:P0:#X/T?[8?\
M0^/]-_L[''?%>%+<Z5&TVI)<^=H^H:K<_P!EQBZ^W3V>G7EK9_9+6[M++I_I
MWVOT_"OZD_V-K;]GRX/_  4DU7]FOP-\3_!]M<?\$HO$-K\2_#_BCP'=>#K'
M0?BQHPO='\0VH\/7M]R=1-G=>(#[7A(]*/@O^R_^QOXP;_@ESX/F_9R\!W.E
M?M@?L>>*/$?Q>\87<.J?VKX5U?PUI5W9Z3XRM,G&C'3K_//']JYZ<9K:GQ]B
MOK;PV.PSLGNHO^6^NGW675;[EU,CG"G?3YVOO;??\=#^6F:W>U_<WMS]IO\
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M4?M@7$%]^U=^T)80_P#$DTW3/V@O'/@W2[?PWH-K!I6CZ/9^*+S1[2UM.?\
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M>:GK+_WZ_P#K5D!+147FIZR_]^O_ *U'FIZR_P#?K_ZU $M%1>:GK+_WZ_\
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M_2/ZIOVG/CY\'_'7[-'[9/AN']H?P'JOB?QC^W]X0^*OPODU#Q1Y^N6?P_\
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M -^O_K4>:GK+_P!^O_K4<]3L_N9'U>GY?C_D2T5%YJ>LO_?K_P"M1YJ>LO\
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M0 ?9X?\ GFOZ_P"-'V>'_GFOZ_XT44 'V>'_ )YK^O\ C1]GA_YYK^O^-%%
M!]GA_P">:_K_ (T?9X?^>:_K_C110 ?9X?\ GFOZ_P"-+Y$/_/-/^^1116^'
MU6NNGZ(TI]?E^H>1#_SS3_OD5!Y47]Q?RHHKMII:Z+I^IH'E1?W%_*CRHO[B
M_E116@7?=_>_\P\J+^XOY4>5%_<7\J** )OL\/\ SS7]?\:/L\/_ #S7]?\
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1[;MW;[G[WP5_R+UZ/_TH_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>cphi-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: cphi%2D20201231.xfr; Date: 2021%2D03%2D26T15:57:02Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:cphi="http://chinapharmaholdings.com/20201231">
    <link:schemaRef xlink:href="cphi-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_Subsidiaries1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">cphi:Subsidiaries1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_PermitOfLandUseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:PermitOfLandUseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_PermitOfLandUseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cphi:PermitOfLandUseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandTenIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cphi:TwoThousandTenIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_RawMaterialPurchasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_SalesRevenueNetOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesRevenueNetOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_SalesRevenueNetTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesRevenueNetTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_SalesRevenueNetThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesRevenueNetThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_SalesRevenueNetOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesRevenueNetOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_SalesRevenueNetTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesRevenueNetTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_SalesRevenueNetThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesRevenueNetThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-08_srt_ManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-07-08_srt_ManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-08_srt_ManagementMember_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-21_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:SuppliersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:SuppliersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2005-05-25_custom_Subsidiaries3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">cphi:Subsidiaries3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2005-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_ManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_ManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ConstructionLoanPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConstructionLoanPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_BankOfCommunicationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_DomesticPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cphi:DomesticPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_DomesticPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cphi:DomesticPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-30_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ChinaCITICBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ChineseYuanRenminbiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:ChineseYuanRenminbiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-23_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ThirdPartyGuaranteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">cphi:ThirdPartyGuaranteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_BankOfCommunicationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_COVID19TestersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cphi:COVID19TestersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_COVID19TestersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cphi:COVID19TestersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AccountsReceivableMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersOne1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:RawMaterialPurchasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:SuppliersOne1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ThirdPartyGuaranteeMember_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">cphi:ThirdPartyGuaranteeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ChinaCITICBankMember_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_BankOfCommunicationsMember_custom_CNYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="cphi:TypesOfCurrencyAxis">cphi:CNYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Customer">
      <xbrli:measure>cphi:Customer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Suppliers">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>cphi:Suppliers</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>cphi:Number</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="CNY">
      <xbrli:measure>iso4217:CNY</xbrli:measure>
    </xbrli:unit>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="INF">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_Subsidiaries1Member" unitRef="pure" decimals="INF">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2005-05-25_custom_Subsidiaries3Member" unitRef="pure" decimals="INF">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_PermitOfLandUseMember">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_VehiclesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_PermitOfLandUseMember">P70Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">P49Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_VehiclesMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9237601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8004531</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">43580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">23590204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">24452684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-25972402</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-28839179</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">11576219</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">12345446</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">17391771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">17720217</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">43580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">23590204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5270358</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">11835349</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">30198775</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-2866777</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2866777</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-20702044</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">-522386</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">-536035</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-20702044</us-gaap:NetIncomeLoss>
    <us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2113994</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2081745</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">314231</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">662999</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1160599</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">960375</us-gaap:InventoryFinishedGoods>
    <us-gaap:LandAndLandImprovements contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">403755</us-gaap:LandAndLandImprovements>
    <us-gaap:LandAndLandImprovements contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">431681</us-gaap:LandAndLandImprovements>
    <us-gaap:BuildingsAndImprovementsGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9375817</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">10024303</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">26309262</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">29018708</us-gaap:MachineryAndEquipmentGross>
    <cphi:MotorVehicleGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">308334</cphi:MotorVehicleGross>
    <cphi:MotorVehicleGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">329660</cphi:MotorVehicleGross>
    <cphi:OfficeEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">217058</cphi:OfficeEquipmentGross>
    <cphi:OfficeEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">259175</cphi:OfficeEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">36614226</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">40063527</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">20300399</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">24499327</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2643820</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">2871134</us-gaap:Depreciation>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4839117</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5173818</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4633506</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4991672</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">205611</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">182146</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">P0Y6M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.0475</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2020-12-31_custom_CNYMember" unitRef="CNY" decimals="0">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:NotesAndLoansPayable contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">109908</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">0</us-gaap:NotesAndLoansPayable>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">45756</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">53736</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">45756</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">53736</us-gaap:CustomersLiabilityForAcceptancesNet>
    <us-gaap:CustomersLiabilityForAcceptancesNet contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueNetAssetLiability contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">45756</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">53736</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">45756</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">53736</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <cphi:AccumulatedDeficit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">28600000</cphi:AccumulatedDeficit>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">960000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingLeaseLiability contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">140007</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">52070</us-gaap:OperatingLeaseLiability>
    <us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">22235222</us-gaap:Assets>
    <us-gaap:Assets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">21117991</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">19793115</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">19473207</us-gaap:Assets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">136779</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">49687</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">16313827</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">15564200</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">5579005</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5321958</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">3095</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">21187</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">3588824</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">3705119</us-gaap:InventoryNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1074979</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">957653</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">3095</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">21187</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">5170</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">294159</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2020-01-01to2020-12-31_custom_BankOfCommunicationsMember" unitRef="USD" decimals="0">25500</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">321718</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2020-01-01to2020-12-31_custom_ChinaCITICBankMember" unitRef="USD" decimals="0">5168</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2019-01-01to2019-12-31_custom_BankOfCommunicationsMember" unitRef="USD" decimals="0">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2020-01-01to2020-12-31_custom_ChinaCITICBankMember_custom_CNYMember" unitRef="CNY" decimals="0">33723</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2020-01-01to2020-12-31_custom_BankOfCommunicationsMember_custom_CNYMember" unitRef="CNY" decimals="0">166388</us-gaap:InterestExpense>
    <us-gaap:Revenues contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">10866449</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">10923936</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-01-01to2020-12-31_custom_DomesticPharmaceuticalsMember" unitRef="USD" decimals="0">9132216</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-01-01to2019-12-31_custom_DomesticPharmaceuticalsMember" unitRef="USD" decimals="0">10923936</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-01-01to2020-12-31_custom_COVID19TestersMember" unitRef="USD" decimals="0">1734233</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-01-01to2019-12-31_custom_COVID19TestersMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalRequiredForCapitalAdequacy contextRef="AsOf2020-12-31_us-gaap_ManagementMember" unitRef="USD" decimals="0">700000</us-gaap:CapitalRequiredForCapitalAdequacy>
    <us-gaap:LineOfCreditFacilityDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Total interest expense under this facility for the years ended December 31, 2020 and 2019 was RMB189,892 ($29,103) &#160;and $0, respectively. The Company repaid RMB 500,000 (approximately $0.07 million) and RMB 300,000 (approximately $0.05 million) to Postal Savings Bank of China in October 2020, and January 2021, respectively, as per the payment schedule.</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:LineOfCreditFacilityDescription contextRef="From2020-01-01to2020-12-31_custom_ChinaCITICBankMember">The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October under this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the advance.</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:LineOfCreditFacilityCommitmentFeeDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank.</us-gaap:LineOfCreditFacilityCommitmentFeeDescription>
    <us-gaap:OperatingLeaseCost contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">96552</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">90306</us-gaap:OperatingLeaseCost>
    <cphi:CashPaidForOperatingLeases contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">102624</cphi:CashPaidForOperatingLeases>
    <cphi:CashPaidForOperatingLeases contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">95985</cphi:CashPaidForOperatingLeases>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Permit of land use&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;431,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;403,755&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Building&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,024,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,375,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plant, machinery and equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,018,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,309,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;259,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;217,058&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,063,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,614,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24,499,327&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,300,399&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,564,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,313,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <cphi:UsefulLivesOfAssetsTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; width: 82%"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/td&gt;&#13;&#13;    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 1%"&gt;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"&gt;&lt;b&gt;Life - years&lt;/b&gt;&lt;/td&gt;&#13;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Permit of land use&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;40 - 70&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Building&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;20 - 49&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Plant, machinery and equipment&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Motor vehicle&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Office equipment&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;3 - 5&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cphi:UsefulLivesOfAssetsTableTextBlock>
    <cphi:IntangibleAssetsUsefulLifeDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.</cphi:IntangibleAssetsUsefulLifeDescription>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;52,814&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(744&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Operating lease liabilities, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,070&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Reporting Date Using&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker's acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Reporting Date Using&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker's acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">48701</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">91306</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">52070</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">505398</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">719786</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">22235222</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">21117991</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">19793115</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">19473207</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1822655</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">522386</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">536035</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">2289520</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-42260</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">-302075</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">-319908</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">608312</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-867307</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-136003</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">624177</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">338000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-1728770</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1354567</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1354567</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31_us-gaap_ManagementMember" unitRef="USD" decimals="0">163825</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.010</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2019-07-08_srt_ManagementMember" unitRef="pure" decimals="INF">0.0435</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseRelatedParty contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">13546</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="From2020-01-01to2020-12-31_srt_ManagementMember" unitRef="USD" decimals="0">43083</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="From2019-01-01to2019-12-31_srt_ManagementMember" unitRef="USD" decimals="0">12393</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">13546</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:OtherNotesPayable contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2307986</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1658706</us-gaap:OtherNotesPayable>
    <cphi:RepaymentOfAdvance contextRef="From2020-01-01to2020-12-31_srt_ManagementMember" unitRef="USD" decimals="0">191639</cphi:RepaymentOfAdvance>
    <cphi:LoanAgreementToBorrowCash contextRef="AsOf2019-07-08_srt_ManagementMember" unitRef="USD" decimals="0">674405</cphi:LoanAgreementToBorrowCash>
    <cphi:LoanAgreementToBorrowCash contextRef="AsOf2019-07-08_srt_ManagementMember_custom_CNYMember" unitRef="CNY" decimals="0">4770000</cphi:LoanAgreementToBorrowCash>
    <cphi:LoanAgreementPayableTerm contextRef="From2019-07-01to2019-07-08_srt_ManagementMember">P1Y</cphi:LoanAgreementPayableTerm>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4337231</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2020-12-31_us-gaap_LineOfCreditMember" unitRef="USD" decimals="0">2298886</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2020-12-31_us-gaap_ConstructionLoanPayableMember" unitRef="USD" decimals="0">2038345</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">904228</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="AsOf2020-12-31_us-gaap_LineOfCreditMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="AsOf2020-12-31_us-gaap_ConstructionLoanPayableMember" unitRef="USD" decimals="0">904228</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5241459</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2020-12-31_us-gaap_LineOfCreditMember" unitRef="USD" decimals="0">2298886</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2020-12-31_us-gaap_ConstructionLoanPayableMember" unitRef="USD" decimals="0">2942573</us-gaap:LongTermDebt>
    <us-gaap:ConstructionLoan contextRef="AsOf2013-06-21_custom_CNYMember" unitRef="CNY" decimals="0">80000000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="AsOf2013-06-21" unitRef="USD" decimals="0">13000000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="AsOf2020-04-30" unitRef="USD" decimals="0">1400000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1200000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="AsOf2020-04-30_custom_CNYMember" unitRef="CNY" decimals="0">10000000</us-gaap:ConstructionLoan>
    <us-gaap:ConstructionLoan contextRef="AsOf2020-06-30_custom_CNYMember" unitRef="CNY" decimals="0">8500000</us-gaap:ConstructionLoan>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2013-06-01to2013-06-21">The loan bears interest based upon 110% of the PRC government's eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The interest rate has remained at 5.39% on the anniversary dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2020-04-01to2020-04-30">The loan bears interest at a rate of 4.25% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2020-01-01to2020-06-30">The loan bears interest at the rate of 4.05% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2174399</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2174669</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-12-31_custom_CNYMember" unitRef="CNY" decimals="0">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-04-30" unitRef="USD" decimals="0">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-04-30_custom_CNYMember" unitRef="CNY" decimals="0">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-07-31" unitRef="USD" decimals="0">400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-07-31_custom_CNYMember" unitRef="CNY" decimals="0">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2019-12-31_custom_CNYMember" unitRef="CNY" decimals="0">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-12-31_custom_ThirdPartyGuaranteeMember" unitRef="USD" decimals="0">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-12-31_custom_ThirdPartyGuaranteeMember_custom_CNYMember" unitRef="CNY" decimals="0">300000</us-gaap:DebtInstrumentFaceAmount>
    <cphi:LoanTerm contextRef="From2020-04-01to2020-04-30">Advances on the line of credit are due two years from the date of the advance.</cphi:LoanTerm>
    <cphi:LoanTerm contextRef="From2020-01-01to2020-06-30">The line of credit is due in one year on the anniversary date of the line of credit.</cphi:LoanTerm>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">37800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2026-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">30738262</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">27666557</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <cphi:DescriptionOfFederalCorporateIncomeTaxRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</cphi:DescriptionOfFederalCorporateIncomeTaxRate>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerMember" unitRef="pure" decimals="INF">0.496</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerOneMember" unitRef="pure" decimals="INF">0.107</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerMember" unitRef="pure" decimals="INF">0.520</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_CustomerOneMember" unitRef="pure" decimals="INF">0.112</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_custom_SalesRevenueNetOneMember" unitRef="pure" decimals="INF">0.326</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_custom_SalesRevenueNetTwoMember" unitRef="pure" decimals="INF">0.199</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_custom_SalesRevenueNetThreeMember" unitRef="pure" decimals="INF">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2019-01-01to2019-12-31_custom_SalesRevenueNetOneMember" unitRef="pure" decimals="INF">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2019-01-01to2019-12-31_custom_SalesRevenueNetTwoMember" unitRef="pure" decimals="INF">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2019-01-01to2019-12-31_custom_SalesRevenueNetThreeMember" unitRef="pure" decimals="INF">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersMember" unitRef="pure" decimals="INF">0.207</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersOneMember" unitRef="pure" decimals="INF">0.1775</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersTwoMember" unitRef="pure" decimals="INF">0.135</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersMember" unitRef="pure" decimals="INF">0.223</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersTwoMember" unitRef="pure" decimals="INF">0.058</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2020-01-01to2020-12-31_us-gaap_AccountsReceivableMember_custom_CustomerTwoMember" unitRef="pure" decimals="INF">0.102</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember_custom_SuppliersOne1Member" unitRef="pure" decimals="INF">0.206</us-gaap:ConcentrationRiskPercentage1>
    <cphi:NumberOfCustomers contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember" unitRef="Customer" xsi:nil="true" />
    <cphi:NumberOfCustomers contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember" unitRef="Customer" decimals="INF">1</cphi:NumberOfCustomers>
    <cphi:NumberOfCustomers contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember" unitRef="Customer" decimals="INF">2</cphi:NumberOfCustomers>
    <cphi:NumberOfCustomers contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember" unitRef="Customer" decimals="INF">3</cphi:NumberOfCustomers>
    <cphi:NumberOfSuppliers contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_RawMaterialPurchasesMember" unitRef="Suppliers" decimals="INF">3</cphi:NumberOfSuppliers>
    <cphi:NumberOfSuppliers contextRef="From2019-01-01to2019-12-31_custom_RawMaterialPurchasesMember" unitRef="Suppliers" decimals="INF">3</cphi:NumberOfSuppliers>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">52814</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">52814</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:ReceivableWithImputedInterestNetAmount contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">744</us-gaap:ReceivableWithImputedInterestNetAmount>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTE 1 &amp;#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations&#13;&#13;&amp;#8211;&amp;#160;&lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation (the "Company"), owns 100% of Onny Investment&#13;&#13;Limited ("Onny"), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;#38; Biotechnology&#13;&#13;Co., Ltd ("Helpson"), a company organized under the laws of the People's Republic of China (the "PRC").&#13;&#13;China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Onny acquired 100% of the ownership in&#13;&#13;Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction&#13;&#13;was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for&#13;&#13;Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing&#13;&#13;its Wholly Foreign Owned Enterprise ("WFOE") status on June 21, 2005.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Helpson is principally engaged in the development,&#13;&#13;manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality&#13;&#13;diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities&#13;&#13;are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules,&#13;&#13;and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been&#13;&#13;approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA",&#13;&#13;formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of December 31, 2020, the Company had&#13;&#13;cash and cash equivalents of $0.96 million and an accumulated deficit of $28.6 million. The Company's Chairperson, Chief&#13;&#13;Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.7 million as of December 31, 2020 to provide&#13;&#13;working capital and enable the Company's required payments related to its construction loan facility. The Company anticipates&#13;&#13;operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing&#13;&#13;products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about&#13;&#13;its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate&#13;&#13;the conditions that raise substantial doubt about the Company's ability to continue as a going concern, management plans&#13;&#13;to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company&#13;&#13;is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes&#13;&#13;that the Company's existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8,&#13;&#13;during 2020 the Company obtained lines of credit from three banks for an aggregate amount of RMB 19,700,000 (approximately $3.0&#13;&#13;million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months,&#13;&#13;there is no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about&#13;&#13;its ability to continue as a going concern.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Pursuant to the requirements of Accounting&#13;&#13;Standards Codification (ASC) 205-40, &lt;i&gt;Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern&lt;/i&gt;&#13;&#13;management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about&#13;&#13;the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.&#13;&#13;This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have&#13;&#13;not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,&#13;&#13;management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's&#13;&#13;ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both&#13;&#13;(1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements&#13;&#13;are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise&#13;&#13;substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial&#13;&#13;statements are issued.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Under ASC 205-40, the strategic alternatives&#13;&#13;being pursued by the Company cannot be considered probable at this time because none of the Company's current plans have&#13;&#13;been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable&#13;&#13;of being effectively implemented as none of the plans are entirely within the Company's control. Accordingly, substantial&#13;&#13;doubt is deemed to exist about the Company's ability to continue as a going concern within one year after the date these&#13;&#13;financial statements are issued.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The accompanying consolidated financial&#13;&#13;statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities&#13;&#13;in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and&#13;&#13;classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of&#13;&#13;the uncertainties described above.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation&amp;#160;&lt;/i&gt;&lt;/b&gt;&amp;#8211;&#13;&#13;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted&#13;&#13;in the United States of America ("U.S. GAAP") and are expressed in United States dollars. They include the accounts&#13;&#13;and operations of the Company including its wholly-owned subsidiaries. All significant intercompany balances and transactions have&#13;&#13;been eliminated in the consolidation.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Helpson's functional currency is&#13;&#13;the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate&#13;&#13;for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses&#13;&#13;from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component&#13;&#13;of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency&#13;&#13;of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates&amp;#160;&lt;/i&gt;-&amp;#160;&lt;/b&gt;The&#13;&#13;methodology used to prepare the Company's financial statements is in conformity with U.S. GAAP, which requires the management&#13;&#13;of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures&#13;&#13;of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses&#13;&#13;during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&amp;#160;&lt;/i&gt;&lt;/b&gt;&amp;#8211;&#13;&#13;Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term&#13;&#13;banker's acceptances notes purchased with maturities of three months or less.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&amp;#160;&lt;/b&gt;&amp;#8211;&lt;b&gt;&amp;#160;&lt;/b&gt;Restricted&#13;&#13;cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes&#13;&#13;issued by the Company as discussed in Note 7.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance&#13;&#13;for Doubtful Accounts &amp;#8211;&amp;#160;&lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance&#13;&#13;for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer&#13;&#13;accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews&#13;&#13;a customer's credit history before extending credit to the customer. If the financial condition of its customers were to&#13;&#13;deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision&#13;&#13;is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled&#13;&#13;$115,186 and $3,153 for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Trade accounts&#13;receivable that has been fully allowed for and determined to be uncollectible are charged against the allowance in the period the&#13;determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $687,715 and $0&#13;against the allowance for the years ended December 31, 2020 and 2019, respectively. Customer balances outstanding for more than one&#13;year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances&#13;&#13;from Customers&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; Common practice in the PRC is to make advances to suppliers for materials and to receive advances&#13;&#13;from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received.&#13;&#13;Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews&#13;&#13;a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers&#13;&#13;were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize&#13;&#13;bad debt expense in the period they are considered unlikely to be collected.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&amp;#160;&amp;#8211; &lt;/i&gt;&lt;/b&gt;Inventory&#13;&#13;consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost&#13;&#13;is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct&#13;&#13;labor and an allocated portion of the Company's production overhead. The Company writes down excess and obsolete inventory&#13;&#13;to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and&#13;&#13;work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary&#13;&#13;course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory&#13;&#13;item is written down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost.&#13;&#13;Provisions for inventory write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories&#13;&#13;are carried at this lower cost basis until sold or scrapped.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases &amp;#8211; &lt;/i&gt;&lt;/b&gt;At lease commencement,&#13;&#13;the Company records a lease liability based on the present value of lease payments over the expected lease term including any options&#13;&#13;to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments&#13;&#13;using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's&#13;&#13;incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount&#13;&#13;equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use&#13;&#13;lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor&#13;&#13;prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term&#13;&#13;Leases"). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the&#13;&#13;leases on the condensed balance sheet.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;After lease commencement, the Company measures&#13;&#13;its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate&#13;&#13;determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any&#13;&#13;unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense&#13;&#13;and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line&#13;&#13;basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate&#13;&#13;that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to&#13;&#13;be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate&#13;&#13;that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the&#13;&#13;projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the&#13;&#13;Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2020 and 2019&#13;&#13;the Company evaluated its long-lived assets and determined that necessary impairment adjustments were $0 and $17,015,117, respectively.&amp;#160;In&#13;&#13;2019, the Company wrote off the remaining four advances for intangible assets.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements&#13;&#13;are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation&#13;&#13;relating to office equipment was included in general and administrative expenses, while all other depreciation was included in&#13;&#13;cost of revenue.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects&#13;&#13;the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires&#13;&#13;disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The&#13;&#13;Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide no significant&#13;&#13;distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange&#13;&#13;for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the&#13;&#13;promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether&#13;&#13;they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable&#13;&#13;consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or&#13;&#13;as) the Company satisfies each performance obligation.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company only applies the five-step&#13;&#13;model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods&#13;&#13;or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception,&#13;&#13;the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance&#13;&#13;obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective&#13;&#13;performance obligation when (or as) the performance obligation is satisfied. The Company's contracts are fixed price and&#13;&#13;reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company's&#13;&#13;performance obligations are transferred to customers at a point in time, typically upon buyer's designated carrier or the&#13;&#13;buyer picks up the goods at the Company's warehouse.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;For all reporting periods, the Company&#13;&#13;has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected&#13;&#13;length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received&#13;&#13;advance deposits for orders less than one year. These advances total $719,786 and $505,398 and are recorded as a liability on the&#13;&#13;accompanying balance sheet as "Advances from customers" at December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cost&#13;of Revenues&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses&#13;associated with the manufacture and delivery of products.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common&#13;&#13;Share&amp;#160;&lt;/i&gt;-&amp;#160;&lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common&#13;&#13;shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common&#13;&#13;shares.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;There were no potentially dilutive common&#13;&#13;shares outstanding during the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk&#13;&#13;in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs&#13;&#13;ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts&#13;&#13;and such allowances in the aggregate have not exceeded management's estimates.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company has its cash in bank deposits&#13;&#13;primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy&#13;&#13;of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&amp;#160;1, 2007, which&#13;&#13;contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not&#13;&#13;subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where&#13;&#13;the Company has accounts declare bankruptcy.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing&#13;&#13;debts and viability of securing future debt instruments within the PRC.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;&#13;Certain amounts in the prior period presented have been reclassified to conform to the current year presentation. There was no&#13;&#13;impact on previously reported assets, net loss or total cash flows.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In June 2016, the Financial Accounting&#13;&#13;Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13,&amp;#160;&lt;i&gt;Financial Instruments&#13;&#13;&amp;#8211; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within&#13;&#13;its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial&#13;&#13;instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting&#13;&#13;model for purchased financial assets with credit deterioration since their origination.&amp;#160;The pronouncement will be effective&#13;&#13;for public business entities that are SEC filers in fiscal years beginning after&amp;#160;December 15, 2022, including interim periods&#13;&#13;within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&amp;#160;December&#13;&#13;15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will have a material&#13;&#13;impact on its financial statements.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In December 2019, the FASB issued ASU 2019-12,&#13;&#13;&lt;i&gt;"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". &lt;/i&gt;The amendment simplifies the accounting&#13;&#13;for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification ("ASC")&#13;&#13;740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application, among other&#13;&#13;things. The guidance is effective for interim and annual reporting periods beginning within 2021 with early adoption permitted.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;From time to time, the FASB or other standards&#13;&#13;setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise&#13;&#13;discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected&#13;&#13;to have a material impact on its consolidated financial statements upon adoption.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <cphi:OrganizationAndNatureOfOperationsPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations&#13;&#13;&amp;#8211;&amp;#160;&lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation (the "Company"), owns 100% of Onny Investment&#13;&#13;Limited ("Onny"), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;#38; Biotechnology&#13;&#13;Co., Ltd ("Helpson"), a company organized under the laws of the People's Republic of China (the "PRC").&#13;&#13;China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Onny acquired 100% of the ownership in&#13;&#13;Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction&#13;&#13;was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for&#13;&#13;Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing&#13;&#13;its Wholly Foreign Owned Enterprise ("WFOE") status on June 21, 2005.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Helpson is principally engaged in the development,&#13;&#13;manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality&#13;&#13;diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities&#13;&#13;are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules,&#13;&#13;and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been&#13;&#13;approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA",&#13;&#13;formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.&lt;/p&gt;</cphi:OrganizationAndNatureOfOperationsPolicyTextBlock>
    <cphi:LiquidityAndGoingConcernPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&#13;and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of December 31, 2020, the Company had&#13;&#13;cash and cash equivalents of $0.96 million and an accumulated deficit of $28.6 million. The Company's Chairperson, Chief&#13;&#13;Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.7 million as of December 31, 2020 to provide&#13;&#13;working capital and enable the Company's required payments related to its construction loan facility. The Company anticipates&#13;&#13;operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing&#13;&#13;products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about&#13;&#13;its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate&#13;&#13;the conditions that raise substantial doubt about the Company's ability to continue as a going concern, management plans&#13;&#13;to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company&#13;&#13;is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes&#13;&#13;that the Company's existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8,&#13;&#13;during 2020 the Company obtained lines of credit from three banks for an aggregate amount of RMB 19,700,000 (approximately $3.0&#13;&#13;million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months,&#13;&#13;there is no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about&#13;&#13;its ability to continue as a going concern.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Pursuant to the requirements of Accounting&#13;&#13;Standards Codification (ASC) 205-40, &lt;i&gt;Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern&lt;/i&gt;&#13;&#13;management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about&#13;&#13;the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.&#13;&#13;This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have&#13;&#13;not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,&#13;&#13;management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's&#13;&#13;ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both&#13;&#13;(1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements&#13;&#13;are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise&#13;&#13;substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial&#13;&#13;statements are issued.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Under ASC 205-40, the strategic alternatives&#13;&#13;being pursued by the Company cannot be considered probable at this time because none of the Company's current plans have&#13;&#13;been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable&#13;&#13;of being effectively implemented as none of the plans are entirely within the Company's control. Accordingly, substantial&#13;&#13;doubt is deemed to exist about the Company's ability to continue as a going concern within one year after the date these&#13;&#13;financial statements are issued.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The accompanying consolidated financial&#13;&#13;statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities&#13;&#13;in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and&#13;&#13;classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of&#13;&#13;the uncertainties described above.&lt;/p&gt;</cphi:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Consolidation&#13;and Basis of Presentation&amp;#160;&lt;/i&gt;&lt;/b&gt;&amp;#8211; The accompanying consolidated financial statements have been prepared in accordance&#13;with accounting principles generally accepted in the United States of America ("U.S. GAAP") and are expressed in United States&#13;dollars. They include the accounts and operations of the Company including its wholly-owned subsidiaries. All significant intercompany&#13;balances and transactions have been eliminated in the consolidation.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Helpson's functional currency is&#13;&#13;the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate&#13;&#13;for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses&#13;&#13;from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component&#13;&#13;of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency&#13;&#13;of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounting&#13;Estimates&amp;#160;&lt;/i&gt;-&amp;#160;&lt;/b&gt;The methodology used to prepare the Company's financial statements is in conformity with U.S. GAAP,&#13;which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and&#13;liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported&#13;amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash&#13;Equivalents&amp;#160;&lt;/i&gt;&lt;/b&gt;&amp;#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money&#13;market accounts, and short-term banker's acceptances notes purchased with maturities of three months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted&#13;Cash&lt;/i&gt;&amp;#160;&lt;/b&gt;&amp;#8211;&lt;b&gt;&amp;#160;&lt;/b&gt;Restricted cash includes cash that has been deposited with a bank to satisfy obligations&#13;outstanding under banker's acceptance notes issued by the Company as discussed in Note 7.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance&#13;&#13;for Doubtful Accounts &amp;#8211;&amp;#160;&lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance&#13;&#13;for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer&#13;&#13;accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews&#13;&#13;a customer's credit history before extending credit to the customer. If the financial condition of its customers were to&#13;&#13;deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision&#13;&#13;is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled&#13;&#13;$115,186 and $3,153 for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Trade accounts&#13;receivable that has been fully allowed for and determined to be uncollectible are charged against the allowance in the period the&#13;determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $687,715 and $0&#13;against the allowance for the years ended December 31, 2020 and 2019, respectively. Customer balances outstanding for more than one&#13;year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advances to&#13;Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; Common practice in the PRC is to make advances to suppliers for materials&#13;and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when&#13;the materials are received. Advances received from customers are applied against trade accounts receivable when finished products&#13;are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial&#13;condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services,&#13;the Company would recognize bad debt expense in the period they are considered unlikely to be collected.&lt;/p&gt;</cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&amp;#160;&amp;#8211;&#13;&lt;/i&gt;&lt;/b&gt;Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable&#13;value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,&#13;direct labor and an allocated portion of the Company's production overhead. The Company writes down excess and obsolete inventory&#13;to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and&#13;work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary&#13;course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory&#13;item is written down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost.&#13;Provisions for inventory write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories&#13;are carried at this lower cost basis until sold or scrapped.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases &amp;#8211;&#13;&lt;/i&gt;&lt;/b&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected&#13;lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates&#13;the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest&#13;rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis&#13;to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding&#13;right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs&#13;paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or&#13;less ("Short-Term Leases"). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does&#13;not record the leases on the condensed balance sheet.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;After lease commencement, the Company measures&#13;&#13;its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate&#13;&#13;determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any&#13;&#13;unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense&#13;&#13;and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line&#13;&#13;basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation&#13;of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever&#13;events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company&#13;projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining&#13;life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated&#13;excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty&#13;both in timing and amount, the Company will use the projected discounted cash flows to be generated by the asset. For the years&#13;ended December 31, 2020 and 2019 the Company evaluated its long-lived assets and determined that necessary impairment adjustments&#13;were $0 and $17,015,117, respectively.&amp;#160;In 2019, the Company wrote off the remaining four advances for intangible assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property,&#13;Plant and Equipment&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; Property, plant and equipment are stated at cost. Maintenance and repairs are charged&#13;to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in&#13;operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative&#13;expenses, while all other depreciation was included in cost of revenue.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects&#13;the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires&#13;disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The&#13;Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide no&#13;significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive&#13;in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification&#13;of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including&#13;whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint&#13;on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue&#13;when (or as) the Company satisfies each performance obligation.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company only applies the five-step&#13;&#13;model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods&#13;&#13;or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception,&#13;&#13;the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance&#13;&#13;obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective&#13;&#13;performance obligation when (or as) the performance obligation is satisfied. The Company's contracts are fixed price and&#13;&#13;reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company's&#13;&#13;performance obligations are transferred to customers at a point in time, typically upon buyer's designated carrier or the&#13;&#13;buyer picks up the goods at the Company's warehouse.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;For all reporting periods, the Company&#13;&#13;has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected&#13;&#13;length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received&#13;&#13;advance deposits for orders less than one year. These advances total $719,786 and $505,398 and are recorded as a liability on the&#13;&#13;accompanying balance sheet as "Advances from customers" at December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture&#13;and delivery of products.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and&#13;Development&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and&#13;Diluted Loss per Common Share&amp;#160;&lt;/i&gt;-&amp;#160;&lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average&#13;number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable&#13;dilutive common shares.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;There were no potentially dilutive common&#13;&#13;shares outstanding during the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation&#13;to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing&#13;credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances&#13;in the aggregate have not exceeded management's estimates.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company has its cash in bank deposits&#13;&#13;primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy&#13;&#13;of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&amp;#160;1, 2007, which&#13;&#13;contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not&#13;&#13;subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where&#13;&#13;the Company has accounts declare bankruptcy.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <cphi:InterestRateRiskPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Interest Rate&#13;Risk&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability&#13;of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt;</cphi:InterestRateRiskPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt;&amp;#160;&amp;#8211;&#13;Certain amounts in the prior period presented have been reclassified to conform to the current year presentation. There was no&#13;impact on previously reported assets, net loss or total cash flows.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting&#13;Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In June 2016, the Financial Accounting&#13;&#13;Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13,&amp;#160;&lt;i&gt;Financial Instruments&#13;&#13;&amp;#8211; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within&#13;&#13;its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial&#13;&#13;instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting&#13;&#13;model for purchased financial assets with credit deterioration since their origination.&amp;#160;The pronouncement will be effective&#13;&#13;for public business entities that are SEC filers in fiscal years beginning after&amp;#160;December 15, 2022, including interim periods&#13;&#13;within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&amp;#160;December&#13;&#13;15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will have a material&#13;&#13;impact on its financial statements.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In December 2019, the FASB issued ASU 2019-12,&#13;&#13;&lt;i&gt;"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". &lt;/i&gt;The amendment simplifies the accounting&#13;&#13;for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification ("ASC")&#13;&#13;740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application, among other&#13;&#13;things. The guidance is effective for interim and annual reporting periods beginning within 2021 with early adoption permitted.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;From time to time, the FASB or other standards&#13;&#13;setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise&#13;&#13;discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected&#13;&#13;to have a material impact on its consolidated financial statements upon adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cphi:LinesOfCredit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">3000000</cphi:LinesOfCredit>
    <cphi:LinesOfCredit contextRef="From2020-01-01to2020-12-31_custom_ChineseYuanRenminbiMember" unitRef="CNY" decimals="0">19700000</cphi:LinesOfCredit>
    <us-gaap:InventoryDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 2 &amp;#8211;&#13;INVENTORY&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Inventory consisted of the following:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,113,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;662,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;960,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,160,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Inventory&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,705,119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,588,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,113,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;662,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;960,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,160,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Inventory&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,705,119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,588,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 3 &amp;#8211;&#13;PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Property, plant and equipment consisted of the following:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Permit of land use&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;431,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;403,755&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Building&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,024,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,375,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plant, machinery and equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,018,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,309,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;259,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;217,058&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,063,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,614,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24,499,327&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,300,399&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,564,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,313,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Depreciation is computed on a straight-line basis over the estimated&#13;&#13;useful lives of the assets as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; width: 82%"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/td&gt;&#13;&#13;    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 1%"&gt;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"&gt;&lt;b&gt;Life - years&lt;/b&gt;&lt;/td&gt;&#13;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Permit of land use&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;40 - 70&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Building&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;20 - 49&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Plant, machinery and equipment&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Motor vehicle&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Office equipment&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: center"&gt;3 - 5&lt;/td&gt;&#13;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Depreciation relating to office equipment&#13;&#13;was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years&#13;&#13;ended December 31, 2020 and 2019, depreciation expense was $2,643,820 and $2,871,134, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 4 - INTANGIBLE&#13;ASSETS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Intangible assets represent the cost of&#13;&#13;medical formulas approved for production by NMPA. The Company did not obtain NMPA production approval for any new medical formulas&#13;&#13;during the years ended December 31, 2020 and 2019 and no costs were reclassified from advances to intangible assets during the&#13;&#13;years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Approved medical formulas are amortized&#13;&#13;from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen&#13;&#13;years.&amp;#160;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could&#13;&#13;occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization&#13;&#13;expense relating to intangible assets was $35,650 and $57,665 for the years ended December 31, 2020 and 2019, respectively, which&#13;&#13;was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of&#13;&#13;their amortization period.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company evaluates each approved medical&#13;&#13;formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial&#13;&#13;statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently&#13;&#13;available market data for the related drug and the Company's estimated market share. If the carrying value of the medical&#13;&#13;formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over&#13;&#13;the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss&#13;&#13;was recognized during the years ended December 31, 2020 and 2019.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Intangible assets consisted solely of NMPA&#13;&#13;approved medical formulas as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Gross carrying amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,173,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,839,117&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,991,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,633,506&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Net carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;205,611&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The estimated aggregate annual amortization expense for each&#13;&#13;of the next five years and thereafter is as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Gross carrying amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,173,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,839,117&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,991,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,633,506&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Net carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;205,611&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">37685</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">37685</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">37685</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">37685</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">31406</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">35650</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">57665</us-gaap:AmortizationOfIntangibleAssets>
    <cphi:AdvancesForPurchasesOfIntangibleAssetsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 5 &amp;#8211;&#13;ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In order to expand the number of medicines&#13;&#13;the Company manufactured and marketed, it entered into contracts with independent laboratories and others for the purchase of medical&#13;&#13;formulas and assistance with the NMPA approval process.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Under the new regulations and policy environment,&#13;&#13;the criteria for formulations' development are more stringent. The Company must supplement and improve the corresponding&#13;&#13;processes and standards to meet the latest requirements of NMPA in accordance with the requirements of consistency evaluation.&#13;&#13;As a result, the Company anticipates an extended timeline on the approval process for its current pipeline products.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;If a medical product is not approved by&#13;&#13;the NMPA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required&#13;&#13;under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula,&#13;&#13;or the Company can require to apply those payments to another medical formula with the same laboratory. As a result of the refund&#13;&#13;right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production&#13;&#13;approval by the NMPA are recorded as advances for purchases of intangible assets.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;To date, no formula has failed to receive&#13;&#13;NMPA production approval nor has the Company been informed or been made aware of any formula that may fail to receive such approval.&#13;&#13;However, there is no assurance that the medical products will receive production approval, and if the Company does not receive&#13;&#13;such approval, it will enforce its contractual rights to receive a refund from the laboratory or have the payments applied to another&#13;&#13;medical formula with the same laboratory.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;During the year ended December 31, 2019,&#13;&#13;the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and&#13;&#13;determined that the advances made by the Company for four formulas were impaired. As a result, the Company recognized an impairment&#13;&#13;loss for the advances made to these laboratories for the year ended December 31, 2019 in the amount of $17,015,117. The management&#13;&#13;determined to impair all remaining advances at December 31, 2019, but may resume the development of these formulas in the future&#13;&#13;if sufficient funding and other favorable conditions arise.&lt;/p&gt;</cphi:AdvancesForPurchasesOfIntangibleAssetsTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">17015117</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DueFromRelatedParties contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">724963</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">740316</us-gaap:DueFromRelatedParties>
    <us-gaap:ConversionOfStockDescription contextRef="From2020-12-01to2020-12-23_us-gaap_CommonStockMember">The Board approved the issuance of 2,000,000 shares of common stock from the Company's 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The shares were issued at a market price of $0.43 per share based on the average of the closing prices during the five trading days prior to the issuance date, and higher than the closing price of $0.42 per share on the issuance date.</us-gaap:ConversionOfStockDescription>
    <us-gaap:BankingAndThriftDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 7 &amp;#8211;&#13;BANKER'S ACCEPTANCE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In April 2016, the Company entered into&#13;&#13;a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's&#13;&#13;acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the&#13;&#13;bank an amount equal to the amounts represented by the banker's acceptance notes issued to the third parties. The amount&#13;&#13;of these deposited balances is shown as "Restricted cash" on the accompanying balance sheets as of December 31, 2020&#13;&#13;and 2019. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately&#13;&#13;$4.5 million) or the amount of cash available to deposit against the banker's acceptance notes. In addition, the agreement&#13;&#13;calls for the payment of fees equal to 0.05% of the note amount to the bank. As of December 31, 2020 and December 31, 2019, the&#13;&#13;Company had outstanding banker's acceptance notes in the amount of $0 and $109,908, respectively.&lt;/p&gt;</us-gaap:BankingAndThriftDisclosureTextBlock>
    <us-gaap:LongTermDebtTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 8 &amp;#8211; CONSTRUCTION LOAN FACILITY&#13;&#13;AND LINES OF CREDIT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Construction Loan Facility&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company obtained a construction loan&#13;&#13;facility dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility is for an&#13;&#13;eight-year term, which commenced on July 11, 2013, the initial draw-down date.&amp;#160;The proceeds of the loan were used for and&#13;&#13;are collateralized by the construction of the Company's new production facility and the included production line equipment&#13;&#13;and machinery. The loan bears interest based upon 110% of the PRC government's eight-year term rate effective on the actual&#13;&#13;draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from&#13;&#13;the draw-down date and its subsequent anniversary dates.&amp;#160;The interest rate has remained at 5.39% on the anniversary&#13;&#13;dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years.&#13;&#13;Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due&#13;&#13;within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over&#13;&#13;the next five years through July 11, 2021 on the identical terms as described above for 2015. The Company has made all required&#13;&#13;payments due under the loan. As of December 31, 2020, the Company had no additional amounts available to it under this facility.&#13;&#13;During the years ended December 31, 2020 and 2019, the Company made principal payments in the amount of $2,174,669 (RMB 15,000,000)&#13;&#13;and $2,174,399 (RMB 15,000,000), respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Lines of Credit&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;In&#13;April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately&#13;$1.4 million), of which RMB 5,000,000 (approximately $0.7 million) were advanced in April, and RMB 3,000,000 (approximately $0.4 million)&#13;were advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from&#13;the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain&#13;land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company's&#13;Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has an additional RMB 2,000,000&#13;(approximately $0.3 million)&lt;/font&gt;&amp;#160; &lt;font style="font-family: Times New Roman, Times, Serif"&gt;available under the line, subject to&#13;a risk review and approval by the third party guarantee company. Total interest expense under this facility for the years ended December&#13;31, 2020 and 2019 was RMB189,892&lt;/font&gt; (&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$29,103)&lt;/font&gt; &amp;#160;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;and&#13;$0, respectively. The Company repaid RMB 500,000 (approximately $0.07 million) and RMB 300,000 (approximately $0.05 million) to Postal&#13;Savings Bank of China in October 2020, and January 2021, respectively, as per the payment schedule.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 30, 2020 the Company obtained a line of&#13;credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million) of which RMB 8,500,000 have been&#13;advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the&#13;line of credit. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of&#13;credit and pledged personal assets as collateral for the loan. Total interest expense for the years ended December 31, 2020 and 2019 was&#13;RMB166,388 ($25,500) and $0, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;The&#13;Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an&#13;advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October under&#13;this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the&#13;advance. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit&#13;and pledged personal assets as collateral for the loan. Total interest for the year ended December 31, 2020 was RMB33,723 ($5,168).&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Principal payments required for the remaining&#13;&#13;terms of the loan facility and the lines of credit for the years ended December 31, are as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lines of Credit&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Construction Loan Facility&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 63%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,298,886&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,038,345&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,337,231&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;904,228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;904,228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,298,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,942,573&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,241,459&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Construction Loan Facility&#13;&#13;and Lines of Credit&lt;/i&gt;&lt;/b&gt; &amp;#8211; Based on the borrowing rates currently available to the Company for bank loans with similar&#13;&#13;terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2020 and December 31,&#13;&#13;2019 approximated their fair value because the underlying instrument bears an interest rate that approximated current market rates.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lines of Credit&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Construction Loan Facility&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 63%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,298,886&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,038,345&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,337,231&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;904,228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;904,228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,298,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,942,573&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,241,459&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <cphi:AdvanceLoanAmount contextRef="AsOf2020-06-30_custom_CNYMember" unitRef="CNY" decimals="0">8500000</cphi:AdvanceLoanAmount>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 9 - LEASES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company has leases for certain office&#13;&#13;and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts.&#13;&#13;Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates&#13;&#13;to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed&#13;&#13;by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company's&#13;&#13;incremental borrowing rate at the initial measurement date. For the years ended December 31, 2020 and 2019, operating lease cost&#13;&#13;was $96,552 and $90,306, respectively and cash paid for amounts included in the measurement of lease liabilities for operating&#13;&#13;cash flows from operating leases was $102,624 and $95,985, respectively. As of December 31, 2020 and December 31, 2019, the Company&#13;&#13;reported operating lease right of use assets of $49,687 and $136,779, respectively and operating use liabilities of $52,070 and&#13;&#13;$140,007, respectively. As of December 31, 2020, its operating leases had a weighted average remaining lease term of 0.52 years&#13;&#13;and a weighted average discount rate of 4.75%.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Minimum lease payments for the Company's operating lease&#13;&#13;liabilities were as follows for the years ended December 31:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;52,814&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(744&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Operating lease liabilities, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,070&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The Company has leases with terms of less than one year for&#13;&#13;certain provincial sales offices that are not material.&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-716694</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-5175512</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8190</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">8103</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">708504</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">5167409</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <cphi:IncomeTaxExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <cphi:IncomeTaxExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4393775</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4537623</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">5682</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6822</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1528482</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">568182</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1085520</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1160601</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">753444</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">805556</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">30759656</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">27667153</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1296813</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1409380</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">12682671</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">9542576</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">807</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">596</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9765906</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">10441373</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <cphi:NetOperatingLossCarryForwardsExpirationDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Approximately $23.1 million of loss carryforwards expired in December 2020. The Company also has net operating losses for United States federal income tax purposes of approximately $6.7 million of which $5.1 million are available to offset future taxable income, if any, through 2039, and $1.6 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.</cphi:NetOperatingLossCarryForwardsExpirationDescription>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 11 &amp;#8211;&#13;FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Fair value is defined as the exchange price&#13;&#13;that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market&#13;&#13;for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value,&#13;&#13;a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable&#13;&#13;inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &amp;#8211;&#13;&#13;Quoted prices in active markets for identical assets or liabilities; Level 2 &amp;#8211; Observable inputs other than Level 1 including&#13;&#13;quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated&#13;&#13;by observable market data; and Level 3 &amp;#8211; Unobservable inputs supported by little or no market activity for financial instruments&#13;&#13;whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments&#13;&#13;for which the determination of fair value requires significant management judgment or estimation.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company uses fair value to measure&#13;&#13;the value of the banker's acceptance notes it holds at December 31, 2020 and 2019.&amp;#160;The banker's acceptance notes&#13;&#13;are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at&#13;&#13;fair value:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Reporting Date Using&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker's acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;53,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Reporting Date Using&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker's acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 12 - STOCKHOLDERS'&#13;EQUITY&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company is authorized to issue 95,000,000&#13;&#13;shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be&#13;&#13;issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely&#13;&#13;by the Company's Board.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;According to relevant PRC laws, companies&#13;&#13;registered in the PRC, including the Company's PRC subsidiary, Helpson, are required to allocate at least 10% of their after&#13;&#13;tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until&#13;&#13;the reserve account balances reach 50% of the company's registered capital prior to their remittance of funds out of the&#13;&#13;PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company&#13;&#13;in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000&#13;&#13;for each of the fiscal years ended December 31, 2020 and 2019.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;Employee Stock Options&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;i&gt;2010 Incentive Plan&lt;/i&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On November 12, 2010, the Company's&#13;&#13;Board adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December&#13;&#13;22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the "Amendment"),&#13;&#13;pursuant to which the term of the 2010 Incentive Plan shall be extended to December 31, 2029. The Amendment was adopted by the&#13;&#13;shareholders on December 19, 2019. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation&#13;&#13;rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants&#13;&#13;of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock.&#13;&#13;Through December 31, 2019, there were 175,000 shares of restricted stock granted and outstanding under the Plan. No options&#13;&#13;were outstanding as of December 31, 2019 under the Plan.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On December 23, 2020 the Board approved&#13;&#13;the issuance of 2,000,000 shares of common stock from the Company's 2010 Long-Term Incentive Plan, as amended for the partial&#13;&#13;conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer&#13;&#13;as discussed in Note 6. There were no securities issued from the Plan during the year ended December 31, 2019.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company recognized no compensation&#13;&#13;expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended&#13;&#13;December 31, 2020 and 2019.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of December 31, 2020, there was no remaining&#13;&#13;unrecognized compensation expense related to stock options or restricted stock grants.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cphi:IntercompanyReceivables contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">8084779</cphi:IntercompanyReceivables>
    <cphi:IntercompanyReceivables contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">7746779</cphi:IntercompanyReceivables>
    <us-gaap:EquityMethodInvestmentAggregateCost contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">11705241</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">11705241</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:OtherLiabilities contextRef="AsOf2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">2401344</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="AsOf2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">1752990</us-gaap:OtherLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLiabilities contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">220311</us-gaap:IncreaseDecreaseInOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLiabilities contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">216127</us-gaap:IncreaseDecreaseInOperatingLiabilities>
    <cphi:ProceedsOfChangeIntercompanyReceivables contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">300000</cphi:ProceedsOfChangeIntercompanyReceivables>
    <cphi:ProceedsOfChangeIntercompanyReceivables contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">338000</cphi:ProceedsOfChangeIntercompanyReceivables>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-01-01to2019-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">-2075</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2020-01-01to2020-12-31_us-gaap_ParentMember" unitRef="USD" decimals="0">18092</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:AssetImpairmentCharges contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetImpairmentCharges contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">17015117</us-gaap:AssetImpairmentCharges>
    <cphi:BadDebtExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">115186</cphi:BadDebtExpense>
    <cphi:BadDebtExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">3153</cphi:BadDebtExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">687715</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;NOTE&#13;15 - CONDENSED PARENT COMPANY ONLY FINANCIAL STATEMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The condensed parent company only financial information for&#13;&#13;China Pharma Holdings Inc. is presented below:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Condensed Comparative Balance Sheets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Current Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Intercompany receivables&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,746,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,084,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Investment in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,705,241&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,705,241&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;TOTAL ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,473,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,793,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities - other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,752,990&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,401,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Stockholders' Equity&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,720,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,391,771&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,473,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,793,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;The parent company had no&amp;#160;contingencies, long-term obligations and guarantees as of December 31, 2020&amp;#160;and 2019.&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Condensed Comparative Schedule of Operations&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt; December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;536,035&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;522,386&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(536,035&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(522,386&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Condensed Comparative Schedule of Cash Flows&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt; December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Cash Flows from Operating Activities:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(536,035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(522,386&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Changes in assets and liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;216,127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;220,311&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net Cash Used in Operating Activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(319,908&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(302,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net Cash Used in Investing Activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Cash Flows from Financing Activities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Change in intercompany receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net Cash Used in Financing Activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Net Decrease in Cash and Cash Equivalents&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,075&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Cash and Cash Equivalents at Beginning of Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,170&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Cash and Cash Equivalents at End of Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Condensed&#13;Comparative Balance Sheets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Current Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Intercompany receivables&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,746,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,084,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Investment in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,705,241&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,705,241&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;TOTAL ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,473,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,793,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities - other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,752,990&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,401,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Stockholders' Equity&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,720,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,391,771&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,473,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,793,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Condensed Comparative Schedule of Operations&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt; December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;536,035&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;522,386&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(536,035&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(522,386&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Condensed Comparative Schedule of Cash Flows&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt; December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Cash Flows from Operating Activities:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(536,035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(522,386&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Changes in assets and liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;216,127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;220,311&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net Cash Used in Operating Activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(319,908&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(302,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net Cash Used in Investing Activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Cash Flows from Financing Activities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Change in intercompany receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Net Cash Used in Financing Activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Net Decrease in Cash and Cash Equivalents&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,075&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Cash and Cash Equivalents at Beginning of Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,170&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Cash and Cash Equivalents at End of Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">0001106644</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCurrentReportingStatus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityShellCompany contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:EntityShellCompany>
    <dei:EntitySmallBusiness contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-22" unitRef="shares" decimals="INF">45579557</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityFileNumber contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">001-34471</dei:EntityFileNumber>
    <dei:EntityInteractiveDataCurrent contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityIncorporationStateCountryCode contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityWellKnownSeasonedIssuer contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">No</dei:EntityVoluntaryFilers>
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">16225327</dei:EntityPublicFloat>
    <cphi:BankersAcceptances contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">45756</cphi:BankersAcceptances>
    <cphi:BankersAcceptances contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">53736</cphi:BankersAcceptances>
    <us-gaap:ReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">635371</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">501892</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">46643</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">27652</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <cphi:AdvanceToSupplies contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">404</cphi:AdvanceToSupplies>
    <cphi:AdvanceToSupplies contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2238</cphi:AdvanceToSupplies>
    <us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">77120</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">73668</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">205611</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">182146</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AccountsPayableTradeCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1366330</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1234594</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">189880</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">177359</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">3560332</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2748208</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2071986</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2134428</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermConstructionLoanCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2150168</us-gaap:LongTermConstructionLoanCurrent>
    <us-gaap:LongTermConstructionLoanCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2298886</us-gaap:LongTermConstructionLoanCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:LinesOfCreditCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2038345</us-gaap:LinesOfCreditCurrent>
    <us-gaap:BankAcceptancesExecutedAndOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">109908</us-gaap:BankAcceptancesExecutedAndOutstanding>
    <us-gaap:BankAcceptancesExecutedAndOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">10045308</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">11403676</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConstructionLoanNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2150168</us-gaap:ConstructionLoanNoncurrent>
    <us-gaap:ConstructionLoanNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermLineOfCredit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermLineOfCredit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">904228</us-gaap:LongTermLineOfCredit>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">753444</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">805556</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">12997621</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">13113460</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">43580</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">45580</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">23590204</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">24452684</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-25972402</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-28839179</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">11576219</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">12345446</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">17575100</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">18150493</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">22729</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">27289</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">43579557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">45579557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">43579557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">45579557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CostOfRevenue contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8913543</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">9441752</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1952906</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">1482184</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2215394</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">2352610</us-gaap:SellingExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">377964</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">229637</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">115186</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">3153</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4531199</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">21890037</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-2578293</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-20407853</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5675</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">27527</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-288484</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-294191</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-2866777</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-20702044</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">769227</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">259130</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-2097550</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-20442914</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USD_per_Share" decimals="INF">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">43623273</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="shares" decimals="INF">43579557</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">43579557</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">45579557</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">43579557</us-gaap:SharesOutstanding>
    <cphi:ForeignCurrencyTranslationAdjustment contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">769227</cphi:ForeignCurrencyTranslationAdjustment>
    <cphi:ForeignCurrencyTranslationAdjustment contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">769227</cphi:ForeignCurrencyTranslationAdjustment>
    <cphi:ForeignCurrencyTranslationAdjustment contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-259130</cphi:ForeignCurrencyTranslationAdjustment>
    <cphi:ForeignCurrencyTranslationAdjustment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-259130</cphi:ForeignCurrencyTranslationAdjustment>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">864480</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">862480</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2679470</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">2928799</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InventoryWriteDown contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:InventoryWriteDown contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">253465</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">613678</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">478918</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <cphi:IncreaseDecreaseInPrepaidSuppliers contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1708</cphi:IncreaseDecreaseInPrepaidSuppliers>
    <cphi:IncreaseDecreaseInPrepaidSuppliers contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">361</cphi:IncreaseDecreaseInPrepaidSuppliers>
    <us-gaap:IncreaseDecreaseInInventories contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-807592</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-1999978</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-214015</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">324180</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-15217</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">391171</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-111160</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-1158728</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">169736</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-12875</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-8311</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-45375</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">867307</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">136003</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:RepaymentsOfConstructionLoansPayable contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2174669</us-gaap:RepaymentsOfConstructionLoansPayable>
    <us-gaap:RepaymentsOfConstructionLoansPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">2174399</us-gaap:RepaymentsOfConstructionLoansPayable>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2856066</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">72489</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">206908</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">691459</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">191639</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">245830</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">58156</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-19179</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-227234</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-1275640</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">237530</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">299164</us-gaap:InterestPaidNet>
    <cphi:AccountsReceivableCollectedWithBankersAcceptances contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">687347</cphi:AccountsReceivableCollectedWithBankersAcceptances>
    <cphi:AccountsReceivableCollectedWithBankersAcceptances contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">869625</cphi:AccountsReceivableCollectedWithBankersAcceptances>
    <cphi:ConversionOfOfficerWagesToCommonStock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">864480</cphi:ConversionOfOfficerWagesToCommonStock>
    <cphi:ConversionOfOfficerWagesToCommonStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <cphi:InventoryPurchasedWithBankersAcceptanceNote contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">682791</cphi:InventoryPurchasedWithBankersAcceptanceNote>
    <cphi:InventoryPurchasedWithBankersAcceptanceNote contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">843867</cphi:InventoryPurchasedWithBankersAcceptanceNote>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">229673</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">229644</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Years Ended &lt;br /&gt;&#13;&#13;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;(Benefit) tax at statutory rate of 25%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(716,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,175,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Prior year refund received&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Other, primarily the difference in U.S. tax rates&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;708,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,167,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred income tax assets:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Allowance for doubtful trade receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,537,623&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,393,775&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Allowance for doubtful other receivables&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Inventory obsolescence reserve&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;568,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,528,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expenses not deductible in current year&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,160,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,085,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Advances for intangible assets impairment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,441,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,765,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Lease liability, net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;596&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;807&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;PRC net operating loss carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,542,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,682,671&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. net operating loss carry forward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,409,380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,296,813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,667,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,759,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,667,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,759,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred income tax asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred income tax liability:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;805,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;753,444&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandTenIncentivePlanMember" unitRef="shares" decimals="INF">4000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandTenIncentivePlanMember" unitRef="shares" decimals="INF">175000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8145000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">8145000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <cphi:AftertaxNetIncomePercentage contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.10</cphi:AftertaxNetIncomePercentage>
    <cphi:ReserveAccountBalancesPercentage contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.50</cphi:ReserveAccountBalancesPercentage>
    <cphi:SharesOfCommonStock contextRef="From2020-01-01to2020-12-23" unitRef="shares" decimals="INF">2000000</cphi:SharesOfCommonStock>
    <cphi:PartialConversionOfUnpaid contextRef="AsOf2020-12-23" unitRef="USD" decimals="0">864480</cphi:PartialConversionOfUnpaid>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 14 &amp;#8211; RISKS &amp;#38; UNCERTAINTIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Current vulnerability&#13;due to certain concentrations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;For&#13;the year ended December 31, 2020, one customer accounted for 16.0% of sales and three customers respectively accounted for 52.0%,&#13;11.2% and 10.2% of accounts receivable. Three suppliers respectively accounted for 20.7%, 17.75 and 13.5%&lt;/font&gt;&amp;#160; &lt;font style="font-family: Times New Roman, Times, Serif"&gt;of&#13;raw material purchases, and three different products respectively accounted for 32.6%, 19.9% and 16.0% of revenue.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;For the year ended December 31, 2019, no&#13;&#13;customer accounted for more than 10% of sales and two customers accounted for 49.6% and 10.7% of accounts receivable. Three suppliers&#13;&#13;accounted for 22.3%, 20.6% and 5.8% of raw material purchases, and three different products accounted for 33%, 21% and 17% of revenue.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Nature of Operations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Impact from the New Coronavirus Global&#13;&#13;Pandemic ("COVID-19") &lt;/b&gt;- The current outbreak of COVID-19 could have a material and adverse effect on the Company's&#13;&#13;business operations. These could include disruptions or restrictions on the Company's ability to distribute its products,&#13;&#13;as well as temporary closures of its facilities or the facilities of the suppliers or customers. Any disruption or delay of the&#13;&#13;Company's suppliers or customers would likely impact the Company's sales and operating results. In addition, COVID-19&#13;&#13;has resulted in a widespread health crisis that could adversely affect the economies and financial markets of China and many other&#13;&#13;countries, resulting in an economic downturn that could significantly impact our operating results.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Economic environment - &lt;/b&gt;Substantially&#13;&#13;all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations&#13;&#13;and significant risks not typically associated with companies operating in the United States of America. These risks include, among&#13;&#13;others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's&#13;&#13;results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes&#13;&#13;in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad,&#13;&#13;and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely&#13;&#13;affect the Company's operations.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Foreign Currency Risk&lt;/b&gt; &amp;#8211; The&#13;&#13;Company is exposed to foreign currency risk related to its operations. All of the Company's revenue and the majority of expenses&#13;&#13;are denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance&#13;&#13;out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval&#13;&#13;of the PRC government. The Company has not entered into any forward contracts or derivative instruments mitigating this risk.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Credit&#13;&#13;Risk&lt;/b&gt; &amp;#8211; The carrying amount of accounts receivable included in the balance sheet represents the Company's&#13;&#13;exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to&#13;&#13;credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company&#13;&#13;maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded management's&#13;&#13;estimates.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company has its cash in bank deposits&#13;&#13;primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy&#13;&#13;of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&amp;#160;1, 2007, which&#13;&#13;contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not&#13;&#13;subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where&#13;&#13;the Company has accounts declare bankruptcy.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 6 &amp;#8211; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;A member of the Company's board of&#13;&#13;directors ("Board") had advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2020 and 2019&#13;&#13;which are recorded as "Other payables &amp;#8211; related parties" on the accompanying consolidated balance sheets. The&#13;&#13;advances bear interest at a rate of 1.0% per year.&amp;#160;Total interest expense for the years ended December 31, 2020 and&#13;&#13;2019 was $13,546 and $13,546, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company received advances totaling $163,825&#13;during the year ended December 31, 2020 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer; and paid back&#13;$191,639&amp;#160;to her in the same period. Total amounts owed were $740,316 and $724,963&amp;#160;and are recorded as "Borrowings from&#13;related parties" on the accompanying consolidated balance sheets as of December 31, 2020 and December 31, 2019, respectively. On&#13;July 8, 2019 the Company entered into a loan agreement for cash of RMB 4,770,000 ($674,405) with its Chairperson, Chief Executive Officer&#13;and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement.&#13;The due date of the loan agreement was extended to July 10, 2021. Total interest expense related to the loan for the years ended December&#13;31, 2020 and 2019 was $43,083 and $12,393, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Compensation payable to the Chairperson,&#13;&#13;Chief Executive Officer and Interim Chief Financial Officer is included in "Other payables" in the accompanying consolidated&#13;&#13;balance sheets totaling $1,658,706 and $2,307,986 as of December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On December 23, 2020 the Board approved&#13;&#13;the issuance of 2,000,000 shares of common stock from the Company's 2010 Long-Term Incentive Plan, as amended for the partial&#13;&#13;conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer.&#13;&#13;The shares were issued at a market price of $0.43 per share based on the average of the closing prices during the five trading&#13;&#13;days prior to the issuance date, and higher than the closing price of $0.42 per share on the issuance date.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1184887</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">957653</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2460527</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">109908</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1184887</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">957653</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTE 10 - INCOME TAXES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Deferred income tax assets and liabilities&#13;&#13;are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected&#13;&#13;to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in&#13;&#13;income in the period that includes the enactment date.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Liabilities are established for uncertain&#13;&#13;tax positions expected to be taken in income tax returns when such positions are judged to meet the "more-likely-than-not"&#13;&#13;threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are&#13;&#13;included as a component of other expenses. Through December 31, 2020, the Company has not identified any uncertain tax positions&#13;&#13;that it has taken. U.S. income tax returns for the years ended December 31, 2017 through December 31, 2020 and the Chinese income&#13;&#13;tax return for the year ended December 31, 2020 are open for possible examination.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Under the current tax law in the PRC, the Company is and will&#13;&#13;be subject to the enterprise income tax rate of 25%.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;There was no provision for income taxes&#13;&#13;for the years ended December 31, 2020 and 2019, respectively due to continued net losses of the Company.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Following is a reconciliation of income&#13;&#13;taxes calculated at the federal statutory rates to the provision for income taxes:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Years Ended &lt;br /&gt;&#13;&#13;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;(Benefit) tax at statutory rate of 25%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(716,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,175,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Prior year refund received&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Other, primarily the difference in U.S. tax rates&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;708,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,167,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The temporary differences which give rise&#13;&#13;to the deferred income tax assets and liability are as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred income tax assets:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Allowance for doubtful trade receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,537,623&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,393,775&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Allowance for doubtful other receivables&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Inventory obsolescence reserve&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;568,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,528,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expenses not deductible in current year&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,160,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,085,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Advances for intangible assets impairment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,441,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,765,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Lease liability, net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;596&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;807&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;PRC net operating loss carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,542,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,682,671&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. net operating loss carry forward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,409,380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,296,813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,667,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,759,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,667,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,759,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred income tax asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred income tax liability:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;805,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;753,444&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of December 31, 2020, the Company had&#13;&#13;net operating loss carryforwards for PRC tax purposes of approximately $37.8 million which are available to offset any future taxable&#13;&#13;income through 2026. Approximately $23.1 million of loss carryforwards expired in December 2020. The Company also has net operating&#13;&#13;losses for United States federal income tax purposes of approximately $6.7 million of which $5.1 million are available to offset&#13;&#13;future taxable income, if any, through 2039, and $1.6 million are available for carryforward indefinitely subject to a limitation&#13;&#13;of 80% of taxable income for each tax year.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Recent U.S. federal tax legislation, commonly&#13;&#13;referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Reform"), was signed into law on December&amp;#160;22, 2017. The&#13;&#13;U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal&#13;&#13;corporate income tax rate from 35% to 21% for taxable years beginning after December&amp;#160;31, 2017; limiting and/or eliminating&#13;&#13;many business deductions; migrating the U.S. to a territorial tax system with a&amp;#160;one-time&amp;#160;transition tax on a mandatory&#13;&#13;deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally&#13;&#13;eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;In&#13;assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all&#13;of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of&#13;future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management&#13;considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level&#13;of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible&#13;or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December&#13;31, 2020 and 2019. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $27,666,557&lt;/font&gt;&amp;#160;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;and&#13;$30,738,262 as of December 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company also incurred various other&#13;&#13;taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any&#13;&#13;unpaid amounts are reflected on the balance sheets as accrued taxes payable.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;NOTE 13 &amp;#8211; REVENUE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The following table summarizes the Company's&#13;&#13;revenues disaggregated by revenue source and geography based on the Company's PRC based business locations:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Domestic Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,132,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,923,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;COVID 19 Testers Exported to Puerto Rico&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,734,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,866,449&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,923,936&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&#13;    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Domestic Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,132,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,923,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&#13;    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;COVID 19 Testers Exported to Puerto Rico&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,734,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&#13;    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,866,449&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,923,936&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cphi-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: cphi%2D20201231.xfr; Date: 2021%2D03%2D26T15:57:02Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9Kopw7xRiXhun8uMZn9cOaKMqbOdxZRxeekxvWB6bTkq/ysiIrFgfi5Hv+b2UeQN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:cphi="http://chinapharmaholdings.com/20201231" elementFormDefault="qualified" targetNamespace="http://chinapharmaholdings.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementsOfOperationsAndComprehensiveIncomeLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" id="OrganizationAndSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - Organization and Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Inventory" id="Inventory">
	  <link:definition>00000008 - Disclosure - Inventory</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
	  <link:definition>00000009 - Disclosure - Property, Plant and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000010 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" id="AdvancesForPurchasesOfIntangibleAssets">
	  <link:definition>00000011 - Disclosure - Advances for Purchases of Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" id="BankersAcceptanceNotesPayable">
	  <link:definition>00000013 - Disclosure - Banker's Acceptance Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacility" id="ConstructionLoanFacility">
	  <link:definition>00000014 - Disclosure - Construction Loan Facility and Lines of Credit</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Leases" id="Leases">
	  <link:definition>00000015 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000017 - Disclosure - Fair Value Measurements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000018 - Disclosure - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Revenue" id="Revenue">
	  <link:definition>00000019 - Disclosure - Revenue</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/RisksUncertainties" id="RisksUncertainties">
	  <link:definition>00000020 - Disclosure - Risks &amp; Uncertainties</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" id="ParentCompanyOnlyFinancialStatement">
	  <link:definition>00000021 - Disclosure - Condensed Parent Company Only Financial Statement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" id="OrganizationAndSignificantAccountingPoliciesPolicies">
	  <link:definition>00000022 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Inventorytables" id="Inventorytables">
	  <link:definition>00000023 - Disclosure - Inventory (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" id="PropertyPlantAndEquipmenttables">
	  <link:definition>00000024 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000025 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" id="ConstructionLoanFacilityTables">
	  <link:definition>00000026 - Disclosure - Construction Loan Facility and Lines of Credit (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000027 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000028 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/RevenueTables" id="RevenueTables">
	  <link:definition>00000030 - Disclosure - Revenue (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" id="ParentCompanyOnlyFinancialStatementTables">
	  <link:definition>00000031 - Disclosure - Condensed Parent Company Only Financial Statement (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" id="Organizationandsignificantaccountingpoliciesdetails">
	  <link:definition>00000032 - Disclosure - Organization and Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Inventorydetails" id="Inventorydetails">
	  <link:definition>00000033 - Disclosure - Inventory (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" id="PropertyPlantAndEquipmentDetails">
	  <link:definition>00000034 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" id="PropertyPlantAndEquipmentDetails1">
	  <link:definition>00000035 - Disclosure - Property, Plant and Equipment (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" id="PropertyPlantAndEquipmentdetailsTextual">
	  <link:definition>00000036 - Disclosure - Property, Plant and Equipment (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetails" id="Intangibleassetsdetails">
	  <link:definition>00000037 - Disclosure - Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000038 - Disclosure - Intangible Assets (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" id="Intangibleassetsdetailstextual">
	  <link:definition>00000039 - Disclosure - Intangible Assets (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" id="AdvancesForPurchasesOfIntangibleAssetsDetails">
	  <link:definition>00000040 - Disclosure - Advances for Purchases of Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
	  <link:definition>00000041 - Disclosure - Related Party Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" id="BankersAcceptanceNotesPayableDetails">
	  <link:definition>00000042 - Disclosure - Banker's Acceptance Notes Payable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" id="ConstructionLoanFacilityDetails">
	  <link:definition>00000043 - Disclosure - Construction Loan Facility and Lines of Credit (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" id="ConstructionLoanFacilityDetailsTextual">
	  <link:definition>00000044 - Disclosure - Construction Loan Facility and Lines of Credit (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/LeasesDetails" id="LeasesDetails">
	  <link:definition>00000045 - Disclosure - Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/LeasesDetailsTextual" id="LeasesDetailsTextual">
	  <link:definition>00000046 - Disclosure - Leases (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000047 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000048 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
	  <link:definition>00000049 - Disclosure - Income Taxes (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
	  <link:definition>00000050 - Disclosure - Fair Value Measurements (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000051 - Disclosure - Stockholders' Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/RevenueDetails" id="RevenueDetails">
	  <link:definition>00000052 - Disclosure - Revenue (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" id="RisksUncertaintiesDetails">
	  <link:definition>00000053 - Disclosure - Risks &amp; Uncertainties (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" id="ParentCompanyOnlyFinancialStatementDetails">
	  <link:definition>00000054 - Disclosure - Condensed Parent Company Only Financial Statement (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" id="ParentCompanyOnlyFinancialStatementDetails1">
	  <link:definition>00000055 - Disclosure - Condensed Parent Company Only Financial Statement (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" id="ParentCompanyOnlyFinancialStatementDetails2">
	  <link:definition>00000056 - Disclosure - Condensed Parent Company Only Financial Statement (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="cphi_MotorVehicleGross" name="MotorVehicleGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_OfficeEquipmentGross" name="OfficeEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AccumulatedDeficit" name="AccumulatedDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CashPaidForOperatingLeases" name="CashPaidForOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_UsefulLivesOfAssetsTableTextBlock" name="UsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_IntangibleAssetsUsefulLifeDescription" name="IntangibleAssetsUsefulLifeDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_RepaymentOfAdvance" name="RepaymentOfAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_LoanAgreementToBorrowCash" name="LoanAgreementToBorrowCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_LoanAgreementPayableTerm" name="LoanAgreementPayableTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_LoanTerm" name="LoanTerm" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_DescriptionOfFederalCorporateIncomeTaxRate" name="DescriptionOfFederalCorporateIncomeTaxRate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_NumberOfCustomers" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_NumberOfSuppliers" name="NumberOfSuppliers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" name="OrganizationAndNatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" name="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_InterestRateRiskPolicyTextBlock" name="InterestRateRiskPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_LinesOfCredit" name="LinesOfCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock" name="AdvancesForPurchasesOfIntangibleAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvanceLoanAmount" name="AdvanceLoanAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_IncomeTaxExpense" name="IncomeTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_NetOperatingLossCarryForwardsExpirationDescription" name="NetOperatingLossCarryForwardsExpirationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_IntercompanyReceivables" name="IntercompanyReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ProceedsOfChangeIntercompanyReceivables" name="ProceedsOfChangeIntercompanyReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_BadDebtExpense" name="BadDebtExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_BankersAcceptances" name="BankersAcceptances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvanceToSupplies" name="AdvanceToSupplies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ForeignCurrencyTranslationAdjustment" name="ForeignCurrencyTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_IncreaseDecreaseInPrepaidSuppliers" name="IncreaseDecreaseInPrepaidSuppliers" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AccountsReceivableCollectedWithBankersAcceptances" name="AccountsReceivableCollectedWithBankersAcceptances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ConversionOfOfficerWagesToCommonStock" name="ConversionOfOfficerWagesToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_InventoryPurchasedWithBankersAcceptanceNote" name="InventoryPurchasedWithBankersAcceptanceNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AftertaxNetIncomePercentage" name="AftertaxNetIncomePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ReserveAccountBalancesPercentage" name="ReserveAccountBalancesPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SharesOfCommonStock" name="SharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_PartialConversionOfUnpaid" name="PartialConversionOfUnpaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_Subsidiaries1Member" name="Subsidiaries1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_PermitOfLandUseMember" name="PermitOfLandUseMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_TwoThousandTenIncentivePlanMember" name="TwoThousandTenIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CustomerMember" name="CustomerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_RawMaterialPurchasesMember" name="RawMaterialPurchasesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CustomerThreeMember" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvancesForIntangibleAssetsMember" name="AdvancesForIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvancesToSuppliersMember" name="AdvancesToSuppliersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SalesRevenueNetOneMember" name="SalesRevenueNetOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SalesRevenueNetTwoMember" name="SalesRevenueNetTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SalesRevenueNetThreeMember" name="SalesRevenueNetThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CNYMember" name="CNYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SuppliersMember" name="SuppliersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SuppliersOneMember" name="SuppliersOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SuppliersTwoMember" name="SuppliersTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_Subsidiaries3Member" name="Subsidiaries3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ChineseYuanRenminbiMember" name="ChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_PostalSavingsBankOfChinaMember" name="PostalSavingsBankOfChinaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_BankOfCommunicationsMember" name="BankOfCommunicationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_DomesticPharmaceuticalsMember" name="DomesticPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ExportMedicalTestKitsMember" name="ExportMedicalTestKitsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ChinaCITICBankMember" name="ChinaCITICBankMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ThirdPartyGuaranteeMember" name="ThirdPartyGuaranteeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_COVID19TestersMember" name="COVID19TestersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_SuppliersOne1Member" name="SuppliersOne1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" name="AdvancesForPurchasesOfIntangibleAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_BankersAcceptanceNotesPayableAbstract" name="BankersAcceptanceNotesPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_RisksUncertaintiesAbstract" name="RisksUncertaintiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CondensedParentCompanyOnlyFinancialStatementAbstract" name="CondensedParentCompanyOnlyFinancialStatementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract" name="CondensedParentCompanyOnlyFinancialStatementTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_TypesOfCurrencyAxis" name="TypesOfCurrencyAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="cphi_TypesOfCurrencyDomain" name="TypesOfCurrencyDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract" name="OrganizationAndSignificantAccountingPoliciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_PropertyAndEquipmentTextualAbstract" name="PropertyAndEquipmentTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_IntangibleAssetsTextualAbstract" name="IntangibleAssetsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract" name="AdvancesForPurchasesOfIntangibleAssetsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_RelatedPartyTransactionsTextualAbstract" name="RelatedPartyTransactionsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_BankersAcceptanceNotesPayableTextualAbstract" name="BankersAcceptanceNotesPayableTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ConstructionLoanFacilityTextualAbstract" name="ConstructionLoanFacilityTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_LeasesTextualAbstract" name="LeasesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_FairValueInputsAssetsQuantitativesInformationTable" name="FairValueInputsAssetsQuantitativesInformationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="cphi_FairValueInputsAssetsQuantitativesInformationLineItems" name="FairValueInputsAssetsQuantitativesInformationLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_StockholdersEquityTextualAbstract" name="StockholdersEquityTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_ConcentrationsTextualAbstract" name="ConcentrationsTextualAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CondensedParentCompanyOnlyFinancialStatemenDetailsAbstract" name="CondensedParentCompanyOnlyFinancialStatemenDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CondensedParentCompanyOnlyFinancialStatemenDetails1Abstract" name="CondensedParentCompanyOnlyFinancialStatemenDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cphi_CondensedParentCompanyOnlyFinancialStatemenDetails2Abstract" name="CondensedParentCompanyOnlyFinancialStatemenDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cphi-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: cphi%2D20201231.xfr; Date: 2021%2D03%2D26T15:57:02Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" xlink:href="cphi-20201231.xsd#idr_DocumentDocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cphi-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" xlink:href="cphi-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="cphi-20201231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" xlink:href="cphi-20201231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfCashFlows" xlink:href="cphi-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" xlink:href="cphi-20201231.xsd#OrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventory" xlink:href="cphi-20201231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssets" xlink:href="cphi-20201231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" xlink:href="cphi-20201231.xsd#AdvancesForPurchasesOfIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactions" xlink:href="cphi-20201231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" xlink:href="cphi-20201231.xsd#BankersAcceptanceNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacility" xlink:href="cphi-20201231.xsd#ConstructionLoanFacility" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Leases" xlink:href="cphi-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxes" xlink:href="cphi-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurements" xlink:href="cphi-20201231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StockholdersEquity" xlink:href="cphi-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Revenue" xlink:href="cphi-20201231.xsd#Revenue" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RisksUncertainties" xlink:href="cphi-20201231.xsd#RisksUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatement" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="cphi-20201231.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventorytables" xlink:href="cphi-20201231.xsd#Inventorytables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmenttables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsTables" xlink:href="cphi-20201231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesTables" xlink:href="cphi-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesTables" xlink:href="cphi-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" xlink:href="cphi-20201231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RevenueTables" xlink:href="cphi-20201231.xsd#RevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" xlink:href="cphi-20201231.xsd#Organizationandsignificantaccountingpoliciesdetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventorydetails" xlink:href="cphi-20201231.xsd#Inventorydetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentdetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetails" xlink:href="cphi-20201231.xsd#Intangibleassetsdetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" xlink:href="cphi-20201231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" xlink:href="cphi-20201231.xsd#Intangibleassetsdetailstextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:href="cphi-20201231.xsd#AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" xlink:href="cphi-20201231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" xlink:href="cphi-20201231.xsd#BankersAcceptanceNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesDetails" xlink:href="cphi-20201231.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesDetailsTextual" xlink:href="cphi-20201231.xsd#LeasesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails" xlink:href="cphi-20201231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" xlink:href="cphi-20201231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" xlink:href="cphi-20201231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" xlink:href="cphi-20201231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StockholdersEquityDetails" xlink:href="cphi-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RevenueDetails" xlink:href="cphi-20201231.xsd#RevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" xlink:href="cphi-20201231.xsd#RisksUncertaintiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails2" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptances" xlink:label="loc_cphiBankersAcceptances" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cphiBankersAcceptances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvanceToSupplies" xlink:label="loc_cphiAdvanceToSupplies" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cphiAdvanceToSupplies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent" xlink:label="loc_us-gaapLongTermConstructionLoanCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermConstructionLoanCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankAcceptancesExecutedAndOutstanding" xlink:label="loc_us-gaapBankAcceptancesExecutedAndOutstanding" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapBankAcceptancesExecutedAndOutstanding" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoanNoncurrent" xlink:label="loc_us-gaapConstructionLoanNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConstructionLoanNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaapLongTermLineOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLineOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncreaseDecreaseInPrepaidSuppliers" xlink:label="loc_cphiIncreaseDecreaseInPrepaidSuppliers" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cphiIncreaseDecreaseInPrepaidSuppliers" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConstructionLoansPayable" xlink:label="loc_us-gaapRepaymentsOfConstructionLoansPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConstructionLoansPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventory" xlink:title="00000008 - Disclosure - Inventory" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" xlink:title="00000009 - Disclosure - Property, Plant and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" xlink:title="00000011 - Disclosure - Advances for Purchases of Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" xlink:title="00000013 - Disclosure - Banker&apos;s Acceptance Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacility" xlink:title="00000014 - Disclosure - Construction Loan Facility and Lines of Credit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Leases" xlink:title="00000015 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurements" xlink:title="00000017 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Revenue" xlink:title="00000019 - Disclosure - Revenue" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RisksUncertainties" xlink:title="00000020 - Disclosure - Risks &amp; Uncertainties" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" xlink:title="00000021 - Disclosure - Condensed Parent Company Only Financial Statement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Organization and Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventorytables" xlink:title="00000023 - Disclosure - Inventory (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" xlink:title="00000024 - Disclosure - Property, Plant and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" xlink:title="00000026 - Disclosure - Construction Loan Facility and Lines of Credit (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesTables" xlink:title="00000027 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" xlink:title="00000029 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RevenueTables" xlink:title="00000030 - Disclosure - Revenue (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" xlink:title="00000031 - Disclosure - Condensed Parent Company Only Financial Statement (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" xlink:title="00000032 - Disclosure - Organization and Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventorydetails" xlink:title="00000033 - Disclosure - Inventory (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" xlink:title="00000034 - Disclosure - Property, Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndLandImprovements" xlink:label="loc_us-gaapLandAndLandImprovements" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLandAndLandImprovements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaapBuildingsAndImprovementsGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapBuildingsAndImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_MotorVehicleGross" xlink:label="loc_cphiMotorVehicleGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_cphiMotorVehicleGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OfficeEquipmentGross" xlink:label="loc_cphiOfficeEquipmentGross" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_cphiOfficeEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" xlink:title="00000035 - Disclosure - Property, Plant and Equipment (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" xlink:title="00000036 - Disclosure - Property, Plant and Equipment (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Intangibleassetsdetails" xlink:title="00000037 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" xlink:title="00000038 - Disclosure - Intangible Assets (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" xlink:title="00000039 - Disclosure - Intangible Assets (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:title="00000040 - Disclosure - Advances for Purchases of Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" xlink:title="00000041 - Disclosure - Related Party Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" xlink:title="00000042 - Disclosure - Banker&apos;s Acceptance Notes Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" xlink:title="00000043 - Disclosure - Construction Loan Facility and Lines of Credit (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" xlink:title="00000044 - Disclosure - Construction Loan Facility and Lines of Credit (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesDetails" xlink:title="00000045 - Disclosure - Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesDetailsTextual" xlink:title="00000046 - Disclosure - Leases (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetails" xlink:title="00000047 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" xlink:title="00000048 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" xlink:title="00000049 - Disclosure - Income Taxes (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" xlink:title="00000050 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomersLiabilityForAcceptancesNet" xlink:label="loc_us-gaapCustomersLiabilityForAcceptancesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFairValueNetAssetLiability" xlink:to="loc_us-gaapCustomersLiabilityForAcceptancesNet" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StockholdersEquityDetails" xlink:title="00000051 - Disclosure - Stockholders&apos; Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RevenueDetails" xlink:title="00000052 - Disclosure - Revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" xlink:title="00000053 - Disclosure - Risks &amp; Uncertainties (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" xlink:title="00000054 - Disclosure - Condensed Parent Company Only Financial Statement (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" xlink:title="00000055 - Disclosure - Condensed Parent Company Only Financial Statement (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" xlink:title="00000056 - Disclosure - Condensed Parent Company Only Financial Statement (Details 2)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cphi-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: cphi%2D20201231.xfr; Date: 2021%2D03%2D26T15:57:02Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" xlink:href="cphi-20201231.xsd#idr_DocumentDocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cphi-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" xlink:href="cphi-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="cphi-20201231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" xlink:href="cphi-20201231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfCashFlows" xlink:href="cphi-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" xlink:href="cphi-20201231.xsd#OrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventory" xlink:href="cphi-20201231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssets" xlink:href="cphi-20201231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" xlink:href="cphi-20201231.xsd#AdvancesForPurchasesOfIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactions" xlink:href="cphi-20201231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" xlink:href="cphi-20201231.xsd#BankersAcceptanceNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacility" xlink:href="cphi-20201231.xsd#ConstructionLoanFacility" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Leases" xlink:href="cphi-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxes" xlink:href="cphi-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurements" xlink:href="cphi-20201231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StockholdersEquity" xlink:href="cphi-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Revenue" xlink:href="cphi-20201231.xsd#Revenue" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RisksUncertainties" xlink:href="cphi-20201231.xsd#RisksUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatement" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="cphi-20201231.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventorytables" xlink:href="cphi-20201231.xsd#Inventorytables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmenttables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsTables" xlink:href="cphi-20201231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesTables" xlink:href="cphi-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesTables" xlink:href="cphi-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" xlink:href="cphi-20201231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RevenueTables" xlink:href="cphi-20201231.xsd#RevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" xlink:href="cphi-20201231.xsd#Organizationandsignificantaccountingpoliciesdetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventorydetails" xlink:href="cphi-20201231.xsd#Inventorydetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentdetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetails" xlink:href="cphi-20201231.xsd#Intangibleassetsdetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" xlink:href="cphi-20201231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" xlink:href="cphi-20201231.xsd#Intangibleassetsdetailstextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:href="cphi-20201231.xsd#AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" xlink:href="cphi-20201231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" xlink:href="cphi-20201231.xsd#BankersAcceptanceNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesDetails" xlink:href="cphi-20201231.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesDetailsTextual" xlink:href="cphi-20201231.xsd#LeasesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails" xlink:href="cphi-20201231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" xlink:href="cphi-20201231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" xlink:href="cphi-20201231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" xlink:href="cphi-20201231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StockholdersEquityDetails" xlink:href="cphi-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RevenueDetails" xlink:href="cphi-20201231.xsd#RevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" xlink:href="cphi-20201231.xsd#RisksUncertaintiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails2" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ForeignCurrencyTranslationAdjustment" xlink:label="loc_cphiForeignCurrencyTranslationAdjustment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiForeignCurrencyTranslationAdjustment_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventory" xlink:title="00000008 - Disclosure - Inventory" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" xlink:title="00000009 - Disclosure - Property, Plant and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" xlink:title="00000011 - Disclosure - Advances for Purchases of Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" xlink:title="00000013 - Disclosure - Banker&apos;s Acceptance Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacility" xlink:title="00000014 - Disclosure - Construction Loan Facility and Lines of Credit" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Leases" xlink:title="00000015 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurements" xlink:title="00000017 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders&apos; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Revenue" xlink:title="00000019 - Disclosure - Revenue" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RisksUncertainties" xlink:title="00000020 - Disclosure - Risks &amp; Uncertainties" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" xlink:title="00000021 - Disclosure - Condensed Parent Company Only Financial Statement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Organization and Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventorytables" xlink:title="00000023 - Disclosure - Inventory (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" xlink:title="00000024 - Disclosure - Property, Plant and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" xlink:title="00000026 - Disclosure - Construction Loan Facility and Lines of Credit (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesTables" xlink:title="00000027 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" xlink:title="00000029 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RevenueTables" xlink:title="00000030 - Disclosure - Revenue (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" xlink:title="00000031 - Disclosure - Condensed Parent Company Only Financial Statement (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" xlink:title="00000032 - Disclosure - Organization and Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="loc_us-gaapChangeInAccountingEstimateLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapChangeInAccountingEstimateLineItems" xlink:to="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_Subsidiaries1Member" xlink:label="loc_cphiSubsidiaries1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_cphiSubsidiaries1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srtSubsidiariesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtSubsidiariesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_Subsidiaries3Member" xlink:label="loc_cphiSubsidiaries3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_cphiSubsidiaries3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember" xlink:label="loc_srtManagementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtManagementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_cphiTypesOfCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ChineseYuanRenminbiMember" xlink:label="loc_cphiChineseYuanRenminbiMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiChineseYuanRenminbiMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapChangeInAccountingEstimateLineItems" xlink:to="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AccumulatedDeficit" xlink:label="loc_cphiAccumulatedDeficit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_cphiAccumulatedDeficit_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalRequiredForCapitalAdequacy" xlink:label="loc_us-gaapCapitalRequiredForCapitalAdequacy_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_us-gaapCapitalRequiredForCapitalAdequacy_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_us-gaapAssetImpairmentCharges_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LinesOfCredit" xlink:label="loc_cphiLinesOfCredit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_cphiLinesOfCredit_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BadDebtExpense" xlink:label="loc_cphiBadDebtExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract_100" xlink:to="loc_cphiBadDebtExpense_100" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventorydetails" xlink:title="00000033 - Disclosure - Inventory (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" xlink:title="00000034 - Disclosure - Property, Plant and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" xlink:title="00000035 - Disclosure - Property, Plant and Equipment (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PermitOfLandUseMember" xlink:label="loc_cphiPermitOfLandUseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cphiPermitOfLandUseMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" xlink:title="00000036 - Disclosure - Property, Plant and Equipment (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Intangibleassetsdetails" xlink:title="00000037 - Disclosure - Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" xlink:title="00000038 - Disclosure - Intangible Assets (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" xlink:title="00000039 - Disclosure - Intangible Assets (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:title="00000040 - Disclosure - Advances for Purchases of Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" xlink:title="00000041 - Disclosure - Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember" xlink:label="loc_srtManagementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtManagementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cphiTypesOfCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="loc_cphiCNYMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiCNYMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_cphiRelatedPartyTransactionsTextualAbstract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_us-gaapInterestExpenseRelatedParty_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_us-gaapOtherNotesPayable_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RepaymentOfAdvance" xlink:label="loc_cphiRepaymentOfAdvance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_cphiRepaymentOfAdvance_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanAgreementToBorrowCash" xlink:label="loc_cphiLoanAgreementToBorrowCash_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_cphiLoanAgreementToBorrowCash_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanAgreementPayableTerm" xlink:label="loc_cphiLoanAgreementPayableTerm_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_cphiLoanAgreementPayableTerm_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_us-gaapDueFromRelatedParties_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract_120" xlink:to="loc_us-gaapConversionOfStockDescription_120" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" xlink:title="00000042 - Disclosure - Banker&apos;s Acceptance Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cphiTypesOfCurrencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="loc_cphiCNYMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiCNYMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptanceNotesPayableTextualAbstract" xlink:label="loc_cphiBankersAcceptanceNotesPayableTextualAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiBankersAcceptanceNotesPayableTextualAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiBankersAcceptanceNotesPayableTextualAbstract_50" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeDescription" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiBankersAcceptanceNotesPayableTextualAbstract_50" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansPayable" xlink:label="loc_us-gaapNotesAndLoansPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiBankersAcceptanceNotesPayableTextualAbstract_50" xlink:to="loc_us-gaapNotesAndLoansPayable_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" xlink:title="00000043 - Disclosure - Construction Loan Facility and Lines of Credit (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapLineOfCreditMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoanPayableMember" xlink:label="loc_us-gaapConstructionLoanPayableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConstructionLoanPayableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" xlink:title="00000044 - Disclosure - Construction Loan Facility and Lines of Credit (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cphiTypesOfCurrencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="loc_cphiCNYMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiCNYMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankOfCommunicationsMember" xlink:label="loc_cphiBankOfCommunicationsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cphiBankOfCommunicationsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ChinaCITICBankMember" xlink:label="loc_cphiChinaCITICBankMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cphiChinaCITICBankMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ThirdPartyGuaranteeMember" xlink:label="loc_cphiThirdPartyGuaranteeMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_cphiThirdPartyGuaranteeMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConstructionLoanFacilityTextualAbstract" xlink:label="loc_cphiConstructionLoanFacilityTextualAbstract_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoan" xlink:label="loc_us-gaapConstructionLoan_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_us-gaapConstructionLoan_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanTerm" xlink:label="loc_cphiLoanTerm_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_cphiLoanTerm_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_us-gaapInterestExpense_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaapLineOfCreditFacilityDescription_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_us-gaapLineOfCreditFacilityDescription_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvanceLoanAmount" xlink:label="loc_cphiAdvanceLoanAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract_240" xlink:to="loc_cphiAdvanceLoanAmount_240" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesDetails" xlink:title="00000045 - Disclosure - Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesDetailsTextual" xlink:title="00000046 - Disclosure - Leases (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetails" xlink:title="00000047 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" xlink:title="00000048 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" xlink:title="00000049 - Disclosure - Income Taxes (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" xlink:title="00000050 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_FairValueInputsAssetsQuantitativesInformationLineItems" xlink:label="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_FairValueInputsAssetsQuantitativesInformationTable" xlink:label="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" xlink:to="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomersLiabilityForAcceptancesNet" xlink:label="loc_us-gaapCustomersLiabilityForAcceptancesNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" xlink:to="loc_us-gaapCustomersLiabilityForAcceptancesNet_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StockholdersEquityDetails" xlink:title="00000051 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TwoThousandTenIncentivePlanMember" xlink:label="loc_cphiTwoThousandTenIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cphiTwoThousandTenIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_StockholdersEquityTextualAbstract" xlink:label="loc_cphiStockholdersEquityTextualAbstract_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_cphiStockholdersEquityTextualAbstract_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapCommonStockSharesAuthorized_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:label="loc_us-gaapStatutoryAccountingPracticesStatutoryNetIncomeAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_us-gaapStatutoryAccountingPracticesStatutoryNetIncomeAmount_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AftertaxNetIncomePercentage" xlink:label="loc_cphiAftertaxNetIncomePercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_cphiAftertaxNetIncomePercentage_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ReserveAccountBalancesPercentage" xlink:label="loc_cphiReserveAccountBalancesPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_cphiReserveAccountBalancesPercentage_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SharesOfCommonStock" xlink:label="loc_cphiSharesOfCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_cphiSharesOfCommonStock_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PartialConversionOfUnpaid" xlink:label="loc_cphiPartialConversionOfUnpaid_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiStockholdersEquityTextualAbstract_80" xlink:to="loc_cphiPartialConversionOfUnpaid_80" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RevenueDetails" xlink:title="00000052 - Disclosure - Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DomesticPharmaceuticalsMember" xlink:label="loc_cphiDomesticPharmaceuticalsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cphiDomesticPharmaceuticalsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_COVID19TestersMember" xlink:label="loc_cphiCOVID19TestersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cphiCOVID19TestersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" xlink:title="00000053 - Disclosure - Risks &amp; Uncertainties (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RawMaterialPurchasesMember" xlink:label="loc_cphiRawMaterialPurchasesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiRawMaterialPurchasesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetOneMember" xlink:label="loc_cphiSalesRevenueNetOneMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiSalesRevenueNetOneMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetTwoMember" xlink:label="loc_cphiSalesRevenueNetTwoMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiSalesRevenueNetTwoMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetThreeMember" xlink:label="loc_cphiSalesRevenueNetThreeMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiSalesRevenueNetThreeMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerMember" xlink:label="loc_cphiCustomerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiCustomerMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerOneMember" xlink:label="loc_cphiCustomerOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiCustomerOneMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerTwoMember" xlink:label="loc_cphiCustomerTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiCustomerTwoMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersMember" xlink:label="loc_cphiSuppliersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersOneMember" xlink:label="loc_cphiSuppliersOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersOneMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersTwoMember" xlink:label="loc_cphiSuppliersTwoMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersTwoMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersOne1Member" xlink:label="loc_cphiSuppliersOne1Member_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersOne1Member_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConcentrationsTextualAbstract" xlink:label="loc_cphiConcentrationsTextualAbstract_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_cphiConcentrationsTextualAbstract_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConcentrationsTextualAbstract_240" xlink:to="loc_us-gaapConcentrationRiskPercentage1_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NumberOfCustomers" xlink:label="loc_cphiNumberOfCustomers_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConcentrationsTextualAbstract_240" xlink:to="loc_cphiNumberOfCustomers_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NumberOfSuppliers" xlink:label="loc_cphiNumberOfSuppliers_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cphiConcentrationsTextualAbstract_240" xlink:to="loc_cphiNumberOfSuppliers_240" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" xlink:title="00000054 - Disclosure - Condensed Parent Company Only Financial Statement (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntercompanyReceivables" xlink:label="loc_cphiIntercompanyReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiIntercompanyReceivables_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" xlink:title="00000055 - Disclosure - Condensed Parent Company Only Financial Statement (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" xlink:title="00000056 - Disclosure - Condensed Parent Company Only Financial Statement (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_30" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilities_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_30" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_30" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ProceedsOfChangeIntercompanyReceivables" xlink:label="loc_cphiProceedsOfChangeIntercompanyReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_cphiProceedsOfChangeIntercompanyReceivables_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_30" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_30" xlink:type="arc" order="10" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cphi-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: cphi%2D20201231.xfr; Date: 2021%2D03%2D26T15:57:02Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Subsidiaries [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_Subsidiaries1Member" xlink:label="cphi_Subsidiaries1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_Subsidiaries1Member" xlink:to="cphi_Subsidiaries1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_Subsidiaries1Member_lbl" xml:lang="en-US">Subsidiaries1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PermitOfLandUseMember" xlink:label="cphi_PermitOfLandUseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PermitOfLandUseMember" xlink:to="cphi_PermitOfLandUseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PermitOfLandUseMember_lbl" xml:lang="en-US">Permit Of Land Use [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TwoThousandTenIncentivePlanMember" xlink:label="cphi_TwoThousandTenIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Ten Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerMember" xlink:label="cphi_CustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerMember" xlink:to="cphi_CustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerOneMember" xlink:label="cphi_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RawMaterialPurchasesMember" xlink:label="cphi_RawMaterialPurchasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RawMaterialPurchasesMember" xlink:to="cphi_RawMaterialPurchasesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RawMaterialPurchasesMember_lbl" xml:lang="en-US">Raw Material Purchases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings / Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Other Comprehensive Income / Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetOneMember" xlink:label="cphi_SalesRevenueNetOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenueNetOneMember" xlink:to="cphi_SalesRevenueNetOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesRevenueNetOneMember_lbl" xml:lang="en-US">Revenue one [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetTwoMember" xlink:label="cphi_SalesRevenueNetTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenueNetTwoMember" xlink:to="cphi_SalesRevenueNetTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesRevenueNetTwoMember_lbl" xml:lang="en-US">Revenue two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetThreeMember" xlink:label="cphi_SalesRevenueNetThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesRevenueNetThreeMember" xlink:to="cphi_SalesRevenueNetThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesRevenueNetThreeMember_lbl" xml:lang="en-US">Revenue three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US">Management [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="cphi_TypesOfCurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TypesOfCurrencyAxis" xlink:to="cphi_TypesOfCurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TypesOfCurrencyAxis_lbl" xml:lang="en-US">Types Of Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="cphi_CNYMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CNYMember" xlink:to="cphi_CNYMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CNYMember_lbl" xml:lang="en-US">RMB [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersMember" xlink:label="cphi_SuppliersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersMember" xlink:to="cphi_SuppliersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersMember_lbl" xml:lang="en-US">Suppliers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersOneMember" xlink:label="cphi_SuppliersOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOneMember" xlink:to="cphi_SuppliersOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersOneMember_lbl" xml:lang="en-US">Suppliers One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersTwoMember" xlink:label="cphi_SuppliersTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersTwoMember" xlink:to="cphi_SuppliersTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersTwoMember_lbl" xml:lang="en-US">Suppliers Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_Subsidiaries3Member" xlink:label="cphi_Subsidiaries3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_Subsidiaries3Member" xlink:to="cphi_Subsidiaries3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_Subsidiaries3Member_lbl" xml:lang="en-US">Onny [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US">Line of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoanPayableMember" xlink:label="us-gaap_ConstructionLoanPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionLoanPayableMember" xlink:to="us-gaap_ConstructionLoanPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionLoanPayableMember_lbl" xml:lang="en-US">Construction Loan Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankOfCommunicationsMember" xlink:label="cphi_BankOfCommunicationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfCommunicationsMember" xlink:to="cphi_BankOfCommunicationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankOfCommunicationsMember_lbl" xml:lang="en-US">Bank of Communications [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DomesticPharmaceuticalsMember" xlink:label="cphi_DomesticPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DomesticPharmaceuticalsMember" xlink:to="cphi_DomesticPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DomesticPharmaceuticalsMember_lbl" xml:lang="en-US">Domestic Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ChinaCITICBankMember" xlink:label="cphi_ChinaCITICBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaCITICBankMember" xlink:to="cphi_ChinaCITICBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChinaCITICBankMember_lbl" xml:lang="en-US">China CITIC Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ChineseYuanRenminbiMember" xlink:label="cphi_ChineseYuanRenminbiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChineseYuanRenminbiMember" xlink:to="cphi_ChineseYuanRenminbiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_ChineseYuanRenminbiMember_lbl" xml:lang="en-US">RMB [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ThirdPartyGuaranteeMember" xlink:label="cphi_ThirdPartyGuaranteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ThirdPartyGuaranteeMember" xlink:to="cphi_ThirdPartyGuaranteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ThirdPartyGuaranteeMember_lbl" xml:lang="en-US">Third party guarantee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_COVID19TestersMember" xlink:label="cphi_COVID19TestersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_COVID19TestersMember" xlink:to="cphi_COVID19TestersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_COVID19TestersMember_lbl" xml:lang="en-US">COVID 19 Testers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerTwoMember" xlink:label="cphi_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersOne1Member" xlink:label="cphi_SuppliersOne1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOne1Member" xlink:to="cphi_SuppliersOne1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_SuppliersOne1Member_lbl" xml:lang="en-US">Suppliers One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DocumentAndEntityInformationAbstract" xlink:label="cphi_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DocumentAndEntityInformationAbstract" xlink:to="cphi_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptances" xlink:label="cphi_BankersAcceptances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankersAcceptances_lbl" xml:lang="en-US">Banker's acceptances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts of $18,150,493 and $17,575,100, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables, less allowance for doubtful accounts of $27,289 and $22,729, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvanceToSupplies" xlink:label="cphi_AdvanceToSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceToSupplies" xlink:to="cphi_AdvanceToSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvanceToSupplies_lbl" xml:lang="en-US">Advances to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Advances from customers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Borrowings from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent" xlink:label="us-gaap_LongTermConstructionLoanCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermConstructionLoanCurrent" xlink:to="us-gaap_LongTermConstructionLoanCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermConstructionLoanCurrent_lbl" xml:lang="en-US">Current portion of construction loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Current portion of lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankAcceptancesExecutedAndOutstanding" xlink:label="us-gaap_BankAcceptancesExecutedAndOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankAcceptancesExecutedAndOutstanding" xlink:to="us-gaap_BankAcceptancesExecutedAndOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankAcceptancesExecutedAndOutstanding_lbl" xml:lang="en-US">Bankers' acceptance notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoanNoncurrent" xlink:label="us-gaap_ConstructionLoanNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionLoanNoncurrent" xlink:to="us-gaap_ConstructionLoanNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionLoanNoncurrent_lbl" xml:lang="en-US">Construction loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US">Lines of credit, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 95,000,000 shares authorized; 45,579,557 shares and 43,579,557 shares issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl" xml:lang="en-US">Other receivables, less allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Net other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income - foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_2_lbl" xml:lang="en-US">Retained Deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ForeignCurrencyTranslationAdjustment" xlink:label="cphi_ForeignCurrencyTranslationAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ForeignCurrencyTranslationAdjustment" xlink:to="cphi_ForeignCurrencyTranslationAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ForeignCurrencyTranslationAdjustment_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Officer wages to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Officer wages to common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xml:lang="en-US">Bad debt expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Trade accounts and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncreaseDecreaseInPrepaidSuppliers" xlink:label="cphi_IncreaseDecreaseInPrepaidSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncreaseDecreaseInPrepaidSuppliers" xlink:to="cphi_IncreaseDecreaseInPrepaidSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cphi_IncreaseDecreaseInPrepaidSuppliers_lbl" xml:lang="en-US">Advances to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Change in bankers' acceptance notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Advances from customers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConstructionLoansPayable" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable_lbl" xml:lang="en-US">Payments of construction term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Payments of line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Borrowings and interest from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Used in Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate Changes on Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Decrease in Cash, Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashCurrent_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Noncash Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl" xml:lang="en-US">Accounts receivable collected with banker's acceptances</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConversionOfOfficerWagesToCommonStock" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfOfficerWagesToCommonStock" xlink:to="cphi_ConversionOfOfficerWagesToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock_lbl" xml:lang="en-US">Conversion of officer wages to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl" xml:lang="en-US">Inventory purchased with banker's acceptances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:to="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Advances for Purchases of Intangible Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock" xlink:to="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock_lbl" xml:lang="en-US">ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptanceNotesPayableAbstract" xlink:label="cphi_BankersAcceptanceNotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptanceNotesPayableAbstract" xlink:to="cphi_BankersAcceptanceNotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankersAcceptanceNotesPayableAbstract_lbl" xml:lang="en-US">Banker's Acceptance Notes Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankingAndThriftDisclosureTextBlock" xlink:label="us-gaap_BankingAndThriftDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftDisclosureTextBlock" xlink:to="us-gaap_BankingAndThriftDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankingAndThriftDisclosureTextBlock_lbl" xml:lang="en-US">BANKER'S ACCEPTANCE NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">CONSTRUCTION LOAN FACILITY AND LINES OF CREDIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RisksUncertaintiesAbstract" xlink:label="cphi_RisksUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RisksUncertaintiesAbstract" xlink:to="cphi_RisksUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RisksUncertaintiesAbstract_lbl" xml:lang="en-US">Risks &amp; Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">RISKS &amp; UNCERTAINTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatementAbstract" xlink:label="cphi_CondensedParentCompanyOnlyFinancialStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CondensedParentCompanyOnlyFinancialStatementAbstract" xlink:to="cphi_CondensedParentCompanyOnlyFinancialStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CondensedParentCompanyOnlyFinancialStatementAbstract_lbl" xml:lang="en-US">Condensed Parent Company Only Financial Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xml:lang="en-US">CONDENSED PARENT COMPANY ONLY FINANCIAL STATEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:to="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Organization and Nature of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl" xml:lang="en-US">Advances to Suppliers and Advances from Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_InterestRateRiskPolicyTextBlock" xlink:label="cphi_InterestRateRiskPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl" xml:lang="en-US">Interest Rate Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_UsefulLivesOfAssetsTableTextBlock" xlink:label="cphi_UsefulLivesOfAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLivesOfAssetsTableTextBlock" xlink:to="cphi_UsefulLivesOfAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UsefulLivesOfAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated aggregate annual amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of principal payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of minimum lease payments for the company's operating leases liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of temporary differences to deferred income tax assets and liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities recorded at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of revenues disaggregated by revenue source and geography</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract" xlink:label="cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract" xlink:to="cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract_lbl" xml:lang="en-US">Condensed Parent Company Only Financial Statement Tables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of condensed comparative balance sheets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of condensed comparative statements of operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of condensed comparative statements of cash Flows</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable_lbl" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_Subsidiaries1Member" xlink:to="cphi_Subsidiaries1Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_Subsidiaries1Member_2_lbl" xml:lang="en-US">British Virgin Islands Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_SubsidiariesMember_2_lbl" xml:lang="en-US">Nevada Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TypesOfCurrencyAxis" xlink:to="cphi_TypesOfCurrencyAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_TypesOfCurrencyAxis_2_lbl" xml:lang="en-US">TypesOfCurrencyAxis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:label="cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Organization and Significant Accounting Policies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AccumulatedDeficit" xlink:label="cphi_AccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccumulatedDeficit" xlink:to="cphi_AccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalRequiredForCapitalAdequacy" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalRequiredForCapitalAdequacy" xlink:to="us-gaap_CapitalRequiredForCapitalAdequacy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalRequiredForCapitalAdequacy_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Trade accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_2_lbl" xml:lang="en-US">Impairment adjustments amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LinesOfCredit" xlink:label="cphi_LinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesOfCredit" xlink:to="cphi_LinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LinesOfCredit_lbl" xml:lang="en-US">Lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BadDebtExpense" xlink:label="cphi_BadDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BadDebtExpense" xlink:to="cphi_BadDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BadDebtExpense_lbl" xml:lang="en-US">Bad debt expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndLandImprovements" xlink:label="us-gaap_LandAndLandImprovements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndLandImprovements" xlink:to="us-gaap_LandAndLandImprovements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndLandImprovements_lbl" xml:lang="en-US">Permit of land use</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="us-gaap_BuildingsAndImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingsAndImprovementsGross" xlink:to="us-gaap_BuildingsAndImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xml:lang="en-US">Building</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Plant, machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_MotorVehicleGross" xlink:label="cphi_MotorVehicleGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleGross" xlink:to="cphi_MotorVehicleGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_MotorVehicleGross_lbl" xml:lang="en-US">Motor vehicle</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OfficeEquipmentGross" xlink:label="cphi_OfficeEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OfficeEquipmentGross" xlink:to="cphi_OfficeEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OfficeEquipmentGross_lbl" xml:lang="en-US">Office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PermitOfLandUseMember" xlink:to="cphi_PermitOfLandUseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_PermitOfLandUseMember_2_lbl" xml:lang="en-US">Permit of land use [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_2_lbl" xml:lang="en-US">Plant, machinery and equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_VehiclesMember_2_lbl" xml:lang="en-US">Motor vehicle [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_2_lbl" xml:lang="en-US">Office equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PropertyAndEquipmentTextualAbstract" xlink:label="cphi_PropertyAndEquipmentTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PropertyAndEquipmentTextualAbstract" xlink:to="cphi_PropertyAndEquipmentTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PropertyAndEquipmentTextualAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntangibleAssetsTextualAbstract" xlink:label="cphi_IntangibleAssetsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsTextualAbstract" xlink:to="cphi_IntangibleAssetsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsTextualAbstract_lbl" xml:lang="en-US">Intangible Assets (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense relating to intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntangibleAssetsUsefulLifeDescription" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsUsefulLifeDescription" xlink:to="cphi_IntangibleAssetsUsefulLifeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription_lbl" xml:lang="en-US">Intangible assets useful life , description</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract" xlink:to="cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract_lbl" xml:lang="en-US">Advances for Purchases of Intangible Assets (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment loss for advances made to laboratories</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RelatedPartyTransactionsTextualAbstract" xlink:label="cphi_RelatedPartyTransactionsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RelatedPartyTransactionsTextualAbstract" xlink:to="cphi_RelatedPartyTransactionsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RelatedPartyTransactionsTextualAbstract_lbl" xml:lang="en-US">Related Party Transactions (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Advance received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="us-gaap_OtherNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RepaymentOfAdvance" xlink:label="cphi_RepaymentOfAdvance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RepaymentOfAdvance" xlink:to="cphi_RepaymentOfAdvance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RepaymentOfAdvance_lbl" xml:lang="en-US">Repayment of advance</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanAgreementToBorrowCash" xlink:label="cphi_LoanAgreementToBorrowCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementToBorrowCash" xlink:to="cphi_LoanAgreementToBorrowCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LoanAgreementToBorrowCash_lbl" xml:lang="en-US">Loan agreement to borrow cash</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanAgreementPayableTerm" xlink:label="cphi_LoanAgreementPayableTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementPayableTerm" xlink:to="cphi_LoanAgreementPayableTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LoanAgreementPayableTerm_lbl" xml:lang="en-US">Loan agreement payable term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Borrowings from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="us-gaap_ConversionOfStockDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Partial conversion, description</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptanceNotesPayableTextualAbstract" xlink:label="cphi_BankersAcceptanceNotesPayableTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptanceNotesPayableTextualAbstract" xlink:to="cphi_BankersAcceptanceNotesPayableTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankersAcceptanceNotesPayableTextualAbstract_lbl" xml:lang="en-US">Banker's Acceptance Notes Payable (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum amount of agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeDescription" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeDescription" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeDescription_lbl" xml:lang="en-US">Agreement payments fees, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xml:lang="en-US">Banker's acceptance notes payable outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditMember_2_lbl" xml:lang="en-US">Lines of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConstructionLoanFacilityTextualAbstract" xlink:label="cphi_ConstructionLoanFacilityTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConstructionLoanFacilityTextualAbstract" xlink:to="cphi_ConstructionLoanFacilityTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConstructionLoanFacilityTextualAbstract_lbl" xml:lang="en-US">Construction Loan Facility and Line of Credit (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoan" xlink:label="us-gaap_ConstructionLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionLoan" xlink:to="us-gaap_ConstructionLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionLoan_lbl" xml:lang="en-US">Construction loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Description of loan interest rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Payment due under the loan</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanTerm" xlink:label="cphi_LoanTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanTerm" xlink:to="cphi_LoanTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LoanTerm_lbl" xml:lang="en-US">Loan facility term, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Total interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="us-gaap_LineOfCreditFacilityDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDescription" xlink:to="us-gaap_LineOfCreditFacilityDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityDescription_lbl" xml:lang="en-US">Line of credit, description</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvanceLoanAmount" xlink:label="cphi_AdvanceLoanAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceLoanAmount" xlink:to="cphi_AdvanceLoanAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvanceLoanAmount_lbl" xml:lang="en-US">Advance loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: Operating lease liabilities, current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LeasesTextualAbstract" xlink:label="cphi_LeasesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LeasesTextualAbstract" xlink:to="cphi_LeasesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LeasesTextualAbstract_lbl" xml:lang="en-US">Leases (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating leases cost</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CashPaidForOperatingLeases" xlink:label="cphi_CashPaidForOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CashPaidForOperatingLeases" xlink:to="cphi_CashPaidForOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CashPaidForOperatingLeases_lbl" xml:lang="en-US">Cash flows from operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating leases liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">(Benefit) tax at statutory rate of 25%</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year refund received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Other, primarily the difference in U.S. tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncomeTaxExpense" xlink:label="cphi_IncomeTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncomeTaxExpense" xlink:to="cphi_IncomeTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IncomeTaxExpense_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred income tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful trade receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl" xml:lang="en-US">Allowance for doubtful other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory obsolescence reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Expenses not deductible in current year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl" xml:lang="en-US">Advances for intangible assets impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Lease liability, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">PRC net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">U.S. net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred income tax liability:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncomeTaxesTextualAbstract" xlink:label="cphi_IncomeTaxesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncomeTaxesTextualAbstract" xlink:to="cphi_IncomeTaxesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IncomeTaxesTextualAbstract_lbl" xml:lang="en-US">Income Taxes (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards for PRC tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Description of income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Operating loss, expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Enterprise income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutary income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="us-gaap_OtherTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTaxExpenseBenefit" xlink:to="us-gaap_OtherTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherTaxExpenseBenefit_lbl" xml:lang="en-US">Company received refund related to 2013 PRC tax return amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:to="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription_lbl" xml:lang="en-US">Net operating loss expiration, description</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DescriptionOfFederalCorporateIncomeTaxRate" xlink:label="cphi_DescriptionOfFederalCorporateIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DescriptionOfFederalCorporateIncomeTaxRate" xlink:to="cphi_DescriptionOfFederalCorporateIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DescriptionOfFederalCorporateIncomeTaxRate_lbl" xml:lang="en-US">Description of federal corporate income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_FairValueInputsAssetsQuantitativesInformationTable" xlink:label="cphi_FairValueInputsAssetsQuantitativesInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueInputsAssetsQuantitativesInformationTable" xlink:to="cphi_FairValueInputsAssetsQuantitativesInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_FairValueInputsAssetsQuantitativesInformationTable_lbl" xml:lang="en-US">FairValueInputsAssetsQuantitativesInformationTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_FairValueInputsAssetsQuantitativesInformationLineItems" xlink:label="cphi_FairValueInputsAssetsQuantitativesInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_FairValueInputsAssetsQuantitativesInformationLineItems" xlink:to="cphi_FairValueInputsAssetsQuantitativesInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_FairValueInputsAssetsQuantitativesInformationLineItems_lbl" xml:lang="en-US">Fair Value Inputs Assets Quantitatives Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_2_lbl" xml:lang="en-US">Level 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_2_lbl" xml:lang="en-US">Level 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_2_lbl" xml:lang="en-US">Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomersLiabilityForAcceptancesNet" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomersLiabilityForAcceptancesNet" xlink:to="us-gaap_CustomersLiabilityForAcceptancesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomersLiabilityForAcceptancesNet_lbl" xml:lang="en-US">Banker's acceptance notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_StockholdersEquityTextualAbstract" xlink:label="cphi_StockholdersEquityTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_StockholdersEquityTextualAbstract" xlink:to="cphi_StockholdersEquityTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_StockholdersEquityTextualAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Common stock issued for equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock granted and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_lbl" xml:lang="en-US">General and statutory capital reserves amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AftertaxNetIncomePercentage" xlink:label="cphi_AftertaxNetIncomePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AftertaxNetIncomePercentage_lbl" xml:lang="en-US">After-tax net income, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ReserveAccountBalancesPercentage" xlink:label="cphi_ReserveAccountBalancesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReserveAccountBalancesPercentage" xlink:to="cphi_ReserveAccountBalancesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ReserveAccountBalancesPercentage_lbl" xml:lang="en-US">Reserve account balances, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SharesOfCommonStock" xlink:label="cphi_SharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SharesOfCommonStock" xlink:to="cphi_SharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SharesOfCommonStock_lbl" xml:lang="en-US">Shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PartialConversionOfUnpaid" xlink:label="cphi_PartialConversionOfUnpaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PartialConversionOfUnpaid" xlink:to="cphi_PartialConversionOfUnpaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PartialConversionOfUnpaid_lbl" xml:lang="en-US">Partial conversion of unpaid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_COVID19TestersMember" xlink:to="cphi_COVID19TestersMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_COVID19TestersMember_2_lbl" xml:lang="en-US">COVID 19 Testers Exported to Puerto Rico [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOneMember" xlink:to="cphi_SuppliersOneMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_SuppliersOneMember_2_lbl" xml:lang="en-US">Supplier Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersTwoMember" xlink:to="cphi_SuppliersTwoMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_SuppliersTwoMember_2_lbl" xml:lang="en-US">Supplier Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConcentrationsTextualAbstract" xlink:label="cphi_ConcentrationsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConcentrationsTextualAbstract" xlink:to="cphi_ConcentrationsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConcentrationsTextualAbstract_lbl" xml:lang="en-US">Risks &amp; Uncertainties (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentrations risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NumberOfCustomers" xlink:label="cphi_NumberOfCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfCustomers" xlink:to="cphi_NumberOfCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NumberOfSuppliers" xlink:label="cphi_NumberOfSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfSuppliers" xlink:to="cphi_NumberOfSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NumberOfSuppliers_lbl" xml:lang="en-US">Number of suppliers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntercompanyReceivables" xlink:label="cphi_IntercompanyReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntercompanyReceivables" xlink:to="cphi_IntercompanyReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntercompanyReceivables_lbl" xml:lang="en-US">Intercompany receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Investment in subsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Total liabilities - other payables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ProceedsOfChangeIntercompanyReceivables" xlink:label="cphi_ProceedsOfChangeIntercompanyReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProceedsOfChangeIntercompanyReceivables" xlink:to="cphi_ProceedsOfChangeIntercompanyReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ProceedsOfChangeIntercompanyReceivables_lbl" xml:lang="en-US">Change in intercompany receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Used in Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net Decrease in Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccumulatedDeficit" xlink:to="cphi_AccumulatedDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AccumulatedDeficit_doc" xml:lang="en-US">Accumulated deficit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:to="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract_doc" xml:lang="en-US">Advances for Purchases of Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock" xlink:to="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock_doc" xml:lang="en-US">The entire disclosure of advances for purchases of intangible assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for advances to Suppliers and advances from Customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_BankersAcceptances_doc" xml:lang="en-US">A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerMember" xlink:to="cphi_CustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerMember_doc" xml:lang="en-US">Customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerOneMember_doc" xml:lang="en-US">Customer one.</link:label>
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerThreeMember" xlink:label="cphi_CustomerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerThreeMember" xlink:to="cphi_CustomerThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerThreeMember_doc" xml:lang="en-US">Customer three.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerTwoMember_doc" xml:lang="en-US">Customer two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsUsefulLifeDescription" xlink:to="cphi_IntangibleAssetsUsefulLifeDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_IntangibleAssetsUsefulLifeDescription_doc" xml:lang="en-US">Description of intangible assets useful life.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InterestRateRiskPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for interest rate risk.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_doc" xml:lang="en-US">The amount of inventory purchased with banker&amp;amp;amp;#8217;s acceptances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_doc" xml:lang="en-US">Liquidity and Going Concern.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_MotorVehicleGross" xlink:to="cphi_MotorVehicleGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_MotorVehicleGross_doc" xml:lang="en-US">Amount before moto vehicle of tangible personal property used to produce goods and services, including, but is not limited to, tools, motor equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OfficeEquipmentGross" xlink:to="cphi_OfficeEquipmentGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OfficeEquipmentGross_doc" xml:lang="en-US">Amount before office equipment of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:to="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OrganizationAndNatureOfOperationsPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for organization and nature of operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PermitOfLandUseMember" xlink:to="cphi_PermitOfLandUseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PermitOfLandUseMember_doc" xml:lang="en-US">Permit of land use.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RawMaterialPurchasesMember" xlink:to="cphi_RawMaterialPurchasesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RawMaterialPurchasesMember_doc" xml:lang="en-US">Raw material purchases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_Subsidiaries1Member" xlink:to="cphi_Subsidiaries1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_Subsidiaries1Member_doc" xml:lang="en-US">Subsidiaries one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_TwoThousandTenIncentivePlanMember_doc" xml:lang="en-US">Two thousand ten incentive plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLivesOfAssetsTableTextBlock" xlink:to="cphi_UsefulLivesOfAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_UsefulLivesOfAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of useful lives of the assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RepaymentOfAdvance" xlink:to="cphi_RepaymentOfAdvance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RepaymentOfAdvance_doc" xml:lang="en-US">Repayment of advance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementToBorrowCash" xlink:to="cphi_LoanAgreementToBorrowCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LoanAgreementToBorrowCash_doc" xml:lang="en-US">loan agreement to borrow cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAgreementPayableTerm" xlink:to="cphi_LoanAgreementPayableTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LoanAgreementPayableTerm_doc" xml:lang="en-US">Loan agreement payable term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanTerm" xlink:to="cphi_LoanTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LoanTerm_doc" xml:lang="en-US">Duration of loan description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:to="cphi_NetOperatingLossCarryForwardsExpirationDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NetOperatingLossCarryForwardsExpirationDescription_doc" xml:lang="en-US">Net operating loss carry forward expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DescriptionOfFederalCorporateIncomeTaxRate" xlink:to="cphi_DescriptionOfFederalCorporateIncomeTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_DescriptionOfFederalCorporateIncomeTaxRate_doc" xml:lang="en-US">Description of federal corporation income tax rete.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfCustomers" xlink:to="cphi_NumberOfCustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NumberOfCustomers_doc" xml:lang="en-US">Number of customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NumberOfSuppliers" xlink:to="cphi_NumberOfSuppliers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NumberOfSuppliers_doc" xml:lang="en-US">Number of suppliers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LinesOfCredit" xlink:to="cphi_LinesOfCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LinesOfCredit_doc" xml:lang="en-US">Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BadDebtExpense" xlink:to="cphi_BadDebtExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_BadDebtExpense_doc" xml:lang="en-US">Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceLoanAmount" xlink:to="cphi_AdvanceLoanAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvanceLoanAmount_doc" xml:lang="en-US">Advance loan amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncomeTaxExpense" xlink:to="cphi_IncomeTaxExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_IncomeTaxExpense_doc" xml:lang="en-US">Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AftertaxNetIncomePercentage_doc" xml:lang="en-US">After tax net income percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PartialConversionOfUnpaid" xlink:to="cphi_PartialConversionOfUnpaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PartialConversionOfUnpaid_doc" xml:lang="en-US">Partial conversion of unpaid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_doc" xml:lang="en-US">Accounts receivable collected with banker's acceptances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfOfficerWagesToCommonStock" xlink:to="cphi_ConversionOfOfficerWagesToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ConversionOfOfficerWagesToCommonStock_doc" xml:lang="en-US">Conversion of officer wages to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChineseYuanRenminbiMember" xlink:to="cphi_ChineseYuanRenminbiMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChineseYuanRenminbiMember_2_lbl" xml:lang="en-US">Document and Entity Information [Abstract] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOne1Member" xlink:to="cphi_SuppliersOne1Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersOne1Member_2_lbl" xml:lang="en-US">SuppliersOne1Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IncreaseDecreaseInPrepaidSuppliers" xlink:to="cphi_IncreaseDecreaseInPrepaidSuppliers_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IncreaseDecreaseInPrepaidSuppliers_2_lbl" xml:lang="en-US">IncreaseDecreaseInPrepaidSuppliers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConstructionLoansPayable" xlink:to="us-gaap_RepaymentsOfConstructionLoansPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConstructionLoansPayable_2_lbl" xml:lang="en-US">Repayments of Construction Loans Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_2_lbl" xml:lang="en-US">Other Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_2_lbl" xml:lang="en-US">Due from Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_2_lbl" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_2_lbl" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cphi-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: cphi%2D20201231.xfr; Date: 2021%2D03%2D26T15:57:02Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" xlink:href="cphi-20201231.xsd#idr_DocumentDocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cphi-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" xlink:href="cphi-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="cphi-20201231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" xlink:href="cphi-20201231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StatementsOfCashFlows" xlink:href="cphi-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" xlink:href="cphi-20201231.xsd#OrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventory" xlink:href="cphi-20201231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssets" xlink:href="cphi-20201231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" xlink:href="cphi-20201231.xsd#AdvancesForPurchasesOfIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactions" xlink:href="cphi-20201231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" xlink:href="cphi-20201231.xsd#BankersAcceptanceNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacility" xlink:href="cphi-20201231.xsd#ConstructionLoanFacility" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Leases" xlink:href="cphi-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxes" xlink:href="cphi-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurements" xlink:href="cphi-20201231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StockholdersEquity" xlink:href="cphi-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Revenue" xlink:href="cphi-20201231.xsd#Revenue" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RisksUncertainties" xlink:href="cphi-20201231.xsd#RisksUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatement" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="cphi-20201231.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventorytables" xlink:href="cphi-20201231.xsd#Inventorytables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmenttables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsTables" xlink:href="cphi-20201231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesTables" xlink:href="cphi-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesTables" xlink:href="cphi-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" xlink:href="cphi-20201231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RevenueTables" xlink:href="cphi-20201231.xsd#RevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" xlink:href="cphi-20201231.xsd#Organizationandsignificantaccountingpoliciesdetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Inventorydetails" xlink:href="cphi-20201231.xsd#Inventorydetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" xlink:href="cphi-20201231.xsd#PropertyPlantAndEquipmentdetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetails" xlink:href="cphi-20201231.xsd#Intangibleassetsdetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" xlink:href="cphi-20201231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" xlink:href="cphi-20201231.xsd#Intangibleassetsdetailstextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:href="cphi-20201231.xsd#AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" xlink:href="cphi-20201231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" xlink:href="cphi-20201231.xsd#BankersAcceptanceNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" xlink:href="cphi-20201231.xsd#ConstructionLoanFacilityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesDetails" xlink:href="cphi-20201231.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/LeasesDetailsTextual" xlink:href="cphi-20201231.xsd#LeasesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails" xlink:href="cphi-20201231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" xlink:href="cphi-20201231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" xlink:href="cphi-20201231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" xlink:href="cphi-20201231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/StockholdersEquityDetails" xlink:href="cphi-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RevenueDetails" xlink:href="cphi-20201231.xsd#RevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" xlink:href="cphi-20201231.xsd#RisksUncertaintiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" xlink:href="cphi-20201231.xsd#ParentCompanyOnlyFinancialStatementDetails2" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DocumentAndEntityInformationAbstract" xlink:label="loc_cphiDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptances" xlink:label="loc_cphiBankersAcceptances" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_cphiBankersAcceptances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvanceToSupplies" xlink:label="loc_cphiAdvanceToSupplies" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_cphiAdvanceToSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent" xlink:label="loc_us-gaapLongTermConstructionLoanCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermConstructionLoanCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankAcceptancesExecutedAndOutstanding" xlink:label="loc_us-gaapBankAcceptancesExecutedAndOutstanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapBankAcceptancesExecutedAndOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoanNoncurrent" xlink:label="loc_us-gaapConstructionLoanNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConstructionLoanNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaapLongTermLineOfCredit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulOtherReceivablesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulOtherReceivablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ForeignCurrencyTranslationAdjustment" xlink:label="loc_cphiForeignCurrencyTranslationAdjustment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiForeignCurrencyTranslationAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncreaseDecreaseInPrepaidSuppliers" xlink:label="loc_cphiIncreaseDecreaseInPrepaidSuppliers" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_cphiIncreaseDecreaseInPrepaidSuppliers" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConstructionLoansPayable" xlink:label="loc_us-gaapRepaymentsOfConstructionLoansPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConstructionLoansPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:label="loc_cphiAccountsReceivableCollectedWithBankersAcceptances" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cphiAccountsReceivableCollectedWithBankersAcceptances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConversionOfOfficerWagesToCommonStock" xlink:label="loc_cphiConversionOfOfficerWagesToCommonStock" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cphiConversionOfOfficerWagesToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:label="loc_cphiInventoryPurchasedWithBankersAcceptanceNote" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cphiInventoryPurchasedWithBankersAcceptanceNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventory" xlink:title="00000008 - Disclosure - Inventory">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipment" xlink:title="00000009 - Disclosure - Property, Plant and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets" xlink:title="00000011 - Disclosure - Advances for Purchases of Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:label="loc_cphiAdvancesForPurchasesOfIntangibleAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock" xlink:label="loc_cphiAdvancesForPurchasesOfIntangibleAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiAdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:to="loc_cphiAdvancesForPurchasesOfIntangibleAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable" xlink:title="00000013 - Disclosure - Banker&apos;s Acceptance Notes Payable">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptanceNotesPayableAbstract" xlink:label="loc_cphiBankersAcceptanceNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankingAndThriftDisclosureTextBlock" xlink:label="loc_us-gaapBankingAndThriftDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiBankersAcceptanceNotesPayableAbstract" xlink:to="loc_us-gaapBankingAndThriftDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacility" xlink:title="00000014 - Disclosure - Construction Loan Facility and Lines of Credit">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Leases" xlink:title="00000015 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurements" xlink:title="00000017 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Revenue" xlink:title="00000019 - Disclosure - Revenue">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RisksUncertainties" xlink:title="00000020 - Disclosure - Risks &amp; Uncertainties">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RisksUncertaintiesAbstract" xlink:label="loc_cphiRisksUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRisksUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement" xlink:title="00000021 - Disclosure - Condensed Parent Company Only Financial Statement">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatementAbstract" xlink:label="loc_cphiCondensedParentCompanyOnlyFinancialStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaapCondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatementAbstract" xlink:to="loc_us-gaapCondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Organization and Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OrganizationAndNatureOfOperationsPolicyTextBlock" xlink:label="loc_cphiOrganizationAndNatureOfOperationsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cphiOrganizationAndNatureOfOperationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_cphiLiquidityAndGoingConcernPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cphiLiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:label="loc_cphiAdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cphiAdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_InterestRateRiskPolicyTextBlock" xlink:label="loc_cphiInterestRateRiskPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cphiInterestRateRiskPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventorytables" xlink:title="00000023 - Disclosure - Inventory (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables" xlink:title="00000024 - Disclosure - Property, Plant and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_UsefulLivesOfAssetsTableTextBlock" xlink:label="loc_cphiUsefulLivesOfAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_cphiUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables" xlink:title="00000026 - Disclosure - Construction Loan Facility and Lines of Credit (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesTables" xlink:title="00000027 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurementsTables" xlink:title="00000029 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RevenueTables" xlink:title="00000030 - Disclosure - Revenue (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables" xlink:title="00000031 - Disclosure - Condensed Parent Company Only Financial Statement (Tables)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract" xlink:label="loc_cphiCondensedParentCompanyOnlyFinancialStatementTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatementTablesAbstract" xlink:to="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatementTablesAbstract" xlink:to="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:label="loc_srtScheduleOfCondensedCashFlowStatementTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatementTablesAbstract" xlink:to="loc_srtScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails" xlink:title="00000032 - Disclosure - Organization and Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="loc_us-gaapChangeInAccountingEstimateLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_us-gaapChangeInAccountingEstimateLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_Subsidiaries1Member" xlink:label="loc_cphiSubsidiaries1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_cphiSubsidiaries1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srtSubsidiariesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtSubsidiariesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_Subsidiaries3Member" xlink:label="loc_cphiSubsidiaries3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_cphiSubsidiaries3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember" xlink:label="loc_srtManagementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfChangeInAccountingEstimateTable" xlink:to="loc_cphiTypesOfCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ChineseYuanRenminbiMember" xlink:label="loc_cphiChineseYuanRenminbiMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiChineseYuanRenminbiMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapChangeInAccountingEstimateLineItems" xlink:to="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AccumulatedDeficit" xlink:label="loc_cphiAccumulatedDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_cphiAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalRequiredForCapitalAdequacy" xlink:label="loc_us-gaapCapitalRequiredForCapitalAdequacy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapCapitalRequiredForCapitalAdequacy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LinesOfCredit" xlink:label="loc_cphiLinesOfCredit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_cphiLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BadDebtExpense" xlink:label="loc_cphiBadDebtExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiOrganizationAndSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_cphiBadDebtExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Inventorydetails" xlink:title="00000033 - Disclosure - Inventory (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails" xlink:title="00000034 - Disclosure - Property, Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndLandImprovements" xlink:label="loc_us-gaapLandAndLandImprovements" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLandAndLandImprovements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaapBuildingsAndImprovementsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapBuildingsAndImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_MotorVehicleGross" xlink:label="loc_cphiMotorVehicleGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_cphiMotorVehicleGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_OfficeEquipmentGross" xlink:label="loc_cphiOfficeEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_cphiOfficeEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1" xlink:title="00000035 - Disclosure - Property, Plant and Equipment (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PermitOfLandUseMember" xlink:label="loc_cphiPermitOfLandUseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cphiPermitOfLandUseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual" xlink:title="00000036 - Disclosure - Property, Plant and Equipment (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PropertyAndEquipmentTextualAbstract" xlink:label="loc_cphiPropertyAndEquipmentTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_cphiPropertyAndEquipmentTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiPropertyAndEquipmentTextualAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Intangibleassetsdetails" xlink:title="00000037 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IntangibleAssetsDetails1" xlink:title="00000038 - Disclosure - Intangible Assets (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual" xlink:title="00000039 - Disclosure - Intangible Assets (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntangibleAssetsTextualAbstract" xlink:label="loc_cphiIntangibleAssetsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_cphiIntangibleAssetsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIntangibleAssetsTextualAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntangibleAssetsUsefulLifeDescription" xlink:label="loc_cphiIntangibleAssetsUsefulLifeDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIntangibleAssetsTextualAbstract" xlink:to="loc_cphiIntangibleAssetsUsefulLifeDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails" xlink:title="00000040 - Disclosure - Advances for Purchases of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:label="loc_cphiAdvancesForPurchasesOfIntangibleAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract" xlink:label="loc_cphiAdvancesForPurchasesOfIntangibleAssetsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiAdvancesForPurchasesOfIntangibleAssetsAbstract" xlink:to="loc_cphiAdvancesForPurchasesOfIntangibleAssetsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiAdvancesForPurchasesOfIntangibleAssetsTextualAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" xlink:title="00000041 - Disclosure - Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember" xlink:label="loc_srtManagementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cphiTypesOfCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="loc_cphiCNYMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiCNYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_cphiRelatedPartyTransactionsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapDueToOtherRelatedPartiesClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapInterestExpenseRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapOtherNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RepaymentOfAdvance" xlink:label="loc_cphiRepaymentOfAdvance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_cphiRepaymentOfAdvance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanAgreementToBorrowCash" xlink:label="loc_cphiLoanAgreementToBorrowCash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_cphiLoanAgreementToBorrowCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanAgreementPayableTerm" xlink:label="loc_cphiLoanAgreementPayableTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_cphiLoanAgreementPayableTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapConversionOfStockDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails" xlink:title="00000042 - Disclosure - Banker&apos;s Acceptance Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptanceNotesPayableAbstract" xlink:label="loc_cphiBankersAcceptanceNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiBankersAcceptanceNotesPayableAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cphiTypesOfCurrencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="loc_cphiCNYMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiCNYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankersAcceptanceNotesPayableTextualAbstract" xlink:label="loc_cphiBankersAcceptanceNotesPayableTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiBankersAcceptanceNotesPayableTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiBankersAcceptanceNotesPayableTextualAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeDescription" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiBankersAcceptanceNotesPayableTextualAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansPayable" xlink:label="loc_us-gaapNotesAndLoansPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiBankersAcceptanceNotesPayableTextualAbstract" xlink:to="loc_us-gaapNotesAndLoansPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails" xlink:title="00000043 - Disclosure - Construction Loan Facility and Lines of Credit (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapLineOfCreditMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoanPayableMember" xlink:label="loc_us-gaapConstructionLoanPayableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConstructionLoanPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual" xlink:title="00000044 - Disclosure - Construction Loan Facility and Lines of Credit (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyAxis" xlink:label="loc_cphiTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cphiTypesOfCurrencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TypesOfCurrencyDomain" xlink:label="loc_cphiTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyAxis" xlink:to="loc_cphiTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CNYMember" xlink:label="loc_cphiCNYMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiTypesOfCurrencyDomain" xlink:to="loc_cphiCNYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_BankOfCommunicationsMember" xlink:label="loc_cphiBankOfCommunicationsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cphiBankOfCommunicationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ChinaCITICBankMember" xlink:label="loc_cphiChinaCITICBankMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cphiChinaCITICBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ThirdPartyGuaranteeMember" xlink:label="loc_cphiThirdPartyGuaranteeMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_cphiThirdPartyGuaranteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConstructionLoanFacilityTextualAbstract" xlink:label="loc_cphiConstructionLoanFacilityTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionLoan" xlink:label="loc_us-gaapConstructionLoan" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_us-gaapConstructionLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LoanTerm" xlink:label="loc_cphiLoanTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_cphiLoanTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaapLineOfCreditFacilityDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AdvanceLoanAmount" xlink:label="loc_cphiAdvanceLoanAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConstructionLoanFacilityTextualAbstract" xlink:to="loc_cphiAdvanceLoanAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesDetails" xlink:title="00000045 - Disclosure - Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount" xlink:label="loc_us-gaapReceivableWithImputedInterestNetAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapReceivableWithImputedInterestNetAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/LeasesDetailsTextual" xlink:title="00000046 - Disclosure - Leases (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_LeasesTextualAbstract" xlink:label="loc_cphiLeasesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_cphiLeasesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiLeasesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CashPaidForOperatingLeases" xlink:label="loc_cphiCashPaidForOperatingLeases" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiLeasesTextualAbstract" xlink:to="loc_cphiCashPaidForOperatingLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiLeasesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiLeasesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiLeasesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiLeasesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetails" xlink:title="00000047 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncomeTaxExpense" xlink:label="loc_cphiIncomeTaxExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_cphiIncomeTaxExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetails1" xlink:title="00000048 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual" xlink:title="00000049 - Disclosure - Income Taxes (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IncomeTaxesTextualAbstract" xlink:label="loc_cphiIncomeTaxesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_cphiIncomeTaxesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaapOperatingLossCarryforwardsExpirationDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapOtherTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NetOperatingLossCarryForwardsExpirationDescription" xlink:label="loc_cphiNetOperatingLossCarryForwardsExpirationDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_cphiNetOperatingLossCarryForwardsExpirationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DescriptionOfFederalCorporateIncomeTaxRate" xlink:label="loc_cphiDescriptionOfFederalCorporateIncomeTaxRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiIncomeTaxesTextualAbstract" xlink:to="loc_cphiDescriptionOfFederalCorporateIncomeTaxRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/FairValueMeasurementsDetails" xlink:title="00000050 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_FairValueInputsAssetsQuantitativesInformationTable" xlink:label="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_FairValueInputsAssetsQuantitativesInformationLineItems" xlink:label="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" xlink:to="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomersLiabilityForAcceptancesNet" xlink:label="loc_us-gaapCustomersLiabilityForAcceptancesNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" xlink:to="loc_us-gaapCustomersLiabilityForAcceptancesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiFairValueInputsAssetsQuantitativesInformationLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/StockholdersEquityDetails" xlink:title="00000051 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_TwoThousandTenIncentivePlanMember" xlink:label="loc_cphiTwoThousandTenIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cphiTwoThousandTenIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_StockholdersEquityTextualAbstract" xlink:label="loc_cphiStockholdersEquityTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_cphiStockholdersEquityTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:label="loc_us-gaapStatutoryAccountingPracticesStatutoryNetIncomeAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_AftertaxNetIncomePercentage" xlink:label="loc_cphiAftertaxNetIncomePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_cphiAftertaxNetIncomePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ReserveAccountBalancesPercentage" xlink:label="loc_cphiReserveAccountBalancesPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_cphiReserveAccountBalancesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SharesOfCommonStock" xlink:label="loc_cphiSharesOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_cphiSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_PartialConversionOfUnpaid" xlink:label="loc_cphiPartialConversionOfUnpaid" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiStockholdersEquityTextualAbstract" xlink:to="loc_cphiPartialConversionOfUnpaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RevenueDetails" xlink:title="00000052 - Disclosure - Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_DomesticPharmaceuticalsMember" xlink:label="loc_cphiDomesticPharmaceuticalsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cphiDomesticPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_COVID19TestersMember" xlink:label="loc_cphiCOVID19TestersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cphiCOVID19TestersMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/RisksUncertaintiesDetails" xlink:title="00000053 - Disclosure - Risks &amp; Uncertainties (Details)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RisksUncertaintiesAbstract" xlink:label="loc_cphiRisksUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiRisksUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_RawMaterialPurchasesMember" xlink:label="loc_cphiRawMaterialPurchasesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiRawMaterialPurchasesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetOneMember" xlink:label="loc_cphiSalesRevenueNetOneMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiSalesRevenueNetOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetTwoMember" xlink:label="loc_cphiSalesRevenueNetTwoMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiSalesRevenueNetTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SalesRevenueNetThreeMember" xlink:label="loc_cphiSalesRevenueNetThreeMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cphiSalesRevenueNetThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerMember" xlink:label="loc_cphiCustomerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerOneMember" xlink:label="loc_cphiCustomerOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CustomerTwoMember" xlink:label="loc_cphiCustomerTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiCustomerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersMember" xlink:label="loc_cphiSuppliersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersOneMember" xlink:label="loc_cphiSuppliersOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersTwoMember" xlink:label="loc_cphiSuppliersTwoMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_SuppliersOne1Member" xlink:label="loc_cphiSuppliersOne1Member" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cphiSuppliersOne1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ConcentrationsTextualAbstract" xlink:label="loc_cphiConcentrationsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_cphiConcentrationsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConcentrationsTextualAbstract" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NumberOfCustomers" xlink:label="loc_cphiNumberOfCustomers" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConcentrationsTextualAbstract" xlink:to="loc_cphiNumberOfCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_NumberOfSuppliers" xlink:label="loc_cphiNumberOfSuppliers" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiConcentrationsTextualAbstract" xlink:to="loc_cphiNumberOfSuppliers" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails" xlink:title="00000054 - Disclosure - Condensed Parent Company Only Financial Statement (Details)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatemenDetailsAbstract" xlink:label="loc_cphiCondensedParentCompanyOnlyFinancialStatemenDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatemenDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_IntercompanyReceivables" xlink:label="loc_cphiIntercompanyReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cphiIntercompanyReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1" xlink:title="00000055 - Disclosure - Condensed Parent Company Only Financial Statement (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatemenDetails1Abstract" xlink:label="loc_cphiCondensedParentCompanyOnlyFinancialStatemenDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatemenDetails1Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2" xlink:title="00000056 - Disclosure - Condensed Parent Company Only Financial Statement (Details 2)">
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_CondensedParentCompanyOnlyFinancialStatemenDetails2Abstract" xlink:label="loc_cphiCondensedParentCompanyOnlyFinancialStatemenDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cphiCondensedParentCompanyOnlyFinancialStatemenDetails2Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cphi-20201231.xsd#cphi_ProceedsOfChangeIntercompanyReceivables" xlink:label="loc_cphiProceedsOfChangeIntercompanyReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_cphiProceedsOfChangeIntercompanyReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880952521384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHINA PHARMA HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,579,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,225,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880954684008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 957,653<span></span>
</td>
<td class="nump">$ 1,074,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">109,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_BankersAcceptances', window );">Banker's acceptances</a></td>
<td class="nump">53,736<span></span>
</td>
<td class="nump">45,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts of $18,150,493 and $17,575,100, respectively</a></td>
<td class="nump">501,892<span></span>
</td>
<td class="nump">635,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $27,289 and $22,729, respectively</a></td>
<td class="nump">27,652<span></span>
</td>
<td class="nump">46,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AdvanceToSupplies', window );">Advances to suppliers</a></td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,705,119<span></span>
</td>
<td class="nump">3,588,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">73,668<span></span>
</td>
<td class="nump">77,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,321,958<span></span>
</td>
<td class="nump">5,579,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">15,564,200<span></span>
</td>
<td class="nump">16,313,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">49,687<span></span>
</td>
<td class="nump">136,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">182,146<span></span>
</td>
<td class="nump">205,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">21,117,991<span></span>
</td>
<td class="nump">22,235,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">1,234,594<span></span>
</td>
<td class="nump">1,366,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">177,359<span></span>
</td>
<td class="nump">189,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">2,748,208<span></span>
</td>
<td class="nump">3,560,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advances from customers</a></td>
<td class="nump">719,786<span></span>
</td>
<td class="nump">505,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Borrowings from related parties</a></td>
<td class="nump">2,134,428<span></span>
</td>
<td class="nump">2,071,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">52,070<span></span>
</td>
<td class="nump">91,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermConstructionLoanCurrent', window );">Current portion of construction loan facility</a></td>
<td class="nump">2,298,886<span></span>
</td>
<td class="nump">2,150,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of lines of credit</a></td>
<td class="nump">2,038,345<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BankAcceptancesExecutedAndOutstanding', window );">Bankers' acceptance notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">109,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">11,403,676<span></span>
</td>
<td class="nump">10,045,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionLoanNoncurrent', window );">Construction loan facility</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Lines of credit, net of current portion</a></td>
<td class="nump">904,228<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">805,556<span></span>
</td>
<td class="nump">753,444<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">13,113,460<span></span>
</td>
<td class="nump">12,997,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized; 45,579,557 shares and 43,579,557 shares issued and outstanding, respectively</a></td>
<td class="nump">45,580<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">24,452,684<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(28,839,179)<span></span>
</td>
<td class="num">(25,972,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">12,345,446<span></span>
</td>
<td class="nump">11,576,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">8,004,531<span></span>
</td>
<td class="nump">9,237,601<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 21,117,991<span></span>
</td>
<td class="nump">$ 22,235,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvanceToSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvanceToSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_BankersAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_BankersAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankAcceptancesExecutedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of drafts and bills of exchange that have been accepted by the reporting bank, or by others for its own account, as its liability to holders of the drafts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankAcceptancesExecutedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionLoanNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionLoanNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermConstructionLoanCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermConstructionLoanCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880952444072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts</a></td>
<td class="nump">$ 18,150,493<span></span>
</td>
<td class="nump">$ 17,575,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent', window );">Other receivables, less allowance for doubtful accounts</a></td>
<td class="nump">$ 27,289<span></span>
</td>
<td class="nump">$ 22,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance for receivables classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880954658728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 10,866,449<span></span>
</td>
<td class="nump">$ 10,923,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">8,913,543<span></span>
</td>
<td class="nump">9,441,752<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,952,906<span></span>
</td>
<td class="nump">1,482,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling</a></td>
<td class="nump">2,215,394<span></span>
</td>
<td class="nump">2,352,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,822,655<span></span>
</td>
<td class="nump">2,289,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">377,964<span></span>
</td>
<td class="nump">229,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt</a></td>
<td class="nump">115,186<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,015,117<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,531,199<span></span>
</td>
<td class="nump">21,890,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,578,293)<span></span>
</td>
<td class="num">(20,407,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">27,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(294,159)<span></span>
</td>
<td class="num">(321,718)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Net other expense</a></td>
<td class="num">(288,484)<span></span>
</td>
<td class="num">(294,191)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(2,866,777)<span></span>
</td>
<td class="num">(20,702,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,866,777)<span></span>
</td>
<td class="num">(20,702,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income - foreign currency translation adjustment</a></td>
<td class="nump">769,227<span></span>
</td>
<td class="nump">259,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (2,097,550)<span></span>
</td>
<td class="num">$ (20,442,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding</a></td>
<td class="nump">43,623,273<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880952277576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 43,580<span></span>
</td>
<td class="nump">$ 23,590,204<span></span>
</td>
<td class="num">$ (5,270,358)<span></span>
</td>
<td class="nump">$ 11,835,349<span></span>
</td>
<td class="nump">$ 30,198,775<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,702,044)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,702,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259,130)<span></span>
</td>
<td class="num">(259,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 43,580<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
<td class="num">(25,972,402)<span></span>
</td>
<td class="nump">11,576,219<span></span>
</td>
<td class="nump">9,237,601<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,866,777)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,866,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769,227<span></span>
</td>
<td class="nump">769,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Officer wages to common stock</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">862,480<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">864,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Officer wages to common stock, shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 45,580<span></span>
</td>
<td class="nump">$ 24,452,684<span></span>
</td>
<td class="num">$ (28,839,179)<span></span>
</td>
<td class="nump">$ 12,345,446<span></span>
</td>
<td class="nump">$ 8,004,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">45,579,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880954735272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,866,777)<span></span>
</td>
<td class="num">$ (20,702,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,679,470<span></span>
</td>
<td class="nump">2,928,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write off</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">253,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">115,186<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,015,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables</a></td>
<td class="num">(613,678)<span></span>
</td>
<td class="num">(478,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_IncreaseDecreaseInPrepaidSuppliers', window );">Advances to suppliers</a></td>
<td class="num">(1,708)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">807,592<span></span>
</td>
<td class="nump">1,999,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="num">(214,015)<span></span>
</td>
<td class="nump">324,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="num">(15,217)<span></span>
</td>
<td class="nump">391,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Change in bankers' acceptance notes payable</a></td>
<td class="num">(111,160)<span></span>
</td>
<td class="num">(1,158,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Advances from customers</a></td>
<td class="nump">169,736<span></span>
</td>
<td class="num">(12,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">8,311<span></span>
</td>
<td class="nump">45,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="num">(42,260)<span></span>
</td>
<td class="nump">608,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(867,307)<span></span>
</td>
<td class="num">(136,003)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(867,307)<span></span>
</td>
<td class="num">(136,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConstructionLoansPayable', window );">Payments of construction term loan</a></td>
<td class="num">(2,174,669)<span></span>
</td>
<td class="num">(2,174,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">2,856,066<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments of line of credit</a></td>
<td class="num">(72,489)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings and interest from related party</a></td>
<td class="nump">206,908<span></span>
</td>
<td class="nump">691,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments to related party</a></td>
<td class="num">(191,639)<span></span>
</td>
<td class="num">(245,830)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="nump">624,177<span></span>
</td>
<td class="num">(1,728,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="nump">58,156<span></span>
</td>
<td class="num">(19,179)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(227,234)<span></span>
</td>
<td class="num">(1,275,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">1,184,887<span></span>
</td>
<td class="nump">2,460,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">957,653<span></span>
</td>
<td class="nump">1,184,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">957,653<span></span>
</td>
<td class="nump">1,074,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">109,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">957,653<span></span>
</td>
<td class="nump">1,184,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">237,530<span></span>
</td>
<td class="nump">299,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AccountsReceivableCollectedWithBankersAcceptances', window );">Accounts receivable collected with banker's acceptances</a></td>
<td class="nump">687,347<span></span>
</td>
<td class="nump">869,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConversionOfOfficerWagesToCommonStock', window );">Conversion of officer wages to common stock</a></td>
<td class="nump">864,480<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_InventoryPurchasedWithBankersAcceptanceNote', window );">Inventory purchased with banker's acceptances</a></td>
<td class="nump">682,791<span></span>
</td>
<td class="nump">843,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 229,673<span></span>
</td>
<td class="nump">$ 229,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AccountsReceivableCollectedWithBankersAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AccountsReceivableCollectedWithBankersAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConversionOfOfficerWagesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of officer wages to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConversionOfOfficerWagesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IncreaseDecreaseInPrepaidSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IncreaseDecreaseInPrepaidSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InventoryPurchasedWithBankersAcceptanceNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory purchased with banker&amp;amp;amp;#8217;s acceptances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InventoryPurchasedWithBankersAcceptanceNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConstructionLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from repayment of borrowings to finance the cost of construction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConstructionLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881057620344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>NOTE 1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Organization and Nature of Operations

&#8211;&#160;</i></b>China Pharma Holdings, Inc., a Nevada corporation (the "Company"), owns 100% of Onny Investment

Limited ("Onny"), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &#38; Biotechnology

Co., Ltd ("Helpson"), a company organized under the laws of the People's Republic of China (the "PRC").

China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Onny acquired 100% of the ownership in

Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction

was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for

Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing

its Wholly Foreign Owned Enterprise ("WFOE") status on June 21, 2005.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Helpson is principally engaged in the development,

manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality

diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities

are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules,

and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been

approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA",

formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Liquidity and Going Concern</i></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had

cash and cash equivalents of $0.96 million and an accumulated deficit of $28.6 million. The Company's Chairperson, Chief

Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.7 million as of December 31, 2020 to provide

working capital and enable the Company's required payments related to its construction loan facility. The Company anticipates

operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing

products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about

its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate

the conditions that raise substantial doubt about the Company's ability to continue as a going concern, management plans

to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company

is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes

that the Company's existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8,

during 2020 the Company obtained lines of credit from three banks for an aggregate amount of RMB 19,700,000 (approximately $3.0

million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months,

there is no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about

its ability to continue as a going concern.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the requirements of Accounting

Standards Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</i>

management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about

the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have

not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,

management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's

ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both

(1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements

are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise

substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial

statements are issued.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under ASC 205-40, the strategic alternatives

being pursued by the Company cannot be considered probable at this time because none of the Company's current plans have

been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable

of being effectively implemented as none of the plans are entirely within the Company's control. Accordingly, substantial

doubt is deemed to exist about the Company's ability to continue as a going concern within one year after the date these

financial statements are issued.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying consolidated financial

statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities

in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and

classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of

the uncertainties described above.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Consolidation and Basis of Presentation&#160;</i></b>&#8211;

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted

in the United States of America ("U.S. GAAP") and are expressed in United States dollars. They include the accounts

and operations of the Company including its wholly-owned subsidiaries. All significant intercompany balances and transactions have

been eliminated in the consolidation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Helpson's functional currency is

the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate

for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses

from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component

of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency

of the entity that is party to the transaction are included in the results of operations.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Accounting Estimates&#160;</i>-&#160;</b>The

methodology used to prepare the Company's financial statements is in conformity with U.S. GAAP, which requires the management

of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures

of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses

during the reporting periods. Therefore, actual results could differ from those estimates.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Cash and Cash Equivalents&#160;</i></b>&#8211;

Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term

banker's acceptances notes purchased with maturities of three months or less.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Restricted Cash</i>&#160;</b>&#8211;<b>&#160;</b>Restricted

cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes

issued by the Company as discussed in Note 7.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Trade Accounts Receivable and Allowance

for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance

for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer

accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews

a customer's credit history before extending credit to the customer. If the financial condition of its customers were to

deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision

is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled

$115,186 and $3,153 for the years ended December 31, 2020 and 2019, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Trade accounts
receivable that has been fully allowed for and determined to be uncollectible are charged against the allowance in the period the
determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $687,715 and $0
against the allowance for the years ended December 31, 2020 and 2019, respectively. Customer balances outstanding for more than one
year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Advances to Suppliers and Advances

from Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials and to receive advances

from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received.

Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews

a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers

were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize

bad debt expense in the period they are considered unlikely to be collected.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Inventory&#160;&#8211; </i></b>Inventory

consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost

is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct

labor and an allocated portion of the Company's production overhead. The Company writes down excess and obsolete inventory

to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and

work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary

course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory

item is written down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost.

Provisions for inventory write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories

are carried at this lower cost basis until sold or scrapped.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Leases &#8211; </i></b>At lease commencement,

the Company records a lease liability based on the present value of lease payments over the expected lease term including any options

to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments

using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's

incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount

equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use

lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor

prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term

Leases"). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the

leases on the condensed balance sheet.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">After lease commencement, the Company measures

its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate

determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any

unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense

and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line

basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Valuation of Long-Lived Assets</i></b>&#160;&#8211;

The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate

that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to

be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate

that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the

projected discounted cash flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the

Company will use the projected discounted cash flows to be generated by the asset. For the years ended December 31, 2020 and 2019

the Company evaluated its long-lived assets and determined that necessary impairment adjustments were $0 and $17,015,117, respectively.&#160;In

2019, the Company wrote off the remaining four advances for intangible assets.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Property, Plant and Equipment</i></b>&#160;&#8211;

Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements

are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation

relating to office equipment was included in general and administrative expenses, while all other depreciation was included in

cost of revenue.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;&#8211;

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects

the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires

disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The

Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide no significant

distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange

for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the

promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether

they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable

consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or

as) the Company satisfies each performance obligation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company only applies the five-step

model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods

or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception,

the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance

obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective

performance obligation when (or as) the performance obligation is satisfied. The Company's contracts are fixed price and

reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company's

performance obligations are transferred to customers at a point in time, typically upon buyer's designated carrier or the

buyer picks up the goods at the Company's warehouse.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For all reporting periods, the Company

has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected

length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received

advance deposits for orders less than one year. These advances total $719,786 and $505,398 and are recorded as a liability on the

accompanying balance sheet as "Advances from customers" at December 31, 2020 and 2019, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Cost
of Revenues</i></b>&#160;&#8211; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses
associated with the manufacture and delivery of products.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Research and Development</i></b>&#160;&#8211;

Research and development expenditures are recorded as expenses in the period in which they occur.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Basic and Diluted Loss per Common

Share&#160;</i>-&#160;</b>Basic loss per common share is computed by dividing net loss by the weighted-average number of common

shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common

shares.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There were no potentially dilutive common

shares outstanding during the years ended December 31, 2020 and 2019, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Credit Risk</i></b>&#160;&#8211;

The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk

in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs

ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts

and such allowances in the aggregate have not exceeded management's estimates.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has its cash in bank deposits

primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy

of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which

contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not

subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where

the Company has accounts declare bankruptcy.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Interest Rate Risk</i></b>&#160;&#8211;

The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing

debts and viability of securing future debt instruments within the PRC.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Reclassification</i></b>&#160;&#8211;

Certain amounts in the prior period presented have been reclassified to conform to the current year presentation. There was no

impact on previously reported assets, net loss or total cash flows.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2016, the Financial Accounting

Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13,&#160;<i>Financial Instruments

&#8211; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within

its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial

instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting

model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective

for public business entities that are SEC filers in fiscal years beginning after&#160;December 15, 2022, including interim periods

within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December

15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will have a material

impact on its financial statements.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2019, the FASB issued ASU 2019-12,

<i>"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". </i>The amendment simplifies the accounting

for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification ("ASC")

740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application, among other

things. The guidance is effective for interim and annual reporting periods beginning within 2021 with early adoption permitted.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">From time to time, the FASB or other standards

setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise

discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected

to have a material impact on its consolidated financial statements upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956097224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 2 &#8211;
INVENTORY</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Inventory consisted of the following:</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,113,994</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Work in process</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">662,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">314,231</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">960,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160,599</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,705,119</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,588,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881036618392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 3 &#8211;
PROPERTY, PLANT AND EQUIPMENT</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Property, plant and equipment consisted of the following:</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Permit of land use</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">431,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">403,755</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Building</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">10,024,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">9,375,817</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plant, machinery and equipment</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">29,018,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">26,309,262</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Motor vehicle</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">329,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">308,334</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">259,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">217,058</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left">Total</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">40,063,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">36,614,226</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,499,327</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,300,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,564,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,313,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Depreciation is computed on a straight-line basis over the estimated

useful lives of the assets as follows:</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; width: 82%"><b>Asset</b></td>

    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 1%"></td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"><b>Life - years</b></td>

    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><b>&#160;</b></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Permit of land use</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">40 - 70</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Building</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">20 - 49</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Plant, machinery and equipment</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">5 - 10</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Motor vehicle</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">5 - 10</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Office equipment</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">3 - 5</td>

    <td>&#160;</td></tr>

</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Depreciation relating to office equipment

was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years

ended December 31, 2020 and 2019, depreciation expense was $2,643,820 and $2,871,134, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881065960920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 4 - INTANGIBLE
ASSETS</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Intangible assets represent the cost of

medical formulas approved for production by NMPA. The Company did not obtain NMPA production approval for any new medical formulas

during the years ended December 31, 2020 and 2019 and no costs were reclassified from advances to intangible assets during the

years ended December 31, 2020 and 2019, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Approved medical formulas are amortized

from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen

years.&#160;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could

occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization

expense relating to intangible assets was $35,650 and $57,665 for the years ended December 31, 2020 and 2019, respectively, which

was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of

their amortization period.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company evaluates each approved medical

formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial

statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently

available market data for the related drug and the Company's estimated market share. If the carrying value of the medical

formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over

the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss

was recognized during the years ended December 31, 2020 and 2019.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Intangible assets consisted solely of NMPA

approved medical formulas as follows:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Gross carrying amount</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,173,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,839,117</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,991,672</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,633,506</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net carrying amount</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,146</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205,611</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The estimated aggregate annual amortization expense for each

of the next five years and thereafter is as follows:</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: left">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td>

    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,685</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2022</td><td style="text-align: left">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">37,685</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2023</td><td style="text-align: left">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">37,685</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2024</td><td style="text-align: left">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">37,685</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,406</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,146</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881036618392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advances for Purchases of Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract', window );"><strong>Advances for Purchases of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock', window );">ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 5 &#8211;
ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In order to expand the number of medicines

the Company manufactured and marketed, it entered into contracts with independent laboratories and others for the purchase of medical

formulas and assistance with the NMPA approval process.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under the new regulations and policy environment,

the criteria for formulations' development are more stringent. The Company must supplement and improve the corresponding

processes and standards to meet the latest requirements of NMPA in accordance with the requirements of consistency evaluation.

As a result, the Company anticipates an extended timeline on the approval process for its current pipeline products.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If a medical product is not approved by

the NMPA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required

under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula,

or the Company can require to apply those payments to another medical formula with the same laboratory. As a result of the refund

right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production

approval by the NMPA are recorded as advances for purchases of intangible assets.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To date, no formula has failed to receive

NMPA production approval nor has the Company been informed or been made aware of any formula that may fail to receive such approval.

However, there is no assurance that the medical products will receive production approval, and if the Company does not receive

such approval, it will enforce its contractual rights to receive a refund from the laboratory or have the payments applied to another

medical formula with the same laboratory.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year ended December 31, 2019,

the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and

determined that the advances made by the Company for four formulas were impaired. As a result, the Company recognized an impairment

loss for the advances made to these laboratories for the year ended December 31, 2019 in the amount of $17,015,117. The management

determined to impair all remaining advances at December 31, 2019, but may resume the development of these formulas in the future

if sufficient funding and other favorable conditions arise.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances for Purchases of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesForPurchasesOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of advances for purchases of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesForPurchasesOfIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880954646792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 6 &#8211; RELATED PARTY TRANSACTIONS</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A member of the Company's board of

directors ("Board") had advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2020 and 2019

which are recorded as "Other payables &#8211; related parties" on the accompanying consolidated balance sheets. The

advances bear interest at a rate of 1.0% per year.&#160;Total interest expense for the years ended December 31, 2020 and

2019 was $13,546 and $13,546, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received advances totaling $163,825
during the year ended December 31, 2020 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer; and paid back
$191,639&#160;to her in the same period. Total amounts owed were $740,316 and $724,963&#160;and are recorded as "Borrowings from
related parties" on the accompanying consolidated balance sheets as of December 31, 2020 and December 31, 2019, respectively. On
July 8, 2019 the Company entered into a loan agreement for cash of RMB 4,770,000 ($674,405) with its Chairperson, Chief Executive Officer
and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement.
The due date of the loan agreement was extended to July 10, 2021. Total interest expense related to the loan for the years ended December
31, 2020 and 2019 was $43,083 and $12,393, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Compensation payable to the Chairperson,

Chief Executive Officer and Interim Chief Financial Officer is included in "Other payables" in the accompanying consolidated

balance sheets totaling $1,658,706 and $2,307,986 as of December 31, 2020 and 2019, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 23, 2020 the Board approved

the issuance of 2,000,000 shares of common stock from the Company's 2010 Long-Term Incentive Plan, as amended for the partial

conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer.

The shares were issued at a market price of $0.43 per share based on the average of the closing prices during the five trading

days prior to the issuance date, and higher than the closing price of $0.42 per share on the issuance date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956017832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Banker's Acceptance Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_BankersAcceptanceNotesPayableAbstract', window );"><strong>Banker's Acceptance Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BankingAndThriftDisclosureTextBlock', window );">BANKER'S ACCEPTANCE NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 7 &#8211;
BANKER'S ACCEPTANCE NOTES PAYABLE</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In April 2016, the Company entered into

a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's

acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the

bank an amount equal to the amounts represented by the banker's acceptance notes issued to the third parties. The amount

of these deposited balances is shown as "Restricted cash" on the accompanying balance sheets as of December 31, 2020

and 2019. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately

$4.5 million) or the amount of cash available to deposit against the banker's acceptance notes. In addition, the agreement

calls for the payment of fees equal to 0.05% of the note amount to the bank. As of December 31, 2020 and December 31, 2019, the

Company had outstanding banker's acceptance notes in the amount of $0 and $109,908, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_BankersAcceptanceNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_BankersAcceptanceNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankingAndThriftDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial services specifically banking and thrift entities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -URI http://asc.fasb.org/topic&amp;trid=2209208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankingAndThriftDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956183336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Construction Loan Facility and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONSTRUCTION LOAN FACILITY AND LINES OF CREDIT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 8 &#8211; CONSTRUCTION LOAN FACILITY

AND LINES OF CREDIT</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Construction Loan Facility</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company obtained a construction loan

facility dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility is for an

eight-year term, which commenced on July 11, 2013, the initial draw-down date.&#160;The proceeds of the loan were used for and

are collateralized by the construction of the Company's new production facility and the included production line equipment

and machinery. The loan bears interest based upon 110% of the PRC government's eight-year term rate effective on the actual

draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from

the draw-down date and its subsequent anniversary dates.&#160;The interest rate has remained at 5.39% on the anniversary

dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years.

Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due

within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over

the next five years through July 11, 2021 on the identical terms as described above for 2015. The Company has made all required

payments due under the loan. As of December 31, 2020, the Company had no additional amounts available to it under this facility.

During the years ended December 31, 2020 and 2019, the Company made principal payments in the amount of $2,174,669 (RMB 15,000,000)

and $2,174,399 (RMB 15,000,000), respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Lines of Credit</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">In
April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately
$1.4 million), of which RMB 5,000,000 (approximately $0.7 million) were advanced in April, and RMB 3,000,000 (approximately $0.4 million)
were advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from
the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain
land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company's
Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has an additional RMB 2,000,000
(approximately $0.3 million)</font>&#160; <font style="font-family: Times New Roman, Times, Serif">available under the line, subject to
a risk review and approval by the third party guarantee company. Total interest expense under this facility for the years ended December
31, 2020 and 2019 was RMB189,892</font> (<font style="font-family: Times New Roman, Times, Serif">$29,103)</font> &#160;<font style="font-family: Times New Roman, Times, Serif">and
$0, respectively. The Company repaid RMB 500,000 (approximately $0.07 million) and RMB 300,000 (approximately $0.05 million) to Postal
Savings Bank of China in October 2020, and January 2021, respectively, as per the payment schedule.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2020 the Company obtained a line of
credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million) of which RMB 8,500,000 have been
advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the
line of credit. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of
credit and pledged personal assets as collateral for the loan. Total interest expense for the years ended December 31, 2020 and 2019 was
RMB166,388 ($25,500) and $0, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The
Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an
advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October under
this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the
advance. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit
and pledged personal assets as collateral for the loan. Total interest for the year ended December 31, 2020 was RMB33,723 ($5,168).</font>&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Principal payments required for the remaining

terms of the loan facility and the lines of credit for the years ended December 31, are as follows:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lines of Credit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Construction Loan Facility</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 63%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,298,886</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,038,345</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,337,231</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">904,228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">904,228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,298,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,942,573</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,241,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Fair Value of Construction Loan Facility

and Lines of Credit</i></b> &#8211; Based on the borrowing rates currently available to the Company for bank loans with similar

terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2020 and December 31,

2019 approximated their fair value because the underlying instrument bears an interest rate that approximated current market rates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956017832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 9 - LEASES</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has leases for certain office

and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts.

Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates

to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed

by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company's

incremental borrowing rate at the initial measurement date. For the years ended December 31, 2020 and 2019, operating lease cost

was $96,552 and $90,306, respectively and cash paid for amounts included in the measurement of lease liabilities for operating

cash flows from operating leases was $102,624 and $95,985, respectively. As of December 31, 2020 and December 31, 2019, the Company

reported operating lease right of use assets of $49,687 and $136,779, respectively and operating use liabilities of $52,070 and

$140,007, respectively. As of December 31, 2020, its operating leases had a weighted average remaining lease term of 0.52 years

and a weighted average discount rate of 4.75%.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Minimum lease payments for the Company's operating lease

liabilities were as follows for the years ended December 31:</p>



<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">52,814</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total undiscounted cash flows</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">52,814</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(744</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">52,070</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Operating lease liabilities, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,070</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Company has leases with terms of less than one year for

certain provincial sales offices that are not material.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959543208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>NOTE 10 - INCOME TAXES</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Deferred income tax assets and liabilities

are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected

to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in

income in the period that includes the enactment date.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Liabilities are established for uncertain

tax positions expected to be taken in income tax returns when such positions are judged to meet the "more-likely-than-not"

threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are

included as a component of other expenses. Through December 31, 2020, the Company has not identified any uncertain tax positions

that it has taken. U.S. income tax returns for the years ended December 31, 2017 through December 31, 2020 and the Chinese income

tax return for the year ended December 31, 2020 are open for possible examination.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Under the current tax law in the PRC, the Company is and will

be subject to the enterprise income tax rate of 25%.</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There was no provision for income taxes

for the years ended December 31, 2020 and 2019, respectively due to continued net losses of the Company.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Following is a reconciliation of income

taxes calculated at the federal statutory rates to the provision for income taxes:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Years Ended <br />

December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">(Benefit) tax at statutory rate of 25%</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(716,694</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,175,512</td><td style="width: 1%; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Prior year refund received</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other, primarily the difference in U.S. tax rates</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">8,190</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">8,103</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">708,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,167,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The temporary differences which give rise

to the deferred income tax assets and liability are as follows:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred income tax assets:</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Allowance for doubtful trade receivables</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,537,623</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,393,775</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Allowance for doubtful other receivables</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">6,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">5,682</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Inventory obsolescence reserve</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">568,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">1,528,482</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenses not deductible in current year</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">1,160,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085,520</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advances for intangible assets impairment</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">10,441,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">9,765,906</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lease liability, net</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">596</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">807</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">PRC net operating loss carry forward</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">9,542,576</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">12,682,671</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">U.S. net operating loss carry forward</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409,380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,296,813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total deferred income tax assets</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">27,667,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">30,759,656</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,667,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,759,656</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net deferred income tax asset</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred income tax liability:</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">805,556</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">753,444</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had

net operating loss carryforwards for PRC tax purposes of approximately $37.8 million which are available to offset any future taxable

income through 2026. Approximately $23.1 million of loss carryforwards expired in December 2020. The Company also has net operating

losses for United States federal income tax purposes of approximately $6.7 million of which $5.1 million are available to offset

future taxable income, if any, through 2039, and $1.6 million are available for carryforward indefinitely subject to a limitation

of 80% of taxable income for each tax year.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Recent U.S. federal tax legislation, commonly

referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Reform"), was signed into law on December&#160;22, 2017. The

U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal

corporate income tax rate from 35% to 21% for taxable years beginning after December&#160;31, 2017; limiting and/or eliminating

many business deductions; migrating the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory

deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally

eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management
considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level
of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible
or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December
31, 2020 and 2019. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $27,666,557</font>&#160;<font style="font-family: Times New Roman, Times, Serif">and
$30,738,262 as of December 31, 2020 and 2019, respectively.</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company also incurred various other

taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any

unpaid amounts are reflected on the balance sheets as accrued taxes payable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956017832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 11 &#8211;
FAIR VALUE MEASUREMENTS</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Fair value is defined as the exchange price

that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market

for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value,

a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable

inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#8211;

Quoted prices in active markets for identical assets or liabilities; Level 2 &#8211; Observable inputs other than Level 1 including

quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated

by observable market data; and Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial instruments

whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments

for which the determination of fair value requires significant management judgment or estimation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company uses fair value to measure

the value of the banker's acceptance notes it holds at December 31, 2020 and 2019.&#160;The banker's acceptance notes

are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at

fair value:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center"><b>December&#160;31,</b></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Reporting Date Using</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Description</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">Banker's acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">53,736</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">53,736</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="margin: 0">&#160;</p>



<p style="margin: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center"><b>December&#160;31,</b></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Reporting Date Using</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Description</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">Banker's acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">45,756</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">45,756</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959935704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 12 - STOCKHOLDERS'
EQUITY</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company is authorized to issue 95,000,000

shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be

issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely

by the Company's Board.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">According to relevant PRC laws, companies

registered in the PRC, including the Company's PRC subsidiary, Helpson, are required to allocate at least 10% of their after

tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until

the reserve account balances reach 50% of the company's registered capital prior to their remittance of funds out of the

PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company

in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000

for each of the fiscal years ended December 31, 2020 and 2019.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><u>Employee Stock Options</u></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>2010 Incentive Plan</i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 12, 2010, the Company's

Board adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December

22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the "Amendment"),

pursuant to which the term of the 2010 Incentive Plan shall be extended to December 31, 2029. The Amendment was adopted by the

shareholders on December 19, 2019. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation

rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants

of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock.

Through December 31, 2019, there were 175,000 shares of restricted stock granted and outstanding under the Plan. No options

were outstanding as of December 31, 2019 under the Plan.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 23, 2020 the Board approved

the issuance of 2,000,000 shares of common stock from the Company's 2010 Long-Term Incentive Plan, as amended for the partial

conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer

as discussed in Note 6. There were no securities issued from the Plan during the year ended December 31, 2019.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company recognized no compensation

expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended

December 31, 2020 and 2019.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, there was no remaining

unrecognized compensation expense related to stock options or restricted stock grants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956105128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 13 &#8211; REVENUE</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes the Company's

revenues disaggregated by revenue source and geography based on the Company's PRC based business locations:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended </td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Domestic Pharmaceuticals</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,132,216</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,923,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">COVID 19 Testers Exported to Puerto Rico</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,734,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,866,449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,923,936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959586280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks &amp; Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_RisksUncertaintiesAbstract', window );"><strong>Risks &amp; Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">RISKS &amp; UNCERTAINTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>NOTE 14 &#8211; RISKS &#38; UNCERTAINTIES</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Current vulnerability
due to certain concentrations</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">For
the year ended December 31, 2020, one customer accounted for 16.0% of sales and three customers respectively accounted for 52.0%,
11.2% and 10.2% of accounts receivable. Three suppliers respectively accounted for 20.7%, 17.75 and 13.5%</font>&#160; <font style="font-family: Times New Roman, Times, Serif">of
raw material purchases, and three different products respectively accounted for 32.6%, 19.9% and 16.0% of revenue.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the year ended December 31, 2019, no

customer accounted for more than 10% of sales and two customers accounted for 49.6% and 10.7% of accounts receivable. Three suppliers

accounted for 22.3%, 20.6% and 5.8% of raw material purchases, and three different products accounted for 33%, 21% and 17% of revenue.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Nature of Operations</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Impact from the New Coronavirus Global

Pandemic ("COVID-19") </b>- The current outbreak of COVID-19 could have a material and adverse effect on the Company's

business operations. These could include disruptions or restrictions on the Company's ability to distribute its products,

as well as temporary closures of its facilities or the facilities of the suppliers or customers. Any disruption or delay of the

Company's suppliers or customers would likely impact the Company's sales and operating results. In addition, COVID-19

has resulted in a widespread health crisis that could adversely affect the economies and financial markets of China and many other

countries, resulting in an economic downturn that could significantly impact our operating results.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Economic environment - </b>Substantially

all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations

and significant risks not typically associated with companies operating in the United States of America. These risks include, among

others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's

results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes

in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad,

and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely

affect the Company's operations.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Foreign Currency Risk</b> &#8211; The

Company is exposed to foreign currency risk related to its operations. All of the Company's revenue and the majority of expenses

are denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance

out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval

of the PRC government. The Company has not entered into any forward contracts or derivative instruments mitigating this risk.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Credit

Risk</b> &#8211; The carrying amount of accounts receivable included in the balance sheet represents the Company's

exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to

credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company

maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded management's

estimates.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has its cash in bank deposits

primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy

of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which

contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not

subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where

the Company has accounts declare bankruptcy.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RisksUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RisksUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956142664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Parent Company Only Financial Statement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_CondensedParentCompanyOnlyFinancialStatementAbstract', window );"><strong>Condensed Parent Company Only Financial Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">CONDENSED PARENT COMPANY ONLY FINANCIAL STATEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-transform: uppercase"><b>NOTE
15 - CONDENSED PARENT COMPANY ONLY FINANCIAL STATEMENT</b></font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The condensed parent company only financial information for

China Pharma Holdings Inc. is presented below:</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt"><b>Condensed Comparative Balance Sheets</b></font></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">21,187</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,095</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Current Assets</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">21,187</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">3,095</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Intercompany receivables</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">7,746,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">8,084,779</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Investment in subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,705,241</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,705,241</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,473,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,793,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities - other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,752,990</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,401,344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Stockholders' Equity</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">17,720,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">17,391,771</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,473,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,793,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The parent company had no&#160;contingencies, long-term obligations and guarantees as of December 31, 2020&#160;and 2019.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>





<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Condensed Comparative Schedule of Operations</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"> December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">536,035</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">522,386</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(536,035</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(522,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Condensed Comparative Schedule of Cash Flows</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"> December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash Flows from Operating Activities:</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(536,035</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(522,386</td><td style="width: 1%; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">220,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(319,908</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(302,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Change in intercompany receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">338,000</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">338,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net Decrease in Cash and Cash Equivalents</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">18,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,075</td><td style="text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,170</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at End of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,187</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CondensedParentCompanyOnlyFinancialStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CondensedParentCompanyOnlyFinancialStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391182&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880954701736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndNatureOfOperationsPolicyTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Organization and Nature of Operations

&#8211;&#160;</i></b>China Pharma Holdings, Inc., a Nevada corporation (the "Company"), owns 100% of Onny Investment

Limited ("Onny"), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &#38; Biotechnology

Co., Ltd ("Helpson"), a company organized under the laws of the People's Republic of China (the "PRC").

China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Onny acquired 100% of the ownership in

Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction

was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for

Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing

its Wholly Foreign Owned Enterprise ("WFOE") status on June 21, 2005.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Helpson is principally engaged in the development,

manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality

diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities

are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules,

and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been

approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA",

formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Liquidity
and Going Concern</i></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had

cash and cash equivalents of $0.96 million and an accumulated deficit of $28.6 million. The Company's Chairperson, Chief

Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.7 million as of December 31, 2020 to provide

working capital and enable the Company's required payments related to its construction loan facility. The Company anticipates

operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing

products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about

its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate

the conditions that raise substantial doubt about the Company's ability to continue as a going concern, management plans

to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company

is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes

that the Company's existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8,

during 2020 the Company obtained lines of credit from three banks for an aggregate amount of RMB 19,700,000 (approximately $3.0

million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months,

there is no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about

its ability to continue as a going concern.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the requirements of Accounting

Standards Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</i>

management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about

the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have

not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,

management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's

ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both

(1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements

are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise

substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial

statements are issued.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under ASC 205-40, the strategic alternatives

being pursued by the Company cannot be considered probable at this time because none of the Company's current plans have

been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable

of being effectively implemented as none of the plans are entirely within the Company's control. Accordingly, substantial

doubt is deemed to exist about the Company's ability to continue as a going concern within one year after the date these

financial statements are issued.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying consolidated financial

statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities

in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and

classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of

the uncertainties described above.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Consolidation
and Basis of Presentation&#160;</i></b>&#8211; The accompanying consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America ("U.S. GAAP") and are expressed in United States
dollars. They include the accounts and operations of the Company including its wholly-owned subsidiaries. All significant intercompany
balances and transactions have been eliminated in the consolidation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Helpson's functional currency is

the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate

for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses

from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component

of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency

of the entity that is party to the transaction are included in the results of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Accounting
Estimates&#160;</i>-&#160;</b>The methodology used to prepare the Company's financial statements is in conformity with U.S. GAAP,
which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported
amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Cash and Cash
Equivalents&#160;</i></b>&#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money
market accounts, and short-term banker's acceptances notes purchased with maturities of three months or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Restricted
Cash</i>&#160;</b>&#8211;<b>&#160;</b>Restricted cash includes cash that has been deposited with a bank to satisfy obligations
outstanding under banker's acceptance notes issued by the Company as discussed in Note 7.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Trade Accounts Receivable and Allowance

for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance

for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer

accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews

a customer's credit history before extending credit to the customer. If the financial condition of its customers were to

deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision

is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled

$115,186 and $3,153 for the years ended December 31, 2020 and 2019, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Trade accounts
receivable that has been fully allowed for and determined to be uncollectible are charged against the allowance in the period the
determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $687,715 and $0
against the allowance for the years ended December 31, 2020 and 2019, respectively. Customer balances outstanding for more than one
year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Advances to
Suppliers and Advances from Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials
and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when
the materials are received. Advances received from customers are applied against trade accounts receivable when finished products
are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial
condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services,
the Company would recognize bad debt expense in the period they are considered unlikely to be collected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Inventory&#160;&#8211;
</i></b>Inventory consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable
value. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials,
direct labor and an allocated portion of the Company's production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and
work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary
course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory
item is written down to its estimated net realizable value. Net realizable value for raw materials is based on replacement cost.
Provisions for inventory write-downs are included in the cost of revenues in the consolidated statements of operations. Inventories
are carried at this lower cost basis until sold or scrapped.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Leases &#8211;
</i></b>At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected
lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates
the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest
rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis
to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding
right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs
paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or
less ("Short-Term Leases"). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does
not record the leases on the condensed balance sheet.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">After lease commencement, the Company measures

its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate

determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any

unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense

and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line

basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Valuation
of Long-Lived Assets</i></b>&#160;&#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever
events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company
projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining
life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated
excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. If there is uncertainty
both in timing and amount, the Company will use the projected discounted cash flows to be generated by the asset. For the years
ended December 31, 2020 and 2019 the Company evaluated its long-lived assets and determined that necessary impairment adjustments
were $0 and $17,015,117, respectively.&#160;In 2019, the Company wrote off the remaining four advances for intangible assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Property,
Plant and Equipment</i></b>&#160;&#8211; Property, plant and equipment are stated at cost. Maintenance and repairs are charged
to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in
operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative
expenses, while all other depreciation was included in cost of revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;&#8211;
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects
the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The
Company does not disaggregate its revenue streams as the economic factors underlying the contracts are similar and provide no
significant distinction. The amount of revenue that is recorded reflects the consideration that the Company expects to receive
in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification
of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including
whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue
when (or as) the Company satisfies each performance obligation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company only applies the five-step

model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods

or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception,

the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance

obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective

performance obligation when (or as) the performance obligation is satisfied. The Company's contracts are fixed price and

reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company's

performance obligations are transferred to customers at a point in time, typically upon buyer's designated carrier or the

buyer picks up the goods at the Company's warehouse.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For all reporting periods, the Company

has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected

length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received

advance deposits for orders less than one year. These advances total $719,786 and $505,398 and are recorded as a liability on the

accompanying balance sheet as "Advances from customers" at December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Cost of Revenues</i></b>&#160;&#8211;
Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture
and delivery of products.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Research and
Development</i></b>&#160;&#8211; Research and development expenditures are recorded as expenses in the period in which they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Basic and
Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic loss per common share is computed by dividing net loss by the weighted-average
number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable
dilutive common shares.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There were no potentially dilutive common

shares outstanding during the years ended December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Credit Risk</i></b>&#160;&#8211;
The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation
to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing
credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances
in the aggregate have not exceeded management's estimates.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has its cash in bank deposits

primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy

of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which

contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not

subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where

the Company has accounts declare bankruptcy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_InterestRateRiskPolicyTextBlock', window );">Interest Rate Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Interest Rate
Risk</i></b>&#160;&#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability
of repayment of existing debts and viability of securing future debt instruments within the PRC.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Reclassification</i></b>&#160;&#8211;
Certain amounts in the prior period presented have been reclassified to conform to the current year presentation. There was no
impact on previously reported assets, net loss or total cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Recent Accounting
Pronouncements</i></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2016, the Financial Accounting

Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13,&#160;<i>Financial Instruments

&#8211; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within

its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial

instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting

model for purchased financial assets with credit deterioration since their origination.&#160;The pronouncement will be effective

for public business entities that are SEC filers in fiscal years beginning after&#160;December 15, 2022, including interim periods

within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December

15, 2019, including interim periods within those fiscal years. The Company does not anticipate the guidance will have a material

impact on its financial statements.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2019, the FASB issued ASU 2019-12,

<i>"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". </i>The amendment simplifies the accounting

for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification ("ASC")

740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application, among other

things. The guidance is effective for interim and annual reporting periods beginning within 2021 with early adoption permitted.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">From time to time, the FASB or other standards

setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise

discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected

to have a material impact on its consolidated financial statements upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advances to Suppliers and advances from Customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestRateRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest rate risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestRateRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OrganizationAndNatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for organization and nature of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OrganizationAndNatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880953286552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,113,994</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Work in process</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">662,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">314,231</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">960,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160,599</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,705,119</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,588,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959336216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Permit of land use</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">431,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">403,755</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Building</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">10,024,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">9,375,817</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plant, machinery and equipment</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">29,018,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">26,309,262</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Motor vehicle</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">329,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">308,334</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">259,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">217,058</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left">Total</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">40,063,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">36,614,226</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,499,327</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,300,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,564,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,313,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_UsefulLivesOfAssetsTableTextBlock', window );">Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left; width: 82%"><b>Asset</b></td>

    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 1%"></td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"><b>Life - years</b></td>

    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><b>&#160;</b></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Permit of land use</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">40 - 70</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Building</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">20 - 49</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Plant, machinery and equipment</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">5 - 10</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Motor vehicle</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">5 - 10</td>

    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Office equipment</td>

    <td style="text-align: right">&#160;</td>

    <td style="text-align: center">3 - 5</td>

    <td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_UsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_UsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880952467944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Gross carrying amount</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,173,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,839,117</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,991,672</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,633,506</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net carrying amount</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,146</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205,611</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate annual amortization expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: left">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td>

    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,685</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2022</td><td style="text-align: left">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">37,685</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2023</td><td style="text-align: left">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">37,685</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">2024</td><td style="text-align: left">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">37,685</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,406</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,146</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959939224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Construction Loan Facility and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of principal payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lines of Credit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Construction Loan Facility</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 63%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,298,886</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,038,345</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,337,231</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">904,228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">904,228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,298,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,942,573</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,241,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880953286552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of minimum lease payments for the company's operating leases liabilities</a></td>
<td class="text"><p style="text-align: justify; margin-top: 0; margin-bottom: 0"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">52,814</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total undiscounted cash flows</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">52,814</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(744</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">52,070</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Operating lease liabilities, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,070</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12069-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121549808&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880952502680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Years Ended <br />

December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">(Benefit) tax at statutory rate of 25%</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(716,694</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,175,512</td><td style="width: 1%; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Prior year refund received</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other, primarily the difference in U.S. tax rates</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">8,190</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">8,103</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">708,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,167,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of temporary differences to deferred income tax assets and liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred income tax assets:</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Allowance for doubtful trade receivables</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,537,623</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,393,775</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Allowance for doubtful other receivables</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">6,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">5,682</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Inventory obsolescence reserve</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">568,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">1,528,482</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenses not deductible in current year</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">1,160,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085,520</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advances for intangible assets impairment</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">10,441,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">9,765,906</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lease liability, net</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">596</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">807</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">PRC net operating loss carry forward</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">9,542,576</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">12,682,671</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">U.S. net operating loss carry forward</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409,380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,296,813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total deferred income tax assets</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">27,667,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">30,759,656</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,667,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,759,656</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net deferred income tax asset</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred income tax liability:</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">805,556</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">753,444</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959759000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities recorded at fair value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center"><b>December&#160;31,</b></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Reporting Date Using</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Description</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">Banker's acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">53,736</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">53,736</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

</table>





<p style="margin: 0">&#160;</p>



<p style="margin: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>

    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center"><b>December&#160;31,</b></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Reporting Date Using</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Description</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">Banker's acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">45,756</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">45,756</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959514296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of revenues disaggregated by revenue source and geography</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"></td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended </td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Domestic Pharmaceuticals</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,132,216</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,923,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">COVID 19 Testers Exported to Puerto Rico</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,734,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,866,449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,923,936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880958763800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Parent Company Only Financial Statement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract', window );"><strong>Condensed Parent Company Only Financial Statement Tables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of condensed comparative balance sheets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt"><b>Condensed
Comparative Balance Sheets</b></font></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">21,187</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,095</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Current Assets</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">21,187</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">3,095</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Intercompany receivables</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">7,746,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">8,084,779</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Investment in subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,705,241</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,705,241</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,473,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,793,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities - other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,752,990</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,401,344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Stockholders' Equity</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">17,720,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">17,391,771</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,473,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,793,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of condensed comparative statements of operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>





<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Condensed Comparative Schedule of Operations</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"> December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">536,035</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">522,386</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(536,035</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(522,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Schedule of condensed comparative statements of cash Flows</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Condensed Comparative Schedule of Cash Flows</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"> December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>

    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash Flows from Operating Activities:</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>

    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(536,035</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>

    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(522,386</td><td style="width: 1%; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">220,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(319,908</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(302,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Change in intercompany receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">338,000</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">338,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net Decrease in Cash and Cash Equivalents</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">18,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>

    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,075</td><td style="text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,170</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">

    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at End of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,187</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>

    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CondensedParentCompanyOnlyFinancialStatementTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948792200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 25, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract', window );"><strong>Organization and Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">28,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="nump">687,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment adjustments amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,015,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advances from customers</a></td>
<td class="nump">719,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LinesOfCredit', window );">Lines of credit</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_BadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">115,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_TypesOfCurrencyAxis=cphi_ChineseYuanRenminbiMember', window );">RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract', window );"><strong>Organization and Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LinesOfCredit', window );">Lines of credit | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract', window );"><strong>Organization and Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalRequiredForCapitalAdequacy', window );">Working capital</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=cphi_Subsidiaries1Member', window );">British Virgin Islands Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract', window );"><strong>Organization and Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Nevada Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract', window );"><strong>Organization and Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=cphi_Subsidiaries3Member', window );">Onny [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract', window );"><strong>Organization and Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OrganizationAndSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalRequiredForCapitalAdequacy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958570-112826<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalRequiredForCapitalAdequacy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TypesOfCurrencyAxis=cphi_ChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TypesOfCurrencyAxis=cphi_ChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=cphi_Subsidiaries1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=cphi_Subsidiaries1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=cphi_Subsidiaries3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=cphi_Subsidiaries3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881057619480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,081,745<span></span>
</td>
<td class="nump">$ 2,113,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">662,999<span></span>
</td>
<td class="nump">314,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">960,375<span></span>
</td>
<td class="nump">1,160,599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 3,705,119<span></span>
</td>
<td class="nump">$ 3,588,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948641320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Permit of land use</a></td>
<td class="nump">$ 431,681<span></span>
</td>
<td class="nump">$ 403,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
<td class="nump">10,024,303<span></span>
</td>
<td class="nump">9,375,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Plant, machinery and equipment</a></td>
<td class="nump">29,018,708<span></span>
</td>
<td class="nump">26,309,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_MotorVehicleGross', window );">Motor vehicle</a></td>
<td class="nump">329,660<span></span>
</td>
<td class="nump">308,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_OfficeEquipmentGross', window );">Office equipment</a></td>
<td class="nump">259,175<span></span>
</td>
<td class="nump">217,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">40,063,527<span></span>
</td>
<td class="nump">36,614,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(24,499,327)<span></span>
</td>
<td class="num">(20,300,399)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 15,564,200<span></span>
</td>
<td class="nump">$ 16,313,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_MotorVehicleGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before moto vehicle of tangible personal property used to produce goods and services, including, but is not limited to, tools, motor equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_MotorVehicleGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OfficeEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before office equipment of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OfficeEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948694024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Permit of land use [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Plant, machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Permit of land use [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">70 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">49 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Plant, machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_PermitOfLandUseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cphi_PermitOfLandUseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881044617208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_PropertyAndEquipmentTextualAbstract', window );"><strong>Property, Plant and Equipment (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,643,820<span></span>
</td>
<td class="nump">$ 2,871,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PropertyAndEquipmentTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PropertyAndEquipmentTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880956082712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 5,173,818<span></span>
</td>
<td class="nump">$ 4,839,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,991,672)<span></span>
</td>
<td class="num">(4,633,506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 182,146<span></span>
</td>
<td class="nump">$ 205,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881120613352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 37,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">37,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">37,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">37,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">31,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 182,146<span></span>
</td>
<td class="nump">$ 205,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880955938984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_IntangibleAssetsTextualAbstract', window );"><strong>Intangible Assets (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense relating to intangible assets</a></td>
<td class="nump">$ 35,650<span></span>
</td>
<td class="nump">$ 57,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_IntangibleAssetsUsefulLifeDescription', window );">Intangible assets useful life , description</a></td>
<td class="text">NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IntangibleAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IntangibleAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IntangibleAssetsUsefulLifeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IntangibleAssetsUsefulLifeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881041074440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advances for Purchases of Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract', window );"><strong>Advances for Purchases of Intangible Assets (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss for advances made to laboratories</a></td>
<td class="nump">$ 17,015,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesForPurchasesOfIntangibleAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880949911032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent', window );">Advance received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,546<span></span>
</td>
<td class="nump">13,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,658,706<span></span>
</td>
<td class="nump">2,307,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Borrowings from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,316<span></span>
</td>
<td class="nump">724,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Partial conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Board approved the issuance of 2,000,000 shares of common stock from the Company's 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The shares were issued at a market price of $0.43 per share based on the average of the closing prices during the five trading days prior to the issuance date, and higher than the closing price of $0.42 per share on the issuance date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent', window );">Advance received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">4.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,083<span></span>
</td>
<td class="nump">$ 12,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_RepaymentOfAdvance', window );">Repayment of advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LoanAgreementToBorrowCash', window );">Loan agreement to borrow cash</a></td>
<td class="nump">$ 674,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LoanAgreementPayableTerm', window );">Loan agreement payable term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member] | RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LoanAgreementToBorrowCash', window );">Loan agreement to borrow cash | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 4,770,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LoanAgreementPayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan agreement payable term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LoanAgreementPayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LoanAgreementToBorrowCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>loan agreement to borrow cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LoanAgreementToBorrowCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RepaymentOfAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RepaymentOfAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TypesOfCurrencyAxis=cphi_CNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880949914728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Banker's Acceptance Notes Payable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_BankersAcceptanceNotesPayableTextualAbstract', window );"><strong>Banker's Acceptance Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum amount of agreement</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeDescription', window );">Agreement payments fees, description</a></td>
<td class="text">In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Banker's acceptance notes payable outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember', window );">RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_BankersAcceptanceNotesPayableTextualAbstract', window );"><strong>Banker's Acceptance Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum amount of agreement | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_BankersAcceptanceNotesPayableTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_BankersAcceptanceNotesPayableTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the fees for amounts available, but unused under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TypesOfCurrencyAxis=cphi_CNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948726632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Construction Loan Facility and Lines of Credit (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 4,337,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">904,228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">5,241,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Lines of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,298,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">2,298,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConstructionLoanPayableMember', window );">Construction Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,038,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">904,228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,942,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConstructionLoanPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConstructionLoanPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948201336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Construction Loan Facility and Lines of Credit (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 21, 2013 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionLoan', window );">Construction loan amount | $</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of loan interest rates</a></td>
<td class="text">The loan bears interest at a rate of 4.25% per annum.<span></span>
</td>
<td class="text">The loan bears interest based upon 110% of the PRC government's eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The interest rate has remained at 5.39% on the anniversary dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015.<span></span>
</td>
<td class="text">The loan bears interest at the rate of 4.05% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,174,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,174,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LoanTerm', window );">Loan facility term, description</a></td>
<td class="text">Advances on the line of credit are due two years from the date of the advance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The line of credit is due in one year on the anniversary date of the line of credit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of credit, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Total interest expense under this facility for the years ended December 31, 2020 and 2019 was RMB189,892 ($29,103) &#160;and $0, respectively. The Company repaid RMB 500,000 (approximately $0.07 million) and RMB 300,000 (approximately $0.05 million) to Postal Savings Bank of China in October 2020, and January 2021, respectively, as per the payment schedule.<span></span>
</td>
<td class="text">Total interest expense under this facility for the years ended December 31, 2020 and 2019 was RMB189,892 ($29,103) &#160;and $0, respectively. The Company repaid RMB 500,000 (approximately $0.07 million) and RMB 300,000 (approximately $0.05 million) to Postal Savings Bank of China in October 2020, and January 2021, respectively, as per the payment schedule.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=cphi_ThirdPartyGuaranteeMember', window );">Third party guarantee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=cphi_BankOfCommunicationsMember', window );">Bank of Communications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=cphi_ChinaCITICBankMember', window );">China CITIC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of credit, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October under this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the advance.<span></span>
</td>
<td class="text">The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October under this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the advance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember', window );">RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionLoan', window );">Construction loan amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8,500,000<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="nump">&#165; 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AdvanceLoanAmount', window );">Advance loan amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember', window );">RMB [Member] | Third party guarantee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember', window );">RMB [Member] | Bank of Communications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 166,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember', window );">RMB [Member] | China CITIC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ConstructionLoanFacilityTextualAbstract', window );"><strong>Construction Loan Facility and Line of Credit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 33,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvanceLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance loan amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvanceLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConstructionLoanFacilityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConstructionLoanFacilityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LoanTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of loan description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LoanTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=cphi_ThirdPartyGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=cphi_ThirdPartyGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=cphi_BankOfCommunicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=cphi_BankOfCommunicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=cphi_ChinaCITICBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=cphi_ChinaCITICBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TypesOfCurrencyAxis=cphi_CNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TypesOfCurrencyAxis=cphi_CNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881044597640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">$ 52,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">52,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Less: Imputed interest</a></td>
<td class="num">(744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease Liability</a></td>
<td class="nump">52,070<span></span>
</td>
<td class="nump">$ 140,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Operating lease liabilities, current portion</a></td>
<td class="nump">52,070<span></span>
</td>
<td class="nump">91,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 48,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881043244984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_LeasesTextualAbstract', window );"><strong>Leases (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating leases cost</a></td>
<td class="nump">$ 96,552<span></span>
</td>
<td class="nump">$ 90,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_CashPaidForOperatingLeases', window );">Cash flows from operating leases</a></td>
<td class="nump">102,624<span></span>
</td>
<td class="nump">95,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">49,687<span></span>
</td>
<td class="nump">136,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating leases liabilities</a></td>
<td class="nump">$ 52,070<span></span>
</td>
<td class="nump">$ 140,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_CashPaidForOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_CashPaidForOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LeasesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LeasesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139881042463656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">(Benefit) tax at statutory rate of 25%</a></td>
<td class="num">$ (716,694)<span></span>
</td>
<td class="num">$ (5,175,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Other, primarily the difference in U.S. tax rates</a></td>
<td class="nump">8,190<span></span>
</td>
<td class="nump">8,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">708,504<span></span>
</td>
<td class="nump">5,167,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_IncomeTaxExpense', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948073960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful trade receivables</a></td>
<td class="nump">$ 4,537,623<span></span>
</td>
<td class="nump">$ 4,393,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses', window );">Allowance for doubtful other receivables</a></td>
<td class="nump">6,822<span></span>
</td>
<td class="nump">5,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory obsolescence reserve</a></td>
<td class="nump">568,182<span></span>
</td>
<td class="nump">1,528,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses not deductible in current year</a></td>
<td class="nump">1,160,601<span></span>
</td>
<td class="nump">1,085,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Advances for intangible assets impairment</a></td>
<td class="nump">10,441,373<span></span>
</td>
<td class="nump">9,765,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Lease liability, net</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">PRC net operating loss carry forward</a></td>
<td class="nump">9,542,576<span></span>
</td>
<td class="nump">12,682,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. net operating loss carry forward</a></td>
<td class="nump">1,409,380<span></span>
</td>
<td class="nump">1,296,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">27,667,153<span></span>
</td>
<td class="nump">30,759,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(27,666,557)<span></span>
</td>
<td class="num">(30,738,262)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 805,556<span></span>
</td>
<td class="nump">$ 753,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the provision for loan losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880953313096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards for PRC tax</a></td>
<td class="nump">$ 37,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss, expiration date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="nump">$ 27,666,557<span></span>
</td>
<td class="nump">$ 30,738,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Enterprise income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_NetOperatingLossCarryForwardsExpirationDescription', window );">Net operating loss expiration, description</a></td>
<td class="text">Approximately $23.1 million of loss carryforwards expired in December 2020. The Company also has net operating losses for United States federal income tax purposes of approximately $6.7 million of which $5.1 million are available to offset future taxable income, if any, through 2039, and $1.6 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_DescriptionOfFederalCorporateIncomeTaxRate', window );">Description of federal corporate income tax rate</a></td>
<td class="text">The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DescriptionOfFederalCorporateIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of federal corporation income tax rete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DescriptionOfFederalCorporateIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NetOperatingLossCarryForwardsExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carry forward expiration date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NetOperatingLossCarryForwardsExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948188664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_FairValueInputsAssetsQuantitativesInformationLineItems', window );"><strong>Fair Value Inputs Assets Quantitatives Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker's acceptance notes</a></td>
<td class="nump">$ 53,736<span></span>
</td>
<td class="nump">$ 45,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">53,736<span></span>
</td>
<td class="nump">45,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_FairValueInputsAssetsQuantitativesInformationLineItems', window );"><strong>Fair Value Inputs Assets Quantitatives Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker's acceptance notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_FairValueInputsAssetsQuantitativesInformationLineItems', window );"><strong>Fair Value Inputs Assets Quantitatives Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker's acceptance notes</a></td>
<td class="nump">53,736<span></span>
</td>
<td class="nump">45,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">53,736<span></span>
</td>
<td class="nump">45,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_FairValueInputsAssetsQuantitativesInformationLineItems', window );"><strong>Fair Value Inputs Assets Quantitatives Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomersLiabilityForAcceptancesNet', window );">Banker's acceptance notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_FairValueInputsAssetsQuantitativesInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_FairValueInputsAssetsQuantitativesInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomersLiabilityForAcceptancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all customer's outstanding debt to the institution that resulted from short-term negotiable time drafts drawn on and accepted by an institution (also known as banker's acceptance transactions), net of allowance for uncollectible customer's liability for acceptances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomersLiabilityForAcceptancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880949777000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount', window );">General and statutory capital reserves amount</a></td>
<td class="nump">$ 8,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,145,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_AftertaxNetIncomePercentage', window );">After-tax net income, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ReserveAccountBalancesPercentage', window );">Reserve account balances, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_SharesOfCommonStock', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_PartialConversionOfUnpaid', window );">Partial conversion of unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember', window );">Two Thousand Ten Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Common stock issued for equity awards</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock granted and outstanding</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AftertaxNetIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>After tax net income percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AftertaxNetIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PartialConversionOfUnpaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial conversion of unpaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PartialConversionOfUnpaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ReserveAccountBalancesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ReserveAccountBalancesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959330424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 10,866,449<span></span>
</td>
<td class="nump">$ 10,923,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cphi_DomesticPharmaceuticalsMember', window );">Domestic Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">9,132,216<span></span>
</td>
<td class="nump">10,923,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cphi_COVID19TestersMember', window );">COVID 19 Testers Exported to Puerto Rico [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,734,233<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cphi_DomesticPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cphi_DomesticPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cphi_COVID19TestersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cphi_COVID19TestersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880958966808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks &amp; Uncertainties (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Customer </div>
<div>Suppliers / Number</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Customer </div>
<div>Suppliers / Number</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">49.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember', window );">Raw Material Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_NumberOfSuppliers', window );">Number of suppliers | Suppliers / Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember', window );">Raw Material Purchases [Member] | Suppliers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">20.70%<span></span>
</td>
<td class="nump">22.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember', window );">Raw Material Purchases [Member] | Supplier Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">17.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember', window );">Raw Material Purchases [Member] | Supplier Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember', window );">Raw Material Purchases [Member] | Suppliers One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetOneMember', window );">Revenue one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">32.60%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetTwoMember', window );">Revenue two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetThreeMember', window );">Revenue three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NumberOfSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NumberOfSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_SuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_SuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_SuppliersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_SuppliersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_SuppliersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_SuppliersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_SuppliersOne1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_SuppliersOne1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesRevenueNetThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880948512616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Parent Company Only Financial Statement (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 957,653<span></span>
</td>
<td class="nump">$ 1,074,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,321,958<span></span>
</td>
<td class="nump">5,579,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">21,117,991<span></span>
</td>
<td class="nump">22,235,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">8,004,531<span></span>
</td>
<td class="nump">9,237,601<span></span>
</td>
<td class="nump">$ 30,198,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">21,117,991<span></span>
</td>
<td class="nump">22,235,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">21,187<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">$ 5,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">21,187<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_IntercompanyReceivables', window );">Intercompany receivables</a></td>
<td class="nump">7,746,779<span></span>
</td>
<td class="nump">8,084,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment in subsidiary</a></td>
<td class="nump">11,705,241<span></span>
</td>
<td class="nump">11,705,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">19,473,207<span></span>
</td>
<td class="nump">19,793,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total liabilities - other payables</a></td>
<td class="nump">1,752,990<span></span>
</td>
<td class="nump">2,401,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">17,720,217<span></span>
</td>
<td class="nump">17,391,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 19,473,207<span></span>
</td>
<td class="nump">$ 19,793,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IntercompanyReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IntercompanyReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880959535544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Parent Company Only Financial Statement (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 1,822,655<span></span>
</td>
<td class="nump">$ 2,289,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,866,777)<span></span>
</td>
<td class="num">(20,702,044)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">536,035<span></span>
</td>
<td class="nump">522,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (536,035)<span></span>
</td>
<td class="num">$ (522,386)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880958999864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Parent Company Only Financial Statement (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,866,777)<span></span>
</td>
<td class="num">$ (20,702,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(42,260)<span></span>
</td>
<td class="nump">608,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(867,307)<span></span>
</td>
<td class="num">(136,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="nump">624,177<span></span>
</td>
<td class="num">(1,728,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">1,074,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">1,074,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(536,035)<span></span>
</td>
<td class="num">(522,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilities', window );">Total liabilities</a></td>
<td class="nump">216,127<span></span>
</td>
<td class="nump">220,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(319,908)<span></span>
</td>
<td class="num">(302,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cphi_ProceedsOfChangeIntercompanyReceivables', window );">Change in intercompany receivables</a></td>
<td class="nump">338,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="nump">338,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="nump">18,092<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">5,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">$ 3,095<span></span>
</td>
<td class="nump">$ 5,170<span></span>
</td>
<td class="nump">$ 21,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ProceedsOfChangeIntercompanyReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ProceedsOfChangeIntercompanyReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>7-A5-.]KWU4QJA5]W$I!<R]-8#?%PK@N;VPKX!WK_S/_@]02P,$%     @
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M&[L:4QL"-Z[2W)1I@@-I;B&^)#W_@@1>X'7 9R?#_:@-=]%P[3JH70>6KW>
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M74[+A"&J8+;)-?+<3P@[;F2*WY$SJ#CUEK2?^1Z)G(F]/XU3'X4]$CO8\=O
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MI@'P?<6Y>GW0Q\3FEXK9?U!+ P04    " "R@'I2M=IF<+4'  "%(   &
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MS(F!.;B=4$9(ULO ^2.W)SCOD@!=CI5^Q(#D7:9<'V.V1$QX/HLZ" K"*V6
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M&W]<*8DJ3 OP^\(B:Z8O=$#W<NB'_P=02P,$%     @ LH!Z4DKAJ/6+ @
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M6U[DRP=O-N'RO#2>KN)AF=%O'[2\@;ZOC/'U SMH?DW-_P%02P,$%     @
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M<#U;+/^$Y6+V]69VOOQT]?7FI:B^;NOKU?(21O#C#Y,P"#[ <=,P@X(7*ZY
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M6IN:T:Y5'I; 2@-JZQ>L\WE.F3$)W)@:/89C&[ G-NE+07#.U!9<YU Q;0_
M##T<O 3"9Z6JI26J/9>[AIW98_L0'HXXN:%+Y%/-7:ADG&.E#&]C(6T#IX08
M6U@@4R:ZF#HJC73S&9>P'#8'_ZH+ /X5@ \P[]/2Z^)H&F4-ZJ!)E<%.DL-F
MP@$Y##"%VDL7>K!&ZDF>.8.,F2( NM6\NBQK8G1Y:%W!7PG&^1$^'2 L-ZC[
M0S1@,G>M<-THH0N%EW79Q=XF\J5ZU72DM0O&/-76J12\],K;: 4:0W9$O;Z=
MC^-A'/L/_,BJ2BLB8Q;%87 Q"2_I5A."+NB?0.FC9#M?%R6PSXP+?RB/JL9V
M-&^,/5^!T'4]RW/N[O_A\WX<9$P( ]N6\ZBMMDAY[ZL?A_'E]UTW.]0^1ZHG
M#R%].<O@LOS-[NC:*QETJ2U8#C0L#>G.F_J=["?Y37HN&H*+47P]O(ZOAM2>
MID(_YL0A?.GBBHX&18EZY\>A@<PA-C.CW^TG;MH,FB?S9ES?,KVC$E"EM^0:
MAV]HP.EF!#8+JRH_=C;*TA#SCP7]:T#M#.C]5E%4[<(1]/]#9E\!4$L#!!0
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MKA&52:ONG>V+TZ6_K\RUH]N/?\SHNHF&#6A]H;7;OG" W05V]@-02P,$%
M  @ LH!Z4HD0$F4-"@  -Q@  !D   !X;"]W;W)K<VAE971S+W-H965T,38N
M>&ULC5E;;]LX%G[7KR",%&@!Q9;E:SII@"3M8+N87M"FL[M8[ ,MT3:GDN@A
MJ3B97[_?.91L.;73>4BB"\_M.W?E<FOL=[=6RHN'LJC<F][:^\WKP<!E:U5*
MUS<;5>'-TMA2>MS:U<!MK)(Y$Y7%($V2Z:"4NNI=7?*SS_;JTM2^T)7Z;(6K
MRU+:QQM5F.V;WK#7/OBB5VM/#P97EQNY4E^5_[;Y;'$WV'')=:DJITTEK%J^
MZ5T/7]^,Z3P?^%VKK>M<"[)D8<QWNGF?O^DEI) J5.:)@\2?>W6KBH(808T_
M&YZ]G4@B[%ZWW']EVV'+0CIU:XI_Z=ROW_3F/9&KI:P+_\5L_Z$:>R;$+S.%
MX]]B&\Z.1CV1U<Z;LB&&!J6NPE_YT.#0(9@G)PC2AB!EO8,@UO*M]/+JTIJM
ML'0:W.B"365J**<K<LI7;_%6@\Y?O:\R4RIQ)Q^4NQQX<*3G@ZRAO@G4Z0GJ
M82H^F,JOG7A7Y2H_9#" *CM]TE:?F_19CF]5UA>C82S2)$V>X3?:V3=B?J.?
MVB?>:I<5QM56B?]>+YRWB(C_/2-BO!,Q9A'C4R(^WG[Z\$[<7?_[W==C$#Y/
M_?'3W3LQ3,2YZ/(1;]526:MRH8,!'@9(YY1W0E:Y*+1<Z$)[K5PD85"I)!F6
MB]KI:B54!=MP1U16>N6$>MBH\,@(N=D4CW2!UW)1J%:&KH1?*_&HI'5TLUWK
M;"V\*C?&(F%%KI=02E49^)'0EF<$5@N%%,W,O2(E#+)>>5^HO"_NP%&!+O/"
M+(44V5I6JR +RA5RZ^AX4!)9FK=VGS98:,>R5I7^BP&*#O7?**L-&*RE)\N*
M.@<-O6!44%"\R"&N+W[K\&1[G <<&LF4"Y0[4<-2ZU'8(E)F8YRF0G*(Y8)<
M\UU5)+SC*JM\;7%TN\8K5P/&/3F)^J/.5X%!2967M.N5QJKS0G]7Q>,YE*_.
M*^-[D5];Y=:FR+GXY(01G?8J6U<ZDP486 V0 "X;WXKIBW?.:Y0MALC#+\XS
MDBCGLF";K2ID8\;.5'%H*G2-&@QSN(/\9Q .%8$(B08B+>-1.>7(V=;4JS6B
M-U/E J_:3(Y9N5O0RNI1K,$)Q@F=@X]>:N*-QR>4B((G/9,QV'WQK?^U?PQO
M<ML^AA45I:?*#&<X<4)-!H@U72--79L9T5[$@83C H@-7$Q]DT_#$*<IS=2#
M1 679!0L &G@E-4(>.#9Y$,;QI^_W!ZBID,F;'511 @[5R_^H*RB/.;@AH\W
M5N^4WB4_.2J=O.!4A%Y;!E]LK+G7W%I)QST)"LK? +&!"FA>Q$#&44*@NZ*L
MY+4BE3*T!5W5H*P0WRB[3NUBM#&H+WXU!88"*EAD&R=UE2$C&2(ZO8<?U CV
MK X1*T/*+!4P1 H@;WWM#4I4J",-)*=-?!W]AVWCKA6Q.61*]/)&56JI_:M0
M?OP3S@V2XDR\G VG\?1B+%[1S20>SB;Q!-WP5?09Q<>&Z,!\40,DF*6 38X2
M?QY]HHR)H1I2TVHJPU!T7UC)^1S;^\H]CX<7"?U.1M'MKGC>RZ(.,$G"4!+M
M+)G'DV0LH,YT%H^3B^C]/A*:)(6ZY_QSQT7D6&D/97\%E06%4]2@F?^]CO3(
MP2\I%4DQ0-T-G0[6ISO<Z^AZ9Q-Y+C?UPB_K0J!EYZK!DQJ7@R7C>#*:Q=-T
MQ->CBU$\FTU.,0CUJLM@&L_3%(A-YRG0ND<6D;/-PAF\S=@E"&]E <9D"B?,
M4S&,)^D\'H/@75/XN)@ADFHD0>BGNZ3F0!C"(4D\38:X2N:(E#2)KO-[R7"'
MV/1P+-,VD&JDB+;<K(9)/!X/X]%L)"[BV7027R33Z#<T?+4'/>8TFUQ,Q3R9
M12@=?(\2A!BB_*($1 )9V 9Y6VES\)J,TW@RFXIA2N;'T]DPXMC[*>F0@BL>
MS1-<I1> <#B*[HQ')CX3)"F\A+ <3D9BE,2SR44\G4RCWX_$\<O.T5?BY?XT
MTNNC\J>%M,%]-+9V6+V&HY_"?0;<X!>(.!.SR0B C\4U%ZR?MK(\.H57 U=P
M,?F$VUIMT1!",<0@9LT#-VE4@K/1K#_'C%\4!$?(0LZE>ZD+GM.0B6:Y)$-)
M]++V-,LV0UP[!+6]#:I.^^+Z4$(ZZ@]W$J# $5U1)W1 ;F\ZF1TFN=9L63@3
MVGC7]JBI\V3OMTI3I?[JN8BUE;KCCV> F/9G72T#%&>3CNXG<(D.,6G$Q4(O
M";&X \X(?8O*UMFP/SW!E:SH8@-NB#Q-=D')3ON5B*U2>P[C"/K.DQ?<Z@ZG
M:V*G) W4,)[*0E]\ <!(<$ZZ%B$.5;72KF!^,0U<I:F*Q\CN1F-#]96BD-::
MV[JIP/]$U1+74.DECY/,E0Y\4;2[]U[%W/J=7E5A)#0\;9BNG],P(+&OHR<,
MF!+#6B8K#_M+DX?)C83QT?<T@6"VQ'G4T9J"!=5Z =@E#%@UQ==CLEHY&AI0
M+BE?B'[?9KM81)FQU)_\CR/-TII2C-"*844Z?!&FL@;O,+8L@&%5D0"YA%X_
M3H&_!*_QB2H?D'?H014BN:0H7] VI9 B36W',/H+@F759/K.<HX!",$@;JQN
MG.@>'?HKQC6/- ;,ZASCN*(>5H7!ED]1U&&?K["1P/PH5ZI4-#)LI+?[.6AC
MU;TVM:/YJHT"F*S@$<24)3,YC]KYN7V'('4ZUY@T%#3OA&Q[<!^X<,D*PP]@
M1ZAUD @6'O4$K6OZGH9XJG'DD>-R>>N@62PG?N2J2FW#($8\GBK=&D01%5%]
M=JY%VRI9Z+_:00,&'UD78X)3KA3W3@R44$19WL0X_K!'8-BD74N$78L6Q8H[
M..\9CJR#K0%Z2VTI:N;68[LI3>-,O&BU:Y?>N@CK5ZMTZ\MC7#2%V(8F;>A<
M;YH=+_BCH3M>VC!NVQ:<L/=V-_<UZNO!:+=0@6@_JH2\.=+DPYY:>]V8]&$'
M:K0'%5[](ZS"Q[7C=8IJ?2%#+M)7%X_,5*QF*;\'Y6G\9T<3_[ZXX4V7<8!K
M]F_:!:) @6&O@) R+@LI]U1RHQTOLA1UQW6D;Q8'^)D]?L=]3L#L(8RX3504
M "U:!R&X0#)!7]=$'L5*$WCMGM4V5>1E$T(4=2#D762W-AU5Y6!&B7Y8SIJE
MCU+K<&X)^=A\Z)!'UPFY0E8ZVKS=4=D0?,:3VA2#TXQ$1F<TJXWF<3I-GZCV
ML[WQR'@!_]0L\QYU!,4O-)"P#');Y&TW[^Q2D+<KV<TQ,DR=RSP/NM.CVB[@
M+@IB;T-5;]^03P,*KK;96MJ5"JV5):,@75>/45UA,L^II]55$PP N AIT&3N
M0A8,(7^792_)++-UJX/8R$<*P?ZQKX^#SL?<4D$%^F2-Y"1QX;ON[NGNJ_AU
M^!B\/QX^J7^ !7 A\F4)TJ0_F_2PTO%GZG#CS88_#2^,]Z;DR[7"CF7I -XO
MC?'M#0G8_:_@ZO]02P,$%     @ LH!Z4M\?IE#Y!   SPL  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&ULK5;;;N,V$'W75PS4HA? C6_))IN+@623
M11?8[*:Y]:'H R6.+384J9!4G/3K.T-=[&SB%"CZ8HOB\,R9X3D4#Y?6W?D"
M,<!CJ8T_2HL0JOWAT.<%EL)OV0H-S<RM*T6@H5L,?>50R+BHU,/):/1N6 IE
MTMEA?'?A9H>V#EH9O'#@Z[(4[ND$M5T>I>.T>W&I%D7@%\/98246>(7AIKIP
M-!KV*%*5:+RR!AS.C]+C\?[)-L?'@%N%2[_V#%Q)9NT=#S[)HW3$A%!C'AA!
MT-\#?D"M&8AHW+>8:9^2%ZX_=^@?8^U42R8\?K#Z=R5#<93NI2!Q+FH=+NWR
M5VSKV6&\W&H??V'9Q$ZW4\AK'VS9+B8&I3+-OWAL^["V8&^T8<&D73")O)M$
MD>6I"&)VZ.P2'$<3&C_$4N-J(J<,;\I5<#2K:%V8?13*P:W0-<(Y"E\[I(X'
M?S@,!,XAP[P%.FF )AN QA,XMR84'LZ,1/D<8$BL>FJ3CMK)Y$W$4\RW8#H>
MP&0T&;V!-^U+G4:\Z;^7>JI\KBU7Z^&/X\P'1^KX\XT<VWV.[9AC>U..XT^7
M<'O\^>8,SL^.KVXNS\[/OEQ?O=;.-X'8B_N^$CD>I60VC^X!T]F7K]=G,![#
M#]_M3<;C@V1#-HB5/L1*E6>-$K@$X2$4"/B8%\(L$"JG<DQ"(0(YI]82,B2;
MY4@ND4!V!T&F\9X.!GJNA)(0+%"GC)\C38)6(E-:A2?XB2+Q484&\F=0)F:B
MD<E5)30#E-8'$/)!F$!FM[4G%;L[# EGXN@^U0J7< C9.HE./S6I16/F#,,2
MT;08Q,X%Q:E(NF";[.5*SB!%P"VXMMU+F/<=&B0""H5.N+QX@H*:E#$P^B R
MK<A8$I:%R@MJS7VM6#!<K G,C_I!5E2E^AMCRMHCV#G8C/>+EE/[354'7B+9
MO"\B:[.*39I8HEG0IJTH42AOG$,$C0^H/2]L<<.J(D9=5<4QL:%-[JZEBNE[
MVEQ-A['?A\\,""M!_5;;0 7';?2Q_?'0;-OLHRJ4Y.ISVM4VP=J6$?Y!"SKI
M0.'KBW98(LN;3IWL&)!2="V5623WSSAP1D]]T\*]GF\ ]]^2UNC]-\P'O*I)
M^W)WH@5RP:J"W#IG,^M(,#+)GM:C6ZV1EL1![&K#?=H7>F->8ONZJJQC?@1&
MC --$15C.[C(D\7$E9)1!5F&>JL,'4IU/(N396%)+FM^#NC*:.G:4\=BY?Q?
M6DGR&("DT\W6AI/FPA<PI\TFG83"2JOM(C9MK:T!\\*H^YI?DSB6](7D_W4&
MS*UQ <NL(R"B%4EI:[KK7>+5PJ@YZ83L5PI#GH]._*N6B_A B.0Q5480%CW"
M!UN2@UO%KV&N5)YP^E[@/,B$N4/W(^]WCE6@[B$U-[ 0 A162YH)0)\2+#/:
M_.YS$O=O,AJ_;S)O1$F$BX<BGT&2D7(^QII6B*IR]I$K>$;W>2T%TL$:O1D]
MQ]NTP9=K69(5VGZRX0O-8<_*ND06&B>@BP#"#4N#(GSN5!4W*M;=^:TS::OA
MY&1C'[^'G>E@=_J.'GYY-DBN;2"E;I[_'YF/W_\GYML[@]V=CMEJT#/?, ^O
MW02&:Y>L$MTB7B4]1*<U]ZW^;7];/6XN::OPYJI[+MR"[$4'U9R6CK9V=U)P
MS?6Q&01;Q2M;9@-= .-C03=N=!Q \W-+!;8#3M#?X6?_ %!+ P04    " "R
M@'I2T$,L"Y,&  !J#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-
M5UUOVS84?=>O((P.W0#7EAVG38HD0+Z*!FN;+$DW#,,>:(FVB%*D2E)QO%^_
M<TE)EE,GVT-B2>0]]Y[[21ZMC/WF"B$\>RR5=L>#POOJ_7CLLD*4W(U,)316
M%L:6W./5+L>NLH+G0:A4XVF:OAV77.K!R5'X=F-/CDSME=3BQC)7ER6WZS.A
MS.IX,!FT'V[ELO#T87QR5/&EN!/^:W5C\3;N4')9"NVDT<R*Q?'@=/+^;$;[
MPX;?I5BYWC,C)G-COM'+57X\2,D@H43F"8'CYT&<"Z4("&9\;S 'G4H2[#^W
MZ!\"=W"9<R?.C?I#YKXX'AP,6"X6O%;^UJP^BH;//N%E1KGPGZWBWBDT9K7S
MIFR$\5Y*'7_Y8^.'GL!!^HS M!&8!KNCHF#E!??\Y,B:%;.T&VCT$*@&:1@G
M-07ESENL2LCYDSMOLF^%4;FP[C6[_%Y+OSX:>R#3^CAK4,XBRO09E,F4?3;:
M%XY=ZESDVP!CF-39-6WM.IN^B'@ALA';FPS9-)VF+^#M=3SW M[>,WB1&?OK
M=.Z\12K\_0+FK,.<!<S9<[Z[OS[_]>/UIXO+VSOX[K>O5_=_[O+=RRA?KN\O
M&1SXAFWA)1&/W1>"G9NRXGK-I&.\]H6Q\A^1,V_PP=6"'>X/TS2EO\05W K'
MS()EIBR1]8[B.V2OTE&:3EC%+7O@JA9#QG7..CFVD4-I+X2UP']&=!1,>K(-
M*;EF<Y$$@W(FH5A8"<25] 4J/BM0*DXN-:=:=,-&7NA,X,5Y[B$5X/%JJ9+P
M^[WF2BYD%F68L4S)4OKFE3M >F%1%&2%44*MD_F:^8W#7CMV9KC-1^PTRXS-
MI5Z2URQZP@/7GMW<GC/%5U"5!0$8G%BQE ZPD06!8=<0SYFJ(\ 6/D&X>NYD
M+M'3ANRC4)4S&OZU HJ0=3:&BBMEP$0P[ID2W'DV27\BAP-/6L87T)EX_DB:
M3$D!VN)7HZYLT,U!I=:>3('?= Y^+D03EM>J<4[?="@G!]?>V#5LM96J'38C
M0 \=FF,$J1(2>K*$IJ<XQ0D+'''<[\QNO$9NZ'DMXQ5BI!!AB8A!>21H!4+G
M"8BD%^"#B-:^@4I@*:(4?1081$'7F1,Y1KF,:V:THHQCM8-.#"?F*I%1MK *
M%(UK!"@,VGB&HM>.,I;/E6C *:<%"#8TDL9I-.G(+&4X92K/'R)]Z,BX0R++
M!YD+V!$K@9?!2VUZ-]8LA1867B ;-MYO?=-Q0D6_.AA.9J$2$Q(,/F[\NY N
MP^ZUX-8Q09V5H2^*<HY4:'MCT#!-)X<C=EE6RJR%8*&IL^LJ>A*+*;L"!4T#
MD-T@FNQ:LR_F(2)-IL.P9[B=VDDH'= W%9':3OM=F#_3E@$]#GX9LE4A062%
M+,9G3-^JLE"8,U2HZ\T<Q+'CE$P;2T9DWW7F33#O7?AX&,V+1L$_%R@L[ !"
M!TWK'Z1%:9WBV)"7%-LFTL_;VVV%T0E2Q]4\BD4"M(>*L W)+B T3Z4H%\6C
MCU&"^-- '<9LV5A&KFF=&]M6[-X[',.(?8PQ802E2P[UO:#$WC"7BL8<]"\M
M\8C-V51-UT7>>2LSO^GN<0.Y$-432B^)[3?D525L./=1U=9:^E"6]".:5 -F
MO@D$)#+HP8$(NK%$]5^@%.%+^%,&)U%S^U_B2>/QEA^6QP D[5W#1</NN22K
M+=4S^@(UVY4+A2CBX.>KT">!65=$8K9C]/5'YBBY+ZRIE\730#:)B+:RHG^3
M=_M/4)[Z.$8";\0/'2\T;>K>FY9.UH]0D&V@D@#=W\L#] ^F_(!QW4N:Z5[3
M(39UTY9*Z/,TJ]M^//T/=["%->6N'O#)Z.6;>RJ0[:((\XN7L1P6QK;]UDNN
M$D3Y 2E.IW(*B*ZXS$,7QF$_Y" BA#9)Q%\=O)T-9P=I6\CG!9<6:1EF['DA
MQ8)=/HJL#HJO%^C_8$Z>OH+/K2R;/1^D!E7H;O<D-%[17FOGXJ3_8C";WX9L
M:F.K,3@!;:67H56'HTWGB)!R.5:;,P%UZ=U-NJW;-I.1\&:IPQD.*OJ\$_%(
MSS3T5!@E#>M-]K9!B5$BHK0>4BR^EB;OGYD6VRV@-;@_97KC)7EIO)SNRL%I
MVI4#/*KI<$570>A(:MTCNA7='2RWK33VF3)RHUWG]G'O_E,*NPRW/!P3:##'
MJU#WM;M(GL;[TV9[O(5^YG8I88$2"XBFHW?[@W@>;5^\J<)M:FX\[F;AL<!E
M6%C:@/6%02(U+Z2@NUZ?_ M02P,$%     @ LH!Z4G>WX'/- @  L 4  !D
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M9,05/41SS&BEHM .9-]PKO:"#G!8TM-_4$L#!!0    ( +* >E)]VZP:D00
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M;M*\6%7Z^T"B+&T<_C&GZQQJ9T#?5XH:J'UQ ;H+XOQO4$L#!!0    ( +*
M>E(L)762L@0  ,H*   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*U6
M6V_J1A!^YU>,4*6FDA-\ 0P(D PA)Z@)T)BTBJH^+'C!J]B[/KM+2/Y]9]=
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M&=Z1@<,N:'^P)U)-%BQM%@Q03 -'KBX1Y*IF);Q=R.('VR!X@!L$0$"*Y'Q
M_]6 ];-QDOGP[1U"QS[-H@)*Q%CRM:SW*<P>#FYIS2:@4J+O<4S/_\ <:X\
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MR>G+D2\5Q@^5*?F'*PM3 ;SRXUI)0&P:@.^7!L$M?* %FI\RO?M_4$L#!!0
M   ( +* >E)H;;1?;P(  ! %   9    >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;(542V_;, R^YU<01@\;8,3//%PD 9IVQ7HH4+3=>AAV4&PF%BI+GJ0T
M[;\?)2=N!K39Q2(I\N-'FM1LI_2SJ1$MO#9"FGE06]N>1Y$I:VR8&:H6)=VL
ME6Z8)55O(M-J9)4/:D24QO$X:AB7P6+F;7=Z,5-;*[C$.PUFVS1,ORU1J-T\
M2(*#X9YO:NL,T6+6L@T^H/W1WFG2HAZEX@U*PY4$C>MY<)&<+W/G[QU^<MR9
M(QE<)2NEGIUR4\V#V!%"@:5U"(R.%[Q$(1P0T?BSQPSZE"[P6#Z@7_O:J985
M,WBIQ!.O;#T/I@%4N&9;8>_5[CONZQDYO%()X[^PZWRS-(!R:ZQJ]L'$H.&R
M.]GKO@]' =/XDX!T'Y!ZWETBS_**6;:8:;4#[;P)S0F^5!]-Y+AT/^7!:KKE
M%&<7-_(%I57Z#;X\LI5 \W466<)UMU&YQUAV&.DG&$D*MTK:VL W66'U+T!$
MA'I6Z8'5,CV)>(7E$+(DA#1.XQ-X65]EYO&R_U9YQ4TIE-EJA%\7*V,UC<7O
M$QGR/D/N,^2?9'B@;:FV D&M@1^R?=3*DS!N!<]-RTJ<![1C!O4+!JX;V*Q0
M^XX<*P/7'NI14@SNV8[&PJ+F3!@X@S2,ITDXR4=>3I(L+(I\\$0;0O2@U:I$
M8V \3LE>$%8>IEDRN.:2TRQ5L%&J,E",XS";C" )$Y)&13%X5)8)>&_G&63A
M)!Y1@L++H^DTG*8Y?-31Z&A*&]0;OXL&2K65MAO8WMJO^T4WY>_NW5MQR_2&
M2P,"UQ0:#R>C '2W?YUB5>MG?J4L;9 7:WJR4#L'NE\K90^*2] _@HN_4$L#
M!!0    ( +* >E*-2+2?3@,  'L'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;)U5WX_;-@Q^SU\A&'WH >I9EG\D/B0!+FV'#>AA0:_;'H8]*#:=
M")4M5Y(OO?]^E)*XN2W-BCTD%BGRXT>*HN9[;3[;'8 C7UO5V46T<ZZ_BV-;
M[: 5]E;WT.%.HTTK'(IF&]O>@*B#4ZMBSE@1MT)VT7(>=&NSG.O!*=G!VA [
MM*TPSRM0>K^(DNBD^"BW.^<5\7+>BRT\@ONM7QN4XA&EEBUT5NJ.&&@6T7UR
MM\J]?3#X7<+>GJV)SV2C]6<O_%(O(N8)@8+*>02!GR=X"TIY(*3QY8@9C2&]
MX_GZA/Y3R!USV0@+;[7Z0]9NMXAF$:FA$8-R'_7^9SCF$PA66MGP3_9'6Q:1
M:K!.MT=G9-#*[O 57X]U^!$'?G3@@?<A4&#Y3CBQG!N])\9;(YI?A%2#-Y*3
MG3^41V=P5Z*?6ZX-GJ]QSY2LE>@<$5U-WG\99(^%=^3U)[%18&_FL<-8WB.N
MCKBK R[_#F["R8/NW,Z2]UT-]4N &$F.3/F)Z8I?17P'U2U)$THXX^P*7CIF
MG@:\]']E_N?]QCJ#/?/7E5#9&"H+H;+OA'K$JU0/"HAN2#^&[<>P< I[J<Y7
MH?V=O;.]J& 1X:6T8)X@\J6"=@,FE.M<F/C:80&3<K(&TTKG&2E/8;! 7I$,
M;8I9XE<LI=,\GZP&J6K9;4G"*.,935E*2II.<SI+II-0.8K]6.V0EWE^F0WA
M)67)C$[9C/ "74O*"SYYT$X;\@0[66%)4C0J"D92-J-IFDU^;1I9P3E(7M)D
MFA.>3"G+9Y-/V@F%_"@K4IKS*4D+6B09Y;R8? !K[_"F5T,[*.&@Q@N*9:FD
M""/@-2:0E4@?O6Y08L@)?V5);B;K:^="28?S\15)<IH7&(HQ+V!*24IG"':E
M1_*Q1_(?[I$7I*4EE6[[P6>#HN]*/VG>>  _D'!?/^'Q@G6R#3GC63:#(@K'
MG?5PPEIP]E)O7:5TN;?N/1CY(!L@;\@S"&,OM5+&<'?*OK4/]XJL_*^.R=$J
M8?]HD:/R7YV1HCZ_6/OX;""V8+9A[/LZ#IT[S,91.[XL]X>!^LW\\"P]"+.5
MG24*&G1EMU.LF3F,^H/@=!_&ZT8['-9AN</7$8PWP/U&:W<2?(#QO5W^#5!+
M P04    " "R@'I2%3UAW\0"  !,!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6R-54UOVS ,O>=7",8.+6#4WTY:) &2=A\]="C:;L,P[*#8C"-4
MEC));MK]^E%RXKIH$NP2DS+Y^/@4TN.-5(]Z!6#(<\V%GG@K8]870:"+%=14
MG\DU"'RSE*JF!EU5!7JM@)8NJ>9!'(9Y4%,FO.G8G=VJZ5@VAC,!MXKHIJZI
M>ID#EYN)%WF[@SM6K8P]"*;C-:W@'LRW]:U"+^A02E:#T$P*HF Y\6;1Q3RS
M\2[@.X.-[MG$=K*0\M$ZU^7$"RTAX% 8BT#Q\027P+D%0AI_MIA>5](F]NT=
M^B?7._:RH!HN)?_!2K.:>"./E+"D#3=W<O,%MOTX@H7DVOV231N;AQXI&FUD
MO4U&!C43[9,^;W7H)8P.)<3;A-CQ;@LYEE?4T.E8R0U1-AK1K.%:==E(C@E[
M*?=&X5N&>69Z+0P5%5MP(#.MP6AR\D#1TZ?CP""^C0J*+=:\Q8H/8$4QN9'"
MK#3Y*$HHWP($2*QC%^_8S>.CB%=0G)$D\DD<QN$1O*3K-G%XR0&\SU*6&\8Y
MH:(D[UN_8KK@4C<*R*_90AN%_YG?1\JF7=G4E4T/E+W'42H;K".7A+U6I:[J
M/IV/PMDYO=!K6L#$PT'4H)[ LU)!O0#EY.H[ ZL="AB=#SXKJ34IJ%(O3%2$
MUK(1AGP@F1\-$W\4C=!._5%R[D?1<# KBJ9N.#50VE!EV%_J)NDD]<_/(S\?
MQN34.GF2^%F8D]/!5]PB[^&C4>Q':8Y6'&9^'D7DB*99IVGVWYJ"-JQN>5:5
M@@I-O&'14/Z6.#SC+M.P3_&CQ?8K_A.H(C/7I-4X(LG0ST>9M>.>G?3LM&=G
M]G+2,!\\2(-$7V7:)T[0F_ :5.7V&%ZE+=X.>W?:K<I9NR%>P]L]>T-5Q80F
M'):8&IX-L775[J[6,7+M]L5"&MP^SESAN@=E _#]4DJS<VR![@,R_0=02P,$
M%     @ LH!Z4BB>5(]K @  ( 4  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL?53?;],P$'[?7W&*>  I+(F3;.G41EH[$$B;-&T#A! /;G)MK#EV
ML)UU^^^QG3846/MBW]GW???#=YYNI'K4#:*!YY8+/0L:8[J+*-)5@RW5I[)#
M86]64K746%6M(]TII+4'M3PB<7P6M92)H)SZLUM53F5O.!-XJT#W;4O5RQRY
MW,R")-@=W+%U8]Q!5$X[NL9[-%^Z6V6U:&2I68M",RE X6H67"87\\S9>X.O
M##=Z3P:7R5+*1Z=\KF=![ )"CI5Q#-1N3[A SAV1#>/7EC,873K@OKQC_^AS
MM[DLJ<:%Y-]8;9I94 10XXKVW-S)S2?<YI,[ODIR[5?8#+;Y60!5KXULMV ;
M0<O$L-/G;1WV $5\ $"V .+C'ASY**^HH>54R0TH9VW9G.!3]6@;'!/N4>Z-
MLK?,XDRYD$(;U0\ENI94P$=:,<[,"U!1P[4UUR!7L%!8,P-O'^B2HWXWC8QU
M[BBB:NMH/C@B!QPE!&ZD,(V&#Z+&^F^"R$8]ADYVH<_)4<8KK$XA34(@,8F/
M\*5C*5+/EQ[D6QJX8KKB4O<*X<?ETI;&MLW/(^392)YY\NP ^;V=IKKGZ&K9
M*28JUE$.'7VQ#6[T:^4\RN=F]4)WM,)98(=1HWK"H/R.5/WW9$=>^$$:RD]L
M^1)X R0DDR(LBC,OQVD1IEENY2Q,T_.0I(DS)/ >)G$6$E+L]I-_H9.,A/EY
M:N4\)%D29OD$7JM@M->U+:JUGTT-E>R%&1IX/!W'_W+H^C_FP]]Q0]6:"0T<
M5Q8:GY[G :AA'@?%R,[/P%(:.U%>;.P7ALH9V/N5E&:G. ?CIUC^!E!+ P04
M    " "R@'I2;MEB]G("  !2!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6R-5%U/VS 4?>=77$63!A(C:1I65+61*&P:$F@(V/8P[<%-;AH+?V2V
M0^F_W[639F6":B^)/\X]/L?V\6RMS:.M$1T\2Z'L/*J=:Z9Q;(L:);,GND%%
M,Y4VDCGJFE5L&X.L#$52Q&F2?(PEXRK*9V'LUN0SW3K!%=X:L*V4S&P6*/1Z
M'HVB[< =7]7.#\3YK&$KO$?WK;DUU(L'EI)+5)9K!0:K>70^FBXRCP^ [QS7
M=J<-WLE2ZT??N2KG4>(%H<#">09&OR>\0"$\$<GXW7-&PY*^<+>]9?\<O).7
M);-XH<4/7KIZ'IU%4&+%6N'N]/H+]GY./5^AA0U?6/?8)(*BM4[+OI@42*ZZ
M/WON]^%_"M*^( VZNX6"RDOF6#XS>@W&HXG--X+54$WBN/*'<N\,S7*J<_DU
MDB4+AP]L*= >S6)'I'XJ+GJ"14>0OD$P2N%&*U=;^*1*+%\2Q*1FD)1N)2W2
MO8R76)S >'0,:9(F>_C&@\5QX!OOM_CS?&F=H5OP:P]G-G!F@3-[@_.>PE&V
M D%7_E2X;"4(OPXT;$-WUEF@P("K$0HM&Z8V[RU0D@QS7*TZJ 7!V9(+[CC:
MUS9^KP2?UJEM6('SB.)HT3QAE-.6C> =G*;'9Z/LX$$[)J!5);>%;I7#$@IF
M:Z@HBG8+ND9KIW EF];/<T(1FX/#29;!T0&!DDG2@[Z^-+"K_Y@NJS%D'!IM
M0MX^'.R%*WIP://^K0K::45X[9#BG7LNT:Q"FBT$;]V5'T:'!^.\R\E?>/?:
MW#"SXHJ. "LJ34XFIQ&8+L%=Q^DFI&:I'64P-&MZ]-!X ,U76KMMQR\P/*/Y
M'U!+ P04    " "R@'I2<HYD@C0$  !*"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6R-5MMNXS80?==7#(042  FUEUV8!O(98L-T&V#)+M%4?2!
MEL8VL9+HDI2=_'V'E*(XA>/=!\LD-7/F<F8XFNZD^J[7B :>ZZK1,W]MS.9R
M--+%&FNN+^0&&WJSE*KFAK9J-=(;A;QT2G4UBH(@&]5<-/Y\ZL[NU7PJ6U.)
M!N\5Z+:NN7JYQDKN9G[HOQX\B-7:V(/1?+KA*WQ$\W5SKV@W&E!*46.CA6Q
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M6X@P8$D2LCB/8<+R+&63(/-^0QH ;U0Q:&ALII,,QD'NW3_<N#T-3"I8T:R
M+AG;ZHIB(WL[KDK"2I.(I7D&863#9UD>>J[0?Z@:VDIF\3B@532A%(:Q]R0-
MW1M'2BLBEJ@'PC2&.&!Y.F%9FGG?#C3-Z9[H&9R^25,O_X[F8R.OG72PMH9<
M71+1_T_W">6->"$3)Y"G,24\.=B.H[WY5J-:N2E.Z9%M8[I1-YP.'PI7W7Q\
M$^^^,KYPM1*-A@J7I!I<Y-1:JIO<W<;(C9N6"VEH]KKEFCYV4%D!>K^4TKQN
MK('A\VG^'U!+ P04    " "R@'I2G.-6*8D"   %!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6RM5$UOVS ,O?=7$,: ;4!7.W;2=D42H&E7;, *
M%/W8#L,.LDS'0F7)D^2D^_>C9,=-@28#AETL4B0?'VF1T[4VC[9"=/!42V5G
M4>5<<Q;'EE=8,WND&U1D*;6IF2/5+&/;&&1%"*IEG";)<5PSH:+Y--S=F/E4
MMTX*A3<&;%O7S/Q>H-3K632*-A>W8EDY?Q'/IPU;XAVZA^;&D!8/*(6H45FA
M%1@L9]'YZ&PQ]O[!X9O M=V2P5>2:_WHE2_%+$H\(93(G4=@=*SP J7T0$3C
M5X\9#2E]X+:\0;\*M5,M.;-XH>5W4;AJ%IU&4&#)6NEN]?HS]O5,/![7TH8O
MK#O?"3GSUCI=]\'$H!:J.]E3WX>M@--D1T#:!Z2!=Y<HL+QDCLVG1J_!>&]"
M\T(H-403.:'\3[ESAJR"XMS\B@D#WYAL$:Z1V=8@==Q9>'?/<HGV_31VE,7[
MQKQ'7'2(Z0[$40K76KG*PB=58/$2("9Z \=TPW&1[D6\1'X$V>@0TB1-]N!E
M0\U9P,O^7O.EL%QJ7[:%'^>Y=8:>R<\].<9#CG'(,=Z1XXZFIV@E@BZ!68O4
M4J8*D(+E0@HG*)]!K@UU")B#TE-:>4JO-7QO*C^V9[9A'&<1S:5%L\)HYW]E
M[H#:B76.)K3T%AMMG%!+H.>#\&!)) _+C6C"V/B>PU=<H811?Z;]F1TLF'I$
M\Y9@.<?&,<41E'94W!N89(<GV3$)'UXH!_?:,;G'_A^9CS[^$_/QY/!DLF'V
MK S,=]CAM6<3;XUFC689%I %KEOENBD=;H<==]Z-]K-[MR"OF5D*94%B2:')
MT<DD M,MG4YQN@F#GFM':R.(%>UI--Z![*6F GO%)Q@V__P/4$L#!!0    (
M +* >E(G>;WYDP(  $0%   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;(54R6[;,!"]^RL&0@\MH$:;X\2!+2"V6S2'H(:3IBB*'BAIM*"4J))4G/Q]
MAY2L.D#B7B3.\MXLG.%B+^1O52)J>*IYHY9.J75[Y7DJ+;%FZDRTV) E%[)F
MFD19>*J5R#(+JKD7^O[,JUG5./'"ZK8R7HA.\ZK!K035U363SROD8K]T N>@
MV%5%J8W"BQ<M*_ .];=V*TGR1I:LJK%1E6A 8KYTKH.KU=3X6X>'"O?JZ RF
MDD2(WT:XR9:.;Q)"CJDV#(Q^C[A&S@T1I?%GX'3&D 9X?#ZP?[:U4RT)4[@6
M_'N5Z7+I7#J08<XZKG=B_P6'>LX-7RJXLE_8][ZS"P?23FE1#V#*H*Z:_L^>
MACX< 2[]-P#A  AMWGT@F^6&:18OI-B#--[$9@ZV5(NFY*K&7,J=EF2M"*?C
M'3YBTR&\OV<)1_5AX6EB-38O'1A6/4/X!D,0PJUH=*G@4Y-A]I+ HW3&G,)#
M3JOP).,&TS.( A="/_1/\$5CC9'EB_Y38RY%#6O*5=(L4)]U"6O;893P\SI1
M5O_K1,#I&'!J T[?"'A'JY-U'$'D-+@VN(*L4JPH)!9,8P;)\\$"2G0R16!-
M!@6*0K*V?'[M&D[&-,M[I5J6XM*A[50H']&)@287=(GP YD<+FA"[<4ZH9JI
MQ1/38NIS,)]LJ ]*5REL2T;CGF)' N,*WL'<#:+0#8,9G0/?G8>1.X]FD_77
MAYL-!'.X)R :_J=62%.=%K#M4-)O5Z4" O<BFKIA%,''B66XG,W<Z73^@@Y>
M:[QW--ET387=7P6IZ!K=#_FH'9^(ZWXS_KGW[\LMDT75*."8$]0_NSAW0/8[
MVPM:M'9/$J%I)NRQI&<.I7$@>RZ$/@@FP/APQG\!4$L#!!0    ( +* >E(=
MQ*Q56@0  #0+   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*U6;6_B
M.!#^SJ^PHI.NE=+&28! !4A Z2ZZ[K;7T#NM3O?!) :L)C9KF]+^^QL[+\VU
MP-WI]@O8SKP\\WAF/(.]D$]J0ZE&+WG&U=#9:+V]\CR5;&A.U*784@Y?5D+F
M1,-6KCVUE92D5BG/O #CKI<3QIW1P)[=R]% ['3&.+V72.WRG,C7"<W$?NCX
M3G7PP-8;;0Z\T6!+UC2F^G%[+V'GU592EE.NF.!(TM70&?M7DZZ1MP*_,;I7
MC34RD2R%>#*;>3ITL %$,YIH8X' WS.=TBPSA@#&]]*F4[LTBLUU9?W&Q@ZQ
M+(FB4Y']SE*]&3H]!Z5T17:9?A#[S[2,IV/L)2)3]A?M"]DN""<[I45>*@."
MG/'BG[R4/#04>OB(0E J!!9WX<BBO"::C 92[)$TTF#-+&RH5AO ,6XN)=82
MOC+0TZ.IX"E03%-T3R3E&DU%OB7\%=WQ[!7=,$YXPDB&8DTTS8W V8(L,ZK.
M!YX&_\:*EY2^)H6OX(@O/T!?!-<;A6;@-/V[ 0^ U^B#"OTD.&GQFB:7*/1=
M%.  G[ 7UFR$UE[XP]@HR$!_C)=*2TBQ/T^@:-<HVA9%^PB*&"HOW644B15*
M:D2)@2*)26+(PPR04&3O71VZB9,>3*5?J2U)Z-"!4E94/E/G+?C6M.%J4KJ*
MK:L6,$[S)96&]99A':CW^ZTI41M$.* T"_I]QYY)!OPH]!,*?-?O1; (7=SO
MM!9" X/3G;0$CY4"LY5,(3'GFLJD9%Z"0S!F68[<J-UUHZB/>B[NM<T*A)^I
MTO8N&(?>LE0L9=!>D.^[$>ZX0=MO+%N+N\7X%HWC>+:( 9+?=]M1Z 8X*C91
M/W1]OP*9,;)D&=,,?%\@H3<0]Y:\%F! WHTZ@=OO8Q.DV\:^&[;;I6JL1?*T
M$5E*I?H9S8 0#9 @@ "[@1^99=@' U$%Z78^GLQOYXOY+$;CK]<H7MQ-?_E\
M=WL]>XC!P*^/\\6WXX#1B;3KU&G7^9]IIZJT5T8&'@9S+OC!!#SMZZW0FKG6
M1'!76V]!^T7 /?I&B2Q[Q[$\_$0YJ&4V%4D*_9*9LK3&Z<O6>#07UPF[+@X[
M9A4$;MCKMK["\Y<)93Z>55_/[:800.<G".[6!'=_*,&VEF[@V3Q(\$E?_U#A
M1UF?UB[_"^MO6F@E15[='5^CL7ET;0%=_0N.6],-X6NX(JAD4C0&<Y&-,KPZ
M4)F!WW7]($(!E%;H^]:/1?1H(@53A^"@LQ"JIX][ .$LQ(&+(T#S4;=H+^]T
M+]#%AYC+Q^%=S$5 QA [UM3"$)H9QBC$V/Q_A'#(\D$MN!V8RY1U5S=DNY@U
M&K(/BOT G54A'Y<D&DWHFG%N?$-RW%/)1%HT:=1Q_0B?5H:<::B]?P@.MBRO
M,<GD5*[MO*:@1G9<%T--?5J/A.-B$GH3+^;)+T0"=H4RN@)5?!E!1Y+%C%9L
MM-C:N6@I-$Q9=KF!L99*(P#?5T+H:F,<U(/RZ"]02P,$%     @ LH!Z4NRS
M'V]-!   $!$  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULQ5C;;N,V
M$/T50KT@"RPBD;)\26T#L9VB >K=(-D+BJ(/M#2VV95(+4G;2=&/+RDIDC>6
MN0[:;OQ@DQ3GS)D9ZI#T<"?D)[4&T.@^2[D:>6NM\PO?5_$:,JK.10[</%D*
MF5%MNG+EJUP"30JC+/5)$'3]C#+NC8?%V(T<#\5&IXS#C41JDV54/DP@%;N1
MA[W'@5NV6FL[X(^'.5W!'>CW^8TT/;]&25@&7#'!D83ER+O$%U<DL@;%C \,
M=FJOC6PH"R$^V<YU,O("RPA2B+6%H.9G"U-(4XMD>'RN0+W:IS7<;S^B_UP$
M;X)94 53D7YDB5Z/O+Z'$EC23:IOQ>X7J (J",8B5<4WVI5SHX&'XHW2(JN,
M#8.,\?*7WE>)V#,@^(@!J0S(J09A91">:M"I##I/#'!XQ""J#(K0_3+V(G$S
MJNEX*,4.23O;H-E&D?W"VN2+<;M0[K0T3YFQT^.W<D4Y^XN65>,)NF,KSI8L
MIERCRS@6&ZX97Z$;D;*8@4)G,]"4I>K5T-?&OT7QX\K7I/1%COC"!,T%UVN%
MKG@"R9< OB%>LR>/["?$B3B#^!R%^#4B 0G>W\W0V?=MO*;/0)F^^0V=_?@=
M[D8_M4'-3H;"@^.$KMPH<_J 2&1!@LB1I;"N<5C A?]9C=_!O=[0])7#>:=V
MWBF<=XXXGU*U+IS&M@&?-VQ+4^!:M:V?$JI;0%F)VXX'W<!\AOZVA4)44XB<
M%$R(FVR34@V)U1 3HVYS7H)$>\Y)O_!^Q'VW=M]UNG\G:0)&$8L\*Z.N,9@<
M+%)H(]$](-'M]WHXJBF4J[![D*@C)'LUR9Z3Y'664R;-#J 13?XTNF.;"M',
MDFXCZH2SV]N%RFD,(\_L7PKD%KPQ:GN?>@<!XUZ (XQ[[0'UZX#Z[J(G6\IC
MLYB74F25DH)L777] PH]/.CUNT]R?C@M"J)PT&_G.:AY#IP\?S5]A<02Q1*2
M]H4Y.' <!HYUB8-&^P.G[PFU+\1"([@W!P_5NB KB"\*9,ISD)UJWOZ2#'$4
M'J&XMSUA)\7;^03]/H=L ?(/AQIAT@"2;R^&N)%B'#ZGW.AO5.XU;;M6!378
M3_V@YZI\(\K8K<ISRLTQL'C=3\ENH[0X>H'L-DJ+W5+[T1Q*+7Q,<Z9IVKJ>
M#Z73F=)&0+%;02>2:6:VN ],KAA'URHU\2LT%3(7LDS(*:EN] WW7R#5C6QA
MMVY=F9U</Z ,]%HDB/$ME'O&:R1VW CMFN4H!QF;(;/26BOA=H"#X#P(?G"=
M$ANA(VZA>P-;FM#GUH(T*D7PMZ\%:32-D/^Y%E]Q<$(M&@4D;@5\R_G#2=EO
MQ(QT7B#[C>81]_'R7V?_ZBL.'-GW]VY^YGBS*J[<"A4AE]>H>K2^UE\6E]DG
MXQ-\,2LOYPU,^5_!G%H]4RB%I8$,SGN&K"ROWV5'B[RX7RZ$-F>LHKD&<^25
M=H)YOA1"/W:L@_I/D/$_4$L#!!0    ( +* >E+N]&[;9 (  "X&   9
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MQJROPE 7*U92?2G7K+(C"ZE*:FQ7+4.]5HS.&U$I0@QA$I:45\%HT'R;JM%
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MTU/-UW:I##B;,$.YT.?@(WBXGX"S#^>#T-BP3AP6;8B;70C\1H@)*RX!01<
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MN;N.D>NF;,VDL46P::[L/84I9V#'%U*:?<=5PN[F,_H+4$L#!!0    ( +*
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M-BWLEALS9$': '._%D*_;6P?#V,[_P]02P,$%     @ LH!Z4DL/\]5) @
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MV_':B>);VS167.D69(>E_DB , 7Z_IISM9^8/M1_=K(_4$L#!!0    ( +*
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M1^3TV_KU U__X_7;U>T(^WG+?A[8SP^P3RIC2?X5X<7C$[>N0^X=Q1MZ"61
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MV(PN,GTGEK^P.J# \,4B4_8_6E:V7M1#\4)ID==@4)#SHOJDSW4B-@ 0:#O
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M _A^)H1^N3&OK<TO)^/_ %!+ P04    " "R@'I2V\XVZ/<"  !I"   &0
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M3,RW $IK8/:7PN2QF%@'Y=?%Z#=02P,$%     @ LH!Z4GWK9EV! @  SP<
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M[$2LI<]#=A>C9!T$-'XZ9[[8G'9P)[_PE2]74EWHGYU$=,GNF?PYNHOA7;]
M\7C PH2+$,5L<=KYB(^_V+92T!*_<+9)*J^1"F4FQ'?UYLH[[5C*(^:SN500
M%/X\L GS?84$?OR9@78*FTJQ^CI'O]3!0S SFK")\'_EGER==D8=Y+$%7?OR
MJ]A\9EE CL*;"S_1O]$FE76=#IJO$RF"3!D\"'B8_J6/62(J"L-Q@P+)%,B6
MPLAJ4+ S!7M?A4&F,-A7P<D4G'T5W$S!W5(@N$%AF"D,]U4890JC?17&F<)X
M7P5LY96S]E8IBKU=[6:5O-QXN][-*GG!\7;%FU7RDF-=\W[:OKKWIU32LY-8
M;%"LY %/O= +2.M#R_-0K?5[&<.G'/3DV42$B8S7Z<*[$31$EW3.?2Z?$ T]
M= /B"1(+-(F9QR4ZFC))N9^@;^Q1KJG_X:0OP0N%U9]G%L]3BZ3!(D:W(I2K
M!%V$'O,,^M-V?7>7_L4.^Z0%H _I*W)(\AR>DU;$CU'<0[;51<0BUL_W4W3T
MSI2723O*]3KL(8(5"K:;4:9[H.SVY:(=9<KF@()WH5P>@#+Y\ALZ^N<_L.O\
M:(+ZM#<4'C<[]/GU'+K:E6=_GPQ='X"RPZ%_'U#X'5 W!_3S#JC; ^JV ^K+
M >NC&:JV@NUB"MH:VW[Y%*P.0?/PJUD>%)8'VO)@'\N^LDP#L0XE^B]Z9YJM
M*9JKT12/>SC# TO].^D_5&>-0<ZV#()3@R"IR]7B<HJXG-:XIBR9QSS284'F
M=&0\E"QFB40QE2PQ1=>.^6W%4J 9HW%2PE'XT9C*TJ!'G/<H8C%4+EP'/=,@
M?ID912D]M(X@(HRM]\J8!-&[KQ.T% \L#H$"RW\E2-/+'YY &8%FD'K&%@NF
M:2T"=:4&)!=:"'DQW?S@B4V(/!#K N>>_0&"2 KM/TA0[P\@ @H[R5S8<F !
MSDH>+E-#0/_UU80&#,FGB!7ISPV'(;@1)\#LT2(6@;Y8=T,W/0=[X$W"_ER#
M[9J:DDEZ2"6J5E.TH@D< -01 ]R$LC@]>_S>9%@CH,V*SU=H P ()N$3PGKF
MX*'^/=)>J+G1!<PD2M/G/Z5V=40Q^,9A399>B!!@(OJ4IBO/Q8+'\)G<"*2J
M IZ?LR4';R!GJ=UTJCA=+1W%/)SS"%*_@7"\M0I2!>,SFJ$<D0]Y=3@L7^K[
MJ;T-EZN*P4PD<P?:21E4>$H.,!/^B )%152[<@$96T 8M50X.@FZGFPNX&4C
M9E7+U5J,0G(7PH?CG!+2#:GZ5,.%,,+ 3>A'G1*X%HOU<E7-!\%YY;@'MO@<
M[*J&3I!*BU[?,U7F&8#J5"M_3>MM^N)EK8R7"]MJ6=BU(>460\IMM7Q75+I]
MZ+K/9N30,$HOGHL1/!RX[K@N]\DL9X^WY*Z>RPU:)O.P"'K8&K3>WA;Y]J8*
MVLVJJ:>U*?YVP(_> PWGZIB0=HN?[9;S=+>DL+I5@Q;+KS)ULM+JZ9"B&/NG
MW?ZWYS9YL6Y%R++.-P^AW'P=H*VY1D6>1^UN":GG0];-[#%B8<(:6NQB]+PG
MQ@/L;+=.*N94Q&SH'3PRM\2X<'7<WA*UX'>UPT4[6$/<:SALJ=$#I2F:+Y_/
M:5LP=1Q#P!A9, /1G!87VX >QU]OS_%HW!V-"3!N,NYBR_Z %!&T?E1R[RS3
M9C$1043#)_@DHMQ3&,BQK"XL)71$HR@6CSR 7H#)]\[J64,X:?L^Q/Y!FU;2
M=K.T4TK#GGTGU': [ND#C-P$G=/PNR:.,.ZI:L>?YE*HX%1@70U_36&@0S.J
M>5OWO:OF;)3-ZWS@JYM]WMHWKI/+OPOS/U>8VGK$5GE7QMHQTWCL 78,Q5B"
M&Q2JQM#OM[H"_VDS4;GQ@]_XS(-):9N\QL9[D<'4QJ+5L@?B\L"'[58/B@80
M0; .@=NH-"1[9;@\VN'!6V>X/'[A':3JH-TG ZON*\1QM@G.ITRL6HZF0I04
M#+=SL'0%3JZ^74W25;E/"4JN@X=O78)R_\>O20#P<P;@8+=A8\?ESHY?=6O?
M@5:=V6(FLW/>-ON"5WHV=TGC=*X,9\T&GW4!C.1[%LETQREVF])FF!/&W!KI
MV@,;_INLV86U;G&>2H^IZF"4 8P<M^NZ)G5<.EO9*2K[IHJ_<BS==8YQK.HY
M!KT*?VVASY=_%_7_JJCU[RA*2D':*85*QQZSE90$@KPU@2 E@2#M!*+EMFEZ
M5]AX SW%'%=&[,@Q'.1O#(+8,MT]_6*"W):LAU@R%-+.4 P<J3&TSQE6S6/'
MY/&U0=)X8_C&(&A$O-W'=CT')8,B[7?'LUL+^U=XL+/"=4]*/D7:^51U]8 +
M+^;GI"1&Q'WKY572)M)^2^6PWALV=%1#SDL"1=H)U%;.7T[924F7R/B-DVZ7
M ]K><>9KXHN-J;_,$&M+SW7M40-MM,O9;N-#4O\2DFZ7P]PF;YWTRA=_[5/V
M)4DW3%![2.RMG/<K#V4$+%[J!YH2-%?K*?U^L+A:/#3U43\ZLG7]'!]/L.'Z
M!3[^9+I^A8^OTT>E2K/IDUNW-%YR6#(^6X +5F\(,R].'X9*WT@1Z4=%9D)*
M$>B7*T:!$BD!^'PAA,S?* /%(VEG?P%02P,$%     @ LH!Z4C;$<(68 @
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M/K'#%^C\S#5?QJ@P3W1H8^>>A;*=D*SJP$I!1>KVC=^Z.AP!W. ,P.L WE2
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M[WH_D6QEJOV"2=4[S+!4W1VX-E#[!6-R/]$'=/\7)G\!4$L#!!0    ( +*
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MU=.I%^7T*@7%UW8 ++G2X\1N4SWP41@%_3WA7!T%XZ#Z"S'^#5!+ P04
M" "R@'I2]@-4P- #  "\#   &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6REEVV/FS@0Q[^*A>Y%*[4! P:R2B*UV3O=2G>GU6ZW]]J!26(5<,YV'O;;
MWQBR;!8<VNN]23#,_/,;9SPSS(Y2?=-; $-.55GKN;<U9G?C^SK?0L7U1.Z@
MQB=KJ2IN<*DVOMXIX$7C5)5^& 2)7W%1>XM9<^]>+69R;TI1P[TB>E]57#U_
MAE(>YQ[U7FX\B,W6V!O^8K;C&W@$\[2[5[CR.Y5"5%!K(6NB8#WW/M&;)676
MH;'X*N"H+ZZ)#64EY3>[N"OF7F")H(3<6 F.7P=80EE:)>3XYRSJ=;]I'2^O
M7]1_:X+'8%9<PU*6?XO";.=>YI$"UGQ?F@=Y_!W. 36 N2QU\TF.K6T<>B3?
M:R.KLS,25*)NO_GIO!$7#C2^XA">'<(?=8C.#E$3:$O6A'7+#5_,E#P29:U1
MS5XT>]-X8S2BMG_CHU'X5*"?6=S5N:R ?.$GT.3=+1@N2DWH>_*1/#W>DG>_
MO)_Y!G_'6OOY6?-SJQE>T;R%?$(B^H&$01@XW)<_[$ZG;]U]C*X+,>Q"#!N]
MZ*K>&I2"@H@V5L-/A&L-1M^,J$>=>M2HQU?4/Y5X$GB= \$S10JY7YGUOB1&
M\0(PSW,0![XJ0;NVL55.&F5[W@Z+F$5I$D8S_W"Y7PZ[:!JE*>OLWJ#''7K\
M,^C2;$%]#[U59A=(21:&/>ZA$4,K-S3KH-DH]%U]@-I(]4SD2DNDR\%&H$"#
M.H +E;DH:-:''9I1%F;Q-=ZDXTU&>7\]8<75>+AJ:;"^%'NL6[BIF(QXO#$M
M:T.>@2L7>#(DHDF0!+1'[K +,L;LV7.1IQUY.IX>Q<$FAVZR0]2&UYN&O#T[
M1%0[+A16=.-B3QU,<4RCM)_;0\-IFK!ID+CALPX^&X7_ ["VDU+PE2B%>?Y
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MN5T8N6NFS94T.+LVEUM\O0!E#?#Y6DKSLK #;/?"LO@74$L#!!0    ( +*
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M'OU(PB ,6@A-SW />T?=9V='I]<=J^G5RO<<7N]=RC_ LRE8=M$1(*H#1"Y
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M0J-MV6F./Q:0)@#/UT+H_<(DZ'Y5R3]02P,$%     @ LH!Z4N@OVO^%!
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M%; %"-- _[[D7.U.3 ?U7RC3_P%02P,$%     @ LH!Z4M2*(^W4 P  7PT
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M]1<0%05 OU]PKEXF1<M<?U,-_P-02P,$%     @ LH!Z4CX]9A.< @  #@<
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M-NW0#=?FP@)I \S^4@B]G]@#NBLP_P502P,$%     @ LH!Z4I3HP<MM!
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "R@'I2!\\A@G($   ")0  #P   'AL+W=O<FMB;V]K+GAM;,6:76_;-A1
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M2P$"% ,4    " "R@'I2 TNHH>X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "R@'I2F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( +* >E*J(^_-5@0  '<0   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "R@'I2C+R$W+@'  #^'P
M&               @(&9#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ LH!Z4@O=*OLY P  >@L  !@              ("!AQ0  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +* >E(1OF[&-04
M $$3   8              " @?87  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "R@'I2RH _23D$  "U$   &               @(%A
M'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ LH!Z4K7:
M9G"U!P  A2   !@              ("!T"$  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( +* >E+8=7BL-A$  "@J   8
M  " @;LI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "R
M@'I22N&H]8L"   Z!0  &               @($G.P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ LH!Z4DQ^^(GB P  1P@  !@
M         ("!Z#T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( +* >E+Z979YI 4  %D-   9              " @0!"  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ LH!Z4@KOMPG;!0  )PX
M !D              ("!VT<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "R@'I2.<UHX#H%  #0#   &0              @('M30
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +* >E)OZMN1
MP@,  ),(   9              " @5Y3  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ LH!Z4D]35V9+"   NA8  !D
M ("!5U<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "R
M@'I2GBKHPJ($  #,"@  &0              @('97P  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +* >E*)$!)E#0H  #<8   9
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M970R,"YX;6Q02P$"% ,4    " "R@'I2+"5UDK($  #*"@  &0
M    @(&\@@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M +* >E+;K%@M=!(  -8T   9              " @:6'  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ LH!Z4FAMM%]O @  $ 4  !D
M             ("!4)H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "R@'I2C4BTGTX#  ![!P  &0              @('VG   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +* >E(5/6'?Q (
M $P&   9              " @7N@  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ LH!Z4BB>5(]K @  ( 4  !D              ("!
M=J,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "R@'I2
M;MEB]G("  !2!0  &0              @($8I@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( +* >E)RCF2"- 0  $H)   9
M      " @<&H  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ LH!Z4ISC5BF) @  !08  !D              ("!+*T  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "R@'I2)WF]^9,"  !$!0
M&0              @('LKP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( +* >E(=Q*Q56@0  #0+   9              " @;:R  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ LH!Z4NRS'V]-
M!   $!$  !D              ("!1[<  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "R@'I2[O1NVV0"   N!@  &0
M@('+NP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +*
M>E+8B-C]#0,   4)   9              " @6:^  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ LH!Z4E0?.A)G P  !A(  !D
M         ("!JL$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "R@'I2]5SPIB\"   <!0  &0              @(%(Q0  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +* >E)!GWFM6 (  ,(%
M   9              " @:['  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ LH!Z4DL/\]5) @  @@8  !D              ("!/<H
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "R@'I25S'D
M6:("   [!@  &0              @(&]S   >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( +* >E*97!: (0(  )L$   9
M  " @9;/  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MLH!Z4LG.4J7F!   11$  !D              ("![M$  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "R@'I2V\XVZ/<"  !I"   &0
M            @($+UP  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( +* >E)]ZV9=@0(  ,\'   9              " @3G:  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ LH!Z4N1.JHDG"
MGB8  !D              ("!\=P  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " "R@'I2-L1PA9@"  !6!P  &0              @(%/
MY0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( +* >E)_
M5]#KT0(  #L(   9              " @1[H  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ LH!Z4B=O)6'W @  3@@  !D
M     ("!)NL  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* >E)=LU?2AP(  +8&   9              "
M@5?^  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ LH!Z
M4N@OVO^%!   3AD  !D              ("!%0$! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " "R@'I2U(HC[=0#  !?#0  &0
M        @('1!0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( +* >E(^/683G (   X'   9              " @=P) 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ LH!Z4I3HP<MM!   /1(
M !D              ("!KPP! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " "R@'I2]4=@+B #  "($0  #0              @ %3$0$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +* >E*7BKL<P    !,"   +
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4!08     0 !  '<1  !''@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>110</ContextCount>
  <ElementCount>346</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Advances for Purchases of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets</Role>
      <ShortName>Advances for Purchases of Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Banker's Acceptance Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable</Role>
      <ShortName>Banker's Acceptance Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Construction Loan Facility and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ConstructionLoanFacility</Role>
      <ShortName>Construction Loan Facility and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Risks &amp; Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/RisksUncertainties</Role>
      <ShortName>Risks &amp; Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Condensed Parent Company Only Financial Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement</Role>
      <ShortName>Condensed Parent Company Only Financial Statement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Inventorytables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Construction Loan Facility and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables</Role>
      <ShortName>Construction Loan Facility and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ConstructionLoanFacility</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/Revenue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Condensed Parent Company Only Financial Statement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables</Role>
      <ShortName>Condensed Parent Company Only Financial Statement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Organization and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Organizationandsignificantaccountingpoliciesdetails</Role>
      <ShortName>Organization and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Inventorydetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/Inventorytables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Property, Plant and Equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentDetails1</Role>
      <ShortName>Property, Plant and Equipment (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmentdetailsTextual</Role>
      <ShortName>Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/PropertyPlantAndEquipmenttables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Intangibleassetsdetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Intangible Assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>Intangible Assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Intangibleassetsdetailstextual</Role>
      <ShortName>Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Advances for Purchases of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssetsDetails</Role>
      <ShortName>Advances for Purchases of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/AdvancesForPurchasesOfIntangibleAssets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/RelatedPartyTransactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Banker's Acceptance Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayableDetails</Role>
      <ShortName>Banker's Acceptance Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/BankersAcceptanceNotesPayable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Construction Loan Facility and Lines of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetails</Role>
      <ShortName>Construction Loan Facility and Lines of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Construction Loan Facility and Lines of Credit (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ConstructionLoanFacilityDetailsTextual</Role>
      <ShortName>Construction Loan Facility and Lines of Credit (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ConstructionLoanFacilityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/LeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/LeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/StockholdersEquity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/RevenueTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Risks &amp; Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/RisksUncertaintiesDetails</Role>
      <ShortName>Risks &amp; Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/RisksUncertainties</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Condensed Parent Company Only Financial Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails</Role>
      <ShortName>Condensed Parent Company Only Financial Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Condensed Parent Company Only Financial Statement (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails1</Role>
      <ShortName>Condensed Parent Company Only Financial Statement (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cphi-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Condensed Parent Company Only Financial Statement (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementDetails2</Role>
      <ShortName>Condensed Parent Company Only Financial Statement (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinapharmaholdings.com/role/ParentCompanyOnlyFinancialStatementTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cphi-20201231.xml</File>
    <File>cphi-20201231.xsd</File>
    <File>cphi-20201231_cal.xml</File>
    <File>cphi-20201231_def.xml</File>
    <File>cphi-20201231_lab.xml</File>
    <File>cphi-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001213900-21-017981-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-017981-xbrl.zip
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M/(3]3?I?Y!I*)E2G_<S,OO,(9I\AD@W%C,L)0VD0QZ=_5I2R<M\D[D;],!&
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M,9P&7_UA\1GVOGV^KKO7_^F%2Y[@A1?>DHYU_<T/_?%T+/7*4@ ^/BBM[!K
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MA^WVIH#.Z:2K:0"MO :P&= 6JV.=[<&Q&HJVA:'.(K]W7E_=(!RK86A&A=\
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M*I>127!4HC+P'@YF0<&+H',LX&)13TA!&068&F) P0?_!9@+'O2:9_=8?6)
M@MO]KR]GG_?><C))HK'1<!D;U?U9"39U6'YB2F4P,R2\]6ZI%H?S+7$\5C3!
MHZ\9> &6Z1!+GV(N,D(+25 R">:R$%_LBRG7F@#E86X-E_&,IO"J,TTHFQ)T
MJ5#0W5!)-'?(+N'>P5=&_NUH'\%"6N%5Z$?C*$X]5'$-- .@#K1R&!0I-;#,
MQN<L,$RN\8(L\1XX1T& ZR#E129C##DUO@H0&R3 \RBPL, )'S>[IW07KR\;
M[!J(\"N@+F+S$G,K+*0EI4B2*U(^%D WB!^<272/4LL/,;<'%60@@, '!C7(
M_HS^F\(?^MXDF>*/+(  ,WT!BX*^"S(84UDQ_PKTY2GMF[G5&$.P/N,?-UH&
M)&X/7AUP<A.@5^?O8&F;SP<!U.2,O#OAW AA,3_-^) <=#D6)M;"W^%P!>X_
M]B:T*&P03Y./1G+*4_HK@*/T@W,%EMT.5BLTI]_.C_8L3#"K!D)G(?XEPH(M
M /=3/+W-?:&&(!U_^73TUBX:'(@QE3/BX0+O&R*]4IW6$/EMOQ+C3U6)OQ)M
M^Q*MOT=XR<@U$X=%FNX.;FF'T7U$6F\N5[)1K]F**%S;@8&RCXUMB'_@'[!4
MDYDI?>B7^D&O[8S](%#V"[!WK]^?CJ?4N@FS&<&")NWBET;W0#_+#$<N"'K4
M\<CS8V##"5X[N)IB:.DI/T1_2D6W9WC'J )NP-FH_I@?=K1YKY_!(E99(<!0
MW8(.=RL5(H"[8\ NQ@DJZIS5*"S=+8K_0H($'NNG6-:+-S^DM-0TLR%=U*K+
M6&/N9H6?1>;:MXJBN?Y/2I*'#&Y@!6"$()Q36\!$RNT#;R8H^E)N8>%C6JZN
MEXW0 R((N.&4A#55543%";O]*,E"R56TD<R,54)!_/"I%ZL!1LF%&ISV3>HD
M(K[S*9\<OT>40W^"]Q,!&.=\7#@;NWFW,M*(\1("N'NXDN&QARH@&E4I(@1+
MKJ,I+.;=1%/+&D4 I0LL@Q*D!>>66$F?68FJWM4E'9Q%K&M,TI&LOQQJRDJT
MYX@DH)\D4Y3O5Q'*.M!JX;<&$GS5@I\^-W<3.?I9;A<UU"ID=R9G F:V12/P
MI@A'E-K/:CJH!)C5+4COD5=#D6>-SF0XC8DDX%1 #X0_AI)487^:"#SIWY=J
M/I+7@?.%W\SP$>M8X!O<'!(US!^3("+5B:7H+<AY+Z#4<J0$HF4<#AJ(F \"
MK?5IB-Z"H1-.TYB3JQ7585ZZ@S.-6&1;^+@1@0_JJXT2=:@&SXJ<X9Q_(*.@
M(@2XWB'1,>$<MX\>=<S[CN#X)CB&7B\)/[WQPK_H"@,PP&!!'^U/DX3U1^RZ
MYG0M!63 :B-S&.N>1S<I%]QC\5!BE1_)VB>T,W$A5J0S#,UCERV\<O'MH^/V
M:IUZO5:OUYTWI&W]\,?P%&#^E^9!W5+BF?V]/<"A>Y)_J>%#1$KRFNIM#E5S
M6;@[H-QY6*"1V0)@9SB5_@]+IY8Z+=6JI]0^B>OE;04U9>TZ<<((SV :2[K-
MGA<O? ,[)H:+=#+"(Z85)8LK(2J\>T1SZV,AE::W$FSGTSB9 N:5:)$2<JQT
M">-V-W!>IE@Y@85OQU2.TI>J_='E\5NX0JW]0U!=M.9H'/KXO>^A+#R@+LS,
M8]&U W]/\>8?F4,^SAQRF<IIF[^*QXQA@PZ:EU.\B& C2I&*U*QL22D"L #E
M#C=;(]D/:D5L3$Q]F6M+B(JLE%E59JQ-\ADPKD9P<R46\'Q L"/,6,T2";S3
M\$'O+\'N-;5Y?I24#."1O$FLU[EEQ89;K>!!&G3#'IDS$8QH71H8<!$T-8$/
MX,+^>!+0.\34E6MPH"3*0JG^+Q1^L_@G<9%H1S)L>PQ''@W()5TK)!%%'8E-
M'L4[):.;-IA,48WU66)J]2)93GFPK.WE&!E;_\OAON:,HGL@9)#U?L*=6FQR
M'N)PUY&!X(W[UN$:6I!$-U)1E@3&6U4\7??6R9W>4\@UZY+ALV55!YN_S(6+
M/#ZA#4F-095X$I*)P=%X'"^=N>C653: S#M!H7C3IFZR!4;QE=XYJ;'+$NT[
M<0&015H4<:UCD0)B(.5F/Q.4AAG_/RDXH'@R([,OE:90.DX@62HTO!%]#SVI
M813JPG,C"[*:7)95,IL$F@@H*B:)A#XJOX/D0!H8_STI8YBRJY&^)+J@$?>2
M3$%GQ_59KTOU/BP[=BA['Y5=?B_)[$_JI3%?E1B?EG<@MWL@@#@*#DBIB#$^
M%SS4;.9IZ>-T!['&GTLST6Q")O\$JVSQO10V1U@H9W>.\'?Y4EY15S89^Y6'
M(O-"T.L\EQ-J?S4ZM2=>+*2+.WNZY.-6$6Q*" &")>G,$@&OE;D(;%#B34G@
MA\G0TX9T8&;S6>8'DS(1+;:5 )TX3HC^52"-I74AT0PBNF=^V ^F T&7T.X[
M1[X=*FQ6&G@?.XDIH@88+;>?'.O0USO!I^.!LI&ET4G2CA18^5?R]\R\:VV5
MI=(8N^MA0[AID)KN'G#AJ/@XLKQ_^/-I1I7/-2VK[L<3'>Z9Q"DZ0&Y@!N=F
MYU#-3SBQ,U,LNV"IN^C,OX(^N92!]D@B<:A0VXHJ>(G.+5/?COZC":PQ<Z^^
MAY2M0DE@;'6. :=]SWFS1W7POQ\=G>^]9<\'2ID?&-V2KISLNP/T"LDX_X.^
M<JG<\32K?,+G+(=(5EC+=RG] +L/4AA\/Z+PMYU%PB%+JTD#MXI362XW7L ]
M=4@HF[R#0N&OZO^- =JWB:"Z4H\)I?\-?5!A7WK+6 'KP_$F66:&@4?4J"Y$
M"&=PXQ]8Z22Q[*Q!804>@L&J !UH( \,V'<A+2I-SD.F?HO4VQ]YX2WW$+3T
M#<FRN5TENBRUB++Y=&Y9^>W,-RW+6B")#Z5800<IW4VYPN_ NDE2<+3" H4X
MOUP$W[!06:H5\553?$&'FCB:@=<A%F"Y)1A5X&862E9C9)H> ,7,SF'#R(0U
M&?=O%.7". S#38CA, M<1/(B&KC5)1N(,+*NE&?.7T59/!G:GR61#"3&#F1)
MB18JC5N10MM:=08=C'V4J70NAN54%_J),M(X)YW/\-R8PG$% G$_]\,;J9):
MGB'C+\)$F &'&4G4Y8R-PAO@)S)U!A,9D$A('FK9I4A=.E=9)35.G!E*LUSW
M8_30";4Y%H%@@(PG5@3+8\>0N>7(&)0BF%%V,YQ$FHD#[9]-,H"P*76+YFK9
M%]*9[F]%V*GII8J@D\PUR7#7F<!,$0=C*1]CFR1@)K+GL[IH0!C! /8VQ$1!
MJ<I&B87*ZO(]54%5*0CTA\\F!>$1*NEQ:3J#4N%,IW PW56T.HS"_9E?4-QO
M +22^$A[8Q K#S(73BN!3)+)".AI']LN6XH8O"UB="J0LLK*6XA#FM Y1(4[
M[/R$3ZH9$4S\& KD"!K)5+0)=_ 87Q2)7<"Y@AV ' ,IQ"*G GYN$Y;^4L%S
MYJ.678UD)TDM82*4P8R$S1Y)3^KL/:8R##R3^P #Q0'YZ<F2F*;HT2+C@6,2
M!53%1&690DF1Y]$K"EQW*L)Z(F%=Q1[P%%43Z9@R)^(+NLEA5CO_A#[)X30P
M[RU=^,'K%>1HR-Q6+XY]H\U'L7^+?F X\+O([UOR$KD*91D40SA0$*J5V"NE
MG^8LA9FG) Q!7^KL>A*"!W2?>GY O?'N?#@<J]L=9H'>^8,IJ<Q<$&K9UOK3
MG'TFQ:YT/-$F[\@KX&#K?=#1^W:LAA4:)?=M]SFO0Q!F$[(8/MNZUT_CBYRT
M,?(3ZO=W0SH#:!NIX%LJ?R^5>?7B@7.2UVHTD"HPJ)Y->-1"&EFJB\!<..J7
M5Y-Z"5<S($)\ -N/58X_+.+'MA^;U#Z5I%;3^1Z) E$?J7-/BLZ-CMRCZ<@9
M<DFFO@&#HD2$MV@^I47$J#Y.>"%2?%#A<A7TF(:!_Q<Z^.%1"H=0#A(N>CR"
M&\EY0C?>@)/.I#H'/TM!G%O\]A?7;=7<+L]2^*59<UM-G2#'C23A8&"YV?2_
MDKD5.\AT=I@A9MD1@6%304;R<>">Z$WEAX=XO*@V46844P+8SS(?C;@H4@T1
MQ$ 37)9LI5TLAW.DTA93GY4)"TRRV8NN/AL-A[E%TS(F:[QP*J]#IV;]TNYV
M:ATY"N07SL,J!OA)Y.D<&\XE0;&5A*')LJ=9,HP,#E+%(HM\G*=Q&PM,?7-D
M*AZ\0V^KZ*)>@V+EBK$K=IK=TJS(V#URW>6K5."44&W4X6*8=@&D5\C?Y#QM
MNIU"N;E$>[=*@[$PC;(MT>5D;A/6?_F)EA^>!4FB(2%BD[T(I!<@4L5A^I4<
MB$;*X=M#3!$><0A<9GL>%2Y%Q$M_X=3E[ 6=R-F[1*7L$=%046DFUZM9&4UZ
M%5W+EH/.7E!?XU*V0 O/;$87TBQ4,-1&9Q4,Q.J-U__K-HXH]9+\0LS4I.[!
MB"9#5LGY9=0-C5L#A]0[G*>H&P,18,M\YS:*!F2^RA1[E3:>9$L16.? T.,M
MEO#:UG-.\L^P^>4UBAV\ZR^*#V%Y:(C46,Q"BIB-><58QGA2LE @]N[-':TY
M6'6!!PRTTF>[9&!N$U,2U5TG[ O4Y@T*LY@LB0B+S+ O=:H"]'@M,3,/A/XQ
M_#:COEHZQS3AFW-/\^#PTQQ<.<!"U4+ K#H_O(^\3U_("@MGSC8'H%3W+4@"
M[T8J0=(0HXI"AWR3QKPQ1HM=K %0CH27XRSWL<_AHOL0 SD*XN@&F)"@WM\S
MIR*K590S<U"(0KL^SO89<PJ-JCT18]Z*JA>U[##&YNR16KPGB^D:9AJ2!3$?
M,)DKKS<&FQ%C*QZ4_82J3YG$EJA3J1@VI>9S,FIL+\/R28350 _HTL?R1)[X
MCL=-*4.8V:2C[ ,_F42)%U B)9,J:5A<<I&D,IT,=#L,^!8=#FX&7\9S3=%W
MA >[U(D= ',H05>&*/'KVDB/Q23P^IS5B@!:\O)<F8$LMPV^B>1H)N%L]([C
MSDF:<<[/Q*/Q7$S\(QO6<D[,_;+D9=[1H?%+JW&-*D9S EG&&CM)/P9I_K)E
MP8Y)A:]<E+U($AQQ#3">^'B,M=ZY6O,THQEA&@A&<?D5%2)Z,#1*.@!GK4B:
MQO0C>EI7XNGQB:@[D,^7'Z YGR8;@ZIR)KD.+)0>B,X<%C#\7KY,Q<^P N7&
MHE>QR4/>HZ0=8LDRX!M8I&Q"]M;G0@HL1HKBF$=%J@A]5D@$?"PR54QI7ZRX
M!52KF1D&FBO4M'A/^9K$="74DL>J*8;ZV[ .ZW:4\(,Q4.^!'8&FW(JR4_FV
MHLI&BY H)*/:@"+^:\JU6>9(]%FS5SSQQWX@)[FB#9%:C]IT)\>W%M,<_!=-
M[8@MZ9CFPT;#_:F=R\F?]"A#+D.3.8*MR<0\[>AX4/BB'G1<LJ1,#Q:;#ZJL
M0NH)4JZ MCTP>T\2N\/'!+7T+&)F=ILEQ;$GNZ%PFHDD%HY$Z+H.OBAPFFXC
M%X=RWNQ=4JCK*A/J8E:P]Y;%/*YCGG+XE\5(YV!L:+1\HA#,L";LTYPMTW)
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M)L3J+-<6:<RI+&&7GXVP297*W)46)JZ"KOAI<,MA7^<CK!E/)REHPE^]>YI
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M(67]/E,C9KK+4M/=K$&QAY-AYDV<> =R=.4%>\:0&GZU(3LGG7<J3>M_,.&
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M^<3/>RBWCXS%T69J<S *U(*X'-?ER@PWH;M7V(1JD(HW"'1RO$)E[%6H%F+
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MPG<IG<+<HLU(3<9KV<\U2:E+ /M:QS!*G*A,QRRMG]F8P;()G/\[Y[LDLWB
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M&^!9!$Q^/%'^ "(HH#WVV(COW--SI&,L/F0-X0DU"$\$X8%0?@S+SP'HJEF
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MFUAK$VMM8JTY*:$VL7:$B;5U$V1__=__^?-/W^]#S_V(_X:__G]02P,$%
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MS@]\+BX""K]9<P9K(\*<8;B$DZL,/P:-Y <"S@\</"+0*M=Y$C9C%)(TOAQ
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M#B@$D+S;;3D@[TWZZ"S@!_(.).^:;>!DWJR7EM8M0$U+&[?+$E"+.IHVEU9
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MKM"#7.A\RN3_>T )9I_\#U!+ P04    " "R@'I2O\<-IW\<  !3P@$ %0
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M5LZ'509]W]7Y"@U[7[EA[QM*9GY5R][7GL>LU+9O^6*&GVYZ_H/O)2B @R.
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M(#6 U4QNZ?:!6&D[PY&:LK(,2)#!4(:JT-D28"S/3>T+&RMW+OK#S^;,U&(
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MYH/VWE\BY#SF@_K67Y  TND*6,J8#TZN_/?.)]H<DA(Q+\X]ZAR2@@P4,]:
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M[FU=I;(@Z&,!4+61K8S61@F56AZ)=!4GF$SI<OF0$?5A1T_*+6VD$+MLZ8@
M(HD,EX(;7!35LAX9<;?&2<(BO@6IFA!=(;=\D 'LTJ$M 8@-$E@*,G!)5(GZ
MY,(F2)+:G5E=KZZ48S;((/;HT!:!Q <)+A4AF"BJ93TRXG*#R0-=N3Z1[*E8
MFZ8)A;1;AF@A=YDB%07$&!T^!7-J%53J )A46JZ5=^N -M)B5^1%D$84I=K<
MTBHYMF,M*M"S9C4:@.AE 5-EV;:<8,]0J8Q:VIXMW.N=Q,M$+N+>MNV"$PW;
M\GM -!% :4Q:5 IZ[/]96F#F;! _XHN@"*H]F+)R*G&WO-"#[G)$+@N(+UJ
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M4Y4@>F*2U"9:>5H@CAJ+#-Q=KQ5:55@R<,^8"0YR?('+_[8LE<J?PYR,P+H
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MG+#W*CC8+0&JO\AA?B*PHA\-QBUS3> .(G41Z/Y%ZB$"FKYEZ/$CN#]I"P)
M9XN*6M!:4PH82W<T=)/[4U."K?N3PZQAP0MS0<R7V23\^RXFF-:>#L7BY8;6
MJ*!6/7-/WDI>AXTIP&E&L<$5Z]SI6VM#,QT&(Q>," IJ36V.G+FE;BME?EJ!
M:TT8U+4?K@>/=Z@3\6$3\*NP*]2XE78%4V2G"[)I%S1UK^*4;AZ/8%-H"P)
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MV:O!M_@%K,*;4VD6Q!-=-=4P^YE##4_\K=2<740-J,3>Y#+K>.?20*##]H[
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M#RL*T(:8.@4_?G$JX'(/N+XT&,89(?9)QJ]W7P?+A-'TB5"DMD.O$O8ZTW4
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MNS[N9ZWV.K276>-#Q8_ JT:A@HT?W4V6Q.&+F0;#BX+)B-'U$))R=!G11$=
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M?I7$S],X>KX4C>,@)-%VIV5=C^%=>-V@#;%1.]R&+97K!&!::FU^N,T;;)A
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MF>:^2C/?T2XWR;?RB$/\'[B8,VXXFYL.\2N-? >CW$3?PM_8SP6W.=]%M4;
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M07O![="I][)? VB!LTRQ*H>L>",Y_RU,EV=9DK(5Y9OA&TZ;G3OR7F)L "4
MR>XEKA3%;AE0:,Y&Z;TRV0!JT2Z=\>\EX0&5/@Y0$502Z_-$SE%R8R\PHN$X
M+Z39SZ&[L2_OE<;Z.W8'R S'YD)L@U0BRST["?Z1A9P*3H2&I\\W$8E3L3N2
M>5UK30[RYOS$H0_O=<CV (QUYOJ%KR8MPNMC9D!0::PW;7&7W M=38HW$GM9
M38Q]>2]@UM]J I 9CM7D5FRBGS<)EBP60\Q4,;UK1N*-QZU'&4;MO739'B#5
M+_+"I37^M4/(*Z!TIDKV7H<QE4P+)DPU:0TDWBNB]:8%5KG@,VT@? 82[[7.
M!C%B&WPOP')OJ;IV?D/$1O></@"-MTD%58!#I_[M9[\ZZ> S83B.9BHHCH?.
M MS/D $XCM26X>+J8S<.UX]#QP/=]<-=<F/WX"[F<QH([^7B:[ D\8+>"A6>
MQE((\L%W\4-&.!Y)1(U)Q&Z]0/4%4PRPBYQPK AR<+4!WE+!:QB(R:I@H/I!
MJ65^1[=YE!)$V4P]H;:31BXAO8X<>AQ0+1O^BBU<R_Q@-?8Y;"^I#:2P</T;
M_F;P@?1O;W5"5?T&HU(YW#<_QA3RW)OI7A0+1;F!]AW#B=AV<OXL9FE5&L6L
M/@!R\)T[9$H"ELQ+4(6JQN=%D8P^>FMS*-3#5[V#0VWD_.5!Z^))V2FA@ ]?
M'Z\KX""/:;38JZLJ2CXDVLCG*IXSOLHALA?L@'8 U83A:^W!-<%1.CA<Z-(;
MD[+BLC&OLMH0"M%PA?D<Y:UY:+'*.!94\N<\Y<@^4>/EV%I#*"K#%=#;$Y56
MQG&@LF%'/KTJ?MTEO\2SEC#J>9@$$4LRR$MG^_<,Q1U3X+$O>0Y4V71SU6)W
M]?:,11&52[W,OC\E\1?*$]&*KE,QV-8C!]E1AWZ@: X6X.L-&K:7' ;%MUR8
M<3J?AP'EOY$%3>Y9Z;D(#:9 6BB.@P7*AL#126X#8;<M6'.3\6!)$HT*?6)I
M6\0AOX_MT ,4Q\$B4T/@V$&&.-;A6_EPWW3^.:&J!LKT(7]0XBK>G -<,KZ]
MYW M3PH M\OVZA1<2V@L^M&'4+0JX[&$YI0O2%S4(A.RN0L7<2AF,)GQGJ].
MLG@OB\*@? Y>J:SYY\F;R4Y^XA_E+B<DGDU*G4YVO4ZVW7I]FJ3&HWUK:J+Q
M^1AY2>J[XJ8YJC<EW9G."_TGT:[L:4G_+3IP+U3M-&K?!Q1#.?Q(/%?WM&M1
M_05S3UCAFGJVRVW[O/+O]7EEUQY!@4079]9(A*':XVY< /,V4WDV10 ^NDJ/
M!B'@LAO[O;2*'?U4MZ,-_?^>J![4$KWKPVM:<CM?=@L#D/K-MVX?G9/=N?7B
MV0[!6#:3KYU%A<LZKT27\4(^:*$\A/9-\]&[YN*V(9L4=/[T]0-CLZ<PBH3\
MZ]RX+'N.W?@]7= ,#[0> H@]FV,G1)LG$5 AX;+(D]FCBIX*UWP3V$FF<YB=
M'M7M=-/99,[X9-N=?#:B'PO6A=Y!/!AL4L6;'3OI]>P ]-TF<X-S@,#NNHB[
MY8"@F]!PF5_Y[HUZ!8ZH2[$:@SNN&UQ!/E'TDTH'/G-^VGFR+XIV2J^I3.V#
M<UH/G3KQO"Y"<6RD.#G+"9=-MIYI-*ZH5PSS?=TP\SZ^)6N6_)),=EU-5%^3
M36<]KB'&45O6/B"M1^.3(\P/*.Z7/)R[.8<@8I^+H1-V-7-SD PN,ZL7@;@D
M0?4HJ&)AW]<MK$P^D?2330<J9G,M;Z>K!\OR^^D^7P5Z2%T\0UU[C]9WS>+%
M/>4K.32 O6F:>U[.S#C4K,K(,2X[4@>IF@WC#W6K*1I[5"4U +L5U-OYU'Z:
MNQ;75'@4U&GE 9!ZMHIV/.K6 )4 +LLH)>VVF\>/S4"CI)CD) C2K-T.T@Q$
M&'+&'0.')BKO!VE6?'3YXZ,QGDL2<G73[*,P?C'<5>5Z2L6,&DDNDG:BB"<5
M:G]*N.5F-T[ (F2F\FA3;>!<Q>O,,3KOV(UGJX-@6#.[3G+"98?Z%]:K1MC(
M""D3YH&(24'OL<B*&H#=\.KM4+UP+YUS)S-SZ,*SB;7C4[^YYBH17 9U2Q]I
MG&D">8U\D$UKGW%G-0)9<:WM.0=(5!W8@=?@NG&,H,@ZM ?O874G/!O1=3=!
M(;.],/F2?(X#RF5J>*I+FSYN9( HPLFW9+7^95*E[S&$WAR=)6YN(O!Y\Y")
M(4G=D.C),3JM5C!JG^%R.T[UJX,. L%E,#=*&&=LM2;Q\S2.GILYS^T6U,C-
M$#*8R==>U&&Q()L4G4YDKY-MMY-=O_U>GLN_',"/Q>:Z=>77&O,!;\=7NN \
MG3?8<#76_3OW:<O[:$;3ROL2-*Y)P.4:DO$ZTG$C@<3U.M+D3YO?_NV/?C-)
M,]75P/I$4B'IZ;RX]\;B'*%G6S*7>S>CN>?3C3VM8?8!VG4H_-B9='WCV0<F
M7U:3.P8>P[ "4X/?H$6!D:-0<-SVK=P8L\.W6SH,5.!'.+S#!F('$UR?$V'U
M%TD:BE7:5(6[W@Y<UP\+).V,X@"AO109W'A@Y.!;[U@@<Q(+9B1M1>=REEP!
MAO8*Q'VP$E,]X>XF1!SJL*N=DZBWX<6H*\]"[_Y^$D7L268>7C)^SK*'=)Y%
MV\>C+>K1[[< U66PRE3.ZC*$D(>J455<F;AGJNY:*'-.X]GV(H6,*1=Q9*"7
MLD^'0* '*UKEMAG>7W0XIH1=&1_H\JZG "(X6+DJ9U.U,=^YZBJ:E]#S#+T\
M7P^,L)$("/)@M:R<00:( (DIKM8DY*H((C\/DS5+2#2=R\SCZ_"1SO+[:W S
M[=0;."*!!MY]I(8#=^TU?C#6\!Z@^"((.3GSA@G3XEA>[/78(@Z=8D\ 4BB*
M>")08'G@@.^,)>ET?B<\.8>PAX$&"AB>^)1= CB0$FXX%6.0#OBYT+&(J;GA
MXNM:GOS9/54 ,10[/($J!YG@ /&"\%@><=Y0?K<4(@';G)40"AZ>:!-0%CB
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MEM>Q=G7],)C3BRKPMYN0Y>5J%LNY6.Z^B]$6&Z13&M-YV"$,VZ%3[Y%9U_*
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M[<E64[_*864CY^//CMZ<VVD1K9WO>:^=TAU-#2>85K76(SD;-$8BM&<#5IP
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MDO'PGSM7I25J8"+RZF/"I<_@'"'%ZX;P*9>):G2F/.$;RM780;CIB;UFSO>
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M:2TR,#(P,3(S,2YX;6Q02P$"% ,4    " "R@'I2R7KC9:X/  !&L   $0
M            @ 'JP@  8W!H:2TR,#(P,3(S,2YX<V102P$"% ,4    " "R
M@'I2- R]$8D3  "!#0$ %0              @ ''T@  8W!H:2TR,#(P,3(S
M,5]C86PN>&UL4$L! A0#%     @ LH!Z4K_'#:=_'   4\(! !4
M     ( !@^8  &-P:&DM,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( +*
M>E*\A\1D'E8  %"5!  5              "  34# 0!C<&AI+3(P,C Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " "R@'I2#?,,5T8X  #(K , %0
M    @ &&60$ 8W!H:2TR,#(P,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$
' /^1 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
